Fast skeletal muscle myosin inhibitors

Abstract

Provided herein are compounds of Formula (I): or a pharmaceutically acceptable salt thereof. Also provided are pharmaceutically acceptable compositions comprising a compound of Formula (I), or a pharmaceutically acceptable salt thereof. Also provided are methods of using a compound of Formula (I), or a pharmaceutically acceptable salt thereof.

Description

498922021940FAST SKELETAL MUSCLE MYOSIN INHIBITORSCROSS-REFERENCE TO RELATED APPLICATIONS

[0001] This application claims priority benefit of United States Provisional Patent Application No. 63 / 738,288 filed December 23, 2024, which is hereby incorporated herein by reference in its entirety.FIELD

[0002] Provided herein are heteroaryl amine compounds, pharmaceutical compositions comprising such compounds, and methods of treating various neuromuscular diseases and conditions with such compounds.BACKGROUND

[0003] Aberrant contraction of skeletal muscle is a contributor to numerous debilitating conditions such as tremor, spasticity, muscular dystrophy, cerebral palsy, and multiple sclerosis. Currently, the treatment options for these and other neuromuscular diseases are severely limited or non-existent. Available therapeutics carry a wide range of neurological and cardiovascular side effects due to significant off-target effects. Thus, there is a need for the development of compounds that selectively modulate skeletal muscle contractility through new mechanisms of action. Such compounds may have better outcomes in terms of relief of symptoms, safety, long- and short-term patient mortality, and improved therapeutic index.SUMMARY

[0004] In one aspect, provided is a compound of Formula (I):NH (I),or a pharmaceutically acceptable salt thereof, wherein:Y is -CH2- or -O-;1MF-365146518498922021940X1, X2, and X3are each independently -N- or -C(RX)-, wherein each Rxis independently selected from the group consisting of H, halogen, and Ci-Ce alkyl, provided that no more than one of X1, X2, and X3is -N-;R1is selected from the group consisting of:5- to 6-membered heteroaryl, wherein the 5- to 6-membered heteroaryl is optionally substituted with 1 to 4 independently selected R1Asubstituents, -C(O)H,-C(O)CH3,-C(O)NRaRb, and-Ci-Ce alkyl substituted with 1 to 5 independently selected halogens;each R1Ais independently selected from the group consisting of:-C3-C8 cycloalkyl optionally substituted with 1 to 5 substituents independently selected from the group consisting of SO2Rc, Ci-Ce alkoxy, and Ci-Ce alkyl, wherein the Ci-Ce alkyl is optionally substituted with 1 to 5 substituents independently selected from the group consisting of OH and Ci-Ce alkoxy, -4 to 10 membered heterocycloalkyl optionally substituted with 1 to 5 substituents independently selected from the group consisting of SO2RC, Ci-Ce alkoxy, and Ci-Ce alkyl, wherein the Ci-Ce alkyl is optionally substituted with 1 to 5 substituents independently selected from the group consisting of OH and Ci- Ce alkoxy, and-Ci-Ce alkyl optionally substituted with 1 to 3 substituents independently selected from the group consisting of Ci-Ce alkoxy, halogen, OH, and -C3-C8 cycloalkyl, wherein the -C3-C8 cycloalkyl is optionally substituted with 1 to 5 independently selected Ci-Ce alkyl substituents, wherein the Ci-Ce alkyl is optionally substituted with OH or Ci-Ce alkoxy;each Rais independently selected from the group consisting of H and Ci-Ce alkyl;each Rbis independently selected from the group consisting of Ce-Cio aryl, -C3-C8 cycloalkyl, and Ci-Ce alkyl, wherein the Ci-Ce alkyl is optionally substituted with Ce-Cio aryl; each Rcis independently Ci-Ce alkyl;2MF-365146518498922021940R2is 5 to 10 membered heteroaryl optionally substituted with 1 to 5 independently selected R2Asubstituents;each R2Ais independently selected from the group consisting of:-Ci-C io alkyl optionally substituted with 1 to 5 substituents independently selected from the group consisting of:-OH,-ORn,halogen,-N(C1-C6alkyl)C(O)(C1-C6alkyl)-CO2C1-C6 alkyl,-Ci-Ce alkoxy optionally substituted with 1 to 5 substituents independently selected from the group consisting of halogen, OH, and Ci-Ce alkoxy, -C3-C8 cycloalkyl optionally substituted with 1 to 5 substituents independently selected from the group consisting of OH, halogen, -Ci-Ce alkyl, and Ci-Ce alkoxy, wherein the Ci-Ce alkyl is optionally substituted with Ci-Ce alkoxy or OH,-4 to 10 membered heterocycloalkyl optionally substituted with 1 to 5 substituents independently selected from the group consisting of OH, halogen, -Ci-Ce alkyl, and Ci-Ce alkoxy, wherein the Ci-Ce alkyl is optionally substituted with Ci-Ce alkoxy or OH, and-Ce-Cio aryl optionally substituted by 1 to 5 substituents independently selected from the group consisting of halogen, OH, Ci-Ce alkoxy, and Ci-Ce alkyl, wherein the Ci-Ce alkyl is optionally substituted with OH or Ci-Ce alkoxy,-C3-C8 cycloalkyl optionally substituted with 1 to 5 substituents independently selected from the group consisting of halogen, OH, SO2-C1-C6 alkyl, -CO2-C1- Ce alkyl, Ci-Ce alkoxy, and Ci-Ce alkyl, wherein the Ci-Ce alkyl is optionally substituted with 1 to 5 substituents independently selected from the group consisting of OH and Ci-Ce alkoxy,-4 to 10 membered heterocycloalkyl optionally substituted with 1 to 5 substituents independently selected from the group consisting of halogen, oxo, -CO2-C1-C63MF-365146518498922021940alkyl, SO2-C1-C6 alkyl, Ci-Ce alkoxy, and Ci-Cs alkyl, wherein the Ci-Cs alkyl is optionally substituted with 1 to 5 substituents independently selected from the group consisting of halogen, Ci-Ce alkoxy, and OH, -Ce-Cio aryl optionally substituted with 1 to 5 substituents independently selected from the group consisting of Ci-Ce alkyl, OH, SO2-C1-C6 alkyl, -CO2-C1-C6 alkyl, Ci-Ce alkoxy, and halogen,-5 to 10 membered heteroaryl optionally substituted with 1 to 5 substituents independently selected from the group consisting of Ci-Ce alkyl, OH, SO2-C1- Ce alkyl, -CO2-C1-C6 alkyl, Ci-Ce alkoxy, and halogen,-Ci-Ce alkoxy optionally substituted with 1 to 5 independently selected halogens, -halogen,-SO2Re,-CN,-C(O)NRfRg,-C(O)ORh,-C(O)C1-C6alkyl,-NRiRj,-OH, and-NRkCORm;each Reis independently selected from the group consisting of H and Ci-Ce alkyl;each Rfis independently selected from the group consisting of H and Ci-Ce alkyl;each Rgis independently selected from the group consisting of H and Ci-Ce alkyl;each Rhis independently selected from the group consisting of H and C1-C6alkyl;each Riis independently selected from the group consisting of H and C1-C6alkyl;each Rjis independently selected from the group consisting of H and Ci-Ce alkyl;each Rkis independently selected from the group consisting of H and Ci-Ce alkyl;each Rmis independently selected from the group consisting of H and Ci-Ce alkyl; and each Rnis independently selected from the group consisting of 4 to 10 membered heterocycloalkyl and -C3-C8 cycloalkyl each of which is optionally substituted with 1 to 5 independently selected halogens;4MF-365146518498922021940provided that the compound is not N-(5-(5-methyl-l,2,4-oxadiazole-3-yl)-2,3-dihydro-lH-inden-l-yl)pyrazin-2-amine or 3-(3-((5-(trifluoromethyl)-2,3-dihydro-lH-inden-l-yl)amino)pyrazin-2-yl)- 1,2,4-oxadiazol-5 (2H)-one.

[0005] Provided in some embodiments are compounds selected from the group consisting of compounds of Table 1, or a pharmaceutically acceptable salt thereof.

[0006] Provided in another aspect is a pharmaceutical composition comprising a compound of Formula (I), (la), (lb), (II), (Ila), (lib), (III), (Illa), or (Illb), or a pharmaceutically acceptable salt thereof, and a pharmaceutically acceptable excipient.

[0007] Provided in some aspects are methods of treating a neuromuscular disease in a subject in need thereof, the method including administering to the subject a compound of Formula (I), (la), (lb), (II), (Ila), (lib), (III), (Illa), or (Illb), or a pharmaceutically acceptable salt thereof, or a pharmaceutical composition containing a compound of Formula (I), (la), (lb), (II), (Ila), (lib), (III), (Illa), or (Illb). In some embodiments, the neuromuscular disease is selected from the group consisting of tremor, spasticity, distal arthrogryposis, and muscular dystrophy. In some embodiments, the neuromuscular disease is associated with movement, gait, hypertonia, hypercontractility, muscle stiffness, spasms, involuntary contractions, tendinitis, or carpal tunnel syndrome. In some embodiments, the neuromuscular disease is multiple sclerosis. In some embodiments, the neuromuscular disease is associated with stroke. In some embodiments, the neuromuscular disease is cerebral palsy. In some embodiments, the neuromuscular disease is associated with physical trauma.

[0008] Also provided are methods of inhibiting fast skeletal muscle myosin, wherein the method involves contacting the fast skeletal muscle myosin with a compound of Formula (I), (la), (lb), (II), (Ila), (lib), (III), (Illa), or (Illb) or any variation thereof, or a pharmaceutically acceptable salt thereof, or a pharmaceutical composition containing a compound of Formula (I), (la), (lb), (II), (Ila), (lib), (III), (Illa), or (Illb) or any variation thereof.DETAILED DESCRIPTIONDefinitions

[0009] As used in the present specification, the following words and phrases are generally intended to have the meanings as set forth below, except to the extent that the context in which they are used indicates otherwise.5MF-365146518498922021940

[0010] Throughout this application, unless the context indicates otherwise, references to a compound of Formula (I) includes all subgroups of Formula (I) defined herein, including all substructures, subgenera, preferences, embodiments, examples and particular compounds defined and / or described herein. References to a compound of Formula (I) include ionic forms, polymorphs, pseudopolymorphs, amorphous forms, solvates, co-crystals, chelates, stereoisomers, geometric isomers (cis / trans), E / Z isomers, tautomers, oxides (e.g., N-oxides, S-oxides), and / or isotopes thereof. In some embodiments, references to a compound of Formula (I) include polymorphs, solvates, co-crystals, stereoisomers, tautomers and / or oxides thereof. In some embodiments, references to a compound of Formula (I) include polymorphs, solvates, and / or co-crystals thereof. In some embodiments, references to a compound of Formula (I) include stereoisomers, tautomers and / or oxides thereof. In some embodiments, references to a compound of Formula (I) include solvates thereof. Similarly, the term “salts” includes solvates of salts of compounds.

[0011] " Alkyl" encompasses straight and branched carbon chains having the indicated number of carbon atoms, for example, from 1 to 20 carbon atoms, or 1 to 8 carbon atoms, or 1 to 6 carbon atoms. For example, Ci-6 alkyl encompasses both straight and branched chain alkyl of from 1 to 6 carbon atoms. When an alkyl residue having a specific number of carbons is named, all branched and straight chain versions having that number of carbons are intended to be encompassed; thus, for example, "propyl" includes n-propyl and isopropyl; and "butyl" includes n-butyl, sec-butyl, isobutyl and t-butyl. Examples of alkyl groups include, but are not limited to, methyl, ethyl, propyl, isopropyl, n-butyl, sec-butyl, tert-butyl, pentyl, 2-pentyl, 3-pentyl, isopentyl, neopentyl, hexyl, 2-hexyl, 3-hexyl, and 3-methylpentyl.

[0012] " Aryl" indicates an aromatic carbocyclic ring having the indicated number of carbon atoms, for example, 6 to 12 or 6 to 10 carbon atoms. Aryl groups may be monocyclic or polycyclic (e.g., bicyclic, tricyclic). In some instances, both rings of a polycyclic aryl group are aromatic (e.g., naphthyl). In other instances, polycyclic aryl groups may include a non-aromatic ring fused to an aromatic ring, provided the polycyclic aryl group is bound to the parent structure via an atom in the aromatic ring. Thus, a l,2,3,4-tetrahydronaphthalen-5-yl group (wherein the moiety is bound to the parent structure via an aromatic carbon atom) is considered an aryl group, while 1,2,3,4-tetrahydronaphthalen-l-yl (wherein the moiety is bound to the parent structure via a non-aromatic carbon atom) is not considered an aryl group. Similarly, a l,2,3,4-tetrahydroquinolin-8-yl group (wherein the moiety is bound to the6MF-365146518498922021940parent structure via an aromatic carbon atom) is considered an aryl group, while 1,2, 3, 4-tetrahydroquinolin-l-yl group (wherein the moiety is bound to the parent structure via a nonaromatic nitrogen atom) is not considered an aryl group. However, the term “aryl” does not encompass or overlap with “heteroaryl”, as defined herein, regardless of the point of attachment (e.g., both quinolin-5-yl and quinolin-2-yl are heteroaryl groups). In some instances, aryl is phenyl or naphthyl. In certain instances, aryl is phenyl. Additional examples of aryl groups comprising an aromatic carbon ring fused to a non-aromatic ring are described below.

[0013] When a range of values is given (e.g., Ci-6 alkyl), each value within the range as well as all intervening ranges are included. For example, “Ci-6 alkyl” includes Ci, C2, C3, C4, C5, Ce, C1-6, C2-6, C3-6, C4-6, C5-6, C1-5, C2-5, C3-5, C4-5, C1-4, C2-4, C3-4, C1-3, C2-3, and C1-2 alkyl.

[0014] " Cycloalkyl" indicates a non-aromatic, fully saturated carbocyclic ring having the indicated number of carbon atoms, for example, 3 to 10, or 3 to 8, or 3 to 6 ring carbon atoms. Cycloalkyl groups may be monocyclic or polycyclic (e.g., bicyclic, tricyclic).Examples of cycloalkyl groups include cyclopropyl, cyclobutyl, cyclopentyl, and cyclohexyl, as well as fused, bridged, spirocyclic, and caged ring groups (e.g., norbornane, bicyclo[l.l.l]pentane, bicyclo[2.2.2]octane). In addition, one ring of a polycyclic cycloalkyl group may be aromatic, provided the polycyclic cycloalkyl group is bound to the parent structure via a non-aromatic carbon. For example, a 1,2,3,4-tetrahydronaphthalen-l-yl group (wherein the moiety is bound to the parent structure via a non-aromatic carbon atom) is a cycloalkyl group, while l,2,3,4-tetrahydronaphthalen-5-yl (wherein the moiety is bound to the parent structure via an aromatic carbon atom) is not considered a cycloalkyl group.

[0015] " Heteroaryl" indicates an aromatic ring containing the indicated number of atoms (e.g., 5 to 12, or 5 to 10 membered heteroaryl) made up of one or more heteroatoms (e.g., 1, 2, 3 or 4 heteroatoms) selected from N, O and S and with the remaining ring atoms being carbon. Heteroaryl groups do not contain adjacent S and O atoms. In some embodiments, the total number of S and O atoms in the heteroaryl group is not more than 2. In some embodiments, the total number of S and O atoms in the heteroaryl group is not more than 1. Unless otherwise indicated, heteroaryl groups may be bound to the parent structure by a carbon or nitrogen atom, as valency permits. For example, “pyridyl” includes 2-pyridyl, 3-7MF-365146518498922021940pyridyl and 4-pyridyl groups, and “pyrrolyl” includes 1 -pyrrolyl, 2-pyrrolyl and 3-pyrrolyl groups.

[0016] In some instances, a heteroaryl group is monocyclic. Examples include pyrrole, pyrazole, imidazole, triazole (e.g., 1,2,3-triazole, 1,2,4-triazole, 1,2,4-triazole), tetrazole, furan, isoxazole, oxazole, oxadiazole (e.g., 1,2,3-oxadiazole, 1,2,4-oxadiazole, 1,3,4-oxadiazole), thiophene, isothiazole, thiazole, thiadiazole (e.g., 1,2,3-thiadiazole, 1,2,4-thiadiazole, 1,3,4-thiadiazole), pyridine, pyridazine, pyrimidine, pyrazine, triazine (e.g., 1,2,4-triazine, 1,3,5-triazine) and tetrazine. In other instances, a heteroaryl group is polycyclic. Polycyclic heteroaryl groups may include a non-aromatic ring (e.g., cycloalkyl, cycloalkenyl, heterocycloalkyl, heterocycloalkenyl) fused to a heteroaryl ring, provided the polycyclic heteroaryl group is bound to the parent structure via an atom in the aromatic ring. For example, a 4,5,6,7-tetrahydrobenzo[d]thiazol-2-yl group (wherein the moiety is bound to the parent structure via an aromatic carbon atom) is considered a heteroaryl group, while 4,5,6,7-tetrahydrobenzo[d]thiazol-5-yl (wherein the moiety is bound to the parent structure via a non-aromatic carbon atom) is not considered a heteroaryl group.

[0017] Examples of polycyclic rings consisting of an aromatic ring (e.g., aryl or heteroaryl) fused to a non-aromatic ring (e.g., cycloalkyl, cycloalkenyl, heterocycloalkyl, heterocycloalkenyl) include indenyl, 2,3-dihydro-lH-indenyl, 1,2,3,4-tetrahydronaphthalenyl, benzo[l,3]dioxolyl, tetrahydroquinolinyl, 2,3-dihydrobenzo[l,4]dioxinyl, indolinyl, isoindolinyl, 2,3-dihydro-lH-indazolyl, 2,3-dihydro-lH-benzo[d]imidazolyl, 2,3-dihydrobenzofuranyl, 1,3-dihydroisobenzofuranyl, l,3-dihydrobenzo[c]isoxazolyl, 2,3-dihydrobenzo[d]isoxazolyl, 2,3-dihydrobenzo[d]oxazolyl, 2,3-dihydrobenzo[b]thiophenyl, l,3-dihydrobenzo[c]thiophenyl, l,3-dihydrobenzo[c]isothiazolyl, 2,3-dihydrobenzo[d] isothiazolyl, 2,3-dihydrobenzo[d]thiazolyl, 5,6-dihydro-4H-cyclopenta[d] thiazolyl, 4,5,6,7-tetrahydrobenzo [d] thiazolyl, 5,6-dihydro-4Hpyrrolo [3,4-d]thiazolyl, 4,5,6,7-tetrahydrothiazolo[5,4-c]pyridinyl, indolin-2-one, indolin-3-one, isoindolin-l-one, l,2-dihydroindazol-3-one, lH-benzo[d]imidazol-2(3H)-one, benzofuran-2(3H)-one, benzofuran-3(2H)-one, isobenzofuran- l(3H)-one, benzo[c]isoxazol-3(lH)-one, benzo[d]isoxazol-3(2H)-one, benzo[d]oxazol-2(3H)-one, benzo[b]thiophen-2(3H)-one, benzo [b] thiophen-3 (2H)-one, benzo [c] thiophen- 1 (3H)-one, benzo [c] isothiazol-3 ( 1 H)-one, benzo[d]isothiazol-3(2H)-one, benzo[d]thiazol-2(3H)-one, 4,5-dihydropyrrolo[3,4-d]thiazol-6-one, l,2-dihydropyrazolo[3,4-d]thiazol-3-one, quinolin-4(3H)-one, quinazolin-4(3H)-one,8MF-365146518498922021940quinazoline-2,4(lH,3H)-dione, quinoxalin-2(lH)-one, quinoxaline-2,3(lH,4H)-dione, cinnolin-4(3H)-one, pyridin-2(lH)-one, pyrimidin-2(lH)-one, pyrimidin-4(3H)-one, pyridazin-3(2H)-one, lH-pyrrolo[3,2-b]pyridin-2(3H)-one, lH-pyrrolo[3,2-c]pyridin-2(3H)-one, lH-pyrrolo[2,3-c]pyridin-2(3H)-one, lH-pyrrolo[2,3-b]pyridin-2(3H)-one, 1,2-dihydropyrazolo[3,4-d]thiazol-3-one and 4,5-dihydropyrrolo[3,4-d]thiazol-6-one. As discussed herein, whether each ring is considered an aryl, heteroaryl, cycloalkyl, cycloalkenyl, heterocycloalkyl or heterocycloalkenyl group is determined by the atom through which the moiety is bound to the parent structure.

[0018] “Heterocyclyl" or “heterocycloalkyl” indicates a non-aromatic, fully saturated ring having the indicated number of atoms (e.g., 3 to 10, or 3 to 7, membered heterocycloalkyl) made up of one or more heteroatoms (e.g., 1, 2, 3 or 4 heteroatoms) selected from N, O and S and with the remaining ring atoms being carbon. Heterocycloalkyl groups may be monocyclic or polycyclic (e.g., bicyclic, tricyclic), fused bridged, or spiro. Examples of heterocyclo alkyl groups include oxiranyl, aziridinyl, azetidinyl, pyrrolidinyl, imidazolidinyl, pyrazolidinyl, piperidinyl, piperazinyl, morpholinyl and thiomorpholinyl. Examples include thiomorpholine S-oxide and thiomorpholine S, S-dioxide. In addition, one ring of a fused polycyclic heterocycloalkyl group may be aromatic (e.g., aryl or heteroaryl), provided the fused polycyclic heterocycloalkyl group is bound to the parent structure via a non-aromatic carbon or nitrogen atom. For example, a 1,2,3,4-tetrahydroquinolin-l-yl group (wherein the moiety is bound to the parent structure via a non-aromatic nitrogen atom) is considered a heterocyclyl or heterocycloalkyl group, while l,2,3,4-tetrahydroquinolin-8-yl group (wherein the moiety is bound to the parent structure via an aromatic carbon atom) is not considered a heterocyclyl or heterocycloalkyl group.

[0019] " Halogen" or "halo" refers to fluorine, chlorine, bromine or iodine.

[0020] Furthermore, some compounds may sometimes exist in tautomeric forms. It will be understood that although structures are shown, or named, in a particular form, the invention also includes the tautomer thereof. Also, some compounds may sometimes exist in atropoisomeric forms. It will be understood that although structures are shown in a particular form, the invention also includes the corresponding atropoisomeric forms thereof.

[0021] The compounds of the invention and disclosure may contain one or more chiral centers and therefore, such compounds (and intermediates thereof) can exist as racemic9MF-365146518498922021940mixtures; pure stereoisomers (i.e., enantiomers or diastereomers); stereoisomer-enriched mixtures and the like. Chiral compounds shown or named herein without a defined stereochemistry at a chiral center are intended to include any or all possible stereoisomer variations at the undefined stereocenter unless otherwise indicated. The depiction or naming of a particular stereoisomer means the indicated stereocenter has the designated stereochemistry with the understanding that minor amounts of other stereoisomers may also be present unless otherwise indicated, provided that the utility of the depicted or named compound is not eliminated by the presence of another stereoisomer.

[0022] “Protecting group” has the meaning conventionally associated with it in organic synthesis, i.e., a group that selectively blocks one or more reactive sites in a multifunctional compound such that a chemical reaction can be carried out selectively on another unprotected reactive site, and such that the group can readily be removed after the selective reaction is complete. A variety of protecting groups are disclosed, for example, in T. H. Greene and P. G. M. Wuts, Protective Groups in Organic Synthesis, Third Edition, John Wiley & Sons, New York (1999). For example, a “hydroxy protected form” contains at least one hydroxy group protected with a hydroxy protecting group. Likewise, amines and other reactive groups may similarly be protected.

[0023] The term "pharmaceutically acceptable salt" refers to a salt of any of the compounds herein which are known to be non-toxic and are commonly used in the pharmaceutical literature. In some embodiments, the pharmaceutically acceptable salt of a compound retains the biological effectiveness of the compounds described herein and are not biologically or otherwise undesirable. Examples of pharmaceutically acceptable salts can be found in Berge et al., Pharmaceutical Salts, J. Pharmaceutical Sciences, January 1977, 66(1), 1-19. Pharmaceutically acceptable acid addition salts can be formed with inorganic acids and organic acids. Inorganic acids from which salts can be derived include, for example, hydrochloric acid, hydrobromic acid, sulfuric acid, nitric acid, and phosphoric acid. Organic acids from which salts can be derived include, for example, acetic acid, propionic acid, glycolic acid, pyruvic acid, lactic acid, oxalic acid, malic acid, maleic acid, malonic acid, succinic acid, fumaric acid, tartaric acid, citric acid, benzoic acid, cinnamic acid, mandelic acid, methanesulfonic acid, ethanesulfonic acid, 2-hydroxyethylsulfonic acid, p-toluenesulfonic acid, stearic acid and salicylic acid. Pharmaceutically acceptable base addition salts can be formed with inorganic and organic bases. Inorganic bases from which10MF-365146518498922021940salts can be derived include, for example, sodium, potassium, lithium, ammonium, calcium, magnesium, iron, zinc, copper, manganese, and aluminum. Organic bases from which salts can be derived include, for example, primary, secondary, and tertiary amines; substituted amines including naturally occurring substituted amines; cyclic amines; and basic ion exchange resins. Examples of organic bases include isopropylamine, trimethylamine, diethylamine, triethylamine, tripropylamine, and ethanolamine. In some embodiments, the pharmaceutically acceptable base addition salt is selected from ammonium, potassium, sodium, calcium, and magnesium salts.

[0024] If the compound described herein is obtained as an acid addition salt, the free base can be obtained by basifying a solution of the acid salt. Conversely, if the compound is a free base, an addition salt, particularly a pharmaceutically acceptable addition salt, may be produced by dissolving the free base in a suitable organic solvent and treating the solution with an acid, in accordance with conventional procedures for preparing acid addition salts from base compounds (see, e.g., Berge et al., Pharmaceutical Salts, J. Pharmaceutical Sciences, January 1977, 66(1), 1-19). Those skilled in the art will recognize various synthetic methodologies that may be used to prepare pharmaceutically acceptable addition salts.

[0025] A “solvate” is formed by the interaction of a solvent and a compound. Suitable solvents include, for example, water and alcohols (e.g., ethanol). Solvates include hydrates having any ratio of compound to water, such as monohydrates, dihydrates and hemi-hydrates.

[0026] The term “substituted” means that the specified group or moiety bears one or more substituents. The term “unsubstituted” means that the specified group bears no substituents. Where the term “substituted” is used to describe a structural system, the substitution is meant to occur at any valency-allowed position on the system. When a group or moiety bears more than one substituent, it is understood that the substituents may be the same or different from one another.

[0027] By "optional" or "optionally" is meant that the subsequently described event or circumstance may or may not occur, and that the description includes instances where the event or circumstance occurs and instances in which it does not. For example, "optionally substituted alkyl" encompasses both "alkyl" and "substituted alkyl" as defined herein. It will be understood by those skilled in the art, with respect to any group containing one or more substituents, that such groups are not intended to introduce any substitution or substitution11MF-365146518498922021940patterns that are sterically impractical, synthetically non-feasible, and / or inherently unstable. It will also be understood that where a group or moiety is optionally substituted, the disclosure includes both embodiments in which the group or moiety is substituted and embodiments in which the group or moiety is unsubstituted.

[0028] The compounds disclosed and / or described herein can be enriched isotopic forms, e.g., enriched in the content of2H,3H,nC,13C and / or14C. In one embodiment, the compound contains at least one deuterium atom. Such deuterated forms can be made, for example, by the procedure described in U. S. Patent Nos. 5,846,514 and 6,334,997. Such deuterated compounds may improve the efficacy and increase the duration of action of compounds disclosed and / or described herein. Deuterium substituted compounds can be synthesized using various methods, such as those described in: Dean, D., Recent Advances in the Synthesis and Applications of Radiolabeled Compounds for Drug Discovery and Development, Curr. Pharm. Des., 2000; 6(10); Kabalka, G. et al., The Synthesis of Radiolabeled Compounds via Organometallic Intermediates, Tetrahedron, 1989, 45(21), 6601-21; and Evans, E., Synthesis of radiolabeled compounds, J. Radioanal. Chem., 1981, 64(1-2), 9-32.

[0029] The term "pharmaceutically acceptable carrier" or "pharmaceutically acceptable excipient" includes any and all solvents, dispersion media, coatings, antibacterial and antifungal agents, isotonic and absorption delaying agents and the like. The use of such media and agents for pharmaceutically active substances is well known in the art. Except insofar as any conventional media or agent is incompatible with the active ingredient, its use in pharmaceutical compositions is contemplated. Supplementary active ingredients can also be incorporated into the pharmaceutical compositions.

[0030] The terms “patient,” “individual,” and “subject” refer to an animal, such as a mammal, bird, or fish. In some embodiments, the patient or subject is a mammal. Mammals include, for example, mice, rats, dogs, cats, pigs, sheep, horses, cows and humans. In some embodiments, the patient or subject is a human, for example a human that has been or will be the object of treatment, observation or experiment. The compounds, compositions and methods described herein can be useful in both human therapy and veterinary applications.

[0031] As used herein, the term "therapeutic" refers to the ability to modulate the fast skeletal muscle myosin. As used herein, “modulation” refers to a change in activity as a12MF-365146518498922021940direct or indirect response to the presence of a chemical entity as described herein, relative to the activity of in the absence of the chemical entity. The change may be an increase in activity or a decrease in activity, and may be due to the direct interaction of the chemical entity with the target or due to the interaction of the chemical entity with one or more other factors that in turn affect the target's activity. For example, the presence of the chemical entity may, for example, increase or decrease the target activity by directly binding to the target, by causing (directly or indirectly) another factor to increase or decrease the target activity, or by (directly or indirectly) increasing or decreasing the amount of target present in the cell or organism.

[0032] The term "therapeutically effective amount" or "effective amount" refers to that amount of a compound disclosed and / or described herein that is sufficient to affect treatment, as defined herein, when administered to a patient in need of such treatment. A therapeutically effective amount of a compound may be an amount sufficient to treat a disease responsive to modulation of fast skeletal muscle myosin. The therapeutically effective amount will vary depending upon, for example, the subject and disease condition being treated, the weight and age of the subject, the severity of the disease condition, the particular compound, the dosing regimen to be followed, timing of administration, the manner of administration, all of which can readily be determined by one of ordinary skill in the art. The therapeutically effective amount may be ascertained experimentally, for example by assaying blood concentration of the chemical entity, or theoretically, by calculating bioavailability.

[0033] " Treatment" (and related terms, such as “treat”, “treated”, "treating") includes one or more of: inhibiting a disease or disorder; slowing or arresting the development of clinical symptoms of a disease or disorder; and / or relieving a disease or disorder (i.e., causing relief from or regression of clinical symptoms). The term encompasses situations where the disease or disorder is already being experienced by a patient. The term covers both complete and partial reduction of the condition or disorder, and complete or partial reduction of clinical symptoms of a disease or disorder. Thus, compounds described and / or disclosed herein may prevent an existing disease or disorder from worsening, assist in the management of the disease or disorder, or reduce or eliminate the disease or disorder.13MF-365146518498922021940

[0034] " ATPase" refers to an enzyme that hydrolyzes ATP. ATPases include proteins comprising molecular motors such as the myosins.

[0035] As used herein, “selective binding” or “selectively binding” refers to preferential binding to a target protein in one type of muscle or muscle fiber as opposed to other types. For example, a compound selectively binds to fast skeletal muscle myosin if the compound preferentially binds fast skeletal muscle myosin in comparison with cardiac myosin.Compounds

[0036] Compounds and salts thereof (such as pharmaceutically acceptable salts) are detailed herein, including in the Brief Summary and in the appended claims. Also provided are the use of all of the compounds described herein, including any and all stereoisomers, including geometric isomers (cis / trans), E / Z isomers, enantiomers, diastereomers, and mixtures thereof in any ratio including racemic mixtures, salts and solvates of the compounds described herein, as well as methods of making such compounds. Any compound described herein may also be referred to as a drug.

[0037] In one aspect, provided are compounds of Formula (I):or a pharmaceutically acceptable salt thereof, wherein:Y is -CH2- or -O-;X1, X2, and X3are each independently -N- or -C(RX)-, wherein each Rxis independently selected from the group consisting of H, halogen, and Ci-Ce alkyl, provided that no more than one of X1, X2, and X3is -N-;R1is selected from the group consisting of:5- to 6-membered heteroaryl, wherein the 5- to 6-membered heteroaryl is optionally substituted with 1 to 4 independently selected R1Asubstituents, -C(O)H,-C(O)CH3,14MF-365146518498922021940-C(O)NRaRb, and-Ci-Ce alkyl substituted with 1 to 5 independently selected halogens;each R1Ais independently selected from the group consisting of:-C3-C8 cycloalkyl optionally substituted with 1 to 5 substituents independently selected from the group consisting of SO2Rc, Ci-Ce alkoxy, and Ci-Ce alkyl, wherein the Ci-Ce alkyl is optionally substituted with 1 to 5 substituents independently selected from the group consisting of OH and Ci-Ce alkoxy, -4 to 10 membered heterocycloalkyl optionally substituted with 1 to 5 substituents independently selected from the group consisting of SO2RC, Ci-Ce alkoxy, and Ci-Ce alkyl, wherein the Ci-Ce alkyl is optionally substituted with 1 to 5 substituents independently selected from the group consisting of OH and Ci- Ce alkoxy, and-Ci-Ce alkyl optionally substituted with 1 to 3 substituents independently selected from the group consisting of Ci-Ce alkoxy, halogen, OH, and -C3-C8 cycloalkyl, wherein the -C3-C8 cycloalkyl is optionally substituted with 1 to 5 independently selected Ci-Ce alkyl substituents, wherein the Ci-Ce alkyl is optionally substituted with OH or Ci-Ce alkoxy;each Rais independently selected from the group consisting of H and Ci-Ce alkyl;each Rbis independently selected from the group consisting of Ce-Cio aryl, -C3-C8 cycloalkyl, and Ci-Ce alkyl, wherein the Ci-Ce alkyl is optionally substituted with Ce-Cio aryl; each Rcis independently Ci-Ce alkyl;R2is 5 to 10 membered heteroaryl optionally substituted with 1 to 5 independently selected R2Asubstituents;each R2Ais independently selected from the group consisting of:-Ci-C 10 alkyl optionally substituted with 1 to 5 substituents independently selected from the group consisting of:-OH,-ORn,halogen,15MF-365146518498922021940-N(C1-C6alkyl)C(O)(C1-C6alkyl)-CO2C1-C6 alkyl,-C1-C6 alkoxy optionally substituted with 1 to 5 substituents independently selected from the group consisting of halogen, OH, and Ci-Ce alkoxy, -C3-C8 cycloalkyl optionally substituted with 1 to 5 substituents independently selected from the group consisting of OH, halogen, -Ci-Ce alkyl, and Ci-Ce alkoxy, wherein the Ci-Ce alkyl is optionally substituted with Ci-Ce alkoxy or OH,-4 to 10 membered heterocycloalkyl optionally substituted with 1 to 5 substituents independently selected from the group consisting of OH, halogen, -Ci-Ce alkyl, and Ci-Ce alkoxy, wherein the Ci-Ce alkyl is optionally substituted with Ci-Ce alkoxy or OH, and-Ce-Cio aryl optionally substituted by 1 to 5 substituents independently selected from the group consisting of halogen, OH, Ci-Ce alkoxy, and Ci-Ce alkyl, wherein the Ci-Ce alkyl is optionally substituted with OH or Ci-Ce alkoxy,-C3-C8 cycloalkyl optionally substituted with 1 to 5 substituents independently selected from the group consisting of halogen, OH, SO2-C1-C6 alkyl, -CO2-C1- Ce alkyl, Ci-Ce alkoxy, and Ci-Ce alkyl, wherein the Ci-Ce alkyl is optionally substituted with 1 to 5 substituents independently selected from the group consisting of OH and Ci-Ce alkoxy,-4 to 10 membered heterocycloalkyl optionally substituted with 1 to 5 substituents independently selected from the group consisting of halogen, oxo, -CO2-C1-C6 alkyl, SO2-C1-C6 alkyl, Ci-Ce alkoxy, and Ci-Cs alkyl, wherein the Ci-Cs alkyl is optionally substituted with 1 to 5 substituents independently selected from the group consisting of halogen, Ci-Ce alkoxy, and OH,-Ce-Cio aryl optionally substituted with 1 to 5 substituents independently selected from the group consisting of Ci-Ce alkyl, OH, SO2-C1-C6 alkyl, -CO2-C1-C6 alkyl, Ci-Ce alkoxy, and halogen,-5 to 10 membered heteroaryl optionally substituted with 1 to 5 substituents independently selected from the group consisting of Ci-Ce alkyl, OH, SO2-C1- Ce alkyl, -CO2-C1-C6 alkyl, Ci-Ce alkoxy, and halogen,16MF-365146518498922021940-Ci-Ce alkoxy optionally substituted with 1 to 5 independently selected halogens, -halogen,-SO2Re,-CN,-C(O)NRfRg,-C(O)ORh,-C(O)C1-C6alkyl,-NRiRj,-OH, and-NRkCORm;each Reis independently selected from the group consisting of H and Ci-Ce alkyl; each Rfis independently selected from the group consisting of H and Ci-Ce alkyl;each Rgis independently selected from the group consisting of H and Ci-Ce alkyl; each R11is independently selected from the group consisting of H and Ci-Ce alkyl; each R1is independently selected from the group consisting of H and Ci-Ce alkyl;each Rjis independently selected from the group consisting of H and Ci-Ce alkyl;each Rkis independently selected from the group consisting of H and Ci-Ce alkyl; each Rmis independently selected from the group consisting of H and Ci-Ce alkyl; and each Rnis independently selected from the group consisting of 4 to 10 membered heterocycloalkyl and -Cs-Cs cycloalkyl each of which is optionally substituted with 1 to 5 independently selected halogens;provided that the compound is not N-(5-(5-methyl-l,2,4-oxadiazole-3-yl)-2,3-dihydro-lH-inden- l-yl)pyrazin-2-amine or 3-(3-((5-(trifluoromethyl)-2,3-dihydro- IH-inden- 1-yl)amino)pyrazin-2-yl)- 1,2,4-oxadiazol-5 (2H)-one.

[0038] In some embodiments of Formula (I), or a pharmaceutically acceptable salt thereof, the compound of Formula (I) is a compound of Formula (la):17MF-365146518498922021940R1, / X1, Y,or a pharmaceutically acceptable salt thereof.

[0039] In some embodiments of Formula (I), or a pharmaceutically acceptable salt thereof, the compound of Formula (I) is a compound of Formula (lb):UX2<or a pharmaceutically acceptable salt thereof.

[0040] In some embodiments of Formula (I), or a pharmaceutically acceptable salt thereof, the compound of Formula (I) is a compound of Formula (II):1 Xlnx2.(II),or a pharmaceutically acceptable salt thereof.

[0041] In some embodiments of Formula (II), or a pharmaceutically acceptable salt thereof, the compound of Formula (II) is a compound of Formula (Ila):1 X1uX2<or a pharmaceutically acceptable salt thereof.

[0042] In some embodiments of Formula (II), or a pharmaceutically acceptable salt thereof, the compound of Formula (II) is a compound of Formula (lib):18MF-365146518498922021940RLor a pharmaceutically acceptable salt thereof.

[0043] In some embodiments of Formula (I), or a pharmaceutically acceptable salt thereof, the compound of Formula (I) is a compound of Formula (III):or a pharmaceutically acceptable salt thereof.

[0044] In some embodiments of Formula (III), or a pharmaceutically acceptable salt thereof, the compound of Formula (III) is a compound of Formula (Illa):UX2<(Illa),or a pharmaceutically acceptable salt thereof.

[0045] In some embodiments of Formula (III), or a pharmaceutically acceptable salt thereof, the compound of Formula (III) is a compound of Formula (Illb):Ri xjIIx2.(Illb),or a pharmaceutically acceptable salt thereof.

[0046] In some embodiments of Formula (I), (la), or (lb), or a pharmaceutically acceptable salt thereof, Y is -CH2- or -O-. In some embodiments, Y is -CH2-. In some19MF-365146518498922021940embodiments, Y is-O-.

[0047] In some embodiments of Formula (I), (la), (lb), (II), (Ila), (lib), (III), (Illa), or (Illb), or a pharmaceutically acceptable salt thereof, X1, X2, and X3are each independently -N- or -C(RX)-, wherein each Rxis independently selected from the group consisting of H, halogen, and Ci-Ce alkyl, provided that no more than one of X1, X2, and X3is -N-. In some embodiments, X1, X2, and X3are each independently C(RX)-, wherein each Rxis independently selected from the group consisting of H, halogen, and Ci-Ce alkyl. In some embodiments, X1is N. In some embodiments, X2is N. In some embodiments, X3is N. In some embodiments, each Rxis independently selected from the group consisting of H, halogen, and Ci-Ce alkyl. In some embodiments, each Rxis independently selected from the group consisting of H, chloro, fluoro, bromo, or C1-C2 alkyl. In some embodiments, each Rxis independently selected from the group consisting of H, chloro, fluoro, and methyl. In some embodiments, each Rxis independently selected from the group consisting of H, fluoro, and methyl. In some embodiments, each Rxis H. In some embodiments, one Rxis halo, and the others are H. In some embodiments, one Rxis halo. In some embodiments, X2is C(RX)-, and Rxis methyl. In some embodiments, X2is C(RX)-, and Rxis fluoro. In some embodiments, X3is C(RX)-, and Rxis fluoro. In some embodiments, X1, X2, and X3are each -CH-.

[0048] In some embodiments of Formula (I), (la), (lb), (II), (Ila), (lib), (III), (Illa), or (Illb), or a pharmaceutically acceptable salt thereof, R1is 5- to 6-membered heteroaryl, wherein the 5- to 6-membered heteroaryl is optionally substituted with 1 to 4 independently selected R1Asubstituents. In some embodiments, R1is 5- to 6-membered heteroaryl, wherein the 5- to 6-membered heteroaryl is optionally substituted with 1 to 4 independently selected R1Asubstituents. In some embodiments, R1is 5- to 6-membered heteroaryl, wherein the 5- to 6-membered heteroaryl is optionally substituted with 1 to 2 independently selected R1Asubstituents. In some embodiments, R1is 5-membered heteroaryl, wherein the 5-membered heteroaryl is optionally substituted with 1 to 4 independently selected R1Asubstituents. In some embodiments, R1is 5-membered heteroaryl, wherein the 5-membered heteroaryl is optionally substituted with one R1Asubstituent. In some embodiments, R1is 6-membered heteroaryl, wherein the 6-membered heteroaryl is optionally substituted with 1 to 4 independently selected R1Asubstituents. In some embodiments, R1is 6-membered heteroaryl, wherein the 6-membered heteroaryl is optionally substituted with one R1Asubstituent. In20MF-365146518498922021940some embodiments, R1is selected from the group consisting of oxadiazolyl, thiadiazolyl, oxazolyl, isoxazolyl, thiazolyl, isothiazolyl, pyrazolyl, pyridazinyl, pyrimidinyl, and pyridinyl, each of which is optionally substituted with 1-3 independently selected R1Asubstituents. In some embodiments, R1is oxadiazolyl optionally substituted with one R1Asubstituent. In some embodiments, R1is a 1,2, 4- oxadiazolyl optionally substituted with one R1Asubstituent. In some embodiments, R1is a 1,2,4-oxadiazolyl substituted with one R1Asubstituent. In some embodiments, R1is selected from the group consisting of:Nsubstituted with 1-4 independently selected R1Asubstituents. In some embodiments, R1is Nselected from the group consisting of R1A, andsome embodiments,R1is. In some embodiments, R1is R1A

[0049] In some embodiments of Formula (I), (la), (lb), (II), (Ila), (lib), (III), (Illa), or (Illb), or a pharmaceutically acceptable salt thereof, R1is selected from the group consisting of: -C(O)H, -C(O)CH3, -C(O)NRaRb, and -Ci-Ce alkyl substituted with 1 to 5 independently selected halogens. In some embodiments, R1is -C(O)H. In some embodiments, R1is -C(O)CH3. In some embodiments, R1is -C(O)NRaRb. In some embodiments, R1is -Ci-Ce alkyl substituted with 1 to 5 independently selected halogens. In some embodiments, R1is -C1-C3 alkyl substituted with 1 to 5 independently selected halogens. In some embodiments, R1is -C1-C3 alkyl substituted with 1 to 5 independently selected chloro or fluoro.

[0050] In some embodiments of Formula (I), (la), (lb), (II), (Ila), (lib), (III), (Illa), or (Illb), or a pharmaceutically acceptable salt thereof, R1Ais -C3-C8 cycloalkyl optionally substituted with 1 to 5 substituents independently selected from the group consisting of SO2RC, Ci-Ce alkoxy, and Ci-Ce alkyl, wherein the Ci-Ce alkyl is optionally substituted with21MF-3651465184989220219401 to 5 substituents independently selected from the group consisting of OH and Ci-Ce alkoxy. In some embodiments, R1Ais -C3-C8 cycloalkyl substituted with SO2RC. In some embodiments, R1Ais -C3-C8 cycloalkyl substituted with Ci-Ce alkoxy. In some embodiments, R1Ais -C3-C8 cycloalkyl substituted with C1-C3 alkoxy. In some embodiments, R1Ais -C3-C8 cycloalkyl optionally substituted with Ci-Ce alkyl, wherein the Ci-Ce alkyl is optionally substituted with 1 to 5 substituents independently selected from the group consisting of OH and Ci-Ce alkoxy. In some embodiments, R1Ais -C3-C8 cycloalkyl substituted with Ci-Ce alkyl. In some embodiments, R1Ais -C3-C8 cycloalkyl substituted with Ci-Ce alkyl, wherein the Ci-Ce alkyl is substituted with 1 to 5 substituents independently selected from the groupconsisting of OH and Ci-Ce alkoxy. In some embodiments, R1AisL

[0051] In some embodiments of Formula (I), (la), (lb), (II), (Ila), (lib), (III), (Illa), or (Illb), or a pharmaceutically acceptable salt thereof, R1Ais -4 to 10 membered heterocycloalkyl optionally substituted with 1 to 5 substituents independently selected from the group consisting of SO2RC, Ci-Ce alkoxy, and Ci-Ce alkyl, wherein the Ci-Ce alkyl is optionally substituted with 1 to 5 substituents independently selected from the group consisting of OH and Ci-Ce alkoxy. In some embodiments, R1Ais -4 to 10 membered heterocycloalkyl substituted with 1 to 5 SO2RC. In some embodiments, R1Ais -4 to 10 membered heterocycloalkyl substituted with 1 to 5 Ci-Ce alkoxy. In some embodiments, R1Ais -4 to 10 membered heterocycloalkyl substituted with 1 to 5 Ci-Ce alkyl, wherein the Ci-Ce alkyl is optionally substituted with 1 to 5 substituents independently selected from the group consisting of OH and Ci-Ce alkoxy. In some embodiments, R1Ais -4 to 10 membered heterocycloalkyl substituted with 1 to 5 Ci-Ce alkyl, wherein the Ci-Ce alkyl is substituted with 1 to 2 substituents independently selected from the group consisting of OH and Ci-Ce alkoxy.

[0052] In some embodiments of Formula (I), (la), (lb), (II), (Ila), (lib), (III), (Illa), or (Illb), or a pharmaceutically acceptable salt thereof, each R1Ais -Ci-Ce alkyl optionally substituted with 1 to 3 substituents independently selected from the group consisting of Ci-Ce alkoxy, halogen, OH, and -C3-C8 cycloalkyl, wherein the -C3-C8 cycloalkyl is optionally substituted with 1 to 5 independently selected Ci-Ce alkyl substituents, wherein the Ci-Ce alkyl is optionally substituted with OH or Ci-Ce alkoxy. In some embodiments, each R1Ais -Ci-Ce alkyl optionally substituted with 1 to 3 substituents independently selected from the22MF-365146518498922021940group consisting of C1-C3 alkoxy, chloro, fluoro, bromo, OH, and -C3-C8 cycloalkyl, wherein the -C3-C8 cycloalkyl is optionally substituted with 1 to 5 independently selected Ci-Ce alkyl substituents, wherein the Ci-Ce alkyl is optionally substituted with OH or Ci-Ce alkoxy. In some embodiments, each R1Ais independently unsubstituted -Ci-Ce alkyl. In some embodiments, each R1Ais independently unsubstituted -C1-C3 alkyl. In some embodiments, each R1Ais unsubstituted ethyl. In some embodiments, each R1Ais independently substituted -Ci-Ce alkyl. In some embodiments, each R1Ais independently -Ci-Ce alkyl substituted with Ci-Ce alkoxy. In some embodiments, each R1Ais independently -CH2OMe. In some embodiments, each R1Ais independently -Ci-Ce alkyl substituted with halogen. In some embodiments, each R1Ais -CHF2.

[0053] In some embodiments of Formula (I), (la), (lb), (II), (Ila), (lib), (III), (Illa), or (Illb), or a pharmaceutically acceptable salt thereof, each Rais independently selected from the group consisting of H and Ci-Ce alkyl. In some embodiments, each Rais H. In some embodiments, each Rais Ci-Ce alkyl. In some embodiments, each Rais C1-C3 alkyl. In some embodiments, each Rais ethyl. In some embodiments, each Rais methyl.

[0054] In some embodiments of Formula (I), (la), (lb), (II), (Ila), (lib), (III), (Illa), or (Illb), or a pharmaceutically acceptable salt thereof, each Rbis independently selected from the group consisting of Ce-Cio aryl, -C3-C8 cycloalkyl, and Ci-Ce alkyl, wherein the Ci-Ce alkyl is optionally substituted with Ce-Cio aryl. In some embodiments, each Rbis Ce-Cio aryl. In some embodiments, each Rbis -C3-C8 cycloalkyl. In some embodiments, each Rbis Ci-Ce alkyl. In some embodiments, each Rbis Ci-Ce alkyl wherein the Ci-Ce alkyl is substituted with Ce-Cio aryl. In some embodiments, each Rbis selected from the group consisting of

[0055] In some embodiments of Formula (I), (la), (lb), (II), (Ila), (lib), (III), (Illa), or (Illb), or a pharmaceutically acceptable salt thereof, each Rcis independently Ci-Ce alkyl. In some embodiments, each Rcis independently C1-C3 alkyl. In some embodiments, each Rcis independently ethyl. In some embodiments, each Rcis independently methyl.

[0056] In some embodiments of Formula (I), (la), (lb), (II), (Ila), (lib), (III), (Illa), or (Illb), or a pharmaceutically acceptable salt thereof, R2is 5 to 10 membered heteroaryl23MF-365146518498922021940optionally substituted with 1 to 5 independently selected R2Asubstituents. In some embodiments, R2is 5- to 6-membered heteroaryl optionally substituted with 1 to 4 independently selected R2Asubstituents. In some embodiments, R2is 5-membered heteroaryl optionally substituted with 1 to 3 independently selected R2Asubstituents. In some embodiments, R2is 5-membered heteroaryl substituted with one R2Asubstituent. In some embodiments, R2is 6-membered heteroaryl optionally substituted with 1 to 4 independently selected R2Asubstituents. In some embodiments, R2is 9-membered heteroaryl optionally substituted with 1 to 5 independently selected R2Asubstituents. In some embodiments, R2is selected from the group consisting of 5-membered heteroaryl, pyridinyl, pyridazinyl, pyrimidinyl, and 9- or 10-membered heteroaryl. In some embodiments, R2is selected from the group consisting of oxadiazolyl, thiadiazolyl, oxazolyl, isoxazolyl, thiazolyl, isothiazolyl, pyrazolyl, triazolyl, pyridazinyl, pyrimidinyl, pyridinyl, benzimidazolyl, benzothiazolyl, benzofuranyl, benzothienyl, and benzoxaloyl, each of which is optionally substituted with 1 to 5 independently selected R2Asubstituents. In some embodiments, R2is selected from thegroup consisting ofwherein: n is 0 or 1,p is 0, 1, or 2,q is 0, 1, 2, or 3, andr is 0, 1, 2, 3, or 4.

[0057] In some embodiments of Formula (I), (la), (lb), (II), (Ila), (lib), (III), (Illa), or (Illb), or a pharmaceutically acceptable salt thereof, R2is selected from the group consisting 24MF-3651465184989220219401. In some embodiments,R2is. In some embodiments, R2isIn some embodiments, R2is R2AIn some embodiments, R2is

[0058] In some embodiments of Formula (I), (la), (lb), (II), (Ila), (lib), (III), (Illa), or (Illb), or a pharmaceutically acceptable salt thereof, each R2Ais -Ci-Cio alkyl optionally substituted with 1 to 5 substituents independently selected from the group consisting of: -OH, -ORn, halogen, -N(Ci-Ce alkyl)C(O)(Ci-C6 alkyl), -CO2C1-C6 alkyl, -Ci-Ce alkoxy optionally substituted with 1 to 5 substituents independently selected from the group consisting of halogen, OH, and Ci-Ce alkoxy, -C3-C8 cycloalkyl optionally substituted with 1 to 5 substituents independently selected from the group consisting of OH, halogen, -Ci-Ce alkyl, and Ci-Ce alkoxy, wherein the Ci-Ce alkyl is optionally substituted with Ci-Ce alkoxy or OH, -4 to 10 membered heterocycloalkyl optionally substituted with 1 to 5 substituents independently selected from the group consisting of OH, halogen, -Ci-Ce alkyl, and Ci-Ce alkoxy, wherein the Ci-Ce alkyl is optionally substituted with Ci-Ce alkoxy or OH, and -Ce-C10 aryl optionally substituted by 1 to 5 substituents independently selected from the group25MF-365146518498922021940consisting of halogen, OH, Ci-Ce alkoxy, and Ci-Ce alkyl, wherein the Ci-Ce alkyl is optionally substituted with OH or Ci-Ce alkoxy. In some embodiments, each R2Ais unsubstituted -C1-C10 alkyl. In some embodiments, each R2Ais unsubstituted -C1-C3 alkyl. In some embodiments, each R2Ais: -C1-C10 alkyl substituted with 1 to 5 substituents independently selected from the group consisting of: -OH, -ORn, halogen, -Ci-Ce alkoxy optionally substituted with 1 to 5 substituents independently selected from the group consisting of halogen, OH, and Ci-Ce alkoxy, -C3-C8 cycloalkyl optionally substituted with 1 to 5 substituents independently selected from the group consisting of OH, halogen, -Ci-Ce alkyl, and Ci-Ce alkoxy, wherein the Ci-Ce alkyl is optionally substituted with Ci-Ce alkoxy or OH, and -4 to 10 membered heterocycloalkyl optionally substituted with 1 to 5 substituents independently selected from the group consisting of OH, halogen, -Ci-Ce alkyl, and Ci-Ce alkoxy, wherein the Ci-Ce alkyl is optionally substituted with Ci-Ce alkoxy or OH. In some embodiments, each R2Ais -C1-C10 alkyl substituted with one to five -OH. In some embodiments, each R2Ais -C1-C10 alkyl substituted with -OR11. In some embodiments, each R2Ais substituted with one to three independently selected chloro, fluoro, or bromo. In some embodiments, R2Ais -C1-C10 alkyl substituted with -CO2C1-C6 alkyl. In some embodiments, each R2Ais -C1-C10 alkyl substituted with -CO2CH3. In some embodiments, each R2Ais -Ci-C10 alkyl substituted with one to five -Ci-Ce alkoxy optionally substituted with 1 to 5 substituents independently selected from the group consisting of halogen, OH, and Ci-Ce alkoxy. In some embodiments, each R2Ais -C1-C10 alkyl substituted with 1 to 3 -Ci-Ce alkoxy substituents, wherein each -Ci-Ce alkoxy is optionally substituted with 1 to 3 substituents independently selected from the group consisting of halogen, OH, and Ci-Ce alkoxy. In some embodiments, each R2Ais -C1-C3 alkyl substituted with one -C1-C3 alkoxy substituent. In some embodiments, each R2Ais -C1-C10 alkyl substituted with -C3-C8 cycloalkyl optionally substituted with 1 to 5 substituents independently selected from the group consisting of OH, halogen, -Ci-Ce alkyl, and Ci-Ce alkoxy, wherein the Ci-Ce alkyl is optionally substituted with Ci-Ce alkoxy or OH. In some embodiments, each R2Ais -C1-C10 alkyl substituted with -4 to 10 membered heterocycloalkyl optionally substituted with 1 to 5 substituents independently selected from the group consisting of OH, halogen, -Ci-Ce alkyl, and Ci-Ce alkoxy, wherein the Ci-Ce alkyl is optionally substituted with Ci-Ce alkoxy or OH. In some embodiments, each R2Ais -C1-C3 alkyl substituted with one 4 to 10 membered heterocycloalkyl, wherein the 4 to 10 membered heterocycloalkyl is optionally substituted26MF-365146518498922021940with 1 to 3 substituents independently selected from the group consisting of OH, halogen, - Ci-Ce alkyl, and Ci-Ce alkoxy, wherein the Ci-Ce alkyl is optionally substituted with Ci-Ce alkoxy or OH. In some embodiments, each R2Ais -C1-C3 alkyl substituted with one unsubstituted 4 to 6 membered heterocycloalkyl. In some embodiments, each R2Ais -C1-C3 alkyl substituted with one unsubstituted 4 to 6 membered heterocycloalkyl selected from theembodiments, each R2Ais -Ci alkyl substituted with one unsubstituted oxetane. In some embodiments, each R2Ais -C1-C10 alkyl substituted with -Ce-Cio aryl optionally substituted by 1 to 5 substituents independently selected from the group consisting of halogen, OH, Ci- Ce alkoxy, and Ci-Ce alkyl, wherein the Ci-Ce alkyl is optionally substituted with OH or Ci- Ce alkoxy. In some embodiments, R2Ais independently selected from the group consisting of OHmethyl, ethyl, propyl, -CHF2, -CF3,OH. In some embodiments, R2Ais methyl. In some embodiments, R2Ais -CF3.In some embodiments, R2Ais. In some embodiments, R2Ais27MF-365146518498922021940

[0059] In some embodiments of Formula (I), (la), (lb), (II), (Ila), (lib), (III), (Illa), or (Illb), or a pharmaceutically acceptable salt thereof, each R2Ais -C3-C8 cycloalkyl optionally substituted with 1 to 5 substituents independently selected from the group consisting of halogen, OH, SO2-C1-C6 alkyl, -CO2-C1-C6 alkyl, Ci-Ce alkoxy, and Ci-Ce alkyl, wherein the Ci-Ce alkyl is optionally substituted with 1 to 5 substituents independently selected from the group consisting of OH and Ci-Ce alkoxy. In some embodiments, each R2Ais unsubstituted -C3-C8 cycloalkyl. In some embodiments, each R2Ais -C3-C8 cycloalkyl substituted with 1 to 5 substituents independently selected from the group consisting of halogen, OH, SO2-C1-C6 alkyl, -CO2-C1-C6 alkyl, Ci-Ce alkoxy, and Ci-Ce alkyl, wherein the Ci-Ce alkyl is optionally substituted with 1 to 5 substituents independently selected from the group consisting of OH and Ci-Ce alkoxy. In some embodiments, each R2Ais -C3-C8 cycloalkyl independently substituted with 1 to 5 chloro, fluoro, and bromo. In some embodiments, each R2Ais -C3-C8 cycloalkyl independently substituted with 1 to 5 -OH. In some embodiments, each R2Ais -C3-C8 cycloalkyl independently substituted with SO2-CH3. In some embodiments, each R2Ais -C3-C8 cycloalkyl independently substituted with -CO2-C1-C6 alkyl. In some embodiments, each R2Ais -C3-C8 cycloalkyl independently substituted with C1-C3 alkoxy. In some embodiments, each R2Ais -C3-C8 cycloalkyl independently substituted with methoxy. In some embodiments, each R2Ais -C3-C8 cycloalkyl independently substituted with unsubstituted Ci-Ce alkyl. In some embodiments, each R2Ais -C3-C8 cycloalkyl independently substituted with Ci-Ce alkyl, wherein the Ci-Ce alkyl is substituted with 1 to 5 substituents independently selected from the group consisting of OH and methoxy. In some embodiments, R2Aisselected from the group consisting ofeach of which is optionally substituted with 1 to 5 substituents independently selected from the group consisting of halogen, OH, SO2-C1-C6 alkyl, -CO2-C1-C6 alkyl, Ci-Ce alkoxy, and Ci-Ce alkyl, wherein the Ci-Ce alkyl is optionally substituted with 1 to 5 substituents independently selected from the group consisting of OH and Ci-Ce alkoxy. In someHOembodiments, R2Ais independently selected from the group consisting of28MF-365146518498922021940. In some embodiments, R2Ais. In someoOHembodiments, R2Ais. In some embodiments, R2Ais. In someembodiments, R2Ais. In some embodiments, R2Ais

[0060] In some embodiments of Formula (I), (la), (lb), (II), (Ila), (lib), (III), (Illa), or (Illb), or a pharmaceutically acceptable salt thereof, each R2Ais -4 to 10 membered heterocycloalkyl optionally substituted with 1 to 5 substituents independently selected from the group consisting of halogen, oxo, -CO2-C1-C6 alkyl, SO2-C1-C6 alkyl, Ci-Ce alkoxy, and Ci-Cs alkyl, wherein the Ci-Cs alkyl is optionally substituted with 1 to 5 substituents independently selected from the group consisting of halogen, Ci-Ce alkoxy, and OH. In some embodiments, each R2Ais unsubstituted -4 to 10 membered heterocycloalkyl. In some embodiments, each R2Ais -4 to 10 membered heterocycloalkyl substituted with 1 to 3 substituents independently selected from the group consisting of halogen, oxo, -CO2-C1-C6 alkyl, SO2-C1-C6 alkyl, Ci-Ce alkoxy, and Ci-Cs alkyl, wherein the Ci-Cs alkyl is optionally substituted with 1 to 5 substituents independently selected from the group consisting of halogen, Ci-Ce alkoxy, and OH. In some embodiments, each R2Ais unsubstituted -4 to 6 membered heterocycloalkyl. In some embodiments, each R2Ais a 4 to 6 membered heterocycloalkyl optionally substituted with 1 to 5 substituents independently selected from the group consisting of halogen, oxo, -CO2-C1-C6 alkyl, SO2-C1-C6 alkyl, Ci-Ce alkoxy, and Ci-Cs alkyl, wherein the Ci-Cs alkyl is optionally substituted with 1 to 5 substituents independently selected from the group consisting of halogen, Ci-Ce alkoxy, and OH. In some embodiments, each R2Ais -4 to 10 membered heterocycloalkyl substituted with 1 to 3 chloro,29MF-365146518498922021940fluoro, or bromo. In some embodiments, each R2Ais -4 to 10 membered heterocyclo alkyl substituted with one to two oxo. In some embodiments, each R2Ais -4 to 10 membered heterocycloalkyl substituted with -CO2-CH3. In some embodiments, each R2Ais -4 to 10 membered heterocycloalkyl substituted with SO2-CH3. In some embodiments, each R2Ais -4 to 10 membered heterocycloalkyl substituted with C1-C3 alkoxy. In some embodiments, each R2Ais -4 to 10 membered heterocycloalkyl substituted with methoxy. In some embodiments, each R2Ais -4 to 10 membered heterocycloalkyl substituted with unsubstituted C1-C3 alkyl. In some embodiments, each R2Ais -4 to 10 membered heterocycloalkyl substituted with methyl. In some embodiments, each R2Ais -4 to 10 membered heterocyclo alkyl substituted with Ci-C3 alkyl, wherein the C1-C3 alkyl is substituted with 1 to 5 substituents independently selected from the group consisting of halogen, Ci-Ce alkoxy, and OH. In some embodiments,R2Ais selected from the group consisting ofH each of which is optionally substituted with 1 to 5 substituents independently selected from the group consisting of halogen, oxo, -CO2-C1-C6 alkyl, SO2-C1-C6 alkyl, Ci-Ce alkoxy, and Ci-Cs alkyl, wherein the Ci-Cs alkyl is optionally substituted with 1 to 5 substituents independently selected from the group consisting of halogen, Ci-Ce alkoxy, and OH. In some embodiments, R2Aistetrahydrofuran. In some embodiments, R2Ais. In some embodiments, R2Ais.0. In some embodiments, R2Ais. In some embodiments, R2Ais. In some embodiments, R2Ais. In some embodiments, R2Ais30MF-365146518498922021940. In some embodiments, R2Ais. In some embodiments, R2Ais

[0061] In some embodiments of Formula (I), (la), (lb), (II), (Ila), (lib), (III), (Illa), or (Illb), or a pharmaceutically acceptable salt thereof, each R2Ais -Ce-Cio aryl optionally substituted with 1 to 5 substituents independently selected from the group consisting of Ci-Ce alkyl, OH, SO2-C1-C6 alkyl, -CO2-C1-C6 alkyl, Ci-Ce alkoxy, and halogen. In some embodiments, each R2Ais unsubstituted -Ce-Cio aryl. In some embodiments, each R2Ais -Ce-C10 aryl substituted with 1 to 5 substituents independently selected from the group consisting of Ci-Ce alkyl, OH, SO2-C1-C6 alkyl, -CO2-C1-C6 alkyl, Ci-Ce alkoxy, and halogen. In some embodiments, each R2Ais -Ce-Cio aryl substituted with Ci-Ce alkyl. In some embodiments, each R2Ais phenyl substituted with methyl. In some embodiments, each R2Ais -Ce-Cio aryl substituted with one to two OH. In some embodiments, each R2Ais -Ce-Cio aryl substituted with SO2-CH3. In some embodiments, each R2Ais -Ce-Cio aryl substituted with -CO2-CH3. In some embodiments, each R2Ais -Ce-Cio aryl substituted with Ci-Ce alkoxy. In some embodiments, each R2Ais -Ce-Cio aryl substituted with methoxy. In some embodiments, each R2Ais -Ce-Cio aryl substituted with 1 to 5 chloro, fluoro, or bromo. In some embodiments, each R2Ais phenyl substituted with 1 chloro. In some embodiments, R2Ais selected from the

[0062] In some embodiments of Formula (I), (la), (lb), (II), (Ila), (lib), (III), (Illa), or (Illb), or a pharmaceutically acceptable salt thereof, each R2Ais -5 to 10 membered heteroaryl optionally substituted with 1 to 5 substituents independently selected from the group consisting of Ci-Ce alkyl, OH, SO2-C1-C6 alkyl, -CO2-C1-C6 alkyl, Ci-Ce alkoxy, and halogen. In some embodiments, R2Ais unsubstituted -5 to 10 membered heteroaryl. In some embodiments, R2Ais -5 to 10 membered heteroaryl substituted with 1 to 5 substituents31MF-365146518498922021940independently selected from the group consisting of Ci-Ce alkyl, OH, SO2-C1-C6 alkyl, -CO2-Ci-Ce alkyl, Ci-Ce alkoxy, and halogen. In some embodiments, R2Ais -5 to 10 membered heteroaryl substituted with Ci-Ce alkyl. In some embodiments, R2Ais -5 to 10 membered heteroaryl substituted with methyl. In some embodiments, R2Ais -5 to 10 membered heteroaryl substituted with OH. In some embodiments, R2Ais -5 to 10 membered heteroaryl substituted with SO2-CH3. In some embodiments, R2Ais -5 to 10 membered heteroaryl substituted with -CO2-C1-C6 alkyl. In some embodiments, R2Ais -5 to 10 membered heteroaryl substituted with Ci-Ce alkoxy. In some embodiments, R2Ais -5 to 10 membered heteroaryl substituted with methoxy. In some embodiments, R2Ais -5 to 10 membered heteroaryl substituted with chloro, fluoro, or bromo.

[0063] In some embodiments of Formula (I), (la), (lb), (II), (Ila), (lib), (III), (Illa), or (Illb), or a pharmaceutically acceptable salt thereof, each R2Ais independently selected from the group consisting of: -Ci-Ce alkoxy optionally substituted with 1 to 5 independently selected halogens, -halogen, -SO2Re, -CN, -C(O)ORh, -C(O)Ci-Ce alkyl, -NRiRj, -OH, and -NRkCORm. In some embodiments, each R2Ais unsubstituted -Ci-Ce alkoxy. In some embodiments, each R2Ais unsubstituted methoxy. In some embodiments, each R2Ais -Ci-Ce alkoxy substituted with 1 to 5 independently selected chloro, fluoro, and bromo. In some embodiments, each R2Ais -Ci-Ce alkoxy substituted with 1 to 3 fluoro. In some embodiments, each R2Ais a halogen. In some embodiments, each R2Ais chloro, fluoro, or bromo. In some embodiments, each R2Ais -SO2Re. In some embodiments, each R2Ais -SO2CH3. In some embodiments, each R2Ais -CN. In some embodiments, each R2Ais -C(O)NRfRg. In some embodiments, each R2Ais -C(O)ORh. In some embodiments, each R2Ais -C(O)OCH3. In some embodiments, each R2Ais -C(O)Ci-Ce alkyl. In some embodiments, each R2Ais -C(O)Ci-C3 alkyl. In some embodiments, each R2Ais -NRiRj. In some embodiments, each R2Ais -OH. In some embodiments, each R2Ais -NRkCORm.

[0064] In some embodiments of Formula (I), (la), (lb), (II), (Ila), (lib), (III), (Illa), or (Illb), or a pharmaceutically acceptable salt thereof, each Reis independently selected from the group consisting of H and Ci-Ce alkyl. In some embodiments, each Reis H. In some embodiments, each Reis Ci-Ce alkyl. In some embodiments, each Reis C1-C3 alkyl. In some embodiments, each Reis propyl. In some embodiments, each Reis ethyl. In some embodiments, each Reis methyl.32MF-365146518498922021940

[0065] In some embodiments of Formula (I), (la), (lb), (II), (Ila), (lib), (III), (Illa), or (Illb), or a pharmaceutically acceptable salt thereof, each Rfis independently selected from the group consisting of H and Ci-Ce alkyl. In some embodiments, each Rfis H. In some embodiments, each Rfis Ci-Ce alkyl. In some embodiments, each Rfis C1-C3 alkyl. In some embodiments, each Rfis propyl. In some embodiments, each Rfis ethyl. In some embodiments, each Rfis methyl.

[0066] In some embodiments of Formula (I), (la), (lb), (II), (Ila), (lib), (III), (Illa), or (Illb), or a pharmaceutically acceptable salt thereof, each Rgis independently selected from the group consisting of H and Ci-Ce alkyl. In some embodiments, each Rgis H. In some embodiments, each Rgis Ci-Ce alkyl. In some embodiments, each Rgis C1-C3 alkyl. In some embodiments, each Rgis propyl. In some embodiments, each Rgis ethyl. In some embodiments, each Rgis methyl.

[0067] In some embodiments of Formula (I), (la), (lb), (II), (Ila), (lib), (III), (Illa), or (Illb), or a pharmaceutically acceptable salt thereof, each Rhis independently selected from the group consisting of H and C1-C6alkyl. In some embodiments, each Rhis H. In some embodiments, each Rhis Ci-Ce alkyl. In some embodiments, each Rhis C1-C3 alkyl. In some embodiments, each Rhis propyl. In some embodiments, each Rhis ethyl. In some embodiments, each Rhis methyl.

[0068] In some embodiments of Formula (I), (la), (lb), (II), (Ila), (lib), (III), (Illa), or (Illb), or a pharmaceutically acceptable salt thereof, each Riis independently selected from the group consisting of H and C1-C6alkyl. In some embodiments, each Riis H. In some embodiments, each Riis C1-C6alkyl. In some embodiments, each Riis C1-C3alkyl. In some embodiments, each Riis propyl. In some embodiments, each Riis ethyl. In some embodiments, each Riis methyl.

[0069] In some embodiments of Formula (I), (la), (lb), (II), (Ila), (lib), (III), (Illa), or (Illb), or a pharmaceutically acceptable salt thereof, each Rjis independently selected from the group consisting of H and Ci-Ce alkyl. In some embodiments, each Rjis H. In some embodiments, each Rjis Ci-Ce alkyl. In some embodiments, each Rjis C1-C3 alkyl. In some embodiments, each Rjis propyl. In some embodiments, each Rjis ethyl. In some embodiments, each R1is methyl.33MF-365146518498922021940

[0070] In some embodiments of Formula (I), (la), (lb), (II), (Ila), (lib), (III), (Illa), or (Illb), or a pharmaceutically acceptable salt thereof, each Rkis independently selected from the group consisting of H and Ci-Ce alkyl. In some embodiments, each Rkis H. In some embodiments, each Rkis Ci-Ce alkyl. In some embodiments, each Rkis C1-C3 alkyl. In some embodiments, each Rkis propyl. In some embodiments, each Rkis ethyl. In some embodiments, each Rkis methyl.

[0071] In some embodiments of Formula (I), (la), (lb), (II), (Ila), (lib), (III), (Illa), or (Illb), or a pharmaceutically acceptable salt thereof, each Rmis independently selected from the group consisting of H and Ci-Ce alkyl. In some embodiments, each Rmis H. In some embodiments, each Rmis Ci-Ce alkyl. In some embodiments, each Rmis C1-C3 alkyl. In some embodiments, each Rmis propyl. In some embodiments, each Rmis ethyl. In some embodiments, each Rmis methyl.

[0072] In some embodiments of Formula (I), (la), (lb), (II), (Ila), (lib), (III), (Illa), or (Illb), or a pharmaceutically acceptable salt thereof, each Rnis independently selected from the group consisting of 4 to 10 membered heterocycloalkyl and -C3-C8 cycloalkyl each of which is optionally substituted with 1 to 5 independently selected halogens. In some embodiments, each Rnis 4 to 10 membered heterocycloalkyl optionally substituted with 1 to 5 independently selected chloro, fluoro, and bromo. In some embodiments, each Rnis -C3-C8 cycloalkyl optionally substituted with 1 to 5 independently selected chloro, fluoro, and bromo.

[0073] In some embodiments of Formula (I), (la), (lb), (II), (Ila), (lib), (III), (Illa), or (Illb) or a pharmaceutically acceptable salt thereof, R1and R1Aare taken together to form amotif selected from the group consisting of:34MF-365146518498922021940

[0074] In some embodiments of Formula (I), (la), (lb), (II), (Ila), (lib), (III), (Illa), or (Illb) or a pharmaceutically acceptable salt thereof, R2and R2Aare taken together to form a motif selected from the group consisting of:35MF-365146518498922021940thereof.thereof.

[0079] In some embodiments, the compound is not N-(5-(5-methyl-l,2,4-oxadiazole-3-yl)-2,3-dihydro- IH-inden- l-yl)pyrazin-2-amine or 3-(3-((5-(trifluoromethyl)-2,3-dihydro- lH-inden-l-yl)amino)pyrazin-2-yl)-l,2,4-oxadiazol-5(2H)-one. In some embodiments, the36MF-365146518498922021940compound is not N-(5-(5-methyl-l,2,4-oxadiazole-3-yl)-2,3-dihydro-lH-inden-l-yl)pyrazin-2-amine. In some embodiments, the compound is not 3-(3-((5-(trifluoromethyl)-2,3-dihydro-IH-inden- 1 -yl)amino)pyrazin-2-yl)- 1,2,4-oxadiazol-5 (2H)-one.

[0080] In some embodiments, provided herein are compounds and pharmaceutically acceptable salts thereof described in Table 1.Table 1Co. Structure Name#(R)-N-(5-(5-ethyl- 1,2,4-oxadiazol-3-yl)- 2,3-dihydro- IH-inden- l-yl)-5- methylbenzo [d] oxazol 1 N-0 -2-amine(R)-N-(5- (difluoromethyl) -2, 3 - roio)- nhdihydro- 1 H-inden- 1 - yl)-5- methylbenzo [d] oxazol 2 F -2-amine(R)-N-(5-(5-ethyl- 1,2,4-oxadiazol-3-yl)- 2,3-dihydro- IH-inden- l-yl)-5- isopropylbenzo [d] oxaz 3 N— O ol-2-amine0—._? N [( )] (R)-N-(5-(5-ethyl- 1,2,4-oxadiazol-3-yl)- 2,3-dihydro- IH-inden- 1 -yl)-4-phenyloxazol- 4 2-amine(R)-l-((5- o ovnhmethylbenzo [d] oxazol -2-yl)amino)-N- phenyl-2,3-dihydro- lH-indene-5-5 carboxamide37MF-365146518498922021940(S)-N-(6-(5- (methoxymethyl) - 1,2,4-oxadiazol-3-yl)- 2,3-NHdihydrobenzofuran-3 - yl)-5- O'' methylbenzo [d] oxazol 6 N-0 -2-amine(R)-5-bromo-N-(5-(5- methyl- 1,2,4- J^IP>— NH— ^"" N > ZZ'XA oxadiazol-3-yl)-2,3- dihydro- 1 H-inden- 1 - V^ \ y yl)benzo [d] oxazol-2- 7 N-O amine(R)-5-methoxy-N- (5 -. JOPXH / ■> (5-methyl- 1,2,4- oxadiazol-3-yl)-2,3- dihydro- 1 H-inden- 1 - °Nyl)benzo [d] oxazol-2- 8 N-0 amine(R)-5-chloro-N-(5-(5- methyl- 1,2,4- f^lO>— NHC|Zx — ^"" N \ — (v M oxadiazol-3-yl)-2,3- dihydro- 1 H-inden- 1 - V^ \ y yl)benzo [d] oxazol-2- 9 N-O amineN F r- HN^F^ (R)-2-(2,2- difluoropropoxy)-N - (5-(5-methyl- 1,2,4- oxadiazol-3-yl)-2,3- dihydro- 1 H-inden- 1 - 10 ^O? N yl)pyrimidin-5 - amine _ O^N(R)-N-(5- (5-methyl- 1,2,4-oxadiazol-3-yl)- 2,3-dihydro- IH-inden- l-yl)-5- "N1X (trifluoromethyl)pyrim11 F idin-2-amine38MF-3651465184989220219400(R)-N-(5- (5-methoxy- 1,2,4-oxadiazol-3-yl)- 2,3-dihydro- IH-inden- l-yl)-5- (trifluoromethyl)pyrim 12 F idin-2-amine N^N(S)-N-(6-(5-methyl- l,3,4-oxadiazol-2-yl)- 2,3- dihydrobenzofuran-3 - yl)-5- (trifluoromethyl)pyrim 13 F idin-2-amine„.-O ^F(R)-N-(5- (5-methyl- l,3,4-oxadiazol-2-yl)- 2,3-dihydro- IH-inden- o JO-y l-yl)-5- (trifluoromethyl)pyrim 14 I^N idin-2-amine„.-O ^.. ■'F(R)-N-(5-(3-methyl- l,2,4-oxadiazol-5-yl)-N2,3-dihydro- IH-inden- JULy l-yl)-5- (trifluoromethyl)pyrim 15 ^r° idin-2-amine ^°\ / ^N(R)-5-chloro-N-(5-(5- methoxy- 1,2,4- oxadiazol-3-yl)-2,3- dihydro- 1 H-inden- 1 -16HN-< QK yl)pyrimidin-2-amine39MF-3651465184989220219400(R)-N-(5- (5-methoxy- 1,2,4-oxadiazol-3-yl)- 2,3-dihydro- IH-inden-HN^^)N\ / Fl-yl)-5- (trifluoromethyl)pyraz 17 F in-2-amine(R)-N-(5-(5- (methoxymethyl) -..? hr l,3,4-oxadiazol-2-yl)- 2,3-dihydro- IH-inden- l-yl)-5- (trifluoromethyl)pyrim 18 idin-2-amine(R)-N-(5-(3- (methoxymethyl) -..? l,2,4-oxadiazol-5-yl)- 2,3-dihydro- IH-inden- l-yl)-5- (trifluoromethyl)pyrim 19 ^o / U idin-2-amine™-©n..? (R)-5-methoxy-N- (5 - (5-methyl- 1,2,4- oxadiazol-3-yl)-2,3- dihydro- 1 H-inden- 1 - 20 yl)pyrimidin-2-amine 0rP -t (R)-N-(5- (5-methyl- 1,2,4-oxadiazol-3-yl)- NJ^CX) 2,3-dihydro- IH-inden- l-yl)-5- (methylsulfonyl)pyrim21 O'Nidin-2-amine40MF-365146518498922021940HN^\k-J / .. ■'N(R)-5-methyl-N- (5- (5 - methyl- 1,2, 4- NyXX) oxadiazol-3-yl)-2,3- dihydro- 1 H-inden- 1 - 22 yl)pyrimidin-2-amine (S)-N-(6-(5-ethyl- 1,3,4-oxadiazol-2-yl)- 2,3- dihydrobenzofuran-3- yl)-5- (trifluoromethyl)pyrim 23 idin-2-amine™< HF(R)-N-(5-(3-ethyl- l,2,4-oxadiazol-5-yl)- 2,3-dihydro- IH-inden- »_ xx > 1-yl)-5- (trifluoromethyl)pyrim 24 idin-2-amine(R)-N-(5-(5-ethyl-..? N""7l,3,4-oxadiazol-2-yl)- 2,3-dihydro- IH-inden- / . JOO 1-yl)-5- (trifluoromethyl)pyrim 25 idin-2-amine— 0 yO^N(R)-5-methoxy-N- (5 -NAW (5-methoxymethyl- 1,2,4-oxadiazol-3-yl)- 2,3-dihydro- IH-inden- l-yl)pyrimidin-2-26 “-O - / amine41MF-3651465184989220219400(R)-N-(5-(5- (methoxymethyl) - 1,2,4-oxadiazol-3-yl)- 2,3-dihydro- IH-inden-HN^A\ F 1-yl)-6- (trifluoromethyl)pyrid 27 azin-3-amine(R)-N-(5-(5-N^xrrjV°\ (methoxymethyl) - 1,2,4-oxadiazol-3-yl)-HN2,3-dihydro- IH-inden- ^A\ F 1-yl)-5- (trifluoromethyl)pyridi 28 n-2-amine(R)-N-(5-(5-NAW methoxymethyl- 1,2,4- oxadiazol-3-yl)-2,3- dihydro- 1 H-inden- 1 - yl)-5-HN^ t (methylsulfonyl)pyrim 29 0 idin-2-amineFF (R)-N-(5-(5-(methyl)-.. ''N~N1,2,4-oxadiazol-3-yl)- 2,3-dihydro- IH-inden- 1-yl)-6- (trifluoromethyl)pyrid 30 azin-3-amine(S)-N-(6-(3-ethyl- l,2,4-oxadiazol-5-yl)- 2,3- dihydrobenzofuran-3 - yl)-5-HN1QU (trifluoromethyl)pyrim31 F idin-2-amine42MF-365146518498922021940— 0 N^O (S)-N-(6-(3- (methoxymethyl) - l,2,4-oxadiazol-5-yl)- 2,3- dihydrobenzofuran-3 - yl)-5- ““dOU (trifluoromethyl)pyrim 32 F idin-2-amine(R)-N-(5- (5-methyl-.. ■'N1,2,4-oxadiazol-3-yl)- 2,3-dihydro- IH-inden- 1-yl)-5- (trifluoromethyl)pyrim 33 idin-2-amine(R)-N-(5-(5- ™43r9 methoxymethyl- 1,2,4-.. ''Noxadiazol-3-yl)-2,3- dihydro- 1 H-inden- 1 - yl)-5- (trifluoromethyl)pyrim 34 idin-2-amine(R)-N-(5-(difluoromethyl)-2,3- dihydro-1H-inden-1- yl)-5- (trifluoromethyl)pyrim 35 idin-2-amine— o / 9^N(S)-5- (difluoromethyl)-N - (6- (5 - (methoxymethyl) - 1,2,4-oxadiazol-3-yl)- 2,3- dihydrobenzofuran-3 -36 F yl)pyrimidin-2-amine43MF-365146518498922021940(S)-2-((6-(5- (methoxymethyl) - 1,2,4-oxadiazol-3-yl)- 2,3- dihydrobenzofuran-3 - yl)amino)pyrimidine- 37 N^Z 5-carbonitrile / p°NAW (S)-5-methyl-N-(6-(3- methyl- 1,2,4- oxadiazol-5-yl)-2,3- dihydrobenzofuran-3 - 38 N^Z yl)pyrimidin-2-amine MoK0(S)-N-(6-(3-ethyl- l,2,4-oxadiazol-5-yl)- oO 2,3- V dihydrobenzofuran-3 - yl)-5- methylpyrimidin-2- 39 "Nl<3- amine(S)-N-(6-(3- 0 / z^p (methoxymethyl) - l,2,4-oxadiazol-5-yl)-NAW 2,3- V dihydrobenzofuran-3 - yl)-5-HNp? yV methylpyrimidin-2- 40 N^Z amine / pp(S)-N-(6-(3-methyl- l,2,4-oxadiazol-5-yl)- 2,3- dihydrobenzofuran-3 - yl)-5- (trifluoromethyl)pyrim 41 "N1QU F idin-2-amineOH1-(2-(((R)-5-(5- methyl-1,2,4- oxadiazol-3-yl)-2,3- dihydro-1H-inden-1- yl)amino)pyrimidin-5-42 yl)ethan-1-ol44MF-365146518498922021940(R)-2-((5-(5-methyl-..? 1,2,4-oxadiazol-3-yl)- 2,3-dihydro- IH-inden- 1- yl)amino)pyrimidine- 43 5-carboxylate\ / ^" N F 3-(ethoxymethyl)-N- [(1R)-5-(5-ethyl-1,3,4- oxadiazol-2-yl)-4- fluoro-2,3-dihydro-1H-inden-1-yl]-1,2,4- oxadiazol-5-amine 44N^N(S)-3-fluoro-N-(6-(5- methyl- 1,3,4- F oxadiazol-2-yl)-2,3- dihydrobenzofuran-3 - yl)-5- (trifluoromethyl)pyridi 45 n-2-amine(S)-N-(6-(5-ethyl- l,3,4-oxadiazol-2-yl)- ° igQf2,3- dihydrobenzofuran-3 -HN^( 5\ / yl)-3-fluoro-5- NV TF (trifluoromethyl)pyridi 46 F n-2-amine— 0 N^N (S)-3-fluoro-N-(6-(5- (methoxymethyl) - (r VY°\ l,3,4-oxadiazol-2-yl)- K JJL?F2,3- dihydrobenzofuran-3 -HN^ \Fyi)-5- N^ X^F (trifluoromethyl)pyridi47 F n-2-amine45MF-365146518498922021940HN^xW / x(R)-2-(2-((5-(5-..? Nmethyl- 1,2,4- oxadiazol-3-yl)-2,3- dihydro- 1 H-inden- 1 - yl)amino)pyrimidin-5- 48 yl)propan-2-ol N^N(S)-5- (difluoromethyl)-N - (6- (5-methyl- 1,3,4- oxadiazol-2-yl)-2,3- dihydrobenzofuran-3 - 49 F yl)pyrimidin-2-amine(S)-5- (difluoromethyl)-N - (6- (5-ethyl- 1,3,4- oxadiazol-2-yl)-2,3- dihydrobenzofuran-3 - 50m^ FFyl)pyrimidin-2-amine -°x / ^N(S)-5- (difluoromethyl)-N - (6- (5 - (methoxymethyl) - l,3,4-oxadiazol-2-yl)- 2,3- dihydrobenzofuran-3 - 51 F yl)pyrimidin-2-amine F HN^kJ / F (R)-N-phenethyl- 1 -? hr ((5- (trifluoromethyl)pyrim JOO idin-2-yl)amino)-2,3- dihydro- lH-indene-5-52 carboxamide46MF-365146518498922021940(S)-5-ethyl-N-(6-(5- (methoxymethyl) - 1,2,4-oxadiazol-3-yl)- 2,3- dihydrobenzofuran-3 - 53 yl)pyrimidin-2-amine —o / 9^NN" |^V0\ (S)-5-isopropyl-N-(6- (5 - (methoxymethyl) - 1,2,4-oxadiazol-3-yl)- 2,3- dihydrobenzofuran-3 - 54 yl)pyrimidin-2-amine (S)-5-cyclopropyl-N- ~°M<Qw (6-(5- (methoxymethyl) - oO 1,2,4-oxadiazol-3-yl)- 2,3- dihydrobenzofuran-3 - 55HN^Q^ yl)pyrimidin-2-amine — OxyO^N afford (S)-5- methoxymethyl-N-(6- (5-(methoxymethyl)- 1,2,4-oxadiazol-3-yl)- 2,3- dihydrobenzofuran-3- 56 yl)pyrimidin-2-amine(R)-5-bromo-N-(5-(5- methyl- 1,2,4- oxadiazol-3-yl)-2,3- dihydro- 1 H-inden- 1 - 57 yl)pyrimidin-2-amine N^N(S)-N-(6-(5-methyl- l,3,4-oxadiazol-2-yl)- 2,3- dihydrobenzofuran-3 - HN A\ F yi)-5- hS^ X^F (trifluoromethyl)pyridi58 F n-2-amine47MF-365146518498922021940(S)-N-(6-(5-ethyl- l,3,4-oxadiazol-2-yl)- ° y Q 2,3- dihydrobenzofuran-3 - yl)-5- N^Z ^F (trifluoromethyl)pyridi 59 F n-2-amine(S)-N-(6-(5- (methoxymethyl) - l,3,4-oxadiazol-2-yl)- 2,3- dihydrobenzofuran-3 -HN^ \ / yl)-5- N^Z ^F (trifluoromethyl)pyridi 60 F n-2-amineN^N(S)-5-methyl-N-(6-(5-oAm methyl- 1,3,4- V oxadiazol-2-yl)-2,3-HN^Z< YI dihydrobenzofuran-3 - 61 yl)pyrimidin-2-amine — 0 N^N(S)-N-(6-(5- (methoxymethyl) - l,3,4-oxadiazol-2-yl)- 2,3- dihydrobenzofuran-3 - yl)-5- ™4QU (trifluoromethyl)pyrim 62 F idin-2-amine V / QN(S)-N-(6-(5-ethyl-oAw l,3,4-oxadiazol-2-yl)- V 2,3- dihydrobenzofuran-3 - 63HN~O yl)pyrimidin-2-amine N^N(S)-3-fluoro-N-(6-(5- methyl- 1,3,4- oxadiazol-2-yl)-2,3- dihydrobenzofuran-3 -64 “lb yl)pyridin-2-amine48MF-365146518498922021940(S)-3-fluoro-N-(6-(5- (methoxymethyl) -0O Q F l,3,4-oxadiazol-2-yl)- 2,3-HN-O dihydrobenzofuran-3 - 65 N^Z yl)pyridin-2-amine(S)-N-(6-(5-ethyl- l,3,4-oxadiazol-2-yl)- A OQ r 2,3- dihydrobenzofuran-3 -HN^n\ yl)- 3 -fluoropyridin-2 - 66 N^Z amine / 9^N(S)-l-(2-((6-(5- methyl- 1,2,4- oxadiazol-3-yl)-2,3- dihydrobenzofuran-3 - yl)amino)pyrimidin-5- 67 0 yl)ethan-l-one(S)-2-(2-((6-(5-ethyl-N”^rQv°\ 1,2,4-oxadiazol-3-yl)- V 2,3- / dihydrobenzofuran-3 - yl)amino)pyrimidin-5- 68 N^z y0Hyl)propan-2-ol(R)-N-(5-(5- ™-O " V cyclopropyl- 1,2,4-.. ''Noxadiazol-3-yl)-2,3- dihydro- 1 H-inden- 1 - yl)-5- (trifluoromethyl)pyrim69 O^N idin-2-amine49MF-365146518498922021940MS?, (S)-N-(6-(5-ethyl- l,3,4-oxadiazol-2-yl)- " I X \ 2,3- dihydrobenzofuran-3 -HN^n\ / yl)-3-methyl-5- (trifluoromethyl)pyridi 70 F n-2-amine— 0 yzXN(S)-2-(6-((6-(5- (methoxymethyl) - l,3,4-oxadiazol-2-yl)- 2,3- dihydrobenzofuran-3 - HN^ \ / yl)amino)pyridin-3- 71 N^Z yOH yl)propan-2-ol U QrV..? hr (R)-N-(5-(5-isopropyl- 1,2,4-oxadiazol-3-yl)- 2,3-dihydro- IH-inden- v NJ©0 l-yl)-5- (trifluoromethyl)pyrim Xpr^72 idin-2-amine(S)-N-(6-(5- MQJL^O (difluoromethyl)-Fz N^x|^jT^cS 1,2,4-oxadiazol-3-yl)- 2,3- dihydrobenzofuran-3 - yl)-5- (trifluoromethyl)pyrim "M4QU73 idin-2-amine FJBr^0H..? N(R)-2-(2-((5-(5-ethyl- 1,2,4-oxadiazol-3-yl)- N^OO 2,3-dihydro- IH-inden- l-yl)amino)pyrimidin- 74 5-yl)propan-2-ol50MF-365146518498922021940(R)-2-(2-((5-(5-..? N(methoxymethyl) - 1,2,4-oxadiazol-3-yl)- 2,3-dihydro- IH-inden- l-yl)amino)pyrimidin- 75 —d < O? N 5-yl)propan-2-olHN' x\— 2 / '0H(R)-2-(2-((5-(5-..? N(difluoromethyl)- 1,2,4-oxadiazol-3-yl)-F\ 2,3-dihydro- IH-inden-Fl-yl)amino)pyrimidin- 76 ^OY^ 5-yl)propan-2-ol HNXO1 ^CI(R)-3-(3- chlorophenyl)-N-(5- ■'Nl( H (5-ethyl- 1,2,4- oxadiazol-3-yl)-2,3- dihydro- 1 H-inden- 1 - yl)-l,2,4-oxadiazol-5- 77 amineO~N(R)-N-(5- (5-methyl- 1.2.4-oxadiazol-3-yl)- 2,3-dihydro- IH-inden- l-yl)-3-(m-tolyl)- 1.2.4-oxadiazol-5- 78 amine0~N? N |( )l (R)-N-(5- (5-methyl- 1,2,4-oxadiazol-3-yl)- 2,3-dihydro- IH-inden- l-yl)-3-(o-tolyl)-l,2,4- 79 ^0? N oxadiazol-5 - amine(S)-2-(2-((6-(5-ethyl-M§Il,3,4-oxadiazol-2-yl)- wV 2,3-HN^7 y< / dihydrobenzofuran-3 - NV y-OH yl)amino)pyrimidin-5-80 yl)propan-2-ol51MF-365146518498922021940? N (R)-3-benzyl-N-(5-(5- methyl- 1,2,4- NJJJOO oxadiazol-3-yl)-2,3- dihydro- 1 H-inden- 1 - yl)-l,2,4-oxadiazol-5- 81 O'N amineN-0(R)-5-benzyl-N - (5 - (5 - ethyl- 1,2,4-oxadiazol- 3-yl)-2,3-dihydro-lH- inden- 1-yl)- 1,2,4- 82 oxadiazol-3 - amine HN(R)-5-benzyl-N - (5 - (5 - ethyl- 1,2,4-oxadiazol- N^CO 3-yl)-2,3-dihydro-lH- inden- 1-yl)- 1,3,4- 83 oxadiazol-2-amine (S)-N-(6-(5-ethyl- 1,2,4-oxadiazol-3-yl)- 2,3- dihydrobenzofuran-3 -84NJ° yl)-3-(tetrahydro-2H- 4 IQ^ pyran-4-yl)- 1,2,4- oxadiazol-5 - amine (S)-N-(6-(5-ethyl-N"^x1,2,4-oxadiazol-3-yl)- rQTT° o\ 2,3- dihydrobenzofuran-3 - yl)-3-(oxetan-3- "^ ylmethyl)- 1,2,4- 0o-TN p85 Uo oxadiazol-5 - amine N-((S)-6-(5-ethyl- 1.2.4-oxadiazol-3-yl)- Mbl ^_02,3- dihydrobenzofuran-3 -nyl)-3-((ls,4R)-4- oQ n-"°" methoxycyclohexyl)- 1.2.4-oxadiazol-5-86HN1QY'Uamine52MF-365146518498922021940(S)-N-(6-(5-ethyl- 1.2.4-oxadiazol-3-yl)- o 2,3- dihydrobenzofuran-3 - OO » N x / yl)-3-(2-HN-<qkp Jxo- methoxypropan-2-yl)- O-N 1.2.4-oxadiazol-5- 87 amine(S)-N-(6-(5-ethyl- 1.2.4-oxadiazol-3-yl)- 2,3- dihydrobenzofuran-3 - V bk yl)-3-(oxetan-3-yl)- 1.2.4-oxadiazol-5- 88HN%QT^ amineN-((S)-6-(5-ethyl- MbT, 1,2,4-oxadiazol-3-yl)- 2,3- n m n dihydrobenzofuran-3 - yl)-3-(tetrahydro-2H- pyran-3-yl)- 1,2,4- 89HNIQA ° oxadiazol-5 - amine™-<cHF(R)-N-cyclobutyl- 1 - ((5-H(OT^ (trifluoromethyl)pyrim idin-2-yl)amino)-2,3- dihydro- lH-indene-5- 90 0 carboxamideN-((S)-6-(5-ethyl- 1,2,4-oxadiazol-3-yl)- 2,3- OO rx dihydrobenzofuran-3 - yl)- 3 - (tetrahydrofuran- H^QT^03 -yl) - 1,2,4-oxadiazol- 91 O-N 5-amine(S)-N-(6-(5-ethyl- 1,2,4-oxadiazol-3-yl)- 2,3-N^XT K^2^Jl ° / \ dihydrobenzofuran-3 - yl)-3-(2- oxaspiro [3.3]heptan-6- yl)-l,2,4-oxadiazol-5-92 O=N amine53MF-365146518498922021940J3L (R)-N-(5-(5-ethyl- 1,2,4-oxadiazol-3-yl)- 2,3-dihydro- IH-inden- l-yl)-5-(4- methylbenzyl)- 1,2,4- 93 oxadiazol-3 - amine (R)-5-(4- chlorophenyl)-N-(5- (5-ethyl- 1,2,4- oxadiazol-3-yl)-2,3- dihydro- 1 H-inden- 1 - yl)- 1,3,4-oxadiazol-2- 94 o amine(S)-N-(6-(5-ethyl- Moji01.2.4-oxadiazol-3-yl)- 2,3- ^ ic dihydrobenzofuran-3 - yl)- 3 - ( (tetrahydro- 2H- pyran-4-yl)methyl)- 955 °'NCo 1.2.4-oxadiazol-5- amineN~N(R)-5-(2- chlorophenyl)-N-(5- (5-ethyl- 1,2,4- N^XjOCl^ oxadiazol-3-yl)-2,3- dihydro- 1 H-inden- 1 - yl)- 1,3,4-oxadiazol-2- 96 amine(S)-N-(6-(5-ethyl- 1.2.4-oxadiazol-3-yl)- 2,3- ^<0^ 0 dihydrobenzofuran-3 - lk_JJL? rv°\ yl)-3-(3- methoxycyclobutyl)- 977 ■x Od-Nr JLS7I 1.2.4-oxadiazol-5- amineN-((S)-6-(5-ethyl- 1,2,4-oxadiazol-3-yl)-N”^TQT"\ 2,3- dihydrobenzofuran-3 - * JL J yl)-3-(tetrahydro-2H- pyran-2-yl)- 1,2,4-98 O~N oxadiazol-5 - amine54MF-365146518498922021940HN(R)-l-ethyl-N-(5-(5- ethyl- 1,2,4-oxadiazol- 3-yl)-2,3-dihydro-lH- inden-l-yl)-lH- 99 pyrazol-4-amine(R)- 1 -cyclobutyl-N - (5-(5-ethyl- 1,2,4- oxadiazol-3-yl)-2,3- dihydro- 1 H-inden- 1 - yl)-lH-pyrazol-4- 100 amine(R)-N-(5-(5-ethyl- 1,2,4-oxadiazol-3-yl)- 2,3-dihydro- IH-inden- l-yl)-l-phenyl-lH- 101 pyrazol-4-amine (S)-N-(6-(5-ethyl- 1,2,4-oxadiazol-3-yl)- 2,3- dihydrobenzofuran-3 - yl)-3-(l- OO• cL / ° oxaspiro [3.3]heptan-6- HN-Vryf ^ yl)-l,2,4-oxadiazol-5- 102 O-*N amineN-((S)-6-(5-ethyl- 1.2.4-oxadiazol-3-yl)- Moji 2,3- dihydrobenzofuran-3 -NUO! yl)-3-(l-(tetrahydro- 2H-pyran-4-yl)ethyl)- 1.2.4-oxadiazol-5- 103 °-NCo amine(S)-N-(6-(5-ethyl- Mc^0l,3,4-oxadiazol-2-yl)- 2,3- dihydrobenzofuran-3 - O0 r° yl)-3-(tetrahydro-2H- pyran-4-yl)- 1,2,4-104 O-N oxadiazol-5-amine55MF-365146518498922021940N-~N(S)-N-(6-(5-methyl- l,3,4-oxadiazol-2-yl)- 2,3- dihydrobenzofuran-3 - yl)- 3 - (3 -methyloxetan- 3 -yl) - 1,2,4-oxadiazol- 105 5-amineV- / nN(S)-2-(3-((l- cyclobutyl-lH- pyrazol-4-yl)methyl)- 2,3- dihydrobenzofuran-6- yl)-5-ethyl- 1,3,4- 106 oxadiazole vJnN(S)- 1 -cyclobutyl-N-(6- (5-ethyl- 1,3,4- oxadiazol-2-yl)-2,3- * NXdihydrobenzofuran-3 - yl)-lH-pyrazol-3- 107 amine(S)-N-(6-(5-ethyl- MoT.01.2.4-oxadiazol-3-yl)- 2,3- dihydrobenzofuran-3 - X / yl)-5-(2-HNmethoxypropan-2-yl)- ^ NQY \< 1.2.4-oxadiazol-3- 108 -0 amine? / cNV^0H(R)-2-(6-((5-(5-ethyl- l,3,4-oxadiazol-2-yl)-0TJOO 2,3-dihydro- IH-inden- l-yl)amino)pyridin-3- 109 / N-N yl)propan-2-ol / ~rNHN^yN^^x(R)-N-(5-(5-ethyl- 1,2,4-oxadiazol-3-yl)- 2,3-dihydro- IH-inden- 1 -yl)- 1 -(oxetan-3-yl)-110 1 H-pyrazol-4-amine56MF-365146518498922021940(S)-N-(6-(5-ethyl- l,3,4-oxadiazol-2-yl)- 2,3- dihydrobenzofuran-3 - yl)-l-(oxetan-3-yl)- 111 1 H-pyrazol- 3 -amine N-((S)-6-(5-ethyl- Mol l,3,4-oxadiazol-2-yl)- 2,3- dihydrobenzofuran-3 - r-yV >0 yl)- 1 -(tetrahydrofuran- 3-yl)-lH-pyrazol-4- 112 '-— N amine(S)-N-(6-(5-ethyl- 1,2,4-oxadiazol-3-yl)- 2,3- MoM o dihydrobenzofuran-3 -Nyl)-3-(3- }NM 7 methoxybicyclo [1.1.1] pentan- 1-yl)- 1,2,4- 113 O^N oxadiazol-5 - amine(S)-2-cyclobutyl-N-(6- (5-ethyl- 1,3,4- oxadiazol-2-yl)-2,3- » N. A / dihydrobenzofuran-3 - yl)-2H- 1,2,3-triazol-4- 114HNM?N" amineN^N (S)-2-(3-((6-(5- methyl- 1,3,4- oxadiazol-2-yl)-2,3-oAw(dihydrobenzofuran-3 - yl)amino)- 1,2,4- oxadiazol-5- 115HM NO-T0 ^°Hyl)propan-2-ol (S)-N-(6-(5-ethyl- 1.2.4-oxadiazol-3-yl)- MoM02,3- dihydrobenzofuran-3 - yl)-3-(4-methoxy-2- methylbutan-2-yl)- 1.2.4-oxadiazol-5-116 O-N amine57MF-365146518498922021940(S)-3-(5-((6-(5-ethyl- 1,2,4-oxadiazol-3-yl)- 2,3- oQ dihydrobenzofuran-3 - yl)amino)- 1,2,4-HNoxadiazol-3-yl)-l- < r methoxy-3- 117 methylbutan-2-one M^o(S)-N-(6-(5-ethyl- 1.3.4-oxadiazol-2-yl)- 2,3- dihydrobenzofuran-3 - N^C° yl)-3-(oxetan-3-yl)- 1.2.4-oxadiazol-5- 118HN-< 0o-yN ^ amine vJnN(S)-N-(6-(5-ethyl- l,3,4-oxadiazol-2-yl)-oA2,3- m dihydrobenzofuran-3 - yl)- 3 - (3 -methyloxetan- 3 -yl) - 1,2,4-oxadiazol- 119 “IQ?005-amineN-N(S)-N-(6-(5- cyclopropyl- 1,3,4- oxadiazol-2-yl)-2,3- dihydrobenzofuran-3 - yl)- 3 - (3 -methyloxetan- 3 -yl) - 1,2,4-oxadiazol- O—N 120 5-amine(S)-2-(6-((6-(5- (difluoromethyl)- 1,2,4-oxadiazol-3-yl)- 2,3-fo0 1 N-^ dihydrobenzofuran-3 - yl)amino)pyridin-3-HNZQ?v \^z y-OH121 yl)propan-2-ol JO' (R)- 1 -cyclopropyl-N-HN^X>N'-V-7(5-(5-ethyl- 1,2,4- oxadiazol-3-yl)-2,3- dihydro- 1 H-inden- 1 - »J0Oyl)-lH-pyrazol-4- 122 amine58MF-365146518498922021940Mol (S)- 1 -cyclopropyl-N- (6-(5-ethyl- 1,3,4- oxadiazol-2-yl)-2,3- dihydrobenzofuran-3 - \U yl)-lH-pyrazol-4- i123 amineN~N(S)-N-(6-(5- cyclopropyl- 1,3,4- oxadiazol-2-yl)-2,3- dihydrobenzofuran-3 - yl)-3-(oxetan-3-yl)- l,2,4-oxadiazol-5- 124 O-N amine(S)-N-(6-(5-isopropyl- 1.3.4-oxadiazol-2-yl)- 2,3- dihydrobenzofuran-3 - yl)-3-(oxetan-3-yl)- 1.2.4-oxadiazol-5- 125HN%or^ amine(S)-2-cyclobutyl-N-(6- o(5-ethyl- 1,2,4- oxadiazol-3-yl)-2,3- * NX7 dihydrobenzofuran-3 - yl)-2H- 1,2,3-triazol-4- 126 amineHN- j\rv_M> / X;0H(R)-2-(6-((5-(5-ethyl- 1,2,4-oxadiazol-3-yl)- NJOO 2,3-dihydro- IH-inden- l-yl)amino)pyridin-3- 127 yl)propan-2-ol (S)-N-(6-(5-isopropyl- l,3,4-oxadiazol-2-yl)- 2,3- dihydrobenzofuran-3 - yl)- 3 - (3 -methyloxetan- 3 -yl) - 1,2,4-oxadiazol-128 O-N 5-amine59MF-365146518498922021940(S)-2-(3-((6-(5-ethyl- l,3,4-oxadiazol-2-yl)- TOO 2,3- dihydrobenzofuran-3 - N > >0Hyl)amino)- 1,2,4- oxadiazol-5- 129 yl)propan-2-ol (S)-N-(6-(5-ethyl- M<^0l,3,4-oxadiazol-2-yl)- 2,3- dihydrobenzofuran-3 - yl)-5-(tetrahydro-2H- pyran-4-yl)- 1,2,4- 130 N=O oxadiazol-3 - amine O-N(R)-2-(5-((5-(5-ethyl- l,3,4-oxadiazol-2-yl)- 2,3-dihydro- IH-inden- o^OO l-yl)amino)- 1,2,4- oxadiazol-3- 131 / ypN yl)propan-2-ol(S)-2-(4-((6-(5-ethyl- l,3,4-oxadiazol-2-yl)- oO 2,3\ N. O >OH- dihydrobenzofuran-3 - yl)amino)thiazol-2- 132 yl)propan-2-ol HNOBI-' N \ \ (R)-2-cyclobutyl-N- (5-(5-ethyl- 1,2,4- oxadiazol-3-yl)-2,3- dihydro- 1 H-inden- 1 - yl)-2H- 1,2,3-triazol-4- 133 amineO-NHN^Ok ^ (R)-N-(5-(5-ethyl- 1.3.4-oxadiazol-2-yl)-& YJ0O 2,3-dihydro- IH-inden- l-yl)-3-(oxetan-3-yl)- 1.2.4-oxadiazol-5-134 / Ypj amine60MF-365146518498922021940(S)-2-(5-((6-(5- cyclopropyl- 1,3,4- oxadiazol-2-yl)-2,3- dihydrobenzofuran-3 - yl)amino)- 1,2,4- oxadiazol-3- 135 yl)propan-2-ol (S)-2-(5-((6-(5- isopropyl- 1,3,4- oxadiazol-2-yl)-2,3- dihydrobenzofuran-3 -H\N^0Y J^-0Hyl)amino)- 1,2,4- I oxadiazol-3- 136 O-N / O yl)propan-2-olO-N (R)-N-(5-(5-ethyl- zr X 1.3.4-oxadiazol-2-yl)- 2,3-dihydro- IH-inden- l-yl)-3-(3- methyloxetan-3-yl)- 1.2.4-oxadiazol-5- amine137N-Nl-(5-(((S)-6-(5- cyclopropyl- 1,3,4- oxadiazol-2-yl)-2,3- ^9JW OH dihydrobenzofuran-3 - f • N. Ji yl)amino)- 1,2,4-HN^OT^ oxadiazol-3-yl)ethan- 138 O-N l-olItN l-(5-(((S)-6-(5-ethyl- l,3,4-oxadiazol-2-yl)- °"\or°> 2,3- OH dihydrobenzofuran-3 - V N. Ji yl)amino)- 1,2,4-HN^OT^ oxadiazol-3-yl)ethan- 139 O-N l-ol\ ZQN(S)-2-(5-((6-(5-ethyl- l,3,4-oxadiazol-2-yl)- 2,3-oAw(dihydrobenzofuran-3 - yl)amino)- 1,2,4-HN^oT^OHoxadiazol-3-140 O-N yl)propan-2-ol61MF-365146518498922021940(S)-(5-((6-(5- cyclopropyl- 1,3,4- oxadiazol-2-yl)-2,3- dihydrobenzofuran-3 - yl)amino)- 1,2,4- oxadiazol-3- 141 O-N yl)methanol(S)-(5-((6-(5-ethyl- l,3,4-oxadiazol-2-yl)- 2,3- dihydrobenzofuran-3 - yl)amino)- 1,2,4- HN-A^OH oxadiazol-3- 142 O-N yl)methanol_ O-N(S)-3-(6-((6-(5- methyl- 1,2,4- oxadiazol-3-yl)-2,3- dihydrobenzofuran-3 - yl)amino)pyridin-3- 143 yl)pentan-3-ol feN (R)-2-(5-((5-(5- cyclopropyl- 1,3,4- ^■^SC0oxadiazol-2-yl)-2,3- dihydro- 1 H-inden- 1 - yl)amino)- 1,2,4- oxadiazol-3- 144 yl)propan-2-olO-N(R)-N-(5-(5-isopropyl- 1.3.4-oxadiazol-2-yl)- 2,3-dihydro- IH-inden- l-yl)-3-(3- \ oU0o methyloxetan-3-yl)- 1.2.4-oxadiazol-5- 145 amineOHHN^xkJ / ' (R)-2-(6-((5-(5-..? methyl- 1,2,4- oxadiazol-3-yl)-2,3- dihydro- 1 H-inden- 1 - yl)amino)pyridin-3-146 ^O? N yl)propan-2-ol62MF-365146518498922021940(S)-2-(5-((6-(5-ethyl- 1,2,4-oxadiazol-3-yl)- 2,3- oO dihydrobenzofuran-3 -H\N^ON. Y< X / 0Hyl)amino)- 1,2,4- O-N oxadiazol-3- 147 yl)propan-2-oll-(5-(((S)-6-(5- isopropyl- 1,3,4- oxadiazol-2-yl)-2,3- OH dihydrobenzofuran-3 - yl)amino)- 1,2,4-HNXOT^ oxadiazol-3-yl)ethan- 148 O-N l-olLOH (R)-l-(5-((5-(5-ethyl- HN-AUXX l,3,4-oxadiazol-2-yl)- 2,3-dihydro- IH-inden- l-yl)amino)- 1,2,4-OyjOO oxadiazol-3-yl)-2- methylpropan-2-ol 149X U, (S)-3-cyclobutyl-N-(6- (5-ethyl- 1,3,4- oxadiazol-2-yl)-2,3- dihydrobenzofuran-3 - yl)-l,2,4-oxadiazol-5- 150HN^ OO-TN ^ amineO-NHN^9^< A (R)-3-cyclobutyl-N- ' N \ \(5-(5-ethyl- 1,3,4- oxadiazol-2-yl)-2,3- U OO dihydro- 1 H-inden- 1 - yl)-l,2,4-oxadiazol-5- 151 / \p\l amineN~O (R)-N-(5-(5-ethyl- l,3,4-oxadiazol-2-yl)- rW b 2,3-dihydro- IH-inden- 1 -y 1) -5 - (tetrahydro- JOO 2H-pyran-4-yl)- 1,2,4- oxadiazol-3 - amine15263MF-365146518498922021940N~O(R)-2-(3-((5-(5-ethyl-NPOH l,3,4-oxadiazol-2-yl)- 2,3-dihydro- IH-inden- l-yl)amino)- 1,2,4- oxadiazol-5- 153 yl)propan-2-olO-N N-((R)-5-(5-ethyl- HN^Qk,.^, 1.3.4-oxadiazol-2-yl)-? N r x 2,3-dihydro- IH-inden-Uo l-yl)-3-((S)- _.o^ jy^Uy tetrahydrofuran-3-yl)- 1.2.4-oxadiazol-5- 154 / YRJ amineO-N N-((R)-5-(5-ethyl- 1.3.4-oxadiazol-2-yl)- •'N\ / 2,3-dihydro- IH-inden- |f )T^\Uo l-yl)-3-((R)- _.o^ jy^Uy tetrahydrofuran-3-yl)- 1.2.4-oxadiazol-5- 155 / YRJ amine(lR,3r)-3-(5-(((R)-5- O^N(5-ethyl- 1,3,4- HN^y^' / ,,.^ oxadiazol-2-yl)-2,3- ■' N \ \dihydro- 1 H-inden- 1 - yl)amino)- 1,2,4- oxadiazol-3- 156 yl)cyclobutan-l-ol N-((R)-5-(5- cyclopropyl- 1,3,4- OrNoxadiazol-2-yl)-2,3- HN dihydro- 1 H-inden- 1 -? N 0yl)-3-((S)- ^^yOo tetrahydrofuran-3-yl)- l,2,4-oxadiazol-5- 157 N-NamineO-N N-((R)-5-(5- cyclopropyl- 1,3,4- oxadiazol-2-yl)-2,3-. Qo dihydro- 1 H-inden- 1 - yl)-3-((R)- tetrahydrofuran-3-yl)- l,2,4-oxadiazol-5-158 N'Namine64MF-365146518498922021940(lR,3r)-3-(5-(((R)-5- (5-cyclopropyl- 1,3,4- oxadiazol-2-yl)-2,3- dihydro- 1 H-inden- 1 - yl)amino)- 1,2,4- oxadiazol-3- 159 N-N yl)cyclobutan-l-ol O-NN-((R)-5-(5-isopropyl- HN^Qk,.^, 1.3.4-oxadiazol-2-yl)-? N r x 2,3-dihydro- IH-inden- l-yl)-3-((S)- tetrahydrofuran-3-yl)- 1.2.4-oxadiazol-5- 160 / N-N o amineO-N N-((R)-5-(5-isopropyl- 1.3.4-oxadiazol-2-yl)- •'N\ / 2,3-dihydro- IH-inden- T:l-yl)-3-((R)- tetrahydrofuran-3-yl)- 1.2.4-oxadiazol-5- 161 / N-N amine(lR,3r)-3-(5-(((R)-5- O^N(5-isopropyl- 1,3,4- HN-^y^' / ,,.^ oxadiazol-2-yl)-2,3- ■' N \ \dihydro- 1 H-inden- 1 - yl)amino)- 1,2,4- oxadiazol-3- 162 yl)cyclobutan-l-ol (R)-N-(5-(5- OrN cyclopropyl- 1,3,4- oxadiazol-2-yl)-2,3- dihydro- 1 H-inden- 1 - yl)-3- (methoxymethyl) - t^br©0l,2,4-oxadiazol-5- 163 N-N amine(R)-N-(5-(5-isopropyl- 1.3.4-oxadiazol-2-yl)- 2,3-dihydro- IH-inden- l-yl)-3- (methoxymethyl) - 1.2.4-oxadiazol-5-164 amine65MF-365146518498922021940OrN (R)-N-(5-(5- cyclopropyl- 1,3,4- oxadiazol-2-yl)-2,3- Vo0 dihydro- 1 H-inden- 1 - yl)-3-(oxetan-3-yl)- l,2,4-oxadiazol-5- 165 N-N amineO-N (R)-N-(5-(5-isopropyl- 1.3.4-oxadiazol-2-yl)- _ O-" Z N \ \ 2,3-dihydro- IH-inden- l-yl)-3-(oxetan-3-yl)- 1.2.4-oxadiazol-5- amine166Z:-^ N-Nieo° Az / oN-((R)-5-(5-ethyl- l,3,4-oxadiazol-2-yl)- 2,3-dihydro- IH-inden- l-yl)-5-((S)- tetrahydro-2H-pyran- 3 -yl) - 1,2,4-oxadiazol- 167 3-amineN-O N-((R)-5-(5-ethyl- l,3,4-oxadiazol-2-yl)- ' N f I 2,3-dihydro- IH-inden- l-yl)-5-((R)- VO tetrahydro-2H-pyran- 3 -yl) - 1,2,4-oxadiazol- 168 3-amineN-0 N-((R)-5-(5-ethyl- 1.3.4-oxadiazol-2-yl)- 2,3-dihydro- IH-inden- VO l-yl)-5-((S)- tetrahydrofuran-3-yl)- 1.2.4-oxadiazol-3- 169 amineOrN (R)-N-(5-(5-ethyl- 1.3.4-oxadiazol-2-yl)- 2,3-dihydro- IH-inden- l-yl)-3- oOO (methoxymethyl) - 1.2.4-oxadiazol-5-170 amine66MF-365146518498922021940O~N (R)-N-(5-(5-ethyl- l,3,4-oxadiazol-2-yl)- 2,3-dihydro- IH-inden- JOO l-yl)-3-(tetrahydro- 2H-pyran-4-yl)- 1,2,4- 171 oxadiazol-5 - amine NrO (R)-N-(5-(5-isopropyl- l,3,4-oxadiazol-2-yl)- 2,3-dihydro- IH-inden- JOT> 1 -y 1) -5 - (tetrahydro- 2H-pyran-4-yl)- 1,2,4- oxadiazol-3 - amine 172N=O (R)-N-(5-(5- cyclopropyl- 1,3,4- oxadiazol-2-yl)-2,3- JOD dihydro- 1 H-inden- 1 - yl)-5-(tetrahydro-2H- N-N pyran-4-yl)- 1,2,4- 173 oxadiazol-3 - amine (R)-N-(5-(5-isopropyl- H,< >0l,3,4-oxadiazol-2-yl)- 2,3-dihydro- IH-inden-V YW l-yl)-3-(oxetan-3- ylmethyl)- 1,2,4- oxadiazol-5 - amine 174(R)-2-(3-((5-(5- HNXOX / isopropyl- 1,3,4- rA. r0Hoxadiazol-2-yl)-2,3- dihydro- 1 H-inden- 1 - yl)amino)- 1,2,4- oxadiazol-5- yl)propan-2-ol 175(R)-2-(6-((5-(5-ethyl- 1,2,4-oxadiazol-3-yl)-.. J / Ar N-V^ ^0H2,3-dihydro- IH-inden- l-yl)amino)pyridin-3- »J0O yl)propan-2-ol17667MF-365146518498922021940(S)-2-(6-((6-(5- methyl- 1,2,4- oxadiazol-3-yl)-2,3- dihydrobenzofuran-3 - yl)amino)pyridin-3- HN^f>\ / yl)propan-2-ol N^Z yOH177(S)-2-(6-((6-(5-ethyl- 1,2,4-oxadiazol-3-yl)- 707 o 2,3- dihydrobenzofuran-3 - yl)amino)pyridin-3-HN^ V / yl)propan-2-ol 178 N^z y0HN-o (R)-N-(5-(5-ethyl- HNXOA^ l,3,4-oxadiazol-2-yl)- 2,3-dihydro- IH-inden- l-yl)-5-(4- JOO fluorotetrahydro-2H- pyran-4-yl)- 1,2,4- 179 / N4J oxadiazol-3 - amine N-((S)-6-(5-ethyl- 1.3.4-oxadiazol-2-yl)- Y U 2,3- dihydrobenzofuran-3 - LUJLvro yi)-3-((S)- tetrahydrofuran-3-yl)- 1.2.4-oxadiazol-5- 180 O-N amineN-((S)-6-(5-ethyl- 1.3.4-oxadiazol-2-yl)- Y U 2,3- LOL / —o dihydrobenzofuran-3 - yi)-3-((R)- tetrahydrofuran-3-yl)- 1.2.4-oxadiazol-5- 181HN~< OQ-Np^ amineO~N (R)-2-(5-((5-(5-HNcyclopropyl- 1,3,4- v\ / oxadiazol-2-yl)-2,3- < V\ '0Hdihydro- 1 H-inden- 1 - yl)amino)- 1,2,4- oxadiazol-3-182 O-Y No'N^u ^ yl)propan-2-ol68MF-365146518498922021940(S)-N-(6-(5-ethyl- 1.3.4-oxadiazol-2-yl)- 1,3,4-oxadiazol-2-yl)- 2,3- dihydrobenzofuran-3 - yi)-3- (methoxymethyl) - 1.2.4-oxadiazol-5- 183 O-N amineNrO (R)-2-(3-((5-(5- cyclopropyl- 1,3,4-HNN1“ OH oxadiazol-2-yl)-2,3- dihydro- 1 H-inden- 1 - yl)amino)- 1,2,4- oxadiazol-5- 184 N-Nyl)propan-2-ol N~O (R)-N-(5-(5-ethyl- l,3,4-oxadiazol-2-yl)- 2,3-dihydro- IH-inden- l-yl)-5-(4- methyltetrahydro-2H- pyran-4-yl)- 1,2,4- 185 oxadiazol-3 - amine _ HO (R)-l-(6-((5-(5-ethyl- 1,2,4-oxadiazol-3-yl)- HNIC / '' 2,3-dihydro- IH-inden- l-yl)amino)pyridin-3- yl)cyclopropan- 1 -ol NJOO186(S)-2-(6-((6-(5-ethyl- (S)-2-(6-((6-(5-ethyl- 1,3,4-oxadiazol-2-yl)- 2,3- OQ dihydrobenzofuran-3 - yl)amino)pyridin-3- yl)propan-2-ol 187HN"01OHNrO (R)-N-(5-(5-isopropyl- ' N [ I l,3,4-oxadiazol-2-yl)- 2,3-dihydro- IH-inden- OT> 1 -y 1) -5 - (tetrahydro- 2H-pyran-4-yl)- 1,2,4- oxadiazol-3 - amine18869MF-365146518498922021940N-O N-((R)-5-(5- cyclopropyl- 1,3,4- I ■'wNoxadiazol-2-yl)-2,3- I 1dihydro- 1 H-inden- 1 - yl)-5-((R)-tetrahydro- 2H-pyran-3-yl)- 1,2,4- 189 N-N oxadiazol-3 - amine N-~NN-((S)-6-(5-methyl- 1.3.4-oxadiazol-2-yl)- 2,3-?>o dihydrobenzofuran-3 - yi)-3-((S)- tetrahydrofuran-3-yl)- 1.2.4-oxadiazol-5- 190HN^ Oo47J'O \^amineN-~NN-((S)-6-(5-methyl- 1.3.4-oxadiazol-2-yl)- 2,3- dihydrobenzofuran-3 - yi)-3-((R)- tetrahydrofuran-3-yl)- 1.2.4-oxadiazol-5- 191HN^ Od-rN ^° amineN^N(S)-3- (methoxymethyl) -N - (6-(5-methyl- 1,3,4- oxadiazol-2-yl)-2,3- dihydrobenzofuran-3 - yl)-l,2,4-oxadiazol-5- amine192 O~N N-((S)-6-(5- cyclopropyl- 1,3,4- oxadiazol-2-yl)-2,3- dihydrobenzofuran-3 - yi)-3-((S)- tetrahydrofuran-3-yl)- l,2,4-oxadiazol-5- 193 amineN-((S)-6-(5- N-N cyclopropyl- 1,3,4- oxadiazol-2-yl)-2,3- dihydrobenzofuran-3 - yi)-3-((R)- ■;M „ rt tetrahydrofuran-3-yl)- l,2,4-oxadiazol-5- 194HN-X OO-VN amine70MF-365146518498922021940N-((R)-5-(5-isopropyl- N~Ol,3,4-oxadiazol-2-yl)- ' N r i 2,3-dihydro- IH-inden- 1-yl)-5-((S)- tetrahydro-2H-pyran- 2-yl)- 1,2,4-oxadiazol- 195 3-amineN-0 N-((R)-5-(5-isopropyl- l,3,4-oxadiazol-2-yl)- ' N i l 2,3-dihydro- IH-inden- 1-yl)-5-((R)- JOO tetrahydro-2H-pyran- 2-yl)- 1,2,4-oxadiazol- 196 3-amineOrN (R)-3- (methoxymethyl) -N - (5-(5-methyl- 1,3,4- oxadiazol-2-yl)-2,3- dihydro- 1 H-inden- 1 - yl)-l,2,4-oxadiazol-5- amine197 i\rNNrO N-((R)-5-(5-isopropyl- HNOyX,.. 1.3.4-oxadiazol-2-yl)- •'N\ / 2,3-dihydro- IH-inden- l-yl)-5-((R)- foOu° tetrahydrofuran-3-yl)- 1.2.4-oxadiazol-3- 198 H r80amine(R)-N-(5-(5-ethyl- O-N j F l,3,4-oxadiazol-2-yl)- H N F? N 2,3-dihydro- IH-inden- l-yl)-3-((2,2,2- O OO trifluoroethoxy)methyl )-l,2,4-oxadiazol-5- 199 amine(S)-N-(6-(5-ethyl- l,3,4-oxadiazol-2-yl)- 2,3- dihydrobenzofuran-3 - >00 yl)-3-((2,2,2- trifluoroethoxy)methyl HN F)-l,2,4-oxadiazol-5-200 (ON 0Famine71MF-365146518498922021940(S)-N-(6-(5-methyl- N-N l,3,4-oxadiazol-2-yl)-02,3- dihydrobenzofuran-3 - oO yl)-3-((2,2,2- * A / x trifluoroethoxy)methylH N F)-l,2,4-oxadiazol-5- 201 (Hl p F amine(R)-N-(5- (5-methyl- OrN j. F l,3,4-oxadiazol-2-yl)- H N F? N 2,3-dihydro- IH-inden- l-yl)-3-((2,2,2- trifluoroethoxy)methyl )-l,2,4-oxadiazol-5- amine202 N-NNrO N-((R)-5-(5-ethyl- 1.3.4-oxadiazol-2-yl)-. 2,3-dihydro- IH-inden- l-yl)-5-((R)- tetrahydrofuran-3-yl)- 1.2.4-oxadiazol-3- 203 amineN-((R)-5-(5- hb-0 cyclopropyl- 1,3,4- HN-Ayk^ / \ oxadiazol-2-yl)-2,3- •'N 0dihydro- 1 H-inden- 1 - yi)-5-((R)- tetrahydrofuran-3-yl)- l,2,4-oxadiazol-3- 204 t^ No-YN ®0amine_ O-M l-(6-(((S)-6-(5- methyl- 1,2,4-NA7QA oxadiazol-3-yl)-2,3- dihydrobenzofuran-3 - V yl)amino)pyridin-3- yl)ethan-l-olHNHQ^ / 205 OHl-(6-(((S)-6-(5-ethyl- H- / ON1,2,4-oxadiazol-3-yl)- 2,3- dihydrobenzofuran-3 - yl)amino)pyridin-3-HNH^\ / yl)ethan-l-ol^7 \206 OH72MF-365146518498922021940O~N N-((R)-5-(5-mnnethyl- 1.3.4-oxadiazol-2-yl)- > N \ > 2,3-dihydro- IH-inden- l-yl)-3-((S)- JOO tetrahydrofuran-3-yl)- 1.2.4-oxadiazol-5- amine207 IXPNO~N N-((R)-5-(5-mnnethyl- 1.3.4-oxadiazol-2-yl)- 2,3-dihydro- IH-inden- l-yl)-3-((R)- JOO tetrahydrofuran-3-yl)- 1.2.4-oxadiazol-5- amine208 IXPNN-((S)-6-(5-ethyl- 1.3.4-oxadiazol-2-yl)- 2,3- dihydrobenzofuran-3 - yl)-3-((ls,3R)-3- methoxycyclobutyl)- 1.2.4-oxadiazol-5- 209HN%Qr amineO-N (R)-2-(5-((5-(5- isopropyl- 1,3,4-Noxadiazol-2-yl)-2,3- POH dihydro- 1 H-inden- 1 - yl)amino)- 1,2,4- oxadiazol-3- w210ZN-N ©0yl)propan-2-ol OH l-(6-(((R)-5-(5- (difluoromethyl)- HN-A^- / / — 1,2,4-oxadiazol-3-yl)- 2,3-dihydro- IH-inden- l-yl)amino)pyridin-3- \ NJOU yl)propan-l-ol 211_ OzN l-(6-(((S)-6-(5- methyl- 1,2,4- oxadiazol-3-yl)-2,3- dihydrobenzofuran-3 - yl)amino)pyridin-3- yl)propan-l-ol212 OH73MF-365146518498922021940N-((S)-6-(5-isopropyl- 1.3.4-oxadiazol-2-yl)- 2,3- dihydrobenzofuran-3 - yi)-3-((S)- \ N 1 0 tetrahydrofuran-3-yl)-HN^Q)"" 1.2.4-oxadiazol-5- 213 O—N amineN-((S)-6-(5-isopropyl- 1.3.4-oxadiazol-2-yl)- y-B 2,3- dihydrobenzofuran-3 - yi)-3-((R)- * bk r-y / > tetrahydrofuran-3-yl)- 1.2.4-oxadiazol-5- 214 O—N amineO—Nl-(5-(((R)-5-(5-ethyl- l,3,4-oxadiazol-2-yl)- 2,3-dihydro- IH-inden- JO3OHl-yl)amino)- 1,2,4- oxadiazol-3-yl)ethan- 215 / N^-N l-olO~N (lS,3s)-3-(5-(((R)-5- (5-isopropyl- 1,3,4- oxadiazol-2-yl)-2,3- - - ", / 0Hdihydro- 1 H-inden- 1 - yl)amino)- 1,2,4- oxadiazol-3- 216 yl)cyclobutan-l-ol (lS,3s)-3-(5-(((R)-5- O~N (5-ethyl- 1,3,4- ■' N \ \ oxadiazol-2-yl)-2,3- rT^rA ^"" OH dihydro- 1 H-inden- 1 - yl)amino)- 1,2,4- oxadiazol-3- 217 yl)cyclobutan-l-ol (lS,3s)-3-(5-(((R)-5- O-N (5-cyclopropyl- 1,3,4-H^'^'N^ZZ',-< A oxadiazol-2-yl)-2,3- f / ^xAA '^"" OH dihydro- 1 H-inden- 1 - yl)amino)- 1,2,4- oxadiazol-3-218 N-N yl)cyclobutan-l-ol74MF-365146518498922021940(S)-N-(6-(5- cyclopropyl- 1,3,4- oxadiazol-2-yl)-2,3- dihydrobenzofuran-3 - yl)-3-((2,2,2- trifluoroethoxy)methyl )-l,2,4-oxadiazol-5- 2199 JcSFamine(S)-N-(6-(5-isopropyl- l,3,4-oxadiazol-2-yl)- 2,3- dihydrobenzofuran-3 - yl)-3-((2,2,2- H trifluoroethoxy)methylNS p S^V-F)-l,2,4-oxadiazol-5- 220 C^N JS amineO-N (lS,3s)-3-(5-(((R)-5- (5-methyl- 1,3,4- oxadiazol-2-yl)-2,3- ^"" OH dihydro- 1 H-inden- 1 -,o^s<<>isy yl)amino)- 1,2,4- 221 N-N oxadiazol-3- yl)cyclobutan-l-ol (lR,3s)-3-(5-(((S)-6- (5-ethyl- 1,3,4- V_ / nNoxadiazol-2-yl)-2,3- dihydrobenzofuran-3 - / \,c'OHyl)amino)- 1,2,4- oxadiazol-3-.47222 O-N yl)cyclobutan-l-ol N^N (lR,3s)-3-(5-(((S)-6- (5-cyclopropyl- 1,3,4- oxadiazol-2-yl)-2,3- ryiOH dihydrobenzofuran-3 - yl)amino)- 1,2,4- oxadiazol-3- SoT'47223 O-N yl)cyclobutan-l-ol N-((S)-6-(5-ethyl- l,3,4-oxadiazol-2-yl)- 2,3- dihydrobenzofuran-3- ^S o HN^< Q yl)- 3 - ( (R) -tetrahydro- 2H-pyran-3-yl)- 1,2,4-224 O-N oxadiazol-5 - amine75MF-365146518498922021940N-((S)-6-(5-ethyl- l,3,4-oxadiazol-2-yl)- 2,3- dihydrobenzofuran-3 - yl)-3-((2S,3S)-2- methyltetrahydrofuran -3-yl)- 1,2,4-oxadiazol- 225 5-amineN-((S)-6-(5- N^N cyclopropyl- 1,3,4- oxadiazol-2-yl)-2,3- dihydrobenzofuran-3 - » N.1 A yl)-3-((S)-tetrahydro-HN~< O7"' 2H-pyran-3-yl)- 1,2,4- 226 O-N cA oxadiazol-5 - amine N-((S)-6-(5-isopropyl- l,3,4-oxadiazol-2-yl)- 2,3- dihydrobenzofuran-3 - * N.1 A yl)-3-((S)-tetrahydro-HN-< OT 2H-pyran-3-yl)- 1,2,4- 227 O-N oxadiazol-5 - amine p N-((S)-6-(5-ethyl-0l,3,4-oxadiazol-2-yl)- 2,3- dihydrobenzofuran-3 - vO o yl)-3-((S)-tetrahydro- 2H-pyran-3-yl)- 1,2,4- 228 O-N oxadiazol-5 - amine N-((R)-5-(5-ethyl- l,3,4-oxadiazol-2-yl)- 2,3-dihydro- IH-inden- l-yl)-3-((S)- 0 5 tetrahydro-2H-pyran- 3 -yl) - 1,2,4-oxadiazol- 229 ' rrN5-amineO-N N-((R)-5-(5-methyl- HN^Cp l,3,4-oxadiazol-2-yl)- 2,3-dihydro- IH-inden- ■'N1 1l-yl)-3-((S)- fOl > tetrahydro-2H-pyran- 3 -yl) - 1,2,4-oxadiazol- 5-amineXrN23076MF-365146518498922021940(S)-N-(6-(5-isopropyl- 1.3.4-oxadiazol-2-yl)- 2,3- dihydrobenzofuran-3 - yi)-3- (methoxymethyl) - 1.2.4-oxadiazol-5- 231 amine(S)-N-(6-(5- cyclopropyl- 1,3,4- oxadiazol-2-yl)-2,3- dihydrobenzofuran-3 - yi)-3- (methoxymethyl) - \ l,2,4-oxadiazol-5- 232 o amine0 (R)-6-((5-(5-methyl- 1,2,4-oxadiazol-3-yl) HN I - ^( 2,3-dihydro- IH-inden- l-yl)amino)-4- (trifluoromethyl)pyridi n-2(lH)-oneNy-O - / F'233N-((S)-6-(5- N^N cyclopropyl- 1,3,4- I oxadiazol-2-yl)-2,3-n Am n dihydrobenzofuran-3- yl)- 3 - ( (R) -tetrahydro- 2H-pyran-3-yl)- 1,2,4- 234 O-N oxadiazol-5-amine N-((S)-6-(5-isopropyl- l,3,4-oxadiazol-2-yl)- 2,3- dihydrobenzofuran-3- HN^< Q yl)- 3 - ( (R) -tetrahydro- 2H-pyran-3-yl)- 1,2,4- 235 O-N oxadiazol-5 - amine N-((R)-5-(5-isopropyl- O-N 1.3.4-oxadiazol-2-yl)- 2,3-dihydro- IH-inden- l-yl)-3-((lr,3R)-3- itV> ° methoxycyclobutyl)- 1.2.4-oxadiazol-5-236 amine77MF-365146518498922021940N-((S)-6-(5- cyclopropyl- 1,3,4- oxadiazol-2-yl)-2,3- dihydrobenzofuran-3 - yl)-3-((lr,3S)-3- methoxycyclobutyl)- l,2,4-oxadiazol-5- 237 amineN-((S)-6-(5-isopropyl- l,3,4-oxadiazol-2-yl)- 2,3- dihydrobenzofuran-3 - yl)-3-((lr,3S)-3- f c methoxycyclobutyl) - l,2,4-oxadiazol-5- 238 O^N amineN-((R)-5-(5-ethyl- O-NHN-^Q), 1.3.4-oxadiazol-2-yl)- 2,3-dihydro- IH-inden- 'N\ Vl-yl)-3-((lr,3R)-3- methoxycyclobutyl)- 1.2.4-oxadiazol-5- 239 amineN-((S)-6-(5-ethyl- 1.3.4-oxadiazol-2-yl)- 2,3- dihydrobenzofuran-3 - A yl)-3-((lr,3S)-3- methoxycyclobutyl)- 1.2.4-oxadiazol-5- 240HN%¥ amine(R)-N-(5-(5-ethyl- l,3,4-oxadiazol-2-yl)- 2,3-dihydro- IH-inden- l-yl)-3-(oxetan-3- ylmethyl)- 1,2,4- oxadiazol-5 - amine 241(S)-N-(6-(5-ethyl- Mgv^0l,3,4-oxadiazol-2-yl)- 2,3- uQ dihydrobenzofuran-3 - yl)-3-(oxetan-3- ylmethyl)- 1,2,4-242HN< Yo oxadiazol-5 - amine78MF-365146518498922021940(S)-N-(6-(5- cyclopropyl- 1,3,4- oxadiazol-2-yl)-2,3- dihydrobenzofuran-3 - yl)-3-(oxetan-3- ylmethyl)- 1,2,4- 243 oxadiazol-5 - amine (R)-N-(5-(5- cyclopropyl- 1,3,4- oxadiazol-2-yl)-2,3- dihydro- 1 H-inden- 1 - yl)-3-(oxetan-3- ylmethyl)- 1,2,4- 244 t^ Nq-Nr^0r°" oxadiazol-5 - amine(S)-N-(6-(5- cyclopropyl- 1,3,4- oxadiazol-2-yl)-2,3- dihydrobenzofuran-3 - r° yl)-3- (isopropoxymethyl)- l,2,4-oxadiazol-5- 245 aminep OrN (R)-3- HN-V^oy (isopropoxymethyl)- N-(5-(5-isopropyl- l,3,4-oxadiazol-2-yl)- 2,3-dihydro- IH-inden- 1 -yl) - 1, 2,4- oxadiazol- 246 A 5-amine(S)-N-(6-(5-ethyl- 1.3.4-oxadiazol-2-yl)- 2,3- dihydrobenzofuran-3 - yO yl)-3- (isopropoxymethyl)-HNprpAA\ 1.2.4-oxadiazol-5- 247 O-N amineOrN (R)-N-(5-(5-ethyl- HN-< OX^0Y 1.3.4-oxadiazol-2-yl)- 2,3-dihydro- IH-inden- l-yl)-3- (isopropoxymethyl)- ^ -78° 1.2.4-oxadiazol-5-248 / N4I amine79MF-365146518498922021940O~N (R)-N-(5- (5-methyl- 1.3.4-oxadiazol-2-yl)- 2,3-dihydro- IH-inden- l-yl)-3-orOO (isopropoxymethyl)- 1.2.4-oxadiazol-5- 249 N'NamineO-N (R)-N-(5-(5-ethyl- l,3,4-oxadiazol-2-yl)- 2,3-dihydro- IH-inden- l-yl)-3- (ethoxymethyl)- 1,2,4- oxadiazol-5 - amine 250(S)-3-(ethoxymethyl)- N-(6-(5-ethyl- 1,3,4- oxadiazol-2-yl)-2,3- dihydrobenzofuran-3 - yl)-l,2,4-oxadiazol-5- amine251 O-N(R)-N-(5-(5- 0— N cyclopropyl- 1,3,4- oxadiazol-2-yl)-2,3- dihydro- 1 H-inden- 1 - <^©0 yl)- 3 - (ethoxymethyl) - l,2,4-oxadiazol-5- 252 amineO-N 3-((lR,5S)-3- oxabicyclo [3.1.0] hexa n-l-yl)-N-((R)-5-(5- ethyl- 1,3,4-oxadiazol- J X5 2-yl)-2,3-dihydro-lH- inden- 1-yl)- 1,2,4- 253 oxadiazol-5 - amine 3-((lR,5S)-3- N-M oxabicyclo [3.1.0] hexa n-l-yl)-N-((S)-6-(5- cyclopropyl- 1,3,4- oxadiazol-2-yl)-2,3- ^9>XX)dihydrobenzofuran-3 -HN~<0< Co yl)-l,2,4-oxadiazol-5-254 O-N amine80MF-3651465184989220219403-((lR,5S)-3- oxabicyclo [3.1.0] hexa n-l-yl)-N-((S)-6-(5- isopropyl- 1,3,4- oxadiazol-2-yl)-2,3- dihydrobenzofuran-3 -HN^O< CO yl)-l,2,4-oxadiazol-5- 255 O-N amineOH l-(6-(((R)-5-(5- methyl- 1,2,4- HN-O < oxadiazol-3-yl)-2,3- dihydro- 1 H-inden- 1 - yl)amino)pyridin-3-NyJ©0 yl)ethan-l-ol 256M0Hl-(5-(((R)-5-(5- methyl- 1,2,4- oxadiazol-3-yl)-2,3- dihydro- 1 H-inden- 1 - yl)amino)pyrazin-2- yl)ethan-l-ol2573-((lS,5R)-3- oxabicyclo [3.1.0] hexa n-l-yl)-N-((S)-5-(5- ethyl- 1,3,4-oxadiazol- pO 2-yl)-2,3-dihydro-lH- W Q inden- 1-yl)- 1,2,4- 258 O-N oxadiazol-5 - amine 3-((lS,5R)-3- OrN oxabicyclo [3.1.0] hexa n-l-yl)-N-((R)-6-(5- ethyl- 1, 3,4- oxadiazol- 2-yl)-2,3- IQO dihydrobenzofuran-3 - yl)-l,2,4-oxadiazol-5- 259 / AN^N amine(S)-N-(6-(5-isopropyl- l,3,4-oxadiazol-2-yl)- 2,3- dihydrobenzofuran-3 - yl)-3-(oxetan-3- ylmethyl)- 1,2,4-260 O-N L—O oxadiazol-5 - amine81MF-3651465184989220219403-((lS,5R)-3- oxabicyclo [3.1.0] hexa n-l-yl)-N-((S)-6-(5- ethyl- 1, 3,4- oxadiazol- 2-yl)-2,3- dihydrobenzofuran-3 - yl)-l,2,4-oxadiazol-5- 261 O-N amine(S)-N-(6-(5- cyclopropyl- 1,3,4- oxadiazol-2-yl)-2,3- dihydrobenzofuran-3 - yl)- 3 - (ethoxymethyl) -HN- / QY^O'^ l,2,4-oxadiazol-5- 262 O-N amine3-((lS,5R)-3- N-Noxabicyclo [3.1.0] hexa n-l-yl)-N-((S)-6-(5- cyclopropyl- 1,3,4- oxadiazol-2-yl)-2,3- dihydrobenzofuran-3 - yl)-l,2,4-oxadiazol-5- 263 O-N amine3-((lS,5R)-3- oxabicyclo [3.1.0] hexa n-l-yl)-N-((S)-6-(5- isopropyl- 1,3,4- oxadiazol-2-yl)-2,3- dihydrobenzofuran-3 - yl)-l,2,4-oxadiazol-5- 264 O-N amineO-N N-((R)-5-(5-ethyl- 1.3.4-oxadiazol-2-yl)- 2,3-dihydro- IH-inden- ■'N\ / l-yl)-3-((R)- ri )T^> tetrahydrofuran-2-yl)- 1.2.4-oxadiazol-5- amine265 / YpjN-((S)-6-(5-ethyl- 1.3.4-oxadiazol-2-yl)- 2,3- dihydrobenzofuran-3 -M^w yi)-3-((R)- » N. / tetrahydrofuran-2-yl)-HN^qf^° 1.2.4-oxadiazol-5-266 O-N amine82MF-365146518498922021940N-((S)-6-(5-isopropyl- 1.3.4-oxadiazol-2-yl)- 2,3- dihydrobenzofuran-3 - yi)-3-((R)- tetrahydrofuran-2-yl)- o 1.2.4-oxadiazol-5- 267 L / Ty-^zHN^ Oo~rN ^° aminez (R)-N-(5-(5- cyclopropyl- 1,3,4- 6? / = oxadiazol-2-yl)-2,3- o dihydro- 1 H-inden- 1 - o yl)-3-((2- methoxyethoxy)methy \ l)-l,2,4-oxadiazol-5- f c268 amine(R)-N-(5-(5-isopropyl- l,3,4-oxadiazol-2-yl)- 2,3-dihydro- IH-inden- l-yl)-3-((2- methoxyethoxy)methy l)-l,2,4-oxadiazol-5- 269 amine(S)-N-(6-(5-ethyl- l,3,4-oxadiazol-2-yl)- 2,3- N~N dihydrobenzofuran-3 - \ — (Qk yi)-3-((2-0vCzLy methoxyethoxy)methy HN-X^TO— °X l)-l,2,4-oxadiazol-5- 270 O^N amine(R)-N-(5-(5-ethyl- l,3,4-oxadiazol-2-yl)- NrN 2,3-dihydro- IH-inden- l-yl)-3-((2- methoxyethoxy)methy HN^Y-O— °- l)-l,2,4-oxadiazol-5- 271 O^N amineO-N (R)- 3 - (ethoxymethyl) -HN-XOk^°^ N-(5-(5-isopropyl- l,3,4-oxadiazol-2-yl)- 2,3-dihydro- IH-inden- W vkC* 1 -yl) - 1, 2,4- oxadiazol- 5-amine27283MF-365146518498922021940(R)-N-(5- (5-methyl- l,3,4-oxadiazol-2-yl)- 2,3-dihydro- IH-inden- JOO l-yl)-3-(oxetan-3- ylmethyl)- 1,2,4- oxadiazol-5 - amine 273 i\rNO-N N-((R)-5-(5-ethyl- 1.3.4-oxadiazol-2-yl)- HN^Qk,.x^ 2,3-dihydro- IH-inden- ■'N\ / l-yl)-3-((S)- ri )T^> tetrahydrofuran-2-yl)- 1.2.4-oxadiazol-5- amine274 / YpjO-N N-((R)-5-(5-isopropyl- 1.3.4-oxadiazol-2-yl)- HN^Qk,.^,? N r > 2,3-dihydro- IH-inden- l-yl)-3-((S)- tetrahydrofuran-2-yl)- 1.2.4-oxadiazol-5- A cO ° amine275 / N-N(S)-3-(ethoxymethyl)- N-(6-(5-isopropyl- l,3,4-oxadiazol-2-yl)- 2,3- dihydrobenzofuran-3 - yl)-l,2,4-oxadiazol-5- 276HN~< Oo-Nr^'0'^ amine(R)-N-(5-(5-ethyl- l,3,4-oxadiazol-2-yl)- NrN 2,3-dihydro- IH-inden- l-yl)-3-((2, 2,3,3-Ftetrafluoropropoxy)meHN~YOl0AFthyl)- 1,2,4-oxadiazol- 277 O^N F F 5-amine(S)-N-(6-(5-ethyl- l,3,4-oxadiazol-2-yl)- 2,3- \ — ( NO— Nk dihydrobenzofuran-3 - ° \oOFyl)-3-((2, 2,3,3- tetrafluoropropoxy)me HN-VQ)^°^>^Fthyl)- 1,2,4-oxadiazol-278 VN F F 5-amine84MF-365146518498922021940(S)-N-(6-(5- cyclopropyl- 1,3,4- oxadiazol-2-yl)-2,3- N-N dihydrobenzofuran-3 - yl)-3-((2, 2,3,3- tetrafluoropropoxy)me thyl)- 1,2,4-oxadiazol- 279 VN F F 5-amine(S)-N-(6-(5-isopropyl- l,3,4-oxadiazol-2-yl)- 2,3- N-N dihydrobenzofuran-3 - yl)-3-((2, 2,3,3- tetrafluoropropoxy)meHN-<or0XFthyl)- 1,2,4-oxadiazol- 280 Vri F F 5-amine(R)-N-(5-(5-ethyl- feN CJ l,3,4-oxadiazol-2-yl)- 2,3-dihydro- IH-inden- l-yl)-3-((tetrahydro- 2H-pyran-4- yl)methyl) -1,2,4- 281 / N4I oxadiazol-5 - amine (S)-N-(6-(5-ethyl- 1.3.4-oxadiazol-2-yl)- 2,3- dihydrobenzofuran-3 - yl)- 3 - ( (tetrahydro- 2H- pyran-4-yl)methyl)- 1.2.4-oxadiazol-5- 282 °-NCo amineN-((S)-6-(5-ethyl- 1.3.4-oxadiazol-2-yl)- C m 2,3-Ndihydrobenzofuran-3 - O yi)-3-((S)- tetrahydrofuran-2-yl)- O 1.2.4-oxadiazol-5- 283 -N amineN-((S)-6-(5- cyclopropyl- 1,3,4- N^N oxadiazol-2-yl)-2,3- dihydrobenzofuran-3 - yi)-3-((S)- tetrahydrofuran-2-yl)-HNl,2,4-oxadiazol-5- ~< O7" '284 O-N amine85MF-365146518498922021940N-((R)-5-(5-ethyl- O-Nl,3,4-oxadiazol-2-yl)- 'j, 2,3-dihydro- IH-inden- 1-yl)-3-((R)- tetrahydro-2H-pyran- 2-yl)- 1,2,4-oxadiazol- 285 5-amineN-((S)-6-(5-ethyl- l,3,4-oxadiazol-2-yl)- 2,3- dihydrobenzofuran-3- n yl)- 3 - ( (R) -tetrahydro-?>oH N2H-pyran-2-yl)- 1,2,4- 286 O—N oxadiazol-5 - amine ° / N-((S)-6-(5-isopropyl- l,3,4-oxadiazol-2-yl)- 2,3- dihydrobenzofuran-3-n° 0 5 n yl)- 3 - ( (R) -tetrahydro-H N'X OCX°^ 2H-pyran-2-yl)- 1,2,4- 287 oxadiazol-5 - amine N-NN-((S)-6-(5- cyclopropyl- 1,3,4- oxadiazol-2-yl)-2,3- dihydrobenzofuran-3- yl)- 3 - ( (R) -tetrahydro- 2H-pyran-2-yl)- 1,2,4- 288 O-N oxadiazol-5 - amine N-((S)-6-(5- cyclopropyl- 1,3,4- oxadiazol-2-yl)-2,3- dihydrobenzofuran-3 - yl)-3-((S)-tetrahydro- 2H-pyran-2-yl)- 1,2,4- 289 oxadiazol-5 - amine N-((S)-6-(5-ethyl- MoT0l,3,4-oxadiazol-2-yl)- 2,3-oAm yx dihydrobenzofuran-3 - • N..1 1 yl)-3-((S)-tetrahydro-HN'~O0>2H-pyran-2-yl)- 1,2,4-290 O-N oxadiazol-5 - amine86MF-365146518498922021940N-((S)-6-(5-isopropyl- l,3,4-oxadiazol-2-yl)- 2,3- dihydrobenzofuran-3 - • N.. L J yl)-3-((S)-tetrahydro-HN'~O0>2H-pyran-2-yl)- 1,2,4- 291 o- N oxadiazol-5 - amine O-N N-((R)-5-(5-ethyl- l,3,4-oxadiazol-2-yl)- 2,3-dihydro- IH-inden- 1-yl)-3-((S)- JOO °Z tetrahydro-2H-pyran- z^OT ^ 2-yl)- 1,2,4-oxadiazol- 292 5-amine(S)-l-(6-((6-(5-ethyl-0l,3,4-oxadiazol-2-yl)- 2,3- dihydrobenzofuran-3 - oOV \ PH yl)amino)pyridin-3- yl)-2-methylpropan-2- 293 N^Z ol(S)-3-cyclopropyl-N- vJnN(6-(5-ethyl- 1,3,4- oxadiazol-2-yl)-2,3- dihydrobenzofuran-3 -0AW A yl)-l,2,4-oxadiazol-5- v I'k ^ZA amineHN^c5f294 O-NN-N(S)-3-cyclopropyl-N- (6-(5-cyclopropyl- l,3,4-oxadiazol-2-yl)- 2,3- A dihydrobenzofuran-3 - V l\k ^Z\ yl)-l,2,4-oxadiazol-5- amine295 O-N(S)-3-((2,2- V_ / oNdifluoroethoxy)methyl )-N-(6-(5-ethyl- 1,3,4-oAoxadiazol-2-yl)-2,3- wV |\L _ dihydrobenzofuran-3 -H N Fyl)-l,2,4-oxadiazol-5- O296 ^N f amine87MF-365146518498922021940N-((S)-6-(5-isopropyl- 1.3.4-oxadiazol-2-yl)- 2,3- dihydrobenzofuran-3 - yi)-3-((S)- N O tetrahydrofuran-2-yl)- 2HN'O 1.2.4-oxadiazol-5- 297 0~N amineN-((R)-5-(5- O~N cyclopropyl- 1,3,4- oxadiazol-2-yl)-2,3- - N \ ) dihydro- 1 H-inden- 1 - yl)-3-((S)- JOO tetrahydrofuran-2-yl)- l,2,4-oxadiazol-5- 298 amine(S)-N-(6-(5-ethyl- 1.3.4-oxadiazol-2-yl)- MS?O2,3- dihydrobenzofuran-3 -0TOO yl)-3-(2-H»N^ONk methoxypropan-2-yl)- Y^V 1.2.4-oxadiazol-5- 299 O-N amineN-((S)-6-(5- N-N cyclopropyl- 1,3,4- oxadiazol-2-yl)-2,3- dihydrobenzofuran-3 - yl)-3-((R)- tetrahydrofuran-2-yl)-HN^O / ^ l,2,4-oxadiazol-5- 300 O4J amine(S)-3-(2-(2,2- difluoroethoxy )ethyl) - N-(6-(5-isopropyl- N-N l,3,4-oxadiazol-2-yl)- 2,3-V1?730Adihydrobenzofuran-3 - HN— (CjlFyl)-l,2,4-oxadiazol-5- 301 b^N amine(R)-3-(2-ethoxyethyl)- O-NHNXO^-0^ N-(5-(5-ethyl- 1,3,4- oxadiazol-2-yl)-2,3- dihydro- 1 H-inden- 1 - yl)-l,2,4-oxadiazol-5-302 amine88MF-365146518498922021940\— (S)-3-(2-ethoxyethyl)- N-(6-(5-ethyl- 1,3,4- oxadiazol-2-yl)-2,3- dihydrobenzofuran-3 - yl)-l,2,4-oxadiazol-5- 303 O—N amine(S)-3-(2-ethoxyethyl)- N-(6-(5-cyclopropyl- l,3,4-oxadiazol-2-yl)- 2,3- dihydrobenzofuran-3 - yl)-l,2,4-oxadiazol-5- 304 amine(R)-3-(2-ethoxyethyl)- N-(5-(5-cyclopropyl- l,3,4-oxadiazol-2-yl)- 2,3-dihydro- IH-inden- 1 -yl) - 1, 2,4- oxadiazol- 305 4 5-amineO-N (R)-3-(2-ethoxyethyl)- N-(5-(5-isopropyl- l,3,4-oxadiazol-2-yl)- 2,3-dihydro- IH-inden- 1 -yl) - 1, 2,4- oxadiazol- 306 ib o 5-amine(S)-3-(2-ethoxyethyl)- A A N-(6-(5-isopropyl- l,3,4-oxadiazol-2-yl)- 2,3- dihydrobenzofuran-3 - yl)-l,2,4-oxadiazol-5- 307 O—N amineJQN (S)-3-(2-ethoxyethyl)- N-(6-(5-methyl- 1,3,4-oAm oxadiazol-2-yl)-2,3- dihydrobenzofuran-3 - HNYOY^^308 O N0^ yl)-l,2,4-oxadiazol-5- - amine— zoN(S)-3-(ethoxymethyl)- N-(6-(5-methyl- 1,3,4- oxadiazol-2-yl)-2,3- Am V N dihydrobenzofuran-3 -HNyl)-l,2,4-oxadiazol-5- YOO-TN ^°^309 amine89MF-365146518498922021940N-N (S)-N-(6-(5-methyl- -XOJ!. o l,3,4-oxadiazol-2-yl)- oQ 2,3- dihydrobenzofuran-3 - yl)-3-(oxetan-3- ylmethyl)- 1,2,4- oxadiazol-5 - amine 310HNIQFU08- (S)-N-(6-(5-ethyl- 1.3.4-oxadiazol-2-yl)- 2,3- dihydrobenzofuran-3 - yl)-3- o» N (propoxymethyl)-HN^O^ 1.2.4-oxadiazol-5- 311 O-N °^ amine(S)-N-(6-(5- cyclopropyl- 1,3,4- oxadiazol-2-yl)-2,3- dihydrobenzofuran-3 - yl)-3- » N (propoxymethyl)- l,2,4-oxadiazol-5- 312 O-N amine(S)-N-(6-(5-methyl- 1.3.4-oxadiazol-2-yl)- 2,3- — / oNdihydrobenzofuran-3 -oAm yl)-3- » N (propoxymethyl)- 1.2.4-oxadiazol-5- 313 O-N amine(R)-N-(5-(5-ethyl- 1.3.4-oxadiazol-2-yl)- 2,3-dihydro- IH-inden- l-yl)-3- (propoxymethyl)- 1.2.4-oxadiazol-5- 314 amine(R)-N-(5- (5-methyl- O-N 1.3.4-oxadiazol-2-yl)- H N 2,3-dihydro- IH-inden- l-yl)-3- (propoxymethyl)- 1.2.4-oxadiazol-5-315 N-N amine90MF-365146518498922021940(R)-N-(5-(5-ethyl- l,3,4-oxadiazol-2-yl)- 2,3-dihydro- IH-inden- Az°Aaz•° l-yl)-3-(3- 4 methoxypropyl)- 1,2,4- 316 oxadiazol-5 - amine (R)-N-(5-(5- A cyclopropyl- 1,3,4- ft oxadiazol-2-yl)-2,3- dihydro- 1 H-inden- 1 - yl)-3-(3- methoxypropyl)- 1,2,4- 317 o oxadiazol-5 - amine t t r O-N (R)-N-(5-(5-isopropyl- HN / O^ o o o / O. l,3,4-oxadiazol-2-yl)- / / 2,3-dihydro- IH-inden- l-yl)-3-(3- methoxypropyl)- 1,2,4- HSr®0318 oxadiazol-5 - amine (R)-3-(3- methoxypropyl) -N- (5 - (5-methyl- 1,3,4- oxadiazol-2-yl)-2,3- dihydro- 1 H-inden- 1 - yl)-l,2,4-oxadiazol-5- 319 amineN-((S)-6-(5-ethyl- l,3,4-oxadiazol-2-yl)- 2,3- dihydrobenzofuran-3 - yl)-3-((R)-l- methoxyethyl)- 1,2,4- 320HN%Q; A oxadiazol-5 - amine (S)-3-(2-(2,2- difluoroethoxy )ethyl) - N-(6-(5-ethyl- 1,3,4- oxadiazol-2-yl)-2,3- dihydrobenzofuran-3 - yl)-l,2,4-oxadiazol-5- 321 amine(S)-3-(2-(2,2- difluoroethoxy )ethyl) - N-(6-(5-cyclopropyl- N— N l,3,4-oxadiazol-2-yl)- 2,3- dihydrobenzofuran-3 - HN-— (QJFyl)-l,2,4-oxadiazol-5-322 O'-N amine91MF-365146518498922021940(S)-3-(2-(2,2- difluoroethoxy )ethyl) - N-(6-(5-methyl- 1,3,4- oxadiazol-2-yl)-2,3- dihydrobenzofuran-3 - yl)-l,2,4-oxadiazol-5- 323 amine(S)-3-((2,2- difluoroethoxy)methyl N-N)-N-(6-(5-cyclopropyl- l,3,4-oxadiazol-2-yl)- 2,3- dihydrobenzofuran-3 - HN Fyl)-l,2,4-oxadiazol-5- 324 O4J T amine(S)-3-((2,2- odifluoroethoxy)methyl )-N-(6-(5-isopropyl- l,3,4-oxadiazol-2-yl)- 2,3- dihydrobenzofuran-3 - yl)-l,2,4-oxadiazol-5- 1 o1H N325 O^NFamine(R)-N-(5-(5-ethyl- OrN l,3,4-oxadiazol-2-yl)- 2,3-dihydro- IH-inden- ^ fCo =■ Nl-yl)-3-((2,2- difluoroethoxy)methyl )-l,2,4-oxadiazol-5- 326 amine(R)-N-(5-(5- cyclopropyl- 1,3,4- OrN oxadiazol-2-yl)-2,3- HN-^Qk^O^z^F dihydro- 1 H-inden- 1 -.- N yl)-3-((2,2- difluoroethoxy)methyl o^zlylL / )-l,2,4-oxadiazol-5- 327LX)$2N amine(R)-N-(5-(5-isopropyl- O-N l,3,4-oxadiazol-2-yl)- HN-^kk^O^z^p? N 2,3-dihydro- IH-inden- l-yl)-3-((2,2- difluoroethoxy)methyl )-l,2,4-oxadiazol-5-328ZN'Namine92MF-365146518498922021940(R)-3- O-N ((difluoromethoxy)met HN-V^O^F hyl)-N-(5-(5-ethyl- l,3,4-oxadiazol-2-yl)-F2,3-dihydro- IH-inden- 1 -yl) - 1, 2,4- oxadiazol- 329 <7^ 5-amine(S)-3- ((difluoromethoxy)met hyl)-N-(6-(5-ethyl- \- / nNl,3,4-oxadiazol-2-yl)- 2,3-oJw dihydrobenzofuran-3 - yl)-l,2,4-oxadiazol-5- 330 O-N amine(S)-3- ((difluoromethoxy)met N-Nhyl)-N-(6-(5- cyclopropyl- 1,3,4- oxadiazol-2-yl)-2,3- dihydrobenzofuran-3 -HN~<or^o'^F yl)-l,2,4-oxadiazol-5- 331 O-N amine(S)-3- ((difluoromethoxy)met hyl)-N-(6-(5- o x isopropyl- 1,3,4- oxadiazol-2-yl)-2,3- dihydrobenzofuran-3 - yl)-l,2,4-oxadiazol-5- 332 O-N amine(S)-3- (cyclobutoxymethyl) - N-(6-(5-ethyl- 1,3,4- oxadiazol-2-yl)-2,3- 0 7dihydrobenzofuran-3 - yl)-l,2,4-oxadiazol-5- 333 O4I amine(S)-3- (cyclobutoxymethyl) - N— N N-(6-(5-cyclopropyl- l,3,4-oxadiazol-2-yl)- 2,3- dihydrobenzofuran-3 - yl)-l,2,4-oxadiazol-5-334 0~ N amine93MF-365146518498922021940N-((S)-6-(5-ethyl- l,3,4-oxadiazol-2-yl)- Mc^.o2,3- dihydrobenzofuran-3 - yi)-3-(((R)- tetrahydrofuran-2- yl)methyl) -1,2,4- 335 O Od-rN 'V Q^xy oxadiazol-5 - amine N-((S)-6-(5-methyl- l,3,4-oxadiazol-2-yl)- — 2,3- dihydrobenzofuran-3 - yl)-3-(((R)- tetrahydrofuran-2- yl)methyl) -1,2,4- 336 ™^ Od-Nr^ orO\ oxadiazol-5 - amine (S)-N-(6-(5-ethyl- l,3,4-oxadiazol-2-yl)- 2,3- dihydrobenzofuran-3 - yl)-3-(2- methoxyethyl)- 1,2,4- 337H NO-N oxadiazol-5 - amine (S)-N-(6-(5-isopropyl- l,3,4-oxadiazol-2-yl)- 2,3- dihydrobenzofuran-3 - yl)-3-(2- HN-^ / QY^^°Xmethoxyethyl)- 1,2,4- 338 O—N oxadiazol-5 - amine N-N(S)-N-(6-(5- cyclopropyl- 1,3,4- oxadiazol-2-yl)-2,3- dihydrobenzofuran-3 - yl)-3-(2- methoxyethyl)- 1,2,4-H N^oT^°xoxadiazol-5 - amine 339 O—N(S)-(l-(5-((6-(5-ethyl- vJnNl,3,4-oxadiazol-2-yl)- 2,3- TOT )0Hdihydrobenzofuran-3 - yl)amino)- 1,2,4- H vN<N^ 2x"l oxadiazol-3- yl)cyclopropyl)methan340 O-N 0194MF-365146518498922021940(S)-(l-(5-((6-(5- N-N cyclopropyl- 1,3,4- oxadiazol-2-yl)-2,3- dihydrobenzofuran-3 - yl)amino)- 1,2,4-HN^OY^1 oxadiazol-3- yl)cyclopropyl)methanol 341 O-N(S)-(l-(5-((6-(5- isopropyl- 1,3,4- oxadiazol-2-yl)-2,3- TOT )0Hdihydrobenzofuran-3 - yl)amino)- 1,2,4- o o o oxadiazol-3- yl)cyclopropyl)methanol 342 O—N(R)-(l-(5-((5-(5-ethyl- JQL. l,3,4-oxadiazol-2-yl)- 2,3-dihydro- IH-inden- l-yl)amino)- 1,2,4- / , J - / / °Hoxadiazol-3- yl)cyclopropyl)methanol343N^N N-((S)-6-(5- cyclopropyl- 1,3,4- oxadiazol-2-yl)-2,3- dihydrobenzofuran-3 - yl)-3-((R)-l- V bk JIHN~<qr^o- methoxyethyl)- 1,2,4- O oxadiazol-5 - amine 344 -NN-((S)-6-(5-ethyl- \ ZQNl,3,4-oxadiazol-2-yl)- 2,3- dihydrobenzofuran-3 -oAW r yi)-3-((S)-i-HN^OT^o- methoxyethyl)- 1,2,4- oxadiazol-5 - amine 345 O4JN-N N-((S)-6-(5- cyclopropyl- 1,3,4- oxadiazol-2-yl)-2,3- dihydrobenzofuran-3 - yi)-3-((S)-i-HN-(OY'\r methoxyethyl)- 1,2,4- < oxadiazol-5 - amine346 >4i95MF-3651465184989220219400— N N-((R)-5-(5-ethyl- l,3,4-oxadiazol-2-yl)- N 1 2,3-dihydro- IH-inden- l-yl)-3-((S)-l- methoxyethyl)- 1,2,4- oxadiazol-5 - amine 347 / ypN(S)-l-(5-((6-(5-ethyl- V / nNl,3,4-oxadiazol-2-yl)- 2,3- dihydrobenzofuran-3 - yl)amino)- 1,2,4- oxadiazol-3-yl)-2- methylpropan-2-ol 348HN^QrKN-~N(S)-3- ((difluoromethoxy)met hyl)-N-(6- (5-methyl- l,3,4-oxadiazol-2-yl)- 2,3- dihydrobenzofuran-3 -HN~< O^X'0^'F yl)-l,2,4-oxadiazol-5- 349 O-N amineOrN (R)-3- HNXO^ °YF((difluoromethoxy)met hyl)-N-(5- (5-methyl- l,3,4-oxadiazol-2-yl)-F2,3-dihydro- IH-inden- 1 -yl) - 1, 2,4- oxadiazol- 5-amine350 VrN(S)-N-(6-(5-ethyl- vJnNl,3,4-oxadiazol-2-yl)- 2,3- dihydrobenzofuran-3 - yl)-3-((l- methoxycyclopropyl) methyl)- 1,2,4- 351 oxadiazol-5 - amine N-N(S)-N-(6-(5- cyclopropyl- 1,3,4- oxadiazol-2-yl)-2,3- dihydrobenzofuran-3 - yl)-3-((l- methoxycyclopropyl) methyl)- 1,2,4- O-N |352 oxadiazol-5 - amine96MF-365146518498922021940(S)-N-(6-(5-ethyl- l,3,4-oxadiazol-2-yl)- 2,3- dihydrobenzofuran-3 - yi)-3-((i- methoxycyclobutyl)m ethyl)- 1,2,4-oxadiazol- 353 5-amineN-N (S)-N-(6-(5- cyclopropyl- 1,3,4- oxadiazol-2-yl)-2,3- dihydrobenzofuran-3 - yl)-3-((l- methoxycyclobutyl)m ethyl)- 1,2,4-oxadiazol- 354 5-amine(R)-N-(5-(5-ethyl- 1.3.4-oxadiazol-2-yl)- ".""^SSOo 2,3-dihydro- IH-inden- l-yl)-3-(3- ethyloxetan-3-yl)- 1.2.4-oxadiazol-5- amine355(S)-N-(6-(5-ethyl- vJnNl,3,4-oxadiazol-2-yl)- 2,3- dihydrobenzofuran-3 -oAW 1 yl)-3-(3-ethyloxetan- 3 -yl) - 1,2,4-oxadiazol- 5-amine356HN1QF°°(S)-N-(6-(5-isopropyl- l,3,4-oxadiazol-2-yl)- 2,3- dihydrobenzofuran-3 - yl)-3-(3-ethyloxetan-HN-AX> 3 -yl) - 1,2,4-oxadiazol- 5-amine357 O-NN-N(S)-N-(6-(5- cyclopropyl- 1,3,4- oxadiazol-2-yl)-2,3- dihydrobenzofuran-3 - yl)-3-(3-ethyloxetan- 3 -yl) - 1,2,4-oxadiazol- 5-amine35897MF-365146518498922021940(S)-N-ethyl-N-((5-((6- (5-ethyl- 1,3,4- oxadiazol-2-yl)-2,3- dihydrobenzofuran-3 - 0 yl)amino)- 1,2,4-HN-^O^NA oxadiazol-3- yl)methyl) acetamide 359 O O--NN3-((R)- 1,4-dioxan-2- yl)-N-((R)-5-(5-ethyl- HNX^. / ^O l,3,4-oxadiazol-2-yl)- r0r> 2,3-dihydro- IH-inden- 1 -yl) - 1, 2,4- oxadiazol- 5-amine360 ' \rvJoNNN-((S)-6-(5-ethyl- l,3,4-oxadiazol-2-yl)-oA2,3- 00 * Nk JL r° dihydrobenzofuran-3 - > — yl)-3-(5- methyltetrahydrofuran -3-yl)- 1,2,4-oxadiazol- 361HN%or^ 5-amine(S)-N-(6-(5-ethyl- l,3,4-oxadiazol-2-yl)- 2,3- dihydrobenzofuran-3 - yl)-3-(3- methoxypropyl)- 1,2,4- 362 O-N oxadiazol-5 - amine M0X N-((S)-6-(5-ethyl- l,3,4-oxadiazol-2-yl)- iOr > 2,3- dihydrobenzofuran-3 - yl)-3-(((R)- tetrahydrofuran- 3 - yl)methyl) -1,2,4- 363 O-N oxadiazol-5 - amine N-N N-((S)-6-(5- cyclopropyl- 1,3,4- ^? Aeo oxadiazol-2-yl)-2,3- dihydrobenzofuran-3 - yl)-3-(((R)- tetrahydrofuran- 3 - yl)methyl) -1,2,4- 364 "^QF-Qoxadiazol-5 - amine 98MF-365146518498922021940N-((S)-6-(5-isopropyl- l,3,4-oxadiazol-2-yl)- 2,3- dihydrobenzofuran-3 - yi)-3-(((R)- 4 tetrahydrofuran- 3 - ™~< Oo-rN 'n yl)methyl) -1,2,4- 365 oxadiazol-5 - amine N^NN-((S)-6-(5-methyl- / I \ / "z l,3,4-oxadiazol-2-yl)- 2,3- dihydrobenzofuran-3 - yl)-3-(((R)- tetrahydrofuran- 3 - yl)methyl) -1,2,4- 366 "^oF'Q oxadiazol-5 - amine N-((R)-5-(5-ethyl- l,3,4-oxadiazol-2-yl)- 2,3-dihydro- IH-inden- l-yl)-3-(((R)- tetrahydrofuran- 3 - yl)methyl) -1,2,4- oxadiazol-5 - amine 367N-((R)-5-(5- cyclopropyl- 1,3,4- oxadiazol-2-yl)-2,3- dihydro- 1 H-inden- 1 - yl)-3-(((R)- tetrahydrofuran- 3 - yl)methyl) -1,2,4- 368 oxadiazol-5 - amine r\ N-((R)-5-(5-isopropyl- l,3,4-oxadiazol-2-yl)- HN^A. Z'- / 2,3-dihydro- IH-inden- l-yl)-3-(((R)- tetrahydrofuran- 3 - yl)methyl) -1,2,4- oxadiazol-5 - amine 3693-((3S,4R)-4- \ ZQN(difluoromethyl)tetrah ydrofuran-3-yl)-N- ((S)-6-(5-ethyl- 1,3,4- n mFV oxadiazol-2-yl)-2,3- dihydrobenzofuran-3 - ™X3 OO7 -Y 0 N ^° yl)-l,2,4-oxadiazol-5- amine99MF-365146518498922021940O-N L (R)-N-(5-(5-ethyl- l,3,4-oxadiazol-2-yl)- 2,3-dihydro- IH-inden- l-yl)-3-((l- methoxycyclopropyl) methyl)- 1,2,4- oxadiazol-5 - amine 371(S)-N-(6-(5-isopropyl- l,3,4-oxadiazol-2-yl)- 2,3- dihydrobenzofuran-3 - yl)-3-((l- methoxycyclopropyl) methyl)- 1,2,4- 372 O-N | oxadiazol-5 - amine 3 - ( 1 -ethoxy ethyl) -N- vJnN((S)-6-(5-ethyl- 1,3,4- oxadiazol-2-yl)-2,3- dihydrobenzofuran-3 - * JL yl)-l,2,4-oxadiazol-5- amine HN^oy\^373 O'NN^N (S)-3-(2- methoxyethyl)-N-(6- (5-methyl- 1,3,4- oxadiazol-2-yl)-2,3-oAw dihydrobenzofuran-3 - yl)-l,2,4-oxadiazol-5-H Namine374 O~NO-N (R)-N-(5-(5-ethyl- l,3,4-oxadiazol-2-yl)- 2,3-dihydro- IH-inden- l-yl)-3-(2- methoxyethyl)- 1,2,4- oxadiazol-5 - amine 375O-N (R)-N-(5-(5-isopropyl- l,3,4-oxadiazol-2-yl)- 2,3-dihydro- IH-inden- l-yl)-3-(2- methoxyethyl)- 1,2,4- oxadiazol-5 - amine376 H X®0100MF-365146518498922021940O-N (R)-N-(5-(5- cyclopropyl- 1,3,4- oxadiazol-2-yl)-2,3- dihydro- 1 H-inden- 1 - yl)-3-(2- methoxyethyl)- 1,2,4- oxadiazol-5 - amine 377 N-NO-N (R)-3-(2- HNXQVX methoxyethyl)-N-(5- (5-methyl- 1,3,4- oxadiazol-2-yl)-2,3- dihydro- 1 H-inden- 1 - 0^ yl)-l,2,4-oxadiazol-5- amine378 IsR(S)-N-(6-(5-ethyl- 1.3.4-oxadiazol-2-yl)- 2,3- dihydrobenzofuran-3 - yl)-3-(l- methoxycyclopropyl) - 1.2.4-oxadiazol-5- 379 O-N amineN-~N(S)-N-(6-(5- cyclopropyl- 1,3,4- oxadiazol-2-yl)-2,3- dihydrobenzofuran-3 - yl)-3-(l- methoxycyclopropyl) - l,2,4-oxadiazol-5- 380 O-N amine0— N (R)-N-(5-(5-ethyl- 1.3.4-oxadiazol-2-yl)- z^NN^xa 2,3-dihydro- IH-inden- l-yl)-3-(l- methoxycyclopropyl) - 1.2.4-oxadiazol-5- amine381(S)-N-(6-(5-ethyl- l,3,4-oxadiazol-2-yl)- 2,3- dihydrobenzofuran-3 - yl)-3-(l- methoxymethylcyclopropyl)-1,2,4-382 O-N oxadiazol-5 - amine101MF-365146518498922021940(S)-N-(6-(5- N-N cyclopropyl- 1,3,4- oxadiazol-2-yl)-2,3- dihydrobenzofuran-3 - yl)-3-(l-HN^OY^1 methoxymethylcyclop ropyl)- 1,2,4- 383 O-N oxadiazol-5 - amine (R)-N-(5-(5-ethyl- 1,3,4-oxadiazol-2-yl)- N 2,3-dihydro- IH-inden- l-yl)-3-(l- oUOO methoxymethylcyclop ropyl)- 1,2,4- oxadiazol-5 - amine 384(S)-N-(6-(5-ethyl- l,3,4-oxadiazol-2-yl)- 2,3- ( ) > \ / 0 dihydrobenzofuran-3 - yl)-3-(l-N'$L-X'7 (methylsulfonyl)cycloHN^6f ^ propyl) -1,2,4- 385 O-N oxadiazol-5 - amine N-N(S)-N-(6-(5- cyclopropyl- 1,3,4- oxadiazol-2-yl)-2,3- x dihydrobenzofuran-3 - LTZl^ / ,sxyl)-3-(l- (methylsulfonyl)cyclo propyl) -1,2,4- 386 O-N oxadiazol-5 - amine (R)-N-(5-(5-ethyl- HN^ J7UK °WJ -~O l,3,4-oxadiazol-2-yl)- ■'Nrx 2,3-dihydro- IH-inden- l-yl)-3-(l- (methylsulfonyl)cyclo propyl) -1,2,4- oxadiazol-5 - amine 387(3R,4S)-4-(5-(((S)-6- (5-ethyl- 1,3,4- oxadiazol-2-yl)-2,3-M? AW ^4 dihydrobenzofuran-3 - yl)amino)- 1,2,4- » N.1 0 oxadiazol-3- yl)tetrahydrofuran-3 - 388HN^ OO-TN ^carboxylate102MF-365146518498922021940((3S,4S)-4-(5-(((S)-6- \ ZQN(5-ethyl- 1,3,4- oxadiazol-2-yl)-2,3- dihydrobenzofuran-3 - OQ yl)amino)- 1,2,4- oxadiazol-3- yl)tetrahydrofuran-3 - 389HNk OO-TN yl)methanol(S)-N-(6-(5-ethyl- l,3,4-oxadiazol-2-yl)- 2,3- dihydrobenzofuran-3 - yl)-3-(2-methoxy-2- methylpropyl)- 1,2,4- oxadiazol-5 - amine 390 ™~<pn cN-~N(S)-N-(6-(5- cyclopropyl- 1,3,4- oxadiazol-2-yl)-2,3- dihydrobenzofuran-3 - yl)-3-(2-methoxy-2- methylpropyl)- 1,2,4- oxadiazol-5 - amine 391 ™~<prx°'\ ZQN(S)-N-(6-(5-ethyl- l,3,4-oxadiazol-2-yl)- 4-fluoro-2,3- n m dihydrobenzofuran-3 - yl)- 3 - (3 -methyloxetan- 3 -yl) - 1,2,4-oxadiazol- FHN^oT^° 5-amine392 O~N(S)-N-(6-(5-ethyl- vJnN1.3.4-oxadiazol-2-yl)- 4-fluoro-2,3- dihydrobenzofuran-3 - yl)-3-(oxetan-3-yl)-oAW T * l\L r»1 HN^OY^ / 1.2.4-oxadiazol-5- amine393 O~NN-((S)-6-(5-ethyl- \ / QN1.3.4-oxadiazol-2-yl)- 4-fluoro-2,3- dihydrobenzofuran-3 - yl)-3-((S)- tetrahydrofuran-3-yl)- F ^YOT'^ 1.2.4-oxadiazol-5-394 O-N0amine103MF-365146518498922021940(S)-N-(6-(5-ethyl- 1.3.4-oxadiazol-2-yl)- I 4-fluoro-2,3-?n ° dihydrobenzofuran-3 - yi)-3- (methoxymethyl) - F 1.2.4-oxadiazol-5- 395 O-N amineOrN (R)-3-((3,3- difluorocyclobutoxy) HNmethyl)-N-(5- (5-ethyl-?>No Ur-F l,3,4-oxadiazol-2-yl)- 2,3-dihydro- IH-inden- 1 -yl) - 1, 2,4- oxadiazol- 396 / c ^ 5-amine(S)-3-((3,3- difluorocyclobutoxy) methyl)-N-(6- (5-ethyl- l,3,4-oxadiazol-2-yl)- KJ1 / F2,3- \ N / V~Fdihydrobenzofuran-3 - 397HN-x Od yl)-l,2,4-oxadiazol-5- -Nr^°^ amine(S)-3-((3,3- difluorocyclobutoxy) methyl)-N-(6-(5- cyclopropyl- 1,3,4- oxadiazol-2-yl)-2,3- dihydrobenzofuran-3 - yl)-l,2,4-oxadiazol-5- 398 amine(lR,3s)-3-((5-(((R)-5- (5-ethyl- 1,3,4- oxadiazol-2-yl)-2,3- dihydro- 1 H-inden- 1 - yl)amino)- 1,2,4-& Y€O oxadiazol-3- yl)methyl)cyclobutan- 399 / N4J l-ol(lS,3s)-3-((5-(((S)-6- Mc^0(5-ethyl- 1,3,4- oxadiazol-2-yl)-2,3- oO dihydrobenzofuran-3 - yl)amino)- 1,2,4- oxadiazol-3- yl)methyl)cyclobutan- 400 O-N » —OH l-ol104MF-365146518498922021940(lS,3s)-3-((5-(((S)-6- (5-isopropyl- 1,3,4- oxadiazol-2-yl)-2,3- dihydrobenzofuran-3 - yl)amino)- 1,2,4- oxadiazol-3- ™-<d;paO-N 1 — yl)methyl)cyclobutan- 401 OH l-olN-N (lS,3s)-3-((5-(((S)-6- (5-cyclopropyl- 1,3,4- H A. oxadiazol-2-yl)-2,3- dihydrobenzofuran-3 - yl)amino)- 1,2,4- oxadiazol-3- O^N LA yl)methyl)cyclobutan- 402 'OH l-ol(S)-N-(6-(5-ethyl- X / QNl,3,4-oxadiazol-2-yl)- 2,3- dihydrobenzofuran-3 - yl)-3-(l- (methoxymethyl)cyclo H^O / V butyl)- 1,2,4- 403 O-N oxadiazol-5 - amine O-N (R)-N-(5-(5-ethyl- l,3,4-oxadiazol-2-yl)-HA9A<> 2,3-dihydro- IH-inden- l-yl)-3-(l- (methoxymethyl)cyclo o^jOO / ° butyl)- 1,2,4- oxadiazol-5 - amine 404 / N^N(S)-(l-(5-((6-(5-ethyl- \ ZQNl,3,4-oxadiazol-2-yl)- 2,3- dihydrobenzofuran-3 -?Hyl)amino)- 1,2,4- oxadiazol-3- H^O / V yl)cyclobutyl)methano 405 O-N 1O-N (R)-(l-(5-((5-(5-ethyl- HN^Q^ / \ l,3,4-oxadiazol-2-yl)- N / v 2,3-dihydro- IH-inden- l-yl)amino)- 1,2,4- oxadiazol-3- o JQO °Hyl)cyclobutyl)methano 1 / 406105MF-365146518498922021940(S)-N-(6-(5-ethyl- l,3,4-oxadiazol-2-yl)- 2,3- dihydrobenzofuran-3 - yi)-3-((i- (methoxymethyl)cyclo propyl)methyl)- 1,2,4- oxadiazol-5 - amine 407xoN'N (S)-N-(6-(5- cyclopropyl- 1,3,4- oxadiazol-2-yl)-2,3- dihydrobenzofuran-3 - yl)-3-((l- (methoxymethyl)cyclo propyl)methyl)- 1,2,4- oxadiazol-5 - amine 408 ^0(R)-N-(5-(5-ethyl- l,3,4-oxadiazol-2-yl)- «4o£S><i 2,3-dihydro- IH-inden- l-yl)-3-((l- (methoxymethyl)cyclo propyl)methyl)- 1,2,4- oxadiazol-5 - amine 409(S)-(l-((5-((6-(5-ethyl- l,3,4-oxadiazol-2-yl)- 2,3- dihydrobenzofuran-3 - yl)amino)- 1,2,4- oxadiazol-3-HNyl)methyl)cyclopropyl 1QZ?<410 HO )methanolN-~N(S)-(l-((5-((6-(5-ethyl- l,3,4-oxadiazol-2-yl)- 2,3- dihydrobenzofuran-3 - yl)amino)- 1,2,4- oxadiazol-3- yl)methyl)cyclopropyl “gQggo)methanol411 HO106MF-365146518498922021940r.H0(R)-(l-((5-((5-(5- ethyl- 1, 3,4- oxadiazol- 2-yl)-2,3-dihydro-lH- inden-l-yl)amino)- l,2,4-oxadiazol-3- yl)methyl)cyclopropyl )methanol412(3-(5-(((R)-5-(5-ethyl- HNAO l,3,4-oxadiazol-2-yl)-NL ^f ^02,3-dihydro- IH-inden- l-yl)amino)- 1,2,4-,-. X / / °hoxadiazol-3- yl)tetrahydrofuran-3 - yl)methanol413 <43 ^ (S)-l-((5-((6-(5-ethyl- l,3,4-oxadiazol-2-yl)- 2,3- oO dihydrobenzofuran-3 - yl)amino)- 1,2,4- oxadiazol-3- yl)methyl)cyclobutan- 414 ”N4§P<> l-ol(S)-l-((5-((6-(5- isopropyl- 1,3,4- oxadiazol-2-yl)-2,3- dihydrobenzofuran-3 - yl)amino)- 1,2,4- oxadiazol-3- yl)methyl)cyclobutan- 415 l-ol(R)-l-((5-((5-(5- cyclopropyl- 1,3,4- HNAO^ O oxadiazol-2-yl)-2,3- dihydro- 1 H-inden- 1 - yl)amino)- 1,2,4- oxadiazol-3- yl)methyl)cyclobutan- 416 C^ No-YN^0l-ol(R)-l-((5-((5-(5- isopropyl- 1,3,4- HN^ > O oxadiazol-2-yl)-2,3- dihydro- 1 H-inden- 1 - yl)amino)- 1,2,4- oxadiazol-3- yl)methyl)cyclobutan-4177N"Nl-ol107MF-365146518498922021940(R)-l-((5-((5-(5- methyl- 1,3,4- HN^ fe> O oxadiazol-2-yl)-2,3- dihydro- 1 H-inden- 1 - yl)amino)- 1,2,4- oxadiazol-3- yl)methyl)cyclobutan- 418 l-ol(R)-l-((5-((5-(5-ethyl- l,3,4-oxadiazol-2-yl)- 2,3-dihydro- IH-inden- l-yl)amino)- 1,2,4- oxadiazol-3- yl)methyl)cyclobutan- l-ol419 / vp\l(S)-N-(6-(5-ethyl- l,3,4-oxadiazol-2-yl)- 2,3- dihydrobenzofuran-3 - yl)-3-((3- methyloxetan-3- yl)methyl) -1,2,4- 420 oxadiazol-5 - amine ((lR,3r)-3-(5-(((R)-5- O-N (5-ethyl- 1,3,4- oxadiazol-2-yl)-2,3- dihydro- 1 H-inden- 1 - yl)amino)- 1,2,4- oxadiazol-3- yl)cyclobutyl)methano 421 1((lS,3r)-3-(5-(((S)-6- (5-ethyl- 1,3,4- H ^ o oxadiazol-2-yl)-2,3- dihydrobenzofuran-3 - lOO yl)amino)- 1,2,4- oxadiazol-3- yl)cyclobutyl)methano 422HN~< Od-9N. 1((lS,3r)-3-(5-(((S)-6- N-N(5-cyclopropyl- 1,3,4- oxadiazol-2-yl)-2,3- dihydrobenzofuran-3 - yl)amino)- 1,2,4- N / j" OH oxadiazol-3-HN^O^ yl)cyclobutyl)methano423 O-N 1108MF-365146518498922021940((lS,3r)-3-(5-(((S)-6- (5-isopropyl- 1,3,4- oxadiazol-2-yl)-2,3- dihydrobenzofuran-3 - yl)amino)- 1,2,4- \ N,. C / 0Hoxadiazol-3- yl)cyclobutyl)methano 424HN^ OO-TN 1(S)-3-(3,3- difluorocyclobutyl)-N- (6-(5-ethyl- 1,3,4- i( )| y F oxadiazol-2-yl)-2,3- dihydrobenzofuran-3 - yl)-l,2,4-oxadiazol-5- 425HN^ OO-TN ^ amineO-N (R)-3-(3,3- difluorocyclobutyl)-N-N(5-(5-ethyl- 1,3,4- vV oxadiazol-2-yl)-2,3- rnr >fdihydro- 1 H-inden- 1 - yl)-l,2,4-oxadiazol-5- amine426 ' ixp'i(S)-N-(6-(5-isopropyl- l,3,4-oxadiazol-2-yl)- 2,3- dihydrobenzofuran-3 - yl)-3-((3- methyloxetan-3- yl)methyl) -1,2,4- 427 ™%Q; P<> oxadiazol-5 - amine (S)-3-(3,3-difluoro-l- M^omethylcyclobutyl)-N- (6-(5-ethyl- 1,3,4- oxadiazol-2-yl)-2,3- oQ dihydrobenzofuran-3 - yl)-l,2,4-oxadiazol-5- amine428 O-NO-N (R)-3-(3,3-difluoro-l- methylcyclobutyl)-N- (5-(5-ethyl- 1,3,4- oxadiazol-2-yl)-2,3- dihydro- 1 H-inden- 1 - yl)-l,2,4-oxadiazol-5- amine429 ' IM^N109MF-365146518498922021940O~N 1 (R)-3-((l- methoxycyclopropyl) methyl)-N-(5-(5- x =o < methyl- 1,3,4- / z — oxadiazol-2-yl)-2,3- dihydro- 1 H-inden- 1 - yl)-l,2,4-oxadiazol-5- 430 i\rN amineN-((S)-6-(5-ethyl- vJnN^3<- z 1.3.4-oxadiazol-2-yl)- 2,3- dihydrobenzofuran-3 - yi)-3-((S)-i- methylazetidin-2-yl)- 1.2.4-oxadiazol-5- 431 amine< JY 3-(5-(((S)-6-(5-ethyl- ° ° O O l,3,4-oxadiazol-2-yl)- 2,3- dihydrobenzofuran-3 - yl)amino)- 1,2,4- oxadiazol-3- yl)tetrahydrothiophene 432 1,1 -dioxide3-(5-(((R)-5-(5-ethyl- l,3,4-oxadiazol-2-yl)- 2,3-dihydro- IH-inden- l-yl)amino)- 1,2,4- oxadiazol-3- yl)tetrahydrothiophene 1,1 -dioxide433(S)-3-(2- vJnNoxabicyclo[2.1. l]hexa n-4-yl)-N- (6- (5 -ethyl-ro l,3,4-oxadiazol-2-yl)- 2,3-H*Nbk ^< 7 dihydrobenzofuran-3 - yl)-l,2,4-oxadiazol-5- 434 ^ Od~Np^ amineO-N (R)-3-(2- oxabicyclo[2.1. l]hexaH?NX9\O0n-4-yl)-N- (5 - (5 -ethyl- l,3,4-oxadiazol-2-yl)- 2,3-dihydro- IH-inden- 1 -yl) - 1, 2,4- oxadiazol- / Y Yp\l05-amine435110MF-365146518498922021940N-((S)-6-(5- (methoxymethyl) - 1.3.4-oxadiazol-2-yl)- 2,3- dihydrobenzofuran-3 - yi)-3-((R)- tetrahydrofuran-3-yl)- 1.2.4-oxadiazol-5- 436HN^ Od-rN ^° amineN-((S)-6-(5- (methoxymethyl) - 1.3.4-oxadiazol-2-yl)- 2,3- dihydrobenzofuran-3 - yi)-3-((S)- tetrahydrofuran-3-yl)- 1.2.4-oxadiazol-5- 437HN^ OO^YN ‘^° amine(S)-3-(ethoxymethyl)- N-(6-(5- (methoxymethyl) - l,3,4-oxadiazol-2-yl)- o O 2,3- > N dihydrobenzofuran-3 - yl)-l,2,4-oxadiazol-5- 438 O—N amineO-N (R)-N-(5-(5-isopropyl- 1.3.4-oxadiazol-2-yl)- 2,3-dihydro- IH-inden- l-yl)-3-(l- methoxycyclobutyl)- 1.2.4-oxadiazol-5- amine439 / N-N(S)-3- V vnN(cyclopropoxymethyl)-N-(6-(5-ethyl- 1,3,4- oxadiazol-2-yl)-2,3- dihydrobenzofuran-3 - yl)-l,2,4-oxadiazol-5- amine440 O-N111MF-365146518498922021940(S)-5-(ethoxymethyl)- N-(6-(5-ethyl- 1,3,4- oxadiazol-2-yl)-2,3- dihydrobenzofuran-3 - yl)- 1,2,4-oxadiazol-3- amine HN^OY^O'^X441 N-0(S)-N-(6-(5- (methoxymethyl) - 1.3.4-oxadiazol-2-yl)- 2,3- dihydrobenzofuran-3 - N yl)-3-(oxetan-3-yl)- 1.2.4-oxadiazol-5- 442 O-N amineN^N (S)-3-(3,3-difluoro-l- methylcyclobutyl)-N- (6-(5-methyl- 1,3,4- oxadiazol-2-yl)-2,3- dihydrobenzofuran-3 -HNY OCO^)N / \ / yl)-l,2,4-oxadiazol-5- ^F amine443 -N (R)-3-(3,3-difluoro-l- methylcyclobutyl)-N- (5-(5-methyl- 1,3,4- oxadiazol-2-yl)-2,3- dihydro- 1 H-inden- 1 - yl)-l,2,4-oxadiazol-5- amine444 XrN (S)-N-(6-(5-ethyl- X / QN1.3.4-oxadiazol-2-yl)- 2,3- dihydrobenzofuran-3 - yl)-3-(l- Y methoxycyclobutyl)- ood?i O 1.2.4-oxadiazol-5- 445 O-N amine(R)-N-(5-(5-ethyl- 1.3.4-oxadiazol-2-yl)- 2,3-dihydro- IH-inden- l-yl)-3-(l-,& YW i methoxycyclobutyl)- 1.2.4-oxadiazol-5- amine446 / YrN112MF-365146518498922021940(S)-N-(6-(5- (methoxymethyl) - l,3,4-oxadiazol-2-yl)- oQ 2,3- dihydrobenzofuran-3 - yl)-3-(oxetan-3- ylmethyl)- 1,2,4- 447HNion?0oxadiazol-5 - amine N-N(S)-3-(3,3- difluorocyclobutyl)-N- (6-(5-methyl- 1,3,4- K JI > F oxadiazol-2-yl)-2,3- Z7CFdihydrobenzofuran-3 - yl)-l,2,4-oxadiazol-5-HN^OT^ amine448 O-NO-N (R)-3-(3,3- difluorocyclobutyl)-N- (5-(5-methyl- 1,3,4- vVFoxadiazol-2-yl)-2,3- 10 1 > F dihydro- 1 H-inden- 1 - yl)-l,2,4-oxadiazol-5- amine449 IxpNN-((S)-6-(5-ethyl- 1.3.4-oxadiazol-2-yl)- 2,3- dihydrobenzofuran-3 - yl)-3-((R)-l- * l\k! methylazetidin-2-yl)-HN^Q 1.2.4-oxadiazol-5- 450 O-N< Aamine(S)-3- (cyclopropoxymethyl) -N-(6-(5-isopropyl- l,3,4-oxadiazol-2-yl)- 2,3- dihydrobenzofuran-3 - ™-<oro^ yl)-l,2,4-oxadiazol-5- 451 0-N amineN-~N(S)-3- (cyclopropoxymethyl) -N - (6- (5-cyclopropyl- l,3,4-oxadiazol-2-yl)- 2,3- dihydrobenzofuran-3 - yl)-l,2,4-oxadiazol-5-452 O'N amine113MF-365146518498922021940(S)-3-((2,2- \_ / QNdifluoropropoxy)meth yl)-N-(6-(5-ethyl- l,3,4-oxadiazol-2-yl)- 2,3- dihydrobenzofuran-3 -HN'X yl)-l,2,4-oxadiazol-5- 3 OO45 -N^°^ F< F amine(S)-2-(l-(5-((6-(5- N-N cyclopropyl- 1,3,4-H0oxadiazol-2-yl)-2,3- dihydrobenzofuran-3 - yl)amino)- 1,2,4- oxadiazol-3- yl)cyclopropyl)ethan- 454 O-N l-ol((S)-2-(l-(5-((6-(5- vJnNethyl- 1, 3,4- oxadiazol- 2-yl)-2,3- dihydrobenzofuran-3 -0o )HCS yl)amino)- 1,2,4- oxadiazol-3- yl)cyclopropyl)ethan- 455 O4J l-ol(S)-N-(6-(5- N-N cyclopropyl- 1,3,4- oxadiazol-2-yl)-2,3- dihydrobenzofuran-3 - yi)-3-(3,3- ^^ 4Fdifluorocyclobutyl)- l,2,4-oxadiazol-5- 456HNA OO-TN^ amine(S)-N-(6-(5-N^N cyclopropyl- 1,3,4- oxadiazol-2-yl)-2,3- dihydrobenzofuran-3 - yl)-3-(3,3-difluoro-l- methylcyclobutyl)- l,2,4-oxadiazol-5- 457 O-N amineO-N (R)- 3 - (ethoxymethyl) - N-((R)-5-(5- (methoxymethyl) - £50 l,3,4-oxadiazol-2-yl)- 2,3-dihydro- IH-inden- l-yl)-3-((R)- tetrahydrofuran-3-yl)-458 — o N-N114MF-365146518498922021940l,2,4-oxadiazol-5- amineO-N (R)- 3 - (ethoxymethyl) - N-(5-(5- (methoxymethyl) - l,3,4-oxadiazol-2-yl)-OYW 2,3-dihydro- IH-inden- 1 -yl) - 1, 2,4- oxadiazol- 459 — 0 N-N 5-amineN-((R)-5-(5- O-N (methoxymethyl) - H 'N^Q N k,.^ 1.3.4-oxadiazol-2-yl)- \ X >2,3-dihydro- IH-inden- l-yl)-3-((S)- or> tetrahydrofuran-3-yl)- 1.2.4-oxadiazol-5- 460 amine(S)-3-((2,2- / QN difluoropropoxy)meth yl)-N-(6- (5-methyl- l,3,4-oxadiazol-2-yl)-oAm2,3- dihydrobenzofuran-3 -HN~< O^Xo^X yl)-l,2,4-oxadiazol-5- 461 O-NF Famine(S)-N-(6-(5- N-N cyclopropyl- 1,3,4- oxadiazol-2-yl)-2,3- dihydrobenzofuran-3 - yl)-3-((2,2- difluoropropoxy)meth yl)-l,2,4-oxadiazol-5- 462 O-N F F amineO-N FF(R)-3-((2,2- difluoropropoxy)meth yl)-N-(5- (5-methyl- l,3,4-oxadiazol-2-yl)- 2,3-dihydro- IH-inden- 1 -yl) - 1, 2,4- oxadiazol- 5-amine463 hrNO-NF\ f (R)-3-((2,2-HNAO^O^< difluoropropoxy)meth yl)-N-(5-(5-ethyl- l,3,4-oxadiazol-2-yl)- 2,3-dihydro- IH-inden- J 0O1 -yl) - 1, 2,4- oxadiazol- 5-amine464115MF-365146518498922021940(S)-N-(6-(5-ethyl- M^ol,3,4-oxadiazol-2-yl)- 2,3- oO dihydrobenzofuran-3 - N / "" P yl)-3-((oxetan-3- ylo4HN^O^o^ xy)methyl)- 1,2,4- 465 O-N oxadiazol-5 - amine OrN (R)-3- (methoxymethyl) -N - (5-(5- (methoxymethyl) - l,3,4-oxadiazol-2-yl)- 2,3-dihydro- IH-inden- 1 -yl) - 1, 2,4- oxadiazol- 466 — ON-N 5-amineO-N (R)-l-(3-((5-(5-ethyl- l,3,4-oxadiazol-2-yl)- 2,3-dihydro- IH-inden- l-yl)amino)- 1,2,4- oxadiazol-5- yl)cyclobutan-l-ol 467 / vpjX / QN(S)-l-(5-((6-(5-ethyl- l,3,4-oxadiazol-2-yl)- 2,3-oAm dihydrobenzofuran-3 - yl)amino)- 1,2,4- NH^ oxadiazol-3- n^'-^oy yl)cyclobutan-l-ol 468 O-N(S)-5-(ethoxymethyl)- vJnNN-(6-(5-ethyl- 1,3,4- oxadiazol-2-yl)-5- fluoro-2,3- N dihydrobenzofuran-3 -HNyOT^crx yl)- 1,2,4-oxadiazol-3- 469 O-N amineN-((S)-6-(5-ethyl- \ ZQN1.3.4-oxadiazol-2-yl)- 5-fluoro-2,3-0>XX> dihydrobenzofuran-3 - yl)-3-((S)- tetrahydrofuran-3-yl)- 1.2.4-oxadiazol-5- 0HN^OO4 -7 7 N' 'amine116MF-365146518498922021940(S)-l-(5-((6-(5-ethyl- l,3,4-oxadiazol-2-yl)- 2,3- dihydrobenzofuran-3 - yl)amino)- 1,2,4- oxadiazol-3- yl)cyclobutan-l-ol 471 N-NO-N(S)-l-(5-((6-(5-ethyl- l,3,4-oxadiazol-2-yl)- 2,3- dihydrobenzofuran-3 - » hk JI yl)amino)- 1,2,4- oxadiazol-3- yl)cyclobutan-l-ol 472 O-N3-((S)-l,4-dioxan-2- vJnNyl)-N-((S)-6-(5-ethyl- l,3,4-oxadiazol-2-yl)- 2,3- dihydrobenzofuran-3 -HNyl)-l,2,4-oxadiazol-5- Y(Jr473 O-N amineO-N N-((R)-5-(5- (methoxymethyl) - 1.3.4-oxadiazol-2-yl)- 2,3-dihydro- IH-inden- l-yl)-3-((R)- O-y JYV^'> tetrahydrofuran-2-yl)- 1.2.4-oxadiazol-5- 474 amineN-((S)-6-(5-ethyl- vJnN1.3.4-oxadiazol-2-yl)- 2,3- dihydrobenzofuran-3 - yl)-5-((R)- * bk JL > tetrahydrofuran-2-yl)-HN^O 1.2.4-oxadiazol-3- 475 N^O^0amine(S)-3-(3,3- difluorocyclobutyl)-N- (6-(5- 'M ^ o (methoxymethyl) - l,3,4-oxadiazol-2-yl)- oO 2,3- dihydrobenzofuran-3 - yl)-l,2,4-oxadiazol-5-476 n^ Oq-Nr7amine117MF-365146518498922021940N^N(S)-N-(6-(5- cyclopropyl- 1,3,4- oxadiazol-2-yl)-2,3- dihydrobenzofuran-3 - yl)- 5 - (ethoxymethyl) - l,2,4-oxadiazol-3- 477 N-0 amineN-((S)-6-(5-ethyl- V- ZON1.3.4-oxadiazol-2-yl)- 2,3- dihydrobenzofuran-3 - yi)-5-((R)- tetrahydrofuran-3-yl)-HN^ ho7 H7 4 D" 1.2.4-oxadiazol-3- 8 amine vJnNN-((S)-6-(5-ethyl- 1.3.4-oxadiazol-2-yl)- 2,3-oAW dihydrobenzofuran-3 - yl)-5-((S)- HN^ N-A r / x0tetrahydrofuran-3-yl)- 1.2.4-oxadiazol-3- 479 0 amine(S)-N-(6-(5-ethyl- M J; l,3,4-oxadiazol-2-yl)- 2,3- KX> dihydrobenzofuran-3 - yl)- 5 - (3 -methyloxetan- 3 -yl) - 1,2,4-oxadiazol- 3-amine480(S)-5-(ethoxymethyl)- N-(6-(5-isopropyl- l,3,4-oxadiazol-2-yl)- 2,3- dihydrobenzofuran-3 - yl)- 1,2,4-oxadiazol-3- amine481 N-0O-N N-((R)-5-(5- (methoxymethyl) - H 'N^Q N k,.^ \ X > 1.3.4-oxadiazol-2-yl)- 2,3-dihydro- IH-inden- l-yl)-3-((S)- or> tetrahydrofuran-2-yl)- 1.2.4-oxadiazol-5-482 amine118MF-365146518498922021940O-N (R)-l-(5-((5-(5-ethyl- l,3,4-oxadiazol-2-yl)- 2,3-dihydro- IH-inden- HO l-yl)amino)- 1,2,4- oxadiazol-3- yl)cyclopropan- 1 -ol 483(S)-l-(5-((6-(5-ethyl- l,3,4-oxadiazol-2-yl)- 2,3- dihydrobenzofuran-3 - HO^. yl)amino)- 1,2,4- oxadiazol-3-HN^d>^ yl)cyclopropan- 1 -ol 484 O-N(S)-l-(5-((6-(5- isopropyl- 1,3,4- oxadiazol-2-yl)-2,3- dihydrobenzofuran-3 - HO. yl)amino)- 1,2,4- oxadiazol-3- yl)cyclopropan- 1 -ol 485 O'NN-N(S)-l-(5-((6-(5- cyclopropyl- 1,3,4- oxadiazol-2-yl)-2,3- dihydrobenzofuran-3 - yl)amino)- 1,2,4- oxadiazol-3- "-x&ro yl)cyclopropan- 1 -ol 486 O-NN^NN-((S)-6-(5-methyl- 1.3.4-oxadiazol-2-yl)- 2,3- ° IOCO> dihydrobenzofuran-3 - yl)-5-((R)- HN^ tetrahydrofuran-3-yl)- 1.2.4-oxadiazol-3- 487 N-" O amineN^NN-((S)-6-(5-methyl- 1.3.4-oxadiazol-2-yl)- 2,3- ° IOCO> dihydrobenzofuran-3 - yl)-5-((S)- •,0 tetrahydrofuran-3-yl)- HN^O^ Z 1.2.4-oxadiazol-3-488 N-0 amine119MF-365146518498922021940N-N(S)-N-(6-(5- cyclopropyl- 1,3,4- oxadiazol-2-yl)-2,3- dihydrobenzofuran-3 - yl)-5-(oxetan-3- » Nylmethyl)- 1,2,4- oxadiazol-3 - amine 489HN-C NO-'0< Y L-0'N^N N-((S)-6-(5-methyl- 1.3.4-oxadiazol-2-yl)- 2,3- dihydrobenzofuran-3 -oAW rx yi)-5-((R)- tetrahydrofuran-2-yl)-HN^O / 01.2.4-oxadiazol-3- 490 N-0 amineN'N N-((S)-6-(5- cyclopropyl- 1,3,4- oxadiazol-2-yl)-2,3- dihydrobenzofuran-3 - yi)-5-((R)- » bk JL > tetrahydrofuran-2-yl)-HN\O / 0l,2,4-oxadiazol-3- 491 N-0 aminebkNN-((S)-6-(5- cyclopropyl- 1,3,4- oxadiazol-2-yl)-2,3- dihydrobenzofuran-3 - yi)-5-((R)- » bk JL ) tetrahydrofuran-3-yl)-HN-X l,2,4-oxadiazol-3- 492 NQ-0T ^ aminebkNN-((S)-6-(5- cyclopropyl- 1,3,4- oxadiazol-2-yl)-2,3- dihydrobenzofuran-3 - V - / r°5yl)-5-((S)- tetrahydrofuran-3-yl)- l,2,4-oxadiazol-3- 493 N-0 amineN^N(S)-N-(6-(5-methyl- l,3,4-oxadiazol-2-yl)- 2,3- dihydrobenzofuran-3 - yl)- 5 - (3 -methyloxetan- HN^ > O 3 -yl) - 1,2,4-oxadiazol- 3-amine494 N-0120MF-365146518498922021940N-N(S)-N-(6-(5- cyclopropyl- 1,3,4- oxadiazol-2-yl)-2,3- dihydrobenzofuran-3 -HN^ > O yl)- 5 - (3 -methyloxetan- 3 -yl) - 1,2,4-oxadiazol- 3-amine495 N-0N^N (S)-5-(ethoxymethyl)- N-(6-(5-methyl- 1,3,4- oxadiazol-2-yl)-2,3- dihydrobenzofuran-3 - yl)- 1,2,4-oxadiazol-3- amine496 N-0(S)-N-(6-(5- (methoxymethyl) - l,3,4-oxadiazol-2-yl)- 2,3- dihydrobenzofuran-3 - yl)-5-(oxetan-3- ylmethyl)- 1,2,4- 497 oxadiazol-3 - amine (S)-5-(ethoxymethyl)- N-(6-(5- (methoxymethyl) - 'M ^ol,3,4-oxadiazol-2-yl)- 2,3- dihydrobenzofuran-3 - yl)- 1,2,4-oxadiazol-3- 498 N-0 amine(S)-N-(6-(5-isopropyl- l,3,4-oxadiazol-2-yl)- 2,3- dihydrobenzofuran-3 - yl)-5-(2- methoxyethyl)- 1,2,4-HN^oT^Oxoxadiazol-3 - amine 499 N-NN-0(S)-N-(6-(5- cyclopropyl- 1,3,4- oxadiazol-2-yl)-2,3- dihydrobenzofuran-3 - yl)-5-(2- methoxyethyl)- 1,2,4-H Noxadiazol-3 - amine500 N-0121MF-365146518498922021940N-((S)-6-(5- cyclopropyl- 1,3,4- oxadiazol-2-yl)-2,3- dihydrobenzofuran-3 - yi)-5-((S)- tetrahydrofuran-2-yl)-HN^O' Ozl,2,4-oxadiazol-3- 501 amineN-((S)-6-(5-methyl- N^N 1.3.4-oxadiazol-2-yl)- 2,3- dihydrobenzofuran-3 - yi)-5-((S)- tetrahydrofuran-2-yl)- 1.2.4-oxadiazol-3- 502 N=O amineN-((S)-6-(5- (methoxymethyl) -o1.3.4-oxadiazol-2-yl)- 2,3- dihydrobenzofuran-3 - TQO yi)-5-((S)- tetrahydrofuran-2-yl)-HN^OT"^° 1.2.4-oxadiazol-3- 503 N=O amine(S)-N-(6-(5-isopropyl- l,3,4-oxadiazol-2-yl)- 2,3- dihydrobenzofuran-3 - yl)-5-(oxetan-3- ylmethyl)- 1,2,4- oxadiazol-3 - amine 504 N-0 UoN-((S)-6-(5-isopropyl- 1.3.4-oxadiazol-2-yl)- 2,3- dihydrobenzofuran-3 - * JL yi)-5-((R)- y tetrahydrofuran-2-yl)-HN\O / 1.2.4-oxadiazol-3- 505 N^O0amineN-((S)-6-(5-isopropyl- l,3,4-oxadiazol-2-yl)- 2,3- dihydrobenzofuran-3 - yi)-5-((S)- » NHN.<^O' ozy tetrahydrofuran-2-yl)-506 N^o122MF-365146518498922021940l,2,4-oxadiazol-3- amineN^N(S)-N-(6-(5-methyl- l,3,4-oxadiazol-2-yl)- 2,3- dihydrobenzofuran-3 - yl)-5-(oxetan-3- ylmethyl)- 1,2,4- oxadiazol-3 - amine 507N-N™-<pru(S)-l-(3-((6-(5- cyclopropyl- 1,3,4- oxadiazol-2-yl)-2,3- dihydrobenzofuran-3 - yl)amino)- 1,2,4- oxadiazol-5- yl)cyclopropan- 1 -ol 508 N-0(S)-N-(6-(5-ethyl- l,3,4-oxadiazol-2-yl)- 2.3- dihydrobenzofuran-3 - yl)-2-(2- * N. n methoxyethyl)-2H- 1.2.3-triazol-4-amine 509N^NN-((S)-6-(5-methyl- l,3,4-oxadiazol-2-yl)- 2,3- dihydrobenzofuran-3 - yl)-5-((S)-oxetan-2-H»NN..4 / ^Q)' 0 yl)- 1,2,4-oxadiazol-3- 510 N-0 amine0N^NN-((S)-6-(5-methyl- l,3,4-oxadiazol-2-yl)- 2,3- dihydrobenzofuran-3 - yl)-5-((R)-oxetan-2- yl)- 1,2,4-oxadiazol-3- amine511 YroN^N5-((R)-l-ethoxyethyl)- N-((S)-6-(5-methyl- l,3,4-oxadiazol-2-yl)- 2,3-oAW r dihydrobenzofuran-3 - * N. JL yl)- 1,2,4-oxadiazol-3-HN^OT^o^ amine512 N-0123MF-365146518498922021940N-~NN-((S)-6-(5- cyclopropyl- 1,3,4- oxadiazol-2-yl)-2,3- dihydrobenzofuran-3 - yl)-5-((R)-l- » bk JI ethoxyethyl)- 1,2,4- oxadiazol-3 - amine 513 N-0N-((S)-6-(5-isopropyl- l,3,4-oxadiazol-2-yl)- 2,3- dihydrobenzofuran-3 - yl)-5-((R)-l- * JL ethoxyethyl)- 1,2,4- 5HNkOY^°^ oxadiazol-3 - amine 14 N-0l-(2-(((S)-6-(5-ethyl- V- / nNl,3,4-oxadiazol-2-yl)- 2,3- 'J XJ’ dihydrobenzofuran-3 - yl)amino)pyrimidin-5- yl)propan-l-ol 515 "Nlk r OHN^N(S)-N-(6-(5-methyl- l,3,4-oxadiazol-2-yl)- 2,3- n m dihydrobenzofuran-3 - yl)-5-(2-HN^O7^ °\ methoxyethyl)- 1,2,4- oxadiazol-3 - amine 516 N-0N^N(S)-(3-((6-(5- cyclopropyl- 1,3,4- oxadiazol-2-yl)-2,3- dihydrobenzofuran-3 - yl)amino)- 1,2,4- oxadiazol-5-HNkokx°Hyl)methanol517 N^OvJnNcyclopropyl(2-(((S)-6- (5-ethyl- 1,3,4- oxadiazol-2-yl)-2,3- dihydrobenzofuran-3 - yl)amino)pyrimidin-5- yl)methanol518 OH124MF-365146518498922021940(S)-N-(6-(6- methylpyridin- 3 -yl) - 2,3- *^300 dihydrobenzofuran-3 - yl)-3-(oxetan-3- ylmethyl)- 1,2,4- oxadiazol-5 - amine 519(S)-N-(6-(5- methylpyrimidin-2- y!)-2,3-NlUL / dihydrobenzofuran-3 - » N yl)-3-(oxetan-3- ylmethyl)- 1,2,4- oxadiazol-5 - amine 520 "iT a,N-[(3S)-6-(6- methylpyridin- 2-yl) - / 6U o 2,3-dihydro-l-NuOL benzofuran- 3 -yl] - 3 - » N (oxetan- 3 -ylmethyl) - l,2,4-oxadiazol-5-HN~<o^V amine521 o- N Uo(S)-N-(6-(4- methylpyrimidin-2- y!)-2,3- dihydrobenzofuran-3 - yl)-3-(oxetan-3- ylmethyl)- 1,2,4- oxadiazol-5 - amine 522 O-N U O(S)-N-(6-(6- methylpyrazin- 2-yl) - 2,3- dihydrobenzofuran-3 - yl)-3-(oxetan-3- ylmethyl)- 1,2,4- oxadiazol-5 - amine 523HN-c bd-Nr^r U-o'(S)-N-(6-(5-ethyl- \ — '1 l,3,4-oxadiazol-2-yl)-05-methyl-2,3- JOO dihydrobenzofuran-3 - yl)-3-(oxetan-3- '^ QrV1ylmethyl)- 1,2,4- oxadiazol-5 - amine524 O-N Lo125MF-365146518498922021940

[0081] In some variations, any of the compounds described herein, such as a compound of Formula (I), (la), (lb), (II), (Ila), (lib), (III), (Illa), or (Illb), or a variation of a pharmaceutically acceptable salt thereof, or a compound of Table 1, may be deuterated (e.g., a hydrogen atom is replaced by a deuterium atom). In some of these variations, the compound is deuterated at a single site. In other variations, the compound is deuterated at multiple sites. Deuterated compounds can be prepared from deuterated starting materials in a manner similar to the preparation of the corresponding non-deuterated compounds.Hydrogen atoms may also be replaced with deuterium atoms using other methods known in the art.

[0082] Any formula given herein, such as Formula (I), (la), (lb), (II), (Ila), (lib), (III), (Illa), or (Illb), is intended to represent compounds having structures depicted by the structural formula as well as certain variations or forms. In particular, compounds of any formula given herein may have asymmetric centers and therefore exist in different enantiomeric or diastereomeric forms. All optical isomers and stereoisomers of the compounds of the general formula, and mixtures thereof in any ratio, are considered within the scope of the formula. Thus, any formula given herein is intended to represent a racemate, one or more enantiomeric forms, one or more diastereomeric forms, one or more atropisomeric forms, and mixtures thereof in any ratio. Where a compound of Table 1 is depicted with a particular stereochemical configuration, also provided herein is any alternative stereochemical configuration of the compound, as well as a mixture of stereoisomers of the compound in any ratio. For example, where a compound of Table 1 has a stereocenter that is in an “S” stereochemical configuration, also provided herein is enantiomer of the compound wherein that stereocenter is in an “R” stereochemical configuration. Likewise, when a compound of Table 1 has a stereocenter that is in an “R” configuration, also provided herein is enantiomer of the compound in an “S” stereochemical configuration. Also provided are mixtures of the compound with both the “S” and the “R” stereochemical configuration. Additionally, if a compound of Table 1 has two or more stereocenters, also provided are any enantiomer or diastereomer of the compound. For example, if a compound of Table 1 contains a first stereocenter and a second stereocenter with “R” and “R” stereochemical configurations, respectively, also provided are stereoisomers of the compound having first and second stereocenters with “S” and “S”126MF-365146518498922021940stereochemical configurations, respectively, “S” and “R” stereochemical configurations, respectively, and “R” and “S” stereochemical configurations, respectively. If a compound of Table 1 contains a first stereocenter and a second stereocenter with “S” and “S” stereochemical configurations, respectively, also provided are stereoisomers of the compound having first and second stereocenters with “R” and “R” stereochemical configurations, respectively, “S” and “R” stereochemical configurations, respectively, and “R” and “S” stereochemical configurations, respectively. If a compound of Table 1 contains a first stereocenter and a second stereocenter with “S” and “R” stereochemical configurations, respectively, also provided are stereoisomers of the compound having first and second stereocenters with “R” and “S” stereochemical configurations, respectively, “R” and “R” stereochemical configurations, respectively, and “S” and “S” stereochemical configurations, respectively. Similarly, if a compound of Table 1 contains a first stereocenter and a second stereocenter with “R” and “S” stereochemical configurations, respectively, also provided are stereoisomers of the compound having first and second stereocenters with “S” and “R” stereochemical configurations, respectively, “R” and “R” stereochemical configurations, respectively, and “S” and “S” stereochemical configurations, respectively. Furthermore, certain structures may exist as geometric isomers (i.e., cis and trans isomers), as tautomers, or as atropisomers. Additionally, any formula given herein is intended to refer also to any one of hydrates, solvates, and amorphous and polymorphic forms of such compounds, and mixtures thereof, even if such forms are not listed explicitly. In some embodiments, the solvent is water and the solvates are hydrates.

[0083] Representative examples of compounds detailed herein, including intermediates and final compounds, are depicted in the tables and elsewhere herein. It is understood that in one aspect, any of the compounds may be used in the methods detailed herein, including, where applicable, intermediate compounds that may be isolated and administered to an individual or subject.

[0084] The compounds depicted herein may be present as salts even if salts are not depicted, and it is understood that the compositions and methods provided herein embrace all salts and solvates of the compounds depicted here, as well as the non-salt and non-solvate form of the compound, as is well understood by the skilled artisan. In some embodiments, the salts of the compounds provided herein are pharmaceutically acceptable salts.127MF-365146518498922021940

[0085] In one variation, the compounds herein are synthetic compounds prepared for administration to an individual or subject. In another variation, compositions are provided containing a compound in substantially pure form. In another variation, provided are pharmaceutical compositions comprising a compound detailed herein and a pharmaceutically acceptable carrier. In another variation, methods of administering a compound are provided. The purified forms, pharmaceutical compositions and methods of administering the compounds are suitable for any compound or form thereof detailed herein.

[0086] Any variation or embodiment of Y, X1, X2, X3, Rx, R1, R1A, Ra, Rb, Rc, R2, R2A, Re, Rf, Rg, Rh, R1, Rj, Rk, Rm, and Rnprovided herein can be combined with every other variation or embodiment of Y, X1, X2, X3, Rx, R1, R1A, Ra, Rb, Rc, R2, R2A, Re, Rf, Rg, Rh, R1, Rj, Rk, Rm, and Rnas if each combination had been individually and specifically described.

[0087] Other embodiments will be apparent to those skilled in the art from the following detailed description.

[0088] As used herein, when any variable occurs more than one time in a chemical formula, its definition on each occurrence is independent of its definition at every other occurrence.

[0089] The compound names provided herein, including in Table 1, are provided by ChemDraw Professional 18.2. One of skilled in the art would understand that the compounds may be named or identified using various commonly recognized nomenclature systems and symbols. By way of example, the compounds may be named or identified with common names, systematic or non- systematic names. The nomenclature systems and symbols that are commonly recognized in the art of chemistry include, for example, Chemical Abstract Service (CAS), ChemBioDraw Ultra, and International Union of Pure and Applied Chemistry (IUPAC).Compositions

[0090] Also provided are compositions, such as pharmaceutical compositions, that include a compound disclosed and / or described herein and one or more additional medicinal agents, pharmaceutical agents, adjuvants, carriers, excipients, and the like. Suitable medicinal and pharmaceutical agents include those described herein. In some embodiments, the pharmaceutical composition includes a pharmaceutically acceptable excipient or adjuvant128MF-365146518498922021940and at least one chemical entity as described herein. Examples of pharmaceutically acceptable excipients include, but are not limited to, mannitol, lactose, starch, magnesium stearate, sodium saccharine, talcum, cellulose, sodium crosscarmellose, glucose, gelatin, sucrose, and magnesium carbonate. In some embodiments, provided are compositions, such as pharmaceutical compositions that contain one or more compounds described herein, or a pharmaceutically acceptable salt thereof.

[0091] In some embodiments, provided is a pharmaceutically acceptable composition comprising a compound of Formula (I), (la), (lb), (II), (Ila), (lib), (III), (Illa), or (Illb), or a compound of Table 1, or a pharmaceutically acceptable salt thereof. In some embodiments, provided is a pharmaceutically acceptable composition comprising a compound of Formula (I), (la), (lb), (II), (Ila), (lib), (III), (Illa), or (nib), or a compound of Table 1, or a pharmaceutically acceptable salt thereof, and a pharmaceutically acceptable excipient. In some aspects, a composition may contain a synthetic intermediate that may be used in the preparation of a compound described herein. The compositions described herein may contain any other suitable active or inactive agents.

[0092] Any of the compositions described herein may be sterile or contain components that are sterile. Sterilization can be achieved by methods known in the art. Any of the compositions described herein may contain one or more compounds or conjugates that are substantially pure.

[0093] Also provided are packaged pharmaceutical compositions, comprising a pharmaceutical composition as described herein and instructions for using the composition to treat a patient suffering from a disease or condition described herein.Methods of Use

[0094] The compounds and pharmaceutical compositions herein may be used to treat or prevent a disease or condition in an individual or subject.

[0095] Without being bound by theory, the compounds and pharmaceutical compositions disclosed herein are believed to act by directly inhibiting myosin, a mechanism that no current drug for neuromuscular diseases employs. This inhibition potentially decreases the number of independent myosin heads interacting with actin filaments, thereby reducing the amount and force of contraction. Reducing contraction of skeletal muscle can be important129MF-365146518498922021940for the treatment of neuromuscular diseases in which over-contraction is an issue.Furthermore, compounds of the invention and disclosure display preferential binding for fast skeletal muscle myosin over cardiac myosin. Selectivity for fast skeletal muscle myosin over cardiac myosin may be important in reducing cardiac -related side-effects.

[0096] In some embodiments, provided are methods of treating or preventing a neuromuscular disease in an individual or subject in need thereof, comprising administering to the individual or subject in need thereof a compound of Formula (I), (la), (lb), (II), (Ila), (lib), (III), (Illa), or (Illb), or a compound of Table 1, or a pharmaceutically acceptable salt thereof. In some embodiments, provided is a method of treating a neuromuscular disease in a subject in need thereof, comprising administering to the subject a compound of Formula (I), (la), (lb), (II), (Ila), (lib), (III), (Illa), or (Illb), or a pharmaceutically acceptable salt thereof, or a pharmaceutical composition comprising a compound of Formula (I), (la), (lb), (II), (Ila), (lib), (III), (Illa), or (Illb), or a pharmaceutically acceptable salt thereof, and a pharmaceutically acceptable excipient. In some embodiments, provided are methods of treating or preventing a neuromuscular disease in a subject in need thereof comprising administering to the subject a therapeutically effective amount of at least one chemical entity as described herein. In some embodiments, provided are methods of treating a neuromuscular disease in a subject in need thereof comprising administering to the subject a therapeutically effective amount of at least one chemical entity as described herein. In some embodiments, provided are methods of treating an established or diagnosed neuromuscular disease in a subject in need thereof comprising administering to the subject a therapeutically effective amount of at least one chemical entity as described herein. In some embodiments, provided are methods of preventing neuromuscular disease in a subject in need thereof comprising administering to the subject a therapeutically effective amount of at least one chemical entity as described herein.

[0097] Also provided herein is the use of a compound of Formula (I), (la), (lb), (II), (Ila), (lib), (III), (Illa), or (Illb), or a compound of Table 1, or a pharmaceutically acceptable salt thereof in the manufacture of a medicament for treatment of a neuromuscular disease in a subject. In some aspects, provided is a compound or composition as described herein for use in a method of treatment of the human or animal body by therapy. In some embodiments, provided herein are compounds of Formula (I), (la), (lb), (II), (Ila), (lib), (III), (Illa), or (Illb), or a compound of Table 1, or a pharmaceutically acceptable salt thereof, for use in a130MF-365146518498922021940method of treatment of the human or animal body by therapy. In some embodiments, provided herein are compounds of Formula (I), (la), (lb), (II), (Ila), (lib), (III), (Illa), or (Illb), or a compound of Table 1, or a pharmaceutically acceptable salt thereof, for use in treating or preventing neuromuscular disease. In some embodiments, provided herein are compounds of Formula (I), (la), (lb), (II), (Ila), (lib), (III), (Illa), or (Illb), or a compound of Table 1, or a pharmaceutically acceptable salt thereof, for use in treating neuromuscular disease. In some embodiments, provided herein are compounds of Formula (I), (la), (lb), (II), (Ila), (lib), (III), (Illa), or (Illb), or a compound of Table 1, or a pharmaceutically acceptable salt thereof, for use in treating an established or diagnosed neuromuscular disease. In other embodiments, provided herein are compounds of Formula (I), (la), (lb), (II), (Ila), (lib), (III), (Illa), or (Illb), or a compound of Table 1, or a pharmaceutically acceptable salt thereof, for use in preventing neuromuscular disease.

[0098] In some embodiments, provided herein are compounds of Formula (I), (la), (lb), (II), (Ila), (lib), (III), (Illa), or (Illb), or a compound of Table 1, or a pharmaceutically acceptable salt thereof, for use in treating a disease or condition associated with tremor. In some embodiments, In some embodiments, provided herein are compounds of Formula (I), (la), (lb), (II), (Ila), (lib), (III), (Illa), or (Illb), or a compound of Table 1, or a pharmaceutically acceptable salt thereof, for use in treating a disease or condition associated with spasticity. In some embodiments, provided herein are compounds of Formula (I), (la), (lb), (II), (Ila), (lib), (III), (Illa), or (Illb), or a compound of Table 1, or a pharmaceutically acceptable salt thereof, for use in ameliorating a symptom associated with neuromuscular disease. In other embodiments, provided herein are compounds of Formula (I), (la), (lb), (II), (Ila), (lib), (III), (Illa), or (Illb), or a compound of Table 1, or a pharmaceutically acceptable salt thereof, for use in reducing the risk of a symptom associated with neuromuscular disease. In other embodiments, provided herein are compounds of Formula (I), (la), (lb), (II), (Ila), (lib), (III), (Illa), or (Illb), or a compound of Table 1, or a pharmaceutically acceptable salt thereof, for use in treating a disease or condition associated with stroke, physical trauma, movement, gait, hypertonia, hypercontractility, muscle stiffness, spasms, involuntary contractions, tendinitis, or carpal tunnel syndrome. In some embodiments, provided herein are compounds of Formula (I), (la), (lb), (II), (Ila), (lib), (III), (Illa), or (Illb), or a compound of Table 1, or a pharmaceutically acceptable salt thereof, for use in treating tremor, spasticity, distal arthrogryposis, muscular dystrophy, multiple sclerosis, or cerebral palsy.131MF-365146518498922021940

[0099] In other embodiments, provided herein are compounds of Formula (I), (la), (lb), (II), (Ila), (lib), (III), (Illa), or (Illb), or a compound of Table 1, or a pharmaceutically acceptable salt thereof, for use in modulating the fast skeletal muscle myosin, such as inhibiting the fast skeletal muscle myosin. In yet other embodiments, provided herein are compounds of Formula (I), (la), (lb), (II), (Ila), (lib), (III), (Illa), or (Illb), or a compound of Table 1, or a pharmaceutically acceptable salt thereof, for use in potentiating fast skeletal muscle myosin.

[0100] In some embodiments, the subject is a mammal. In some embodiments, the subject is a mouse, rat, dog, cat, pig, sheep, horse, cow, or human. In some embodiments, the subject is a human. In some embodiments, the subject has an established or diagnosed neuromuscular disease. In some embodiments, the subject has established or diagnosed tremor. In some embodiments, the subject has established or diagnosed spasticity. In some embodiments, the subject is at risk for developing neuromuscular disease. In some embodiments, the subject has a mutation that increases risk for neuromuscular disease. In some embodiments, the subject has a mutation that increases risk for tremor. In some embodiments, the subject has a mutation that increases risk for spasticity. In some embodiments, the mutation is a sarcomeric mutation.

[0101] In some embodiments, the subject has a high risk of progressive symptoms. In some embodiments, the subject is eligible for surgical intervention or dorsal rhizotomy to treat the neuromuscular disease.

[0102] In some embodiments, the neuromuscular disease is associated with stroke, trauma, movement, gait, hypertonia, hypercontractility, muscle stiffness, spasms, involuntary contractions, tendinitis, or carpal tunnel syndrome. In some embodiments, the neuromuscular disease is associated with a sarcomeric mutation. In some embodiments, the neuromuscular disease is associated with a non-sarcomeric mutation. In some embodiments, the neuromuscular disease is associated with a mutation in myosin binding protein Cl (MYBPC1).

[0103] In some embodiments, provided are methods of treating tremor in an individual or subject in need thereof, comprising administering to the individual or subject a compound of Formula (I), (la), (lb), (II), (Ila), (lib), (III), (Illa), or (Illb), or a compound of Table 1, or a pharmaceutically acceptable salt thereof. In some embodiments, the tremor is resting tremor132MF-365146518498922021940or action tremor. In some embodiments, the tremor is essential tremor, dystonic tremor, or orthostatic tremor. Also provided herein is the use of a compound of Formula (I), (la), (lb), (II), (Ila), (lib), (III), (Illa), or (Illb), or a compound of Table 1, or a pharmaceutically acceptable salt thereof, in the manufacture of a medicament for treatment of tremor. In some embodiments, the tremor is resting tremor or action tremor. In some embodiments, the tremor is essential tremor, dystonic tremor, or orthostatic tremor.

[0104] In some embodiments, provided are methods of treating spasticity in an individual or subject in need thereof, comprising administering to the individual or subject a compound of Formula (I), (la), (lb), (II), (Ila), (lib), (III), (Illa), or (Illb), or a compound of Table 1, or a pharmaceutically acceptable salt thereof. Also provided herein is the use of a compound of Formula (I), (la), (lb), (II), (Ila), (lib), (III), (Illa), or (Illb), or a compound of Table 1, or a pharmaceutically acceptable salt thereof, in the manufacture of a medicament for treatment of spasticity.

[0105] In some embodiments, provided are methods of treating distal arthrogryposis in an individual or subject in need thereof, comprising administering to the individual or subject a compound of Formula (I), (la), (lb), (II), (Ila), (lib), (III), (Illa), or (Illb), or a compound of Table 1, or a pharmaceutically acceptable salt thereof. In some embodiments, the distal arthrogryposis is associated with a mutation in myosin binding protein Cl (MYBPC1). Also provided herein is the use of a compound of Formula (I), (la), (lb), (II), (Ila), (lib), (III), (Illa), or (Illb), or a compound of Table 1, or a pharmaceutically acceptable salt thereof, in the manufacture of a medicament for treatment of distal arthrogryposis. In some embodiments, the distal arthrogryposis is associated with a mutation in myosin binding protein Cl (MYBPC1).

[0106] In some embodiments, provided are methods of treating muscular dystrophy in an individual or subject in need thereof, comprising administering to the individual or subject a compound of Formula (I), (la), (lb), (II), (Ila), (lib), (III), (Illa), or (Illb), or a compound of Table 1, or a pharmaceutically acceptable salt thereof. In some embodiments, the muscular dystrophy is Duchenne Muscular Dystrophy, Becker muscular dystrophy, myotonic dystrophy 1, myotonic dystrophy 2, facioscapulohumeral muscular dystrophy, oculopharyngeal muscular dystrophy, or limb girdle muscular dystrophy. Also provided herein is the use of a compound of Formula (I), (la), (lb), (II), (Ila), (lib), (III), (Illa), or133MF-365146518498922021940(Illb), or a compound of Table 1, or a pharmaceutically acceptable salt thereof, in the manufacture of a medicament for treatment of muscular dystrophy. In some embodiments, the muscular dystrophy is Duchenne Muscular Dystrophy, Becker muscular dystrophy, myotonic dystrophy 1, myotonic dystrophy 2, facioscapulohumeral muscular dystrophy, oculopharyngeal muscular dystrophy, or limb girdle muscular dystrophy.

[0107] In some embodiments, provided are methods of treating multiple sclerosis in an individual or subject in need thereof, comprising administering to the individual or subject a compound of Formula (I), (la), (lb), (II), (Ila), (lib), (III), (Illa), or (Illb), or a compound of Table 1, or a pharmaceutically acceptable salt thereof. Also provided herein is the use of a compound of Formula (I), (la), (lb), (II), (Ila), (lib), (III), (Illa), or (Illb), or a compound of Table 1, or a pharmaceutically acceptable salt thereof, in the manufacture of a medicament for treatment of multiple sclerosis.

[0108] In some embodiments, provided are methods of treating cerebral palsy in an individual or subject in need thereof, comprising administering to the individual or subject a compound of Formula (I), (la), (lb), (II), (Ila), (lib), (III), (Illa), or (Illb), or a compound of Table 1, or a pharmaceutically acceptable salt thereof. Also provided herein is the use of a compound of Formula (I), (la), (lb), (II), (Ila), (lib), (III), (Illa), or (Illb), or a compound of Table 1, or a pharmaceutically acceptable salt thereof, in the manufacture of a medicament for treatment of cerebral palsy.

[0109] In some embodiments, provided are methods of treating a neuromuscular disease in an individual or subject in need thereof, comprising administering to the individual or subject a compound of Formula (I), (la), (lb), (II), (Ila), (lib), (III), (Illa), or (Illb), or a compound of Table 1, or a pharmaceutically acceptable salt thereof. In some embodiments, the neuromuscular disease is associated with movement, gait, hypertonia, hypercontractility, muscle stiffness, spasms, involuntary contractions, tendinitis, or carpal tunnel syndrome. In some embodiments, the neuromuscular disease is associated with stroke. In some embodiments, the neuromuscular disease is associated with physical trauma. In some embodiments, the physical trauma is a brain injury or a spinal cord injury. Also provided herein is the use of a compound of Formula (I), (la), (lb), (II), (Ila), (lib), (III), (Illa), or (Illb), or a compound of Table 1, or a pharmaceutically acceptable salt thereof, in the manufacture of a medicament for treatment of a neuromuscular disease. In some134MF-365146518498922021940embodiments, the neuromuscular disease is associated with movement, gait, hypertonia, hypercontractility, muscle stiffness, spasms, involuntary contractions, tendinitis, or carpal tunnel syndrome. In some embodiments, the neuromuscular disease is associated with stroke. In some embodiments, the neuromuscular disease is associated with physical trauma. In some embodiments, the physical trauma is a brain injury or a spinal cord injury.

[0110] Also provided are methods for modulating fast skeletal muscle myosin in an individual or subject which method comprises administering to an individual or subject in need thereof a therapeutically effective amount of at least one chemical entity as described herein. In some embodiments, provided are methods of inhibiting fast skeletal muscle myosin, comprising contacting the fast skeletal muscle myosin with at least one chemical entity as described herein, such as a compound of Formula (I), (la), (lb), (II), (Ila), (lib), (III), (Illa), or (Illb), or a compound of Table 1, or a pharmaceutically acceptable salt thereof. In some embodiments, provided are methods of inhibiting fast skeletal muscle myosin, comprising contacting the fast skeletal muscle myosin with at least one chemical entity as described herein, such as a compound of Formula (I), (la), (lb), (II), (Ila), (lib), (III), (Illa), or (Illb), or a compound of Table 1, or a pharmaceutically acceptable salt thereof.Additionally provided herein is the use of at least one chemical entity as described herein, such as a compound of Formula (I), (la), (lb), (II), (Ila), (lib), (III), (Illa), or (Illb), or a compound of Table 1, or a pharmaceutically acceptable salt thereof in the manufacture of a medicament for inhibiting the fast skeletal muscle myosin of an individual or subject.

[0111] In some embodiments, the compound reduces the contractility of a muscle fiber. In some embodiments, the compound reduces the contractility of a muscle fiber by greater than 40%, such as greater than 45%, 50%, 60%, 70%, 80%, or 90%. In some embodiments, the compound reduced the contractility of a muscle fiber 40%-90%, such as 40%-80%, 40-70%, 50%-90%, 50%-80% or 50%-70%. In some embodiments, the compound does not significantly alter calcium transients in the muscle fiber. In some embodiments, the compound decreases the ATPase activity in a muscle fiber. Methods of measuring contractility, ATPase activity, and calcium transients are known in the art, for example, by calcium labeling, electrophysiological recordings, and microscopic imaging. In some embodiments, the compound does not significantly inhibit or induce a cytochrome P450 (CYP) protein.135MF-365146518498922021940

[0112] One consideration that may limit the use of muscle relaxant drugs in patients is the wide range of neurological and cardiovascular side effects associated with these drugs.Surprisingly, it has been discovered that a compound of Formula (I), (la), (lb), (II), (Ila), (lib), (III), (Illa), or (Illb), or a compound of Table 1, or a pharmaceutically acceptable salt thereof, is capable of selectively modulating fast skeletal myosin relative to cardiac myosin. Accordingly, in some embodiments, provided is a method of modulating fast skeletal myosin while not modulating cardiac myosin in a subject, comprising administering a compound of Formula (I), (la), (lb), (II), (Ila), (lib), (III), (Illa), or (Illb), or a compound of Table 1, or a pharmaceutically acceptable salt thereof. In some such embodiments, provided is a method of inhibiting fast skeletal myosin while not inhibiting cardiac myosin in a subject, comprising administering a compound of Formula (I), (la), (lb), (II), (Ila), (lib), (III), (Illa), or (Illb), or a compound of Table 1, or a pharmaceutically acceptable salt thereof.

[0113] In some embodiments, provided is a method of treating or preventing a neuromuscular disease in an individual or subject comprising administering a compound of Formula (I), (la), (lb), (II), (Ila), (lib), (III), (Illa), or (Illb), or a compound of Table 1, or a pharmaceutically acceptable salt thereof, wherein the treatment does not result in reduction in either cardiac contractility, ejection fraction, fractional shortening, or cardiac output.

[0114] The pharmacological activity of a compound of Formula (I), (la), (lb), (II), (Ila), (lib), (III), (Illa), or (Illb), or a compound of Table 1, or a pharmaceutically acceptable salt thereof, can be measured using methods known in the art. Such methods include, but are not limited to, cardiac or skeletal myofibril assays, ATPase activity assays, actin-binding assays, in vitro motility assays, tissue-based ex vivo assays, skinned fiber assays, in situ muscle force assays, in situ force measurement assays, and in vivo studies.

[0115] In some embodiments, the selectivity of a compound of Formula (I), (la), (lb), (II), (Ila), (lib), (III), (Illa), or (Illb), or a compound of Table 1, or a pharmaceutically acceptable salt thereof is measured using the ratio of the IC50 of the compound for cardiac myosin, or IC50(CDMF), to the IC50of the compound for fast skeletal myosin, or IC50(FSKMF). In some embodiments, provided is a compound of Formula (I), (la), (lb), (II), (Ila), (lib), (III), (Illa), or (Illb), or a compound of Table 1, or a pharmaceutically acceptable salt thereof wherein the ratio of the IC50(CDMF) of the compound to the IC50(FSKMF) of the compound is at least 2. In some such embodiments, the ratio is at least 5. In some such136MF-365146518498922021940embodiments, the ratio is at least 10. In some such embodiments, the ratio is at least 20. In some such embodiments, the ratio is at least 50. In some such embodiments, the ratio is at least 100. In some such embodiments, the ratio is at least 150. In some such embodiments, the ratio is at least 200. In some such embodiments, the ratio is at least 250. In some such embodiments, the ratio is at least 275.

[0116] In some embodiments, the selectivity of a compound of Formula (I), (la), (lb), (II), (Ila), (lib), (III), (Illa), or (Illb), or a compound of Table 1, or a pharmaceutically acceptable salt thereof is measured using the ratio of the IC15of the compound for cardiac myosin, or IC15(CDMF), to the IC15of the compound for fast skeletal myosin, or IC15(FSKMF). In some embodiments, provided is a compound of Formula (I), (la), (lb), (II), (Ila), (lib), (III), (Illa), or (Illb), or a compound of Table 1, or a pharmaceutically acceptable salt thereof wherein the ratio of the IC15(CDMF) of the compound to the IC15(FSKMF) of the compound is at least 2. In some such embodiments, the ratio is at least 5. In some such embodiments, the ratio is at least 10. In some such embodiments, the ratio is at least 20. In some such embodiments, the ratio is at least 50. In some such embodiments, the ratio is at least 100. In some such embodiments, the ratio is at least 150. In some such embodiments, the ratio is at least 200. In some such embodiments, the ratio is at least 250. In some such embodiments, the ratio is at least 275.

[0117] In some embodiments, the compounds of the disclosure, or a pharmaceutically acceptable salt thereof, may have advantages related to one or more of the following: hERG profile, toxicity profile, safety window, selectivity, off-target profile, favorable drug / drug interaction profile, PK parameters including bioavailability, clearance and half-life, mechanism of action, CYP inhibition and time dependent inhibition profile, permeability and / or efflux, solubility, metabolism, unbound fraction, adequate human dose, and ease of synthesis on a large scale.Dosages

[0118] The compounds and compositions disclosed and / or described herein are administered at a therapeutically effective dosage, e.g., a dosage sufficient to provide treatment for the disease state. While human dosage levels have yet to be optimized for the chemical entities described herein, generally, a daily dose ranges from about 0.01 to 100 mg / kg of body weight; in some embodiments, from about 0.05 to 10.0 mg / kg of body weight,137MF-365146518498922021940and in some embodiments, from about 0.10 to 1.4 mg / kg of body weight. Thus, for administration to a 70 kg person, in some embodiments, the dosage range would be about from 0.7 to 7000 mg per day; in some embodiments, about from 3.5 to 700.0 mg per day, and in some embodiments, about from 7 to 100.0 mg per day. The amount of the chemical entity administered will be dependent, for example, on the subject and disease state being treated, the severity of the affliction, the manner and schedule of administration and the judgment of the prescribing physician. For example, an exemplary dosage range for oral administration is from about 5 mg to about 500 mg per day, and an exemplary intravenous administration dosage is from about 5 mg to about 500 mg per day, each depending upon the compound pharmacokinetics.

[0119] A daily dose is the total amount administered in a day. A daily dose may be, but is not limited to be, administered each day, every other day, each week, every 2 weeks, every month, or at a varied interval. In some embodiments, the daily dose is administered for a period ranging from a single day to the life of the subject. In some embodiments, the daily dose is administered once a day. In some embodiments, the daily dose is administered in multiple divided doses, such as in 2, 3, or 4 divided doses. In some embodiments, the daily dose is administered in 2 divided doses.

[0120] Administration of the compounds and compositions disclosed and / or described herein can be via any accepted mode of administration for therapeutic agents including, but not limited to, oral, sublingual, subcutaneous, parenteral, intravenous, intranasal, topical, transdermal, intraperitoneal, intramuscular, intrapulmonary, vaginal, rectal, or intraocular administration. In some embodiments, the compound or composition is administered orally or intravenously. In some embodiments, the compound or composition disclosed and / or described herein is administered orally.

[0121] Pharmaceutically acceptable compositions include solid, semi-solid, liquid and aerosol dosage forms, such as tablet, capsule, powder, liquid, suspension, suppository, and aerosol forms. The compounds disclosed and / or described herein can also be administered in sustained or controlled release dosage forms (e.g., controlled / sustained release pill, depot injection, osmotic pump, or transdermal (including electrotransport) patch forms) for prolonged timed, and / or pulsed administration at a predetermined rate. In some embodiments,138MF-365146518498922021940the compositions are provided in unit dosage forms suitable for single administration of a precise dose.

[0122] The compounds disclosed and / or described herein can be administered either alone or in combination with one or more conventional pharmaceutical carriers or excipients (e.g., mannitol, lactose, starch, magnesium stearate, sodium saccharine, talcum, cellulose, sodium crosscarmellose, glucose, gelatin, sucrose, magnesium carbonate). If desired, the pharmaceutical composition can also contain minor amounts of nontoxic auxiliary substances such as wetting agents, emulsifying agents, solubilizing agents, pH buffering agents and the like (e.g., sodium acetate, sodium citrate, cyclodextrine derivatives, sorbitan monolaurate, triethanolamine acetate, triethanolamine oleate). Generally, depending on the intended mode of administration, the pharmaceutical composition will contain about 0.005% to 95%, or about 0.5% to 50%, by weight of a compound disclosed and / or described herein. Actual methods of preparing such dosage forms are known, or will be apparent, to those skilled in this art; for example, see Remington 's Pharmaceutical Sciences, Mack Publishing Company, Easton, Pennsylvania.

[0123] In some embodiments, the compositions will take the form of a pill or tablet and thus the composition may contain, along with a compounds disclosed and / or described herein, one or more of a diluent (e.g., lactose, sucrose, dicalcium phosphate), a lubricant (e.g., magnesium stearate), and / or a binder (e.g., starch, gum acacia, polyvinylpyrrolidine, gelatin, cellulose, cellulose derivatives). Other solid dosage forms include a powder, marume, solution or suspension (e.g., in propylene carbonate, vegetable oils or triglycerides) encapsulated in a gelatin capsule.

[0124] Liquid pharmaceutically administrable compositions can, for example, be prepared by dissolving, dispersing or suspending etc. a compound disclosed and / or described herein and optional pharmaceutical additives in a carrier (e.g., water, saline, aqueous dextrose, glycerol, glycols, ethanol or the like) to form a solution or suspension. Injectables can be prepared in conventional forms, either as liquid solutions or suspensions, as emulsions, or in solid forms suitable for dissolution or suspension in liquid prior to injection. The percentage of the compound contained in such parenteral compositions depends, for example, on the physical nature of the compound, the activity of the compound and the needs of the subject. However, percentages of active ingredient of 0.01% to 10% in solution are139MF-365146518498922021940employable, and may be higher if the composition is a solid which will be subsequently diluted to another concentration. In some embodiments, the composition will comprise from about 0.2 to 2% of a compound disclosed and / or described herein in solution.

[0125] Pharmaceutical compositions of the compounds disclosed and / or described herein may also be administered to the respiratory tract as an aerosol or solution for a nebulizer, or as a microfine powder for insufflation, alone or in combination with an inert carrier such as lactose. In such a case, the particles of the pharmaceutical composition may have diameters of less than 50 microns, or in some embodiments, less than 10 microns.

[0126] In addition, pharmaceutical compositions can include a compound disclosed and / or described herein and one or more additional medicinal agents, pharmaceutical agents, adjuvants, and the like. Suitable medicinal and pharmaceutical agents include those described herein.Kits

[0127] Also provided are articles of manufacture and kits containing any of the compounds or pharmaceutical compositions provided herein. The article of manufacture may comprise a container with a label. Suitable containers include, for example, bottles, vials, and test tubes. The containers may be formed from a variety of materials such as glass or plastic. The container may hold a pharmaceutical composition provided herein. The label on the container may indicate that the pharmaceutical composition is used for preventing, treating or suppressing a condition described herein, and may also indicate directions for either in vivo or in vitro use.

[0128] In one aspect, provided herein are kits containing a compound or composition described herein and instructions for use. The kits may contain instructions for use in the treatment of a neuromuscular disease in an individual or subject in need thereof. A kit may additionally contain any materials or equipment that may be used in the administration of the compound or composition, such as vials, syringes, or IV bags. A kit may also contain sterile packaging.Combinations140MF-365146518498922021940

[0129] The compounds and compositions described and / or disclosed herein may be administered alone or in combination with other therapies and / or therapeutic agents useful in the treatment of the aforementioned disorders, diseases, or conditions.

[0130] The compounds and compositions described and / or disclosed herein may be combined with one or more other therapies to treat a neuromuscular disease, such as tremor, spasticity, distal arthrogryposis, muscular dystrophy, multiple sclerosis, or cerebral palsy. In some embodiments, compounds and compositions described and / or disclosed herein may be combined with one or more other therapies to treat a condition associated with stroke, trauma, movement, gait, hypertonia, hypercontractility, muscle stiffness, spasms, involuntary contractions, tendinitis, or carpal tunnel syndrome. In some embodiments, the one or more therapies include therapies that retard the progression of neuromuscular diseases by selectively binding fast skeletal muscle myosin.General Synthetic Methods

[0131] Compounds of Formula (I), (la), (lb), (II), (Ila), (lib), (III), (Illa), and (Illb) will now be described by reference to illustrative synthetic schemes for their general preparation below and the specific examples that follow. Artisans will recognize that, to obtain the various compounds herein, starting materials may be suitably selected so that the ultimately desired substituents will be carried through the reaction scheme with or without protection as appropriate to yield the desired product. Alternatively, it may be necessary or desirable to employ, in the place of the ultimately desired substituent, a suitable group that may be carried through the reaction scheme and replaced as appropriate with the desired substituent. In addition, one of skill in the art will recognize that protecting groups may be used to protect certain functional groups (amino, carboxy, or side chain groups) from reaction conditions, and that such groups are removed under standard conditions when appropriate. Unless otherwise specified, the variables are as defined above in reference to Formula (I).

[0132] Where it is desired to obtain a particular enantiomer of a compound, this may be accomplished from a corresponding mixture of enantiomers using any suitable conventional procedure for separating or resolving enantiomers. Thus, for example, diastereomeric derivatives may be produced by reaction of a mixture of enantiomers, e.g. a racemate, and an appropriate chiral compound. The diastereomers may then be separated by any convenient141MF-365146518498922021940means, for example by crystallization and the desired enantiomer recovered. In another resolution process, a racemate may be separated using chiral High Performance Liquid Chromatography. Alternatively, if desired a particular enantiomer may be obtained by using an appropriate chiral intermediate in one of the processes described.

[0133] Chromatography, recrystallization and other conventional separation procedures may also be used with intermediates or final products where it is desired to obtain a particular isomer of a compound or to otherwise purify a product of a reaction.

[0134] General methods of preparing compounds described herein are depicted in exemplified methods below. Variable groups in the schemes provided herein are defined as for Formula (I), (la), (lb), (II), (Ila), (lib), (III), (Illa), or (Illb), or any variation thereof. Other compounds described herein may be prepared by similar methods.

[0135] In some embodiments, compounds provided herein may be synthesized according to Schemes A, B, C, or D, wherein R1Ais defined as in other embodiments described herein, wherein R4is H, halogen, or C1-C6alkyl and RNis H, C6-C10aryl, -C3-C8cycloalkyl, or C1-C6alkyl, wherein the C1-C6alkyl is optionally substituted with C6-C10aryl.142MF-365146518498922021940Scheme A. Synthesis of Intermediates 1.1-1.3orIntermediates 1.1 -1.3143MF-365146518498922021940Scheme A. Synthesis of Intermediates 2.1-2.3Tf2ODCM, Py-15~0 °C(S, S)-N-(p-Toluenesulfonyl)- 1,2-diphenylethanediamine(chloro) DPPA(p-cymene)ruthenium(ll), formic acid,NEt3DBU, Tol, 0 °C~r.tovernight DCM, rtK4Fe(CN)6·3H2O 2nd-Xphos, X-phos, KOAc NHBoc dioxane / H2O, 100 °CScheme C. Synthesis of Intermediates 3.1 and 3.2144MF-365146518498922021940Dry ice MeLi(1.5eq), THF, -78 °C, 10min NHBoc n-BuLi(2eq), -78°C, 1 h, 60%Intermediates 3.1 -3.3 Scheme D. Synthesis of Intermediates 4.1 and 4.2RNHN HATU, HOBt, DIPEA DMF, rt. 99%Intermediates 4.1 -4.3

[0136] Particular non-limiting examples are provided in the Examples section below.EXAMPLES145MF-365146518498922021940Synthetic Examples

[0137] The following examples are offered to illustrate but not to limit the compositions, uses, and methods provided herein. The compounds are prepared using the general methods described above or below. Starting materials were either purchased from commercial sources or prepared according to literature procedures.

[0138] The following abbreviations are used throughout the Examples: TEA (triethylamine), DCM (dichloromethane), (Boc)20 (di-tert-butyl decarbonate), EA (Ethyl acetate), PE (Petroleum ether, DMF (N, N-dimethylformamide), DIEA (N-ethyl-Nisopropylpropan-2-amine), DMAP [4-(dimethylamino)pyridine], HATU (1-[Bis(dimethylamino)methylene]-1H-1,2,3-triazolo[4,5-b]pyridinium 3-oxid hexafluorophosphate), HOAt (1-Hydroxy-7-azabenzotriazole), HOBt (Hydroxybenzotriazole), EDCI (1-Ethyl-3-(3-dimethylaminopropyl)carbodiimide), MeOH (methanol), EtOH (ethanol), iPrOH (propan-2-ol), ACN (acetonitrile), TFA (trifluoroacetic acid), DPPA (Diphenylphosphoryl azide), DBU (1,8-Diazabicyclo(5.4.0)undec-7-ene), THF (tetrahydro furan), PPh3(triphenylphosphine), SM (starting material), Hex (hexane), NCS (N-chloro succinimide), r.t. or rt (room temperature around 21 to 24 °C), DCE (dichloroethane), FA (formic acid), CHCl3(Chloroform), BnBr (benzyl bromide), HCl (hydrogen chloride), equiv (equivalent), and DSC (bis(2,5-dioxopyrrolidin-l-yl) carbonate), HBTU (O-(benzotriazol-l-yl)-N, N, N’, N’-tetramethyluronium hexafluorophosphate).Example SI: Synthesis of (R)-5-(5-ethyl-l,3,4-oxadiazol-2-yl)-2,3-dihydro-lH-inden-l-amine hydrochloride (Intermediate 1.1 )Step 1. Synthesis of tert-butyl (R)-(5-(5-ethyl-l,3,4-oxadiazol-2-yl)-2,3-dihydro-lH-inden-l-yl)carbamate

[0139] (7?)-l-((t -Butoxycarbonyl)amino)-2,3-dihydro-l / / -indene-5-carboxylic acid (2 g, 7.2 mmol, 1 equiv.) and triphenylphosphine (5.675 g, 21.6 mmol, 3 equiv.) was suspended in MeCN (50 mL, 0.14 M) and triethylamine (3.3 mL, 23.8 mmol, 3.3 equiv.). The resulting146MF-365146518498922021940mixture was cooled to 0 °C with an ice bath and stirred at for 15 min before carbon tetrachloride (7.0 mL, 72.1 mmol, 10 equiv.) was added and the resulting mixture was stirred for additional 15 min at 0 °C. Propionic acid hydrazide (0.635 g, 7.2 mmol, 1 equiv.) was added and the reaction was stirred overnight, during which time it was allowed to warm to r.t. The mixture was filtered, the filtered solid was washed with ACN (25 mL) and the filtrate was concentrated under reduced pressure and purified with silica gel (30% EtOAc / Hexanes) to provide the desired tert-butyl (R)-(5-(5-ethyl-l,3,4-oxadiazol-2-yl)-2,3-dihydro-l / / -inden-l-yl)carbamate which was contaminated with a small amount of triphenylphosphine oxide. LRMS (ES) m / z 330.2 [M+H],Step 2. Synthesis of(R)-5-(5-ethyl-l,3,4-oxadiazol-2-yl)-2,3-dihydro-lH-inden-l-amine hydrochloride

[0140] (R)-(5-(5-Ethyl-l,3,4-oxadiazol-2-yl)-2,3-dihydro-l / / -inden-l-yl)carbamate (1.0 g, 3.18 mmol, 1 equiv.) was dissolved in 4 M HC1 in 1,4-dioxane (20 mL, 4 M, 79.6 mmol, 25 equiv.) and stirred at r.t. for 1 h. The resulting solid was filtered and washed with dioxane, diethyl ether, and hexane to provide (R)-5-(5-ethyl-l,3,4-oxadiazol-2-yl)-2,3-dihydro- l / 7-inden- 1 -amine hydrochloride (Intermediate 1.1, 0.773 g, 2.91 mmol, Yield 91.371%) as a white hygroscopic solid. LRMS (ES) m / z 230.2 [M+H],Example S2: Synthesis of (3S)-6-(5-methyl-l, 2, 4-oxadiazol-3-yl)-2,3-dihydro-l-benzofuran-3-amine hydrochloride (Intermediate 2.1)Step 1: Preparation of 3-oxo-2,3-dihydro-l-benzofuran-6-yl trifluoromethanesulfonate Tf2ODCM, Py° -15-0 °C °

[0141] To a stirred solution of 6-hydroxy-2,3-dihydro-l-benzofuran-3-one (10 g, 66.6 mmol, 1 equiv) and pyridine (16.2 mL, 199.8 mmol, 3 equiv) in DCM (250 mL) was added (trifluoromethane) sulfonyl trifluoromethanesulfonate (17.9 mL, 106.6 mmol, 1.6 equiv) dropwise at -15 °C under nitrogen atmosphere. The resulting mixture was stirred for 3 h at -5 °C under nitrogen atmosphere. The reaction was quenched with water (500 ml) at 5 °C. The aqueous layer was extracted with DCM (3 x 300 mL), the combined organic layer was washed with citric acid (2 x 200mL) and brine (200 mL), dried over anhydrous sodium sulfate, and concentrated under reduced pressure to give 3-oxo-2,3-dihydro-l-benzofuran-6-147MF-365146518498922021940yl trifluoromethanesulfonate (18.6 g, 99%) as a dark brown solid. LRMS (ES) m / z: 283 (M+H).Step 2: Preparation of (3R)-3-hydroxy-2,3-dihydro-l-benzofuran-6-yl trifluoromethanesulfonate(S, S)-N-(p-Toluenesulfonyl)- 1,2-diphenylethanediamine(chloro)Tfo o (p-cymene)ruthenium(ll), formic acid, TfOYY)NEt3 _J DCM, rt OH

[0142] Triethylamine (27.49 mL, 197.739 mmol, 3 equiv) was added to astirred solution of formic acid (8.70 mL, 230.7 mmol, 3.5 equiv) at 0 °C.The resulting mixture was stirred for 30 min at 0 °C before 3-oxo-2,3-dihydro-l-benzofuran-6-yl trifluoromethanesulfonate (18.6 g, 65.9 mmol, 1.0 equiv) in DCM (300 mL) was added dropwise, followed by (5,5)-A-( / ?-toluenesulfonyl)-l-2-diphenylethanediamine(chloro)(p-cymene)ruthenium(II) (0.84 g, 1.32 mmol, 0.02 equiv). The resulting mixture was stirred for 16 h at room temperature before being quenched with water (500 mL), extracted with DCM (2 x 200 mL), the combined organic layer washed with brine (300 mL), dried over sodium sulfate, filtered, and solvent removed under reduced pressure to give (3R)-3-hydroxy-2,3-dihydro-l-benzofuran-6-yl trifluoromethanesulfonate (18.4 g, 98%) as a brown oil. LRMS (ES) m / z'. 267 (M+H- 18).Step 3: Preparation of (3S)-3-azido-2,3-dihydro-l -benzofuran-6-yl trifluoromethanesulfonateOH overnight

[0143] DPPA (16.8 mL, 77.7 mmol, 1.2 equiv) was added to a stirred solution of (3R)-3-hydroxy-2,3-dihydro-l-benzofuran-6-yl trifluoromethanesulfonate (18.4 g, 64.7 mmol, 1 equiv) in toluene (300 mL) at -5°C. DBU (14.5 mL, 97.1 mmol, 1.5 equiv) in toluene (30 mL) was added then added dropwise and the reaction allowed to return to rt. After 6 h, the reaction was diluted with EtOAc (100 mL), and water (300 mL). The reaction was then extracted with EtOAc (3 x 200 mL), the organic layers combined, washed with brine (300 mL), dried over sodium sulfate, filtered and solvent removed by rotary evaporation to give148MF-365146518498922021940(3S)-3-azido-2,3-dihydro-l-benzofuran-6-yl trifluoromethanesulfonate (18.9 g, 94%) as a brown oil which was used in the next step directly.Step 4: Preparation of (3S)-3-amino-2,3-dihydro-l-benzofuran-6-yl trifluoromethanesulfonate

[0144] To a solution of (3S)-3-azido-2,3-dihydro-l-benzofuran-6-yl trifluoromethanesulfonate (18.9 g, 61.1 mmol, 1.0 equiv ) in THF (300 mL) and water (60.00 mL) was added PPh3 (19.2 g, 73.3 mmol, 1.2 equiv ) slowly before being heated to 50 °C for 16 h. The reaction was diluted with EtOAc (500 mL), washed with brine (3 x 200 mL) three times, dried over anhydrous sodium sulfate, and concentrated under reduced pressure to give (3S)-3-amino-2,3-dihydro-l-benzofuran-6-yl trifluoromethanesulfonate (17.1 g, 99%) as a dark brown solid, which was used for next step without further purification. LRMS (ES) m / z: 267 (M+H-17).Step 5: Preparation oftert-butylN-[(3S)-6-[(trifluoromethane)sulfonyloxy]-2,3-dihydro-l-benzofuran-3-yl ] carbamateIl I Boc2o Tj £ \TEA, DCMNH2NHBOC

[0145] To a solution of (3S)-3-amino-2,3-dihydro-l-benzofuran-6-yl trifluoromethanesulfonate (20.4 g, 72.0 mmol, 1.0 equiv) in DCM (300 mL) cooled to 0 °C were added TEA (14.6 g, 144.1 mmol, 2 equiv) and a solution of Boc20 (15.7 g, 72.0 mmol, 1 equiv ) in DCM (100 mL) dropwise. The mixture was stirred at r.t. overnight, washed with water (2 x 200 mL), dried over anhydrous sodium sulfate, concentrated under reduced pressure, and purified by silica gel chromatography (DCM / PE, 4 / 6) to give tert-butyl N-[(3S)-6-[(trifluoromethane)sulfonyloxy]-2,3-dihydro-1-benzofuran-3-yl]carbamate (6.4 g, 23%) as a white solid. LRMS (ES) m / z: 328 (M+H-56).149MF-365146518498922021940Step 6: Preparation of tert-butyl N-[(3S)-6-cyano-2,3-dihydro-l-benzofuran-3-yl]carbamateK4Fe(CN)63H2O 2nd-Xphos, X-phos, KOAcNHBocdioxane / H2O, 100 °C NHBoc

[0146] To a solution of tert-butyl N-[(3S)-6-[(trifluoromethane)sulfonyloxy]-2,3-dihydro-l-benzofuran-3-yl]carbamate (3 g, 7.83 mmol, 1 equiv ) in dioxane (50 mL) and water (25 mL) was added K4Fe(CN)6.3H2O (1.8 g, 4.261 mmol, 0.54 equiv), KOAc (1.5 g, 15.284 mmol, 1.95 equiv), X-Phos (72 mg, 0.151 mmol, 0.02 equiv) and 2nd Generation XPhos Precatalyst (60 mg, 0.076 mmol, 0.01 equiv). The mixture was stirred at 100 °C for 2 h, cooled to r.t., filtered to remove the insoluble solids, and the filter cake was washed with ethyl acetate (3 x 20 mL). The filtrate was diluted with water (100 mL), extracted with EtOAc (3 x 100 mL), the combined organic layers dried over Na2SO4, filtered, and concentrated under reduced pressure. The material was resolved by silica gel column chromatography, eluted with CH2C12 / MeOH (10:1) to afford tert-butyl N-[(3S)-6-cyano-2,3-dihydro-l-benzofuran-3-yl]carbamate (1.9 g, 87 %) as a white solid. LRMS (ES) m / z 261 [M+H],Step 7: Preparation oftert-butylN-[(3S)-6-(N-hydroxycarbamimidoyl)-2,3-dihydro-l-benzofuran-3-yl ] carbamateNHBoc

[0147] To a solution of tert-butyl N-[(3S)-6-cyano-2,3-dihydro-l-benzofuran-3-yl]carbamate (1.87 g, 7.18 mmol, 1 equiv) in EtOH (20 mL) were added NH2OH•HCl (0.99 g, 14.2 mmol, 1.98 equiv) and triethylamine (1.82 g, 18 mmol, 2.5 equiv). The resulting mixture was stirred for overnight at 60 °C, then cooled to room temperature, diluted with CH2C12 (100 mL), and then washed with brine(2 x 50 mL), dried over anhydrous sodium sulfate, concentrated under reduced pressure to afford tert-butyl N-[(3S)-6-(N-hydroxycarbamimidoyl)-2,3-dihydro-l-benzofuran-3-yl]carbamate (1.9 g, crude) as a white solid. LRMS (ES) m / z 294 (M+H).150MF-365146518498922021940Step 8: Preparation of tert-butyl N-[(3S)-6-(5-ethyl-l, 2, 4-oxadiazol-3-yl)-2,3-dihydro-l-benzofuran-3-yl Jcarbamate

[0148] To a solution of tert-butyl (S)-(6-(N-hydroxycarbamimidoyl)-2,3-dihydrobenzofuran-3-yl)carbamate (1.23 g, 4.193 mmol, 1.00 equiv) in dioxane (15 mL) was added ( 1,1 -dimethoxy ethyl)dimethylamine (2.36 g, 17.7 mmol, 4.2 equiv). The resulting mixture was stirred for overnight at 60 °C, cooled to room temperature, concentrated under reduced pressure. The residue was purified by silica gel column chromatography, eluted with CH2C12 / MeOH (20:1) to afford tert-butyl (S)-(6-(5-methyl-l,2,4-oxadiazol-3-yl)-2,3-dihydrobenzofuran-3-yl)carbamate (1.2 g, 76%) as a brown solid. LRMS (ES) m / z 318 [M+H],Step 9: Preparation of(S)-6-(5-methyl-l,2,4-oxadiazol-3-yl)-2,3-dihydrobenzofuran-3-amine hydrochloride

[0149] To a solution of tert-butyl N-[(3S)-6-(5-methyl-l,2,4-oxadiazol-3-yl)-2,3-dihydro-l-benzofuran-3-yl]carbamate (1.20 mg, 19.7 mmol, 1.0 equiv) in DCM (6 mL )was added HC1 (4 M in dioxane, 6 mL). The resulting solution was stirred for overnight at room temperature, then concentrated under reduced pressure to afford 873 mg of (3S)-6-(5-methyl-l,2,4-oxadiazol-3-yl)-2,3-dihydro-l-benzofuran-3-amine hydrochloride (Intermediate 2.1) as a white solid. LRMS (ES) m / z 201 [M+H- 17].

[0150] Intermediates in the following table were prepared in a similar manner as Intermediate 2.1 using the appropriate starting materials.Intermediate Structure, Name, Data151MF-365146518498922021940\ / °'<\NIIl l )HC|NH22.2(S)-6-(5-ethyl-l,2,4-oxadiazol-3-yl)-2,3- dihydrobenzofuran-3-amine hydrochloride. LRMS (ES) m / z.' 232 (M+H).-o P-Nx— <\ ifN" \r^Xr-01 1 )HCI NH22.3(S)-6-(5-(methoxymethyl)-l,2,4-oxadiazol-3- yl)-2,3-dihydrobenzofuran-3-amine hydrochloride. LRMS (ES) m / z'. 248 (M+H).Example S3: Synthesis of (R)-5-(3-methyl-l,2,4-oxadiazol-5-yl)-2,3-dihydro-lH-inden-l-amine hydrochloride (Intermediate 3.1 )Step 1: Preparation of (lR)-l-[[(tert-butoxy)carbonyl]amino]-2,3-dihydro-lH-indene-5-carboxylic acidO JT \ _ Dry ice _MeLi(1.5eq), THF, -78 °C, 10minNHBocn-BuLi(2eq), -78°C, 1h, 60% NHBoc

[0151] To a solution of tert-butyl N-[(lR)-5-bromo-2,3-dihydro-lH-inden-l-yl]carbamate (10 g, 32.2 mmol, 1.0 equiv) in THF (300 mL) cooled to -78 °C was added MeLi (30.1 mL, 1.6 M, 1.5 equiv) dropwise. The mixture was stirred at -78 °C for 10 min and n-BuLi (25.7 mL, 2.5 M, 2.0 equiv) was added dropwise at -78 °C. The mixture was stirred for an additional hour at -78 °C and dry ice (30 g) was added. The mixture was then stirred for 30 min at -78 °C and quenched by adding saturated NH4C1 solution (30 mL) at -78 °C slowly. The resulting solution was warmed to r.t. and extracted with EtOAc (2 x 400 mL). The combined organic layers were concentrated under reduced pressure and triturated with a152MF-365146518498922021940mixture of EA, PE, and ethyl ether (1 / 20 / 10) to afford 6.2 g (70%) of (lR)-l-[[(tert-butoxy)carbonyl]amino]-2,3-dihydro-lH-indene-5-carboxylic acid as a white solid.Step 2: Preparation of tert-butyl N-[(lR)-5-(3-methyl-l, 2,- 4-oxadiazol-5-yl)-2,3-dihydro-lH-inden-1 -yl ] carbamate

[0152] (lR)-l-[(tert-butoxycarbonyl)amino]-2,3-dihydro-lH-indene-5-carboxylic acid (2.081 g, 7.504 mmol, 1.1 equiv.) was dissolved in anhydrous DMSO (8 mL) and CDI (1.327 g, 8.186 mmol, 1.2 equiv.) was added all at once. The resulting mixture was stirred at r.t. for 30 min and then acetamide, oxime (0.505 g, 6.82 mmol, 1 equiv.) was added. The resulting mixture was stirred at r.t. o / n. powdered NaOH (0.327 g, 8.186 mmol, 1.2 equiv.) was then added and the resulting mixture was stirred at r.t. for 2 h. Water was added (100 ml) and the resulting precipitate was sonicated and then filtered. The white filtered solid was dried under high vacuum to give tert-butyl N-[(lR)-5-(3-methyl-l,2,4-oxadiazol-5-yl)-2,3-dihydro-lH-inden-l-yl] carbamate (2 g, 93%).Step 3: Preparation of(R)-5-(3-methyl-l,2,4-oxadiazol-5-yl)-2,3-dihydro-lH-inden-l-amine hydrochloride

[0153] Tert-Butyl N-[(1R)-5-(3-methyl-1,2,4-oxadiazol-5-yl)-2,3-dihydro-1H-inden-1-yl]carbamate (2 g, 6.342 mmol, 1 equiv) was combined with HC1 (31 mL, 4M in 1,4-dioxane) and stirred at r.t. for 1.5 h. The resulting off-white precipitate was filtered and the filtered solid washed with excess diethyl ether, collected, dried under high vacuum to give (R)-5-(3-methyl- 1,2, 4-oxadiazol-5-yl)-2,3-dihydro- 1H-inden-1-amine hydrochloride (Intermediate 3.1, 1.1 g, 69%).

[0154] Intermediate 3.2 was prepared in a similar manner as Intermediate 3.1 using the appropriate starting materials.153MF-365146518498922021940Intermediate Structure, NameHCI3.2 NH2(R)-5-(3-(methoxymethyl)-l,2,4- oxadiazol-5-yl)-2,3-dihydro-lH-inden- 1 -amine hydrochlorideExample S4: Synthesis of (R)-5-(3-methyl-l,2,4-oxadiazol-5-yl)-2,3-dihydro-lH-inden-l-amine hydrochloride (Intermediate 4.1 )Step 1: Preparation of (lR)-l-[[(tert-butoxy)carbonyl]amino]-2,3-dihydro-lH-indene-5-carboxylic acidoA >_Drylce_ MeLi(1.5eq), THF, -78 °C, 10minNHBocn-BuLi(2eq), -78°C, 1h, 60% NHBoc

[0155] To a solution of tert-butyl N-[(lR)-5-bromo-2,3-dihydro-lH-inden-l-yl]carbamate (10 g, 32.2 mmol, 1.0 equiv) in THF (300 mL) cooled to -78 °C was added MeLi (30.1 mL, 1.6 M, 1.5 equiv) dropwise. The mixture was stirred at -78 °C for 10 min and n-BuLi (25.7 mL, 2.5 M, 2.0 equiv) was added dropwise at -78 °C. The mixture was stirred for an additional hour at -78 °C and dry ice (30 g) was added. The mixture was then stirred for 30 min at -78 °C and quenched by adding saturated NH4C1 solution (30 mL) at -78 °C slowly. The resulting solution was warmed to r.t. and extracted with EtOAc (2 x 400 mL). The combined organic layers were concentrated under reduced pressure and triturated with a mixture of EA, PE, and ethyl ether (1 / 20 / 10) to afford 6.2 g (70%) of (lR)-l-[[(tert-butoxy)carbonyl]amino]-2,3-dihydro-lH-indene-5-carboxylic acid as a white solid.Step 2: Preparation of tert-butyl N-[(lR)-5-(3-methyl-l, 2, 4-oxadiazol-5-yl)-2,3-dihydro-lH-inden-1 -yl ] carbamate154MF-365146518498922021940N0 if, N'OA >. H2N^X' CDI, NaOH — \H0>[ L ) ~ — 5DMSO, rt, 93%NHBoc NHBoc

[0156] (lR)-l-[(tert-butoxycarbonyl)amino]-2,3-dihydro-lH-indene-5-carboxylic acid (2.081 g, 7.504 mmol, 1.1 equiv.) was dissolved in anhydrous DMSO (8 mL) and CDI (1.327 g, 8.186 mmol, 1.2 equiv.) was added all at once. The resulting mixture was stirred at r.t. for 30 min and then acetamide, oxime (0.505 g, 6.82 mmol, 1 equiv.) was added. The resulting mixture was stirred at r.t. o / n. powdered NaOH (0.327 g, 8.186 mmol, 1.2 equiv.) was then added and the resulting mixture was stirred at r.t. for 2 h. Water was added (100 ml) and the resulting precipitate was sonicated and then filtered. The white filtered solid was dried under high vacuum to give tert-butyl N-[(lR)-5-(3-methyl-l,2,4-oxadiazol-5-yl)-2,3-dihydro-lH-inden-l-yl] carbamate (2 g, 93%).Step 3: Preparation of(R)-5-(3-methyl-l,2,4-oxadiazol-5-yl)-2,3-dihydro-lH-inden-l-amine hydrochloride

[0157] Tert-Butyl N-[(lR)-5-(3-methyl-l,2,4-oxadiazol-5-yl)-2,3-dihydro-lH-inden-l-yl]carbamate (2 g, 6.342 mmol, 1 equiv) was combined with HC1 (31 mL, 4M in 1,4-dioxane) and stirred at r.t. for 1.5 h. The resulting off-white precipitate was filtered and the filtered solid washed with excess diethyl ether, collected, dried under high vacuum to give (R)-5-(3-methyl-l,2,4-oxadiazol-5-yl)-2,3-dihydro-lH-inden-l-amine hydrochloride (Intermediate 4.1, 1.1 g, 69%).

[0158] Intermediate 4.2 was prepared in a similar manner as Intermediate 4.1 using the appropriate starting materials.Intermediate Structure, Name155MF-365146518498922021940Example S5: Synthesis of (R)-5-(5-ethyl-l,2,4-oxadiazol-3-yl)-2,3-dihydro-lH-inden-l-amine hydrochloride (Intermediate 5.1 )Step 1: Preparation of tert-butyl N-[(lR)-5-(N-hydroxycarbamimidoyl)-2,3-dihydro-lH-inden-1 -yl ] carbamate

[0159] To a solution of tert-butyl N-[(lR)-5-cyano-2,3-dihydro-lH-inden-l-yl]carbamate (42.2 g, 163.4 mmol, 1 equiv) in ethanol (420 mL) were added hydroxylamine hydrochloride (22.7 g, 326.7 mmol, 2.0 equiv) and triethylamine (33.1 g, 326.7 mmol, 2.0 equiv). The mixture was stirred at 50 °C for 4 h, concentrated under reduced pressure, dissolved in EA (1 L), washed with water, dried over Na2SO4, and concentrated under reduced pressure to give 54.6 g (98%) of tert-butyl N-[(lR)-5-(N-hydroxycarbamimidoyl)-2,3-dihydro-lH-inden-l-yl]carbamate as an off-white solid. LRMS (ES) m / z: 292 (M+H). Step 2: Preparation of tert-butyl N-[(lR)-5-(5-ethyl-l,2,4-oxadiazol-3-yl)-2,3-dihydro-lH-inden-l-yl] carbamatedioxane, 100 °C

[0160] To a solution of tert-butyl N-[(lR)-5-(N-hydroxycarbamimidoyl)-2,3-dihydro-lH-inden-l-yl] carbamate (16 g, 54.9 mmol, 1.0 equiv) in dioxane (300 mL) was added156MF-365146518498922021940propanoyl propanoate (8.4 g, 64.5 mmol, 1.2 equiv). The mixture was stirred at 105 °C for 8 h, cooled to r.t., concentrated under reduced pressure, and purified by silica gel chromatography (EA / PE, 1 / 9) to give (17.5 g, 97%) of tert-butyl N-[(lR)-5-(5-ethyl-l,2,4-oxadiazol-3-yl)-2,3-dihydro-lH-inden-l-yl]carbamate as a white solid.Step 3: Preparation of (! R)-5-(5-ethyl-l,2,4-oxadiazol-3-yl)-2,3-dihydro-lH-inden-l-amine hydrochloride

[0161] To a solution of tert-butyl N-[(lR)-5-(5-ethyl-l,2,4-oxadiazol-3-yl)-2,3-dihydro-IH-inden-l-yl] carbamate (23 g, 70 mmol, 1 equiv) in DCM was added HC1 (4 M in dioxane, 175 mL, 698 mmol, 10 equiv) at r.t. The mixture was stirred at r.t. overnight and diluted with EtOAc (500 mL). The precipitated solids were collected by filtration, washed with PE (2 x 200 mL), and dried under high vacuum to afford (lR)-5-(5-ethyl-l,2,4-oxadiazol-3-yl)-2,3-dihydro-lH-inden-l-amine hydrochloride (Intermediate 5.1, 16 g, 86%) as a white solid. LRMS (ES) m / z: 214.2 (M+H-17).

[0162] Intermediates in the following table were prepared in a similar manner as Intermediate 5.1 using the appropriate starting materials.Intermediate Structure, Name, DataP'N— X5.2 HCINH2(R)-5-(5-methyl-l,2,4-oxadiazol-3-yl)-2,3-dihydro-lH-inden-l-amine hydrochloride. LRMS (ES) m / z'. 199.1 (M+H-17).—o o-N— \\ 15.3HCI NH2157MF-365146518498922021940(R)-5-(5-(methoxymethyl)-l,2,4-oxadiazol-3-yl)-2,3-dihydro-lH-inden-1 -amine hydrochloride. LRMS (ES) m / z'. 229.1 (M+H-17).Example S6: Synthesis of N-((S)-6-(5-ethyl-l,3,4-oxadiazol-2-yl)-2,3-dihydrobenzofuran-3-yl)-3-( ( S )-tetrahydrofuran-3-yl)-l,2,4-oxadiazol-5-amine ( Compound 180)

[0163] Step 1: Triethylamine (79 g, 783 mmol, 3 equiv.) and Pd(dppf)C12 (5.7 g, 7.8 mmol, 0.03 equiv) were added to a solution of (S)-3-((tert-butoxycarbonyl)amino)-2,3-dihydrobenzofuran-6-yl trifluoromethanesulfonate (100g, 0.26 mmol, 1 equiv) in MeOH (500 mL). The reaction was then heated to 75 °C under CO (10 atm) for 14 h, before being cooled to rt, adding activated carbon (0.1% w / w) and silica gel (0.1% w / w) and the reaction was stirred for 12 h. The reaction was then filtered and concentrated to 1.5v under reduced pressure. EtOAc (500mL) and water (500 mL) were then charged into the reaction, the water removed, and organic layer washed with water (500 mL) before being concentrated under vacuum to afford crude methyl (S)-3-((tert-butoxycarbonyl)amino)-2,3-dihydrobenzofuran-6-carboxylate (69 g, 90% yield) as a brown solid LRMS (ESI) m / z = 238 (M-tBu+H).O O> AfV0)K0H Ho / V^°>MeOH, H2ONHBoc NHBoc

[0164] Step 2: Methyl (S)-3-((tert-butoxycarbonyl)amino)-2,3-dihydrobenzofuran-6-carboxylate (22.434 g, 76.483 mmol, 1 equiv.) was dissolved in MeOH (300 mL) and 3 M aq KOH (51 mL, 153 mmol, 2 equiv.) was added. The resulting mixture was heated at 70 °C in an oil bath for 1 h. The resulting homogeneous solution was cooled to rt, diluted with water (500 mL) and ethyl acetate (400 mL). The organic layer was removed, the aqueous phase extracted with EtOAc (300 mL). The organic layers were combined and extracted with 1 M aq. KOH (300 mL). The aqueous phases were combined, acidified to pH 1 with HC1 (3M in water), extracted with EtOAc (2 X 400 mL), organics combined, dried over sodium sulfate and concentrated under reduced pressure to provide (S)-3-((tert-butoxycarbonyl)amino)-2,3-158MF-365146518498922021940dihydrobenzofuran-6-carboxylic acid as a white solid (17.2 g, 81% yield). LCMS (ESI) m / z = 224.0 (M+H-tBu).H PPh3, CCI4, NEt3NHBoc

[0165] Step 3: Triethylamine (8.2 mL, 59.0 mmol, 3.3 equiv.) was added to a solution of (S)-3-((tert-butoxycarbonyl)amino)-2,3-dihydrobenzofuran-6-carboxylic acid (5 g, 17.90mmol, 1 equiv.) and triphenylphosphine (14 g, 53.7 mmol, 3 equiv.) in acetonitrile (100 mL) at 0 °C. After 15 min, carbon tetrachloride (17 mL, 179.0 mmol, 10 equiv.) was added and the reaction stirred for an additional 15 min. Propionic acid hydrazide (1.7 g, 18.8 mmol, 1.05 equiv.) was added and the reaction was warmed to rt (room temperature) while stirring over 16 h. The reaction was filtered, concentrated by rotary evaporation and the resulting residue resolved by silica gel chromatography (50% EtOAc / Hex) to yield tert-butyl (S)-(6-(5-ethyl-l,3,4-oxadiazol-2-yl)-2,3-dihydrobenzofuran-3-yl)carbamate (4.9 g, 83% yield) as an off-white solid. LRMS (ESI) m / z = 332.2 (M+H).dioxane, quantNHBoc

[0166] Step 4: A solution of tert-butyl (S)-(6-(5-ethyl-l,3,4-oxadiazol-2-yl)-2,3-dihydrobenzofuran-3-yl)carbamate (4.9 g, 14.787 mmol, 1 equiv.) in hydrogen chloride (10.783 g, 73.935 mL, 4 M, 295.74 mmol, 20 equiv.) was stirred at rt for 30 min. The reaction was then concentrated under reduced pressure and dried under vacuum to give (S)-6-(5-ethyl-l,3,4-oxadiazol-2-yl)-2,3-dihydrobenzofuran-3-amine hydrochloride (3.9 g, Yield 99%) as a white solid. LRMS (ESI) m / z = 232.1 (M+H).Br— NH4OAC, MeOH, DCMNH2159MF-365146518498922021940

[0167] Step 5: To a solution of (S)-6-(5-ethyl-l,3,4-oxadiazol-2-yl)-2,3-dihydrobenzofuran-3 -amine hydrochloride (700 mg, 2.6 mmol, 1 equiv.) and ammonium acetate (806 mg, 10.5 mmol, 4 equiv.) in methanol (10 mL) was added cyanogen bromide (1.1 g, 10.5 mmol, 4 equiv.) in DCM (5 mL) at 0 °C. The mixture was stirred at 0 °C for 10 minutes then at 24 °C for 1 h. The reaction was diluted with water and saturated sodium bicarbonate. The aqueous layer was extracted with DCM and the combined organic layers were dried over sodium sulfate and concentrated to afford (S)-N-(6-(5-ethyl-l,3,4-oxadiazol-2-yl)-2,3-dihydrobenzofuran-3-yl)cyanamide (636 mg, 95% yield), which was used in next reaction without further purification. LRMS (ES) 257 [M+H],HCI HO'NH2Na2CO3, EtOH

[0168] Step 6: To a solution of (S)-tetrahydrofuran-3-carbonitrile (1 g, 10.3 mmol, 1 equiv.) and hydroxylamine hydrochloride (751 mg, 10.8 mmol, 1.05 equiv.) in ethyl alcohol (25 mL) was added sodium carbonate (2.2 g, 20.6 mmol, 2 equiv.). The reaction mixture was stirred at 80 °C overnight, cooled to 24 °C, filtered, washed with DCM, concentrated, and purified via silica gel chromatography (0->10% MeOH / DCM gradient) to afford (S, Z)-N'-hydroxytetrahydrofuran-3-carboximidamide (628 mg, 47% yield).pTsOH, ZnCI2, DMF

[0169] Step 7: To a solution of (S)-N-(6-(5-ethyl-l,3,4-oxadiazol-2-yl)-2,3-dihydrobenzofuran-3-yl)cyanamide (60 mg, 0.23 mmol, 1 equiv.) and (S, Z)-N'-hydroxytetrahydrofuran-3-carboximidamide (61 mg, 0.47 mmol, 2 equiv.) in DMF(1.2 mL) was added zinc chloride (0.47 mL, 0.47 mmol, 2 equiv. 1 M in Et2O) and paratoluene sulfonate (60 mg, 0.35 mmol, 1.5 equiv.). The mixture was stirred at 80 °C for 18 h, cooled to 24 °C, filtered, and purified by prep-HPLC (10-> 100% water / acetonitrile with 0.1% formic acid) to afford N-((S)-6-(5-ethyl-l,3,4-oxadiazol-2-yl)-2,3-dihydrobenzofuran-3-yl)-3-((S)-tetrahydrofuran-3-yl)-l,2,4-oxadiazol-5-amine (Compound 180, 37 mg, 43% yield).160MF-365146518498922021940LRMS (ES) 370 [M+H], ‘H NMR (400 MHz, DMSO-6) 69.06 (d, J= 7.5 Hz, 1H), 7.63 -7.52 (m, 2H), 7.42 (s, 1H), 5.54 (td, J = 8.0, 4.5 Hz, 1H), 4.83 (dd, J= 10.0, 8.5 Hz, 1H), 4.48 (dd, J = 10.1, 4.5 Hz, 1H), 3.98 (t, J = 8.1 Hz, 1H), 3.87 - 3.72 (m, 3H), 3.45 - 3.35 (m, 1H), 2.94 (q, J = 7.5 Hz, 2H), 2.25 - 2.15 (m, 1H), 2.13 - 2.03 (m, 1H), 1.32 (t, J = 7.5 Hz, 3H).Example S7: Synthesis of N-((S)-6-(5-ethyl-l,3,4-oxadiazol-2-yl)-2,3-dihydrobenzofuran-3-yl)-3-( (R)-tetrahydrofuran-3-yl)-l,2,4-oxadiazol-5-amine ( Compound 181 )Br— NH4OAC, MeOH, DCM

[0170] Step 3: To a solution of (S)-6-(5-ethyl-l,3,4-oxadiazol-2-yl)-2,3-dihydrobenzofuran-3 -amine hydrochloride (700 mg, 2.6 mmol, 1 equiv.) and ammonium acetate (806 mg, 10.5 mmol, 4 equiv.) in methanol (10 mL) was added cyanogen bromide (1.1 g, 10.5 mmol, 4 equiv.) in DCM (5 mL) at 0 °C. The mixture was stirred at 0 °C for 10 minutes then at 24 °C for 1 h. The reaction was diluted with water and saturated sodium bicarbonate. The aqueous layer was extracted with DCM and the combined organic layers were dried over sodium sulfate and concentrated to afford (S)-N-(6-(5-ethyl-l,3,4-oxadiazol-2-yl)-2,3-dihydrobenzofuran-3-yl)cyanamide (636 mg, 95% yield), which was used in next reaction without further purification. LRMS (ES) 257 [M+H],NHHCInHO'NH2Na2CO3, EtOHNH2

[0171] Step 2: To a solution of (R)-tetrahydrofuran-3-carbonitrile (1 g, 10.3 mmol, 1 equiv.) and hydroxylamine hydrochloride (751 mg, 10.8 mmol, 1.05 equiv.) in ethyl alcohol (25 mL) was added sodium carbonate (2.2 g, 20.6 mmol, 2 equiv.). The reaction mixture was stirred at 80 °C overnight, cooled to 24 °C, filtered, washed with DCM, concentrated, and purified via silica gel chromatography (0->10% MeOH / DCM gradient) to afford (R, Z)-N'-hydroxytetrahydrofuran-3-carboximidamide (779 mg, 58% yield).161MF-365146518498922021940pTsOH, ZnCI2, DMF

[0172] Step 3: To a solution of (S)-N-(6-(5-ethyl-l,3,4-oxadiazol-2-yl)-2,3-dihydrobenzofuran-3-yl) cyanamide (60 mg, 0.24 mmol, 1 equiv.) and (R, Z)-N'-hydroxytetrahydrofuran-3-carboximidamide (61 mg, 0.47 mmol, 2 equiv.) in DMF(1.2 mL) was added zinc chloride (0.47 mL, 0.47 mmol, 2 equiv. IM in Et20) and paratoluene sulfonate (60 mg, 0.35 mmol, 1.5 equiv.). The mixture was stirred at 80 °C overnight, cooled to 24 °C, filtered, and purified by prep-HPLC (10-> 100% water / acetonitrile with 0.1% formic acid) to afford N-((S)-6-(5-ethyl-l,3,4-oxadiazol-2-yl)-2,3-dihydrobenzofuran-3-yl)-3-((R)-tetrahydrofuran-3-yl)-l,2,4-oxadiazol-5-amine (Compound 181, 32 mg, 37% yield). LRMS (ES) 370.1 [M+H],1H NMR (400 MHz, DMSO-6) δ 9.06 (d, J = 7.5 Hz, 1H), 7.63 – 7.52 (m, 2H), 7.42 (s, 1H), 5.54 (td, J = 8.0, 4.5 Hz, 1H), 4.83 (dd, J = 10.0, 8.5 Hz, 1H), 4.48 (dd, J = 10.1, 4.4 Hz, 1H), 3.98 (t, J = 8.1 Hz, 1H), 3.89 - 3.71 (m, 3H), 3.45 - 3.35 (m, 1H), 2.94 (q, J = 7.5 Hz, 2H), 2.26 - 2.15 (m, 1H), 2.14 - 2.05 (m, 1H), 1.32 (t, J = 7.5 Hz, 3H).Example S8: Synthesis of (S)-N-(6-(5-ethyl-l,3,4-oxadiazol-2-yl)-2,3-dihydrobenzofuran-3-yl)-3-( oxetan-3-ylmethyl)-l,2,4-oxadiazol-5-amine ( Compound 242 )Br— NH4OAc, MeOH, DCM

[0173] Step 1: To a solution of (S)-6-(5-ethyl-l,3,4-oxadiazol-2-yl)-2,3-dihydrobenzofuran-3 -amine hydrochloride (700 mg, 2.6 mmol, 1 equiv.) and ammonium acetate (806 mg, 10.5 mmol, 4 equiv.) in methanol (10 mL, 0.26 M) was added cyanogen bromide (1.1 g, 10.5 mmol, 4 equiv.) in DCM (5 mL, 0.52 M) at 0 °C. The mixture was stirred at 0 °C for 10 minutes then at 24 °C for 1 h. The reaction was diluted with water and saturated sodium bicarbonate. The aqueous layer was extracted with DCM and the combined organic layers were dried over sodium sulfate and concentrated to afford (S)-N-(6-(5-ethyl-162MF-365146518498922021940l,3,4-oxadiazol-2-yl)-2,3-dihydrobenzofuran-3-yl)cyanamide (636 mg, 95% yield), which was used in next reaction without further purification. LRMS (ES) 257 [M+H],

[0174] Step 2: To a solution of 2-(oxetan-3-yl)acetonitrile (5 g, 51.2 mmol, 1 equiv.) in ethyl alcohol (50 mL) was added hydroxylamine (6.3 mL, 103.0 mmol, 2 equiv., 50% in water). The reaction mixture was stirred overnight at room temperature, concentrated, and dried under high vacuum to afford (Z)-N'-hydroxy-2-(oxetan-3-yl)acetimidamide (6.5 g, 97% yield) as a white solid.

[0175] Step 3: To a solution of (S)-N-(6-(5-ethyl-l,3,4-oxadiazol-2-yl)-2,3-dihydrobenzofuran-3-yl)cyanamide (60 mg, 0.23 mmol, 1 equiv.) and (Z)-N'-hydroxy-2- (oxetan-3-yl)acetimidamide (61 mg, 0.47 mmol, 2 equiv.) in DMF (1.2 mL) was added zinc chloride (64 mg, 0.47 mL, 0.47 mmol, 2 equiv. 1 M in Et20) and para-toluene sulfonate(60 mg, 0.35 mmol, 1.5 equiv.). The mixture was stirred at 80 °C overnight, cooled to 24 °C, diluted with water, filtered, and purified by prep-HPLC (10-> 100% water / acetonitrile with 0.1% formic acid) to afford (S)-N-(6-(5-ethyl-l,3,4-oxadiazol-2-yl)-2,3-dihydrobenzofuran-3-yl)-3-(oxetan-3-ylmethyl)-l,2,4-oxadiazol-5-amine (Compound 242, 34 mg, 57% yield). LRMS (APCI) 370.2 [M+H],1H NMR (400 MHz, DMSO-6) δ 9.04 (d, J = 7.4 Hz, 1H), 7.61 -7.51 (m, 2H), 7.41 (s, 1H), 5.51 (td, 7 = 7.9, 4.4 Hz, 1H), 4.82 (t, J = 10.0, 8.5 Hz, 1H), 4.72 - 4.63 (m, 2H), 4.47 (dd, J = 10.1, 4.5 Hz, 1H), 4.36 (t, J= 6.2 Hz, 2H), 3.31 - 3.25 (m, 1H), 2.99 - 2.84 (m, 4H), 1.32 (t, J = 7.5 Hz, 3H).

[0176] Compounds in the following table were prepared in a similar manner as Compound 242 using the appropriate reagents specified in the table.Compound Amine Structure / Name / CharacterizationNitrileNo.163MF-365146518498922021940154 (R)-5-(5-ethyl- 1,3,4- oxadiazol-2-0CO r°> yl)-2,3- dihydro-lH- inden-1 -amineNHC-NN-((R)-5-(5-ethyl-l,3,4-oxadiazol-2-yl)-2,3- hydrochloride(S)- dihydro- IH-inden- 1 -yl)-3-((S)- tetrahydrofur tetrahydrofuran-3-yl)-l,2,4-oxadiazol-5- an-3- amine. LRMS (ES) 368.1 [M+H] ’H NMR carbonitrile (400 MHz, DMSO-6) δ 8.81 (d, J = 8.3 Hz,1H), 7.88 (s, 1H), 7.86 - 7.79 (m, 1H), 7.46 (d, J = 7.9 Hz, 1H), 5.23 (q, J = 8.0 Hz, 1H), 3.98 (t, J= 8.1 Hz, 1H), 3.86 - 3.70 (m, 3H), 3.43 - 3.35 (m, 1H), 3.11 - 3.02 (m, 1H), 2.98 - 2.86 (m, 3H), 2.61 - 2.53 (m, 1H), 2.26 - 2.15 (m, 1H), 2.15 - 2.06 (m, 1H), 2.01 - 1.90 (m, 1H), 1.32 (t, J = 7.6 Hz, 3H).157 (R)-5-(5- cyclopropyl- ^71,3,4- oxadiazol-2-0XX> f°> y!)-2,3- dihydro-lH-NHXN inden-1 -amine N-((R)-5-(5-cyclopropyl-l,3,4-oxadiazol-2- hydrochloride yl)-2,3-dihydro-lH-inden-l-yl)-3-((S)- (S)- tetrahydrofuran-3-yl)-l,2,4-oxadiazol-5- tetrahydrofuramine. LRMS (ES) 380.1 [M+H], *HNMR an-3- (400 MHz, DMSO-6) δ 8.80 (d, J = 8.3 Hz, carbonitrile1H), 7.85 (s, 1H), 7.84 - 7.78 (m, 1H), 7.45 (d, J = 7.9 Hz, 1H), 5.22 (q, J = 7.9 Hz, 1H), 3.98 (t, J= 8.1 Hz, 1H), 3.86 - 3.72 (m, 3H), 3.44 - 3.36 (m, 1H), 3.11 - 3.00 (m, 1H), 2.96 - 2.85 (m, 1H), 2.61 - 2.53 (m, 1H), 2.34 - 2.25 (m, 1H), 2.25 - 2.15 (m, 1H), 2.14 - 2.04 (m, 1H), 1.95 (dq, J= 12.3, 8.4 Hz, 1H), 1.22- 1.06 (m, 4H).160 (R)-5-(5- isopropyl- 1,3,4- oxadiazol-2-potD c°> y!)-2,3- (S)- dihydro-lH- tetrahydrofurNHX inden-1 -amine an-3- N-((R)-5-(5-isopropyl-l,3,4-oxadiazol-2-yl)- hydrochloride carbonitrile 2,3-dihydro-lH-inden-l-yl)-3-((S)- tetrahydrofuran-3-yl)-l,2,4-oxadiazol-5- amine. LRMS (ES) 382.1 [M+H], ’H NMR (400 MHz, DMSO-6) δ 8.81 (d, J = 8.3 Hz,1H), 7.89 (s, 1H), 7.84 (dd, J = 7.8, 1.6 Hz,164MF-3651465184989220219401H), 7.46 (d, J= 7.9 Hz, 1H), 5.23 (q, J = 7.9 Hz, 1H), 3.98 (t, J= 8.1 Hz, 1H), 3.88 - 3.70 (m, 3H), 3.43 - 3.34 (m, 1H), 3.30 - 3.23 (m, 1H), 3.11 - 3.02 (m, 1H), 2.97 - 2.87 (m, 1H), 2.62 - 2.58 (m, 1H), 2.25 - 2.15 (m, 1H), 2.14 - 2.04 (m, 1H), 1.96 (dq, J= 12.7, 8.5 Hz, 1H), 1.40 - 1.34 (m, 6H).190 (S)-6-(5- N'Nmethyl- 1,3,4- — < IIoxadiazol-2- r°\ yl)-2,3- dihydrobenzof NH— Jl uran-3-amine O"Nhydrochloride N-((S)-6-(5-methyl-l,3,4-oxadiazol-2-yl)- (S)- 2,3-dihydrobenzofuran-3-yl)-3-((S)- tetrahydrofur tetrahydrofuran-3-yl)-l,2,4-oxadiazol-5- an-3- amine. LRMS (ES) 356.1 [M+H], ’H NMR carbonitrile (400 MHz, DMSO-6) δ 9.06 (d, J = 7.5 Hz,1H), 7.60 (d, J = 7.8 Hz, 1H), 7.57 - 7.52 (m, 1H), 7.40 (d, J= 1.4 Hz, 1H), 5.54 (td, J = 8.0, 4.5 Hz, 1H), 4.83 (dd, J= 10.1, 8.4 Hz, 1H), 4.48 (dd, 7= 10.0, 4.4 Hz, 1H), 3.98 (t, J= 8.1 Hz, 1H), 3.86 - 3.72 (m, 3H), 3.45 - 3.35 (m, 1H), 2.58 (s, 3H), 2.26 - 2.15 (m,1H), 2.15 - 2.03 (m, 1H).193 (S)-6-(5- cyclopropyl- N-N 'i1,3,4- o' yV0, f-o oxadiazol-2- y!)-2,3- dihydrobenzofuran-3-amineNH^0XN-((S)-6-(5-cyclopropyl-l,3,4-oxadiazol-2- hydrochloride yl)-2,3-dihydrobenzofuran-3-yl)-3-((S)- (S)- tetrahydrofuran-3-yl)-l,2,4-oxadiazol-5- tetrahydrofuramine. LRMS (ES) 382.1 [M+H], *HNMR an-3- (400 MHz, DMSO-6) δ 9.05 (d, J = 7.5 Hz, carbonitrile1H), 7.58 (d, J = 7.8 Hz, 1H), 7.53 (dd, 7 = 7.8, 1.5 Hz, 1H), 7.40 (d, 7= 1.3 Hz, 1H), 5.58 - 5.48 (m, 1H), 4.83 (dd, 7= 10.0, 8.5 Hz, 1H), 4.47 (dd, 7= 10.1, 4.4 Hz, 1H), 3.98 (t, 7= 8.1 Hz, 1H), 3.87 - 3.72 (m, 3H), 3.44 - 3.35 (m, 1H), 2.37 - 2.26 (m, 1H), 2.25 - 2.16 (m, 1H), 2.13 - 2.03 (m, 1H), 1.25 - 1.05(m, 4H).165MF-365146518498922021940207 (R)-5-(5- N'Nmethyl- 1,3,4- — ifoxadiazol-2- °^if^ — syl)-2,3- dihydro-lH- NH— Jl inden-1 -amine O"Nhydrochloride N-((R)-5-(5-mnnethyl-l,3,4-oxadiazol-2-yl)- 2,3-dihydro-lH-inden-l-yl)-3-((S)- (S)- tetrahydrofuran-3-yl)-l,2,4-oxadiazol-5- tetrahydrofuramine. LRMS (ES) 354.1 [M+H], ’H NMR an-3- (400 MHz, DMSO-6) δ 8.81 (d, J = 8.3 Hz, carbonitrile1H), 7.88 (s, 1H), 7.83 (d, 7= 7.9 Hz, 1H), 7.47 (d, J = 7.9 Hz, 1H), 5.24 (q, J = 7.9 Hz, 1H), 3.98 (t, 7= 8.1 Hz, 1H), 3.89 - 3.72 (m, 3H), 3.45 - 3.37 (m, 1H), 3.06 (ddd, 7= 16.1, 8.6, 3.4 Hz, 1H), 2.97 - 2.87 (m, 1H), 2.62 - 2.55 (m, 1H), 2.58 (s, 3H), 2.26 - 2.16 (m, 1H), 2.14 - 2.05 (m, 1H), 1.96 (dq, 7= 12.6,8.5 Hz, 1H).213 (S)-6-(5- isopropyl- 1,3,4- oxadiazol-2- y!)-2,3- dihydrobenzofNH^0Xuran-3-amine N-((S)-6-(5-isopropyl-l,3,4-oxadiazol-2-yl)- hydrochloride (S)- 2,3-dihydrobenzofuran-3-yl)-3-((S)- tetrahydrofur tetrahydrofuran-3-yl)-l,2,4-oxadiazol-5- an-3- amine. LRMS (ES) 384.1 [M+H], *HNMR carbonitrile (400 MHz, DMSO-6) δ 9.06 (d, J = 7.5 Hz,1H), 7.64 - 7.53 (m, 2H), 7.43 (d, 7 = 1.4 Hz, 1H), 5.54 (td, 7= 8.0, 4.5 Hz, 1H), 4.83 (dd, 7= 10.1, 8.5 Hz, 1H), 4.48 (dd, 7= 10.1, 4.5 Hz, 1H), 3.98 (t, 7= 8.1 Hz, 1H), 3.87 - 3.72 (m, 3H), 3.44 - 3.36 (m, 1H), 3.27 (hept, 7= 6.9 Hz, 1H), 2.26 - 2.15 (m, 1H), 2.15 - 2.03 (m, 1H), 1.40 - 1.32 (m, 6H).394 (S)-6-(5-ethyl- 1,3,4- \ _ N-Noxadiazol-2- yl)-4-fluoro- (S)- 2,3- tetrahydrofurdihydrobenzof JNH^0Ian-3- uran-3-amine N-((S)-6-(5-ethyl-l,3,4-oxadiazol-2-yl)-4- carbonitrilehydrochloride fluoro-2,3-dihydrobenzofuran-3-yl)-3-((S)- tetrahydrofuran-3-yl)-l,2,4-oxadiazol-5- amine. LRMS (ES) 388.1 [M+H],1H NMR(400 MHz, DMSO-6) δ 9.14 (d, J = 8.1 Hz,166MF-3651465184989220219401H), 7.35 (d, J = 9.0 Hz, 1H), 7.31 (s, 1H), 5.75 - 5.69 (m, 1H), 4.89 (dd, J= 10.0, 8.4 Hz, 1H), 4.55 (dd, J= 10.1, 4.0 Hz, 1H), 3.96 (t, J = 8.1 Hz, 1H), 3.85 - 3.69 (m, 3H), 3.44 - 3.36 (m, 1H), 2.94 (q, J = 7.5 Hz, 2H), 2.24 - 2.14 (m, 1H), 2.12 - 2.02 (m, 1H), 1.33(t, 7= 7.5 Hz, 3H).470 (S)-6-(5-ethyl- \ FN1,3,4-X( '1oxadiazol-2- ° ]Py°\ <^°\ yl)-5-fluoro- 2,3- NH— IL dihydrobenzof CTNuran-3-amine N-((S)-6-(5-ethyl-l,3,4-oxadiazol-2-yl)-5- (S)- hydrochloride fluoro-2,3-dihydrobenzofuran-3-yl)-3-((S)- tetrahydrofurtetrahydrofuran-3-yl)-l,2,4-oxadiazol-5- an-3- amine. LRMS (ES) 388.1 [M+H], *HNMR carbonitrile(400 MHz, DMSO-6) δ 9.08 (s, 1H), 7.54 (d, J = 9.6 Hz, 1H), 7.40 (d, J = 5.3 Hz, 1H), 5.54 (s, 1H), 4.89 - 4.80 (m, 1H), 4.53 - 4.46 (m, 1H), 3.98 (t, J = 8.1 Hz, 1H), 3.86 - 3.73 (m, 3H), 3.43 - 3.37 (m, 1H), 2.95 (q, J = 7.5 Hz, 2H), 2.25 - 2.17 (m, 1H), 2.13 - 2.04 (m, 1H), 1.32 (t, J = 7.5 Hz, 3H).155 (R)-5-(5-ethyl- \ / ^N1,3,4- \ { ifoxadiazol-2-0J VA -^°\ y!)-2,3- dihydro-lH- inden-1 -amineNH^0I hydrochloride N-((R)-5-(5-ethyl-l,3,4-oxadiazol-2-yl)-2,3- dihydro- IH-inden- 1 -yl)-3-((R)- (R)- tetrahydrofuran-3-yl)-l,2,4-oxadiazol-5- tetrahydrofuramine. LRMS (ES) 368.1 [M+H], *HNMR an- 3- (400 MHz, DMSO-6) δ 8.81 (d, J = 8.3 Hz, carbonitrile1H), 7.88 (s, 1H), 7.83 (dd, J = 7.9, 1.6 Hz, 1H), 7.46 (d, J = 7.9 Hz, 1H), 5.23 (q, J = 7.9 Hz, 1H), 3.98 (t, J= 8.1 Hz, 1H), 3.88 - 3.71 (m, 3H), 3.45 - 3.35 (m, 1H), 3.06 (ddd, J = 16.1, 8.6, 3.4 Hz, 1H), 2.98 - 2.85 (m, 3H), 2.61 - 2.53 (m, 1H), 2.25 - 2.15 (m, 1H), 2.14 - 2.04 (m 1H), 1.96 (dq, J= 12.6, 8.5 Hz,1H), 1.32 (t, 7= 7.5 Hz, 3H).167MF-365146518498922021940158 (R)-5-(5- N'Ncyclopropyl- r>-X 11,3,4- oxadiazol-2- yl)-2,3- dihydro-lH-NH^0Xinden-1 -amine N-((R)-5-(5-cyclopropyl-l,3,4-oxadiazol-2- hydrochloride yl)-2,3-dihydro-lH-inden-l-yl)-3-((R)- (R)- tetrahydrofuran-3-yl)-l,2,4-oxadiazol-5- tetrahydrofuramine. LRMS (ES) 380.1 [M+H], *HNMR an-3- (400 MHz, DMSO-6) δ 8.80 (d, J = 8.3 Hz, carbonitrile1H), 7.85 (s, 1H), 7.83 - 7.78 (m, 1H), 7.45 (d, J = 7.9 Hz, 1H), 5.22 (q, J = 7.9 Hz, 1H), 3.98 (t, J= 8.1 Hz, 1H), 3.88 - 3.66 (m, 3H), 3.43 - 3.34 (m, 1H), 3.05 (ddd, J= 11.9, 8.8, 4.4 Hz, 1H), 2.96 - 2.85 (m, 1H), 2.61 - 2.53 (m, 1H), 2.34 - 2.26 (m, 1H), 2.25 - 2.16 (m, 1H), 2.15 - 2.05 (m, 1H), 1.95 (dq, J= 12.5, 8.4 Hz, 1H), 1.23 - 1.08 (m, 4H).161 (R)-5-(5- isopropyl- 1,3,4- oxadiazol-2-rVjtX> r°> y!)-2,3- dihydro-lH-NH^0Iinden-1 -amine N-((R)-5-(5-isopropyl-l,3,4-oxadiazol-2-yl)- hydrochloride 2,3-dihydro-lH-inden-l-yl)-3-((R)- (R)- tetrahydrofuran-3-yl)-l,2,4-oxadiazol-5- tetrahydrofuramine. LRMS (ES) 382.1 [M+H], *HNMR an- 3- (400 MHz, DMSO-6) δ 8.81 (d, J = 8.3 Hz, carbonitrile1H), 7.89 (s, 1H), 7.87 - 7.79 (m, 1H), 7.47 (d, J = 7.9 Hz, 1H), 5.23 (q, J = 7.9 Hz, 1H), 3.98 (t, J= 8.1 Hz, 1H), 3.87 - 3.70 (m, 3H), 3.44 - 3.34 (m, 1H), 3.30 - 3.23 (m, 1H), 3.07 (ddd, 7= 16.2, 8.7, 3.4 Hz, 1H), 2.97 - 2.86 (m, 1H), 2.61 - 2.52 (m, 1H), 2.28 - 2.15 (m, 1H), 2.15 - 2.04 (m, 1H), 1.96 (dq, J= 12.5, 8.5 Hz, 1H), 1.40 - 1.32 (m, 6H).191 (S)-6-(5- N~Nmethyl- 1,3,4- — '1_^o oxadiazol-2- y!)-2,3- (R)- N^> X-y dihydrobenzof tetrahydrofururan-3-amine an- 3- hydrochloride carbonitrile N-((S)-6-(5-methyl-1,3,4-oxadiazol-2-yl)- 2,3-dihydrobenzofuran-3-yl)-3-((R)- tetrahydrofuran-3-yl)-l,2,4-oxadiazol-5-amine.1H NMR (400 MHz, DMSO-6) δ168MF-3651465184989220219409.06 (d, J = 7.5 Hz, 1H), 7.60 (d, J = 7.8 Hz, 1H), 7.55 (dd, J = 7.8, 1.4 Hz, 1H), 7.40 (s, 1H), 5.54 (td, J = 8.0, 4.4 Hz, 1H), 4.83 (dd, 7= 10.0, 8.5 Hz, 1H), 4.47 (dd, 7= 10.1, 4.4 Hz, 1H), 3.98 (t, 7= 8.1 Hz, 1H), 3.88 - 3.69 (m, 3H), 3.44 - 3.35 (m, 1H), 2.58 (s, 3H), 2.26 - 2.16 (m, 1H), 2.14 - 2.05 (m, 1H). LRMS (ES) 356.1 [M+H], 194 (S)-6-(5- N'Ncyclopropyl- r>— < II1,3,4- oxadiazol-2- yl)-2,3- dihydrobenzofNHO^uran-3-amine N-((S)-6-(5-cyclopropyl-l,3,4-oxadiazol-2- hydrochloride yl)-2,3-dihydrobenzofuran-3-yl)-3-((R)- (R)- tetrahydrofuran-3-yl)-l,2,4-oxadiazol-5- tetrahydrofuramine.1H NMR (400 MHz, DMSO-6) δ an-3- 9.05 (d, 7 = 7.5 Hz, 1H), 7.58 (d, 7 = 7.8 Hz, carbonitrile1H), 7.53 (dd, 7 = 7.8, 1.4 Hz, 1H), 7.40 (s, 1H), 5.53 (td, 7= 8.0, 4.4 Hz, 1H), 4.82 (dd, 7= 10.0, 8.5 Hz, 1H), 4.47 (dd, 7= 10.1, 4.4 Hz, 1H), 3.98 (t, 7= 8.1 Hz, 1H), 3.88 - 3.69 (m, 3H), 3.39 (p, 7 = 7.1 Hz, 1H), 2.38 - 2.26 (m, 1H), 2.26 - 2.15 (m, 1H), 2.15 - 2.04 (m, 1H), 1.25 - 1.06 (m, 4H). LRMS (ES)382.1 [M+H]208 (R)-5-(5- rwmethyl- 1,3,4- oxadiazol-2-0CO r°> y!)-2,3- dihydro-lH-NH^ 1inden-1 -amine O"Nhydrochloride N-((R)-5-(5-mnnethyl-l,3,4-oxadiazol-2-yl)- 2,3-dihydro-lH-inden-l-yl)-3-((R)- (R)- tetrahydrofuran-3-yl)-l,2,4-oxadiazol-5- tetrahydrofuramine.1H NMR (400 MHz, DMSO-6) δan- 3- 8.81 (d, 7= 8.3 Hz, 1H), 7.87 (s, 1H), 7.82 carbonitrile(dd, 7 = 7.8, 1.6 Hz, 1H), 7.46 (d, 7 = 7.9 Hz, 1H), 5.23 (q, 7 = 7.9 Hz, 1H), 3.98 (t, 7= 8.1 Hz, 1H), 3.88 - 3.71 (m, 3H), 3.45 - 3.36 (m, 1H), 3.06 (ddd, 7= 16.1, 8.8, 3.4 Hz, 1H), 2.96 - 2.85 (m, 1H), 2.63 - 2.54 (m, 1H), 2.58 (s, 3H), 2.28 - 2.16 (m, 1H), 2.14 - 2.04 (m, 1H), 1.95 (dq, 7= 12.7, 8.6 Hz, 1H). LRMS(ES) 354.1 [M+H]169MF-365146518498922021940214 (S)-6-(5- \ / XNisopropyl- \-X 11,3,4- oxadiazol-2- yl)-2,3- dihydrobenzofuran-3-amine N-((S)-6-(5-isopropyl-l,3,4-oxadiazol-2-yl)- hydrochloride (R)- 2,3-dihydrobenzofuran-3-yl)-3-((R)- tetrahydrofur tetrahydrofuran-3-yl)-l,2,4-oxadiazol-5- an- 3- amine.1H NMR (400 MHz, DMSO-6) δ carbonitrile 9.06 (d, J = 7.6 Hz, 1H), 7.66 - 7.52 (m, 2H),7.43 (s, 1H), 5.57 - 5.51 (m, 1H), 4.83 (dd, J= 10.0, 8.5 Hz, 1H), 4.48 (dd, J= 10.0, 4.4 Hz, 1H), 3.98 (t, 7= 8.1 Hz, 1H), 3.87 - 3.71 (m, 3H), 3.46 - 3.36 (m, 1H), 3.31 - 3.21 (m, 1H), 2.26 - 2.16 (m, 1H), 2.15 - 2.05 (m, 1H), 1.41 - 1.31 (m, 6H). LRMS (ES) 384.1[M+H]174 (R)-5-(5- isopropyl- 1,3,4- oxadiazol-2-r jCX>y!)-2,3- NHXZy, vo dihydro-lH- CTNinden-1 -amine (R)-N-(5-(5-isopropyl-l,3,4-oxadiazol-2-yl)- hydrochloride 2,3-dihydro-lH-inden-l-yl)-3-(oxetan-3- 2-(oxetan-3- ylmethyl)-l,2,4-oxadiazol-5-amine. ’ll yi) NMR (400 MHz, DMSO-6) δ 8.79 (d, J = acetonitrile8.2 Hz, 1H), 7.89 (s, 1H), 7.84 (d, J = 7.9 Hz, 1H), 7.45 (d, J = 7.9 Hz, 1H), 5.20 (q, J = 7.9 Hz, 1H), 4.72 - 4.62 (m, 2H), 4.36 (t, J = 6.2 Hz, 2H), 3.30 - 3.23 (m, 2H), 3.11 - 3.02 (m, 1H), 2.96 - 2.90 (m, 1H), 2.87 (d, J = 7.7 Hz, 2H), 2.59 - 2.53 (m, 1H), 1.96 (dq, J = 12.6, 8.5 Hz, 1H), 1.37 (d, J= 6.9 Hz, 6H). LRMS (ES) 382.1 [M+H]241 (R)-5-(5-ethyl- 1,3,4- MNIoxadiazol-2-0T ny!)-2,3- dihydro-lH- 2-(oxetan-3- NHXZy, vo inden-1 -amine CTNhydrochloride yi) (R)-N-(5-(5-ethyl-l,3,4-oxadiazol-2-yl)-2,3- acetonitriledihydro- IH-inden- 1 -yl)-3-(oxetan-3- ylmethyl)-l,2,4-oxadiazol-5-amine. ’ll NMR (400 MHz, DMSO-6) δ 8.78 (d, J = 8.2 Hz, 1H), 7.87 (s, 1H), 7.83 (d, J = 7.9, 1.6Hz, 1H), 7.44 (d, 7= 7.9 Hz, 1H), 5.20 (q, 7 =170MF-3651465184989220219407.9 Hz, 1H), 4.67 (t, J= 6.7, 1.7 Hz, 2H), 4.36 (t, J= 6.2 Hz, 2H), 3.32 - 3.26 (m, 1H), 3.10 - 2.99 (m, 1H), 2.97 - 2.82 (m, 5H), 2.60 - 2.53 (m, 1H), 2.02 - 1.87 (m, 1H), 1.32 (t, J = 7.5 Hz, 3H). LRMS (APCI) 368.2 [M+H] 243 (S)-6-(5- N'Ncyclopropyl- r>— < II1,3,4- ° COoxadiazol-2- yl)-2,3- NH— (zII, VO dihydrobenzof CTNuran-3-amine (S)-N-(6-(5-cyclopropyl-l,3,4-oxadiazol-2- hydrochloride 2-(oxetan-3- yl)-2,3-dihydrobenzofuran-3-yl)-3-(oxetan- yi) 3-ylmethyl)- 1,2,4-oxadiazol-5-amine. ’ll acetonitrile NMR (400 MHz, DMSO de) 69.03 (d, J= 7.4Hz, 1H), 7.61 - 7.48 (m, 2H), 7.39 (s, 1H), 5.50 (td, J= 8.0, 4.5 Hz, 1H), 4.81 (t, J = 10.1, 8.5 Hz, 1H), 4.72 - 4.61 (m, 2H), 4.46 (dd, J = 10.0, 4.5 Hz, 1H), 4.36 (t, J = 6.2 Hz, 2H), 3.32 - 3.25 (m, 1H), 2.88 (d, J = 7.7 Hz, 2H), 2.30 (tt, J= 8.1, 5.0 Hz, 1H), 1.27 - 1.03 (m, 4H). LRMS (APCI) 382.2 [M+H] 244 (R)-5-(5- N-Ncyclopropyl- l>— V if1,3,4- oxadiazol-2- OOy!)-2,3- NH— P J, VO dihydro-lH- O"Ninden-1 -amine (R)-N-(5-(5-cyclopropyl- 1,3,4-oxadiazol-2- hydrochloride yl)-2,3-dihydro-lH-inden-l-yl)-3-(oxetan-3- 2-(oxetan-3- ylmethyl)-l,2,4-oxadiazol-5-amine. ’ll yi) NMR (400 MHz, DMSO-d6) 68.78 (d, J = acetonitrile8.2 Hz, 1H), 7.85 (s, 1H), 7.80 (d, J = 7.9 Hz, 1H), 7.43 (d, J = 7.9 Hz, 1H), 5.19 (q, J = 7.9 Hz, 1H), 4.67 (dd, J = 7.7, 6.1 Hz, 2H), 4.36 (t, J= 6.1 Hz, 2H), 3.31 - 3.23 (m, 1H), 3.11 - 2.98 (m, 1H), 2.96 - 2.81 (m, 3H), 2.60 - 2.52 (m, 1H), 2.35 - 2.25 (m, 1H), 1.95 (dq, J = 12.2, 8.4 Hz, 1H), 1.21 - 1.05 (m, 4H). LRMS (APCI) 380.2 [M+H] 273 (R)-5-(5- methyl- 1,3,4- A loxadiazol-2- 2-(oxetan-3- y!)-2,3-0UOdihydro-lH- yi)acetonitrile NHCZCo inden-1 -amine O"Nhydrochloride (R)-N-(5-(5-methyl-l,3,4-oxadiazol-2-yl)-2,3-dihydro-lH-inden-l-yl)-3-(oxetan-3-171MF-365146518498922021940ylmethyl)-l,2,4-oxadiazol-5-amine.NMR (400 MHz, DMSO-d6) δ 8.79 (d, J = 8.2 Hz, 1H), 7.87 (s, 1H), 7.82 (d, J = 7.8 Hz, 1H), 7.45 (d, J = 7.9 Hz, 1H), 5.23 - 5.17 (m, 1H), 4.67 (t, J = 6.9 Hz, 2H), 4.36 (t, J = 6.1 Hz, 2H), 3.32 - 3.27 (m, 1H), 3.09 - 3.02 (m, 1H), 2.96 - 2.89 (m, 1H), 2.87 (d, J = 7.7 Hz, 2H), 2.58 (s, 3H), 2.56 - 2.52 (m, 1H), 2.00 - 1.91 (m, 1H).LRMS (ES) 354.1 [M+H]310 (S)-6-(5- N-Nmethyl- 1,3,4- — '1oxadiazol-2- yl)-2,3-0uOdihydrobenzof NH— (zJ, VO uran-3-amine crNhydrochloride (S)-N-(6-(5-methyl-l,3,4-oxadiazol-2-yl)- 2-(oxetan-3- 2,3-dihydrobenzofuran-3-yl)-3-(oxetan-3- yi) ylmethyl)-l,2,4-oxadiazol-5-amine. ’ll acetonitrileNMR (400 MHz, DMSO-d6) δ 9.04 (d, J = 7.4 Hz, 1H), 7.56 (q, J = 7.8 Hz, 2H), 7.40 (s, 1H), 5.56 - 5.46 (m, 1H), 4.82 (t, J = 9.2 Hz, 1H), 4.72 - 4.63 (m, 2H), 4.47 (dd, J = 10.1, 4.5 Hz, 1H), 4.36 (t, J = 6.1 Hz, 2H), 3.31 - 3.23 (m, 1H), 2.88 (d, J = 7.6 Hz, 2H), 2.58 (s, 3H). LRMS (ES) 356.1 [M+H] 447 (S)-6-(5- — OKN-N(methoxymethX'1yl)- 1,3,4- oxadiazol-2- y!)-2,3- dihydrobenzof O-N L-o uran-3-amine (S)-N-(6-(5-(methoxymethyl)-l,3,4- hydrochloride 2-(oxetan-3- oxadiazol-2-yl)-2,3-dihydrobenzofuran-3- yi) yl)-3-(oxetan-3-ylmethyl)-l,2,4-oxadiazol-5- acetonitrile amine. LRMS (ES) 386.1 [M+H], ’H NMR (400 MHz, DMSO-6) 69.05 (d, 7= 7.5 Hz, 1H), 7.64 - 7.54 (m, 2H), 7.44 (s, 1H), 5.52 (td, 7= 8.0, 4.6 Hz, 1H), 4.83 (dd, 7= 10.0, 8.5 Hz, 1H), 4.73 (s, 2H), 4.70 - 4.63 (m, 2H), 4.47 (dd, 7= 10.0, 4.6 Hz, 1H), 4.36 (t, 7= 6.2 Hz, 2H), 3.39 (s, 3H), 3.27 (m, 1H),2.88 (d, 7 = 7.7 Hz, 2H).172MF-365146518498922021940150 (S)-6-(5-ethyl- \1,3,4- N— / / / ^'NIoxadiazol-2- yl)-2,3-0UO D dihydrobenzofuran-3-aminehydrochloride (S)-3-cyclobutyl-N-(6-(5-isopropyl-l,3,4- oxadiazol-2-yl)-2,3-dihydrobenzofuran-3- cyclobutanec yl)-l,2,4-oxadiazol-5-amine. NMR (400 arbonitrile MHz, DMSO-6) 88.97 (d, J= 7.6 Hz, 1H),7.60 (d, 7= 7.8 Hz, 1H), 7.56 (dd, 7 = 7.8, 1.5 Hz, 1H), 7.41 (d, 7= 1.4 Hz, 1H), 5.56 (td, 7= 8.0, 4.4 Hz, 1H), 4.84 (dd, 7= 10.0, 8.4 Hz, 1H), 4.47 (dd, 7= 10.0, 4.5 Hz, 1H), 3.48 - 3.40 (m, 1H), 2.94 (q, 7 = 7.5 Hz, 2H), 2.32 - 2.16 (m, 4H), 2.08 - 1.97 (m, 1H), 1.95 - 1.85 (m, 1H), 1.32 (t, 7= 7.6 Hz, 3H).LRMS (ES) 354.1 [M+H]151 (R)-5-(5-ethyl- 1,3,4- M ioxadiazol-2- y!)-2,3- ° TT> n dihydro-lH- inden-1 -amineNH^I hydrochloride (R)-3-cyclobutyl-N-(5-(5-ethyl-l,3,4- oxadiazol-2-yl)-2,3-dihydro- IH-inden- 1 -y I ) - cyclobutanecl,2,4-oxadiazol-5-amine. ’ll NMR (400 arbonitrileMHz, DMSO-d6) δ 8.72 (d, J = 8.4 Hz, 1H), 7.88 (s, 1H), 7.84 (dd, J = 8.0, 1.6 Hz, 1H), 7.46 (d, J = 7.9 Hz, 1H), 5.25 (q, J = 7.9 Hz, 1H), 3.43 (p, J = 8.4 Hz, 1H), 3.06 (ddd, J = 16.3, 8.6, 3.3 Hz, 1H), 2.99 - 2.86 (m, 3H), 2.62 - 2.53 (m, 1H), 2.29 - 2.18 (m, 4H), 2.08 - 1.85 (m, 3H), 1.32 (t, J = 7.6 Hz, 3H).LRMS (ES) 352.1 [M+H]156 (R)-5-(5-ethyl- 1,3,4- V— # IIoxadiazol-2-0y!)-2,3- dihydro-lH- (lr,3r)-3- inden-1 -amineNH^0IN hydroxycyclhydrochloride (lR,3r)-3-(5-(((R)-5-(5-ethyl-l,3,4- obutane-1- oxadiazol-2-yl)-2,3-dihydro-lH-inden-l- carbonitrileyl)amino)-l,2,4-oxadiazol-3-yl)cyclobutan- l-ol.1H NMR (400 MHz, DMSO-d6) δ 8.74 (d, J = 8.3 Hz, 1H), 7.88 (s, 1H), 7.84 (dd, J = 7.9, 1.7 Hz, 1H), 7.47 (d, J = 7.9 Hz, 1H),5.23 (q, 7 = 7.9 Hz, 1H), 5.17 (d, 7 = 6.3 Hz,173MF-3651465184989220219401H), 4.39 (h, J = 6.6 Hz, 1H), 3.27 - 3.19 (m, 1H), 3.06 (ddd, J = 16.2, 8.7, 3.4 Hz, 1H), 2.98 - 2.86 (m, 3H), 2.62 - 2.53 (m, 1H), 2.43 - 2.35 (m, 2H), 2.27 - 2.17 (m, 2H), 1.96 (dq, J = 12.7, 8.6 Hz, 1H), 1.32 (t, J = 7.6 Hz, 3H). LRMS (ES) 368.1 [M+H] 163 (R)-5-(5- cyclopropyl- r>—1,3,4- oxadiazol-2-0uOyl)-2,3- dihydro-lH-NH^0IN inden-1 -amine (R)-N-(5-(5-cyclopropyl- 1,3,4-oxadiazol-2- 2- hydrochloride yl)-2,3-dihydro-lH-inden-l-yl)-3- methoxyacet(methoxymethyl)-l,2,4-oxadiazol-5-amine. onitrile‘H NMR (400 MHz, DMSO-6) 68.87 (d, J = 8.3 Hz, 1H), 7.90 - 7.79 (m, 2H), 7.44 (d, J = 7.9 Hz, 1H), 5.24 (q, J = 7.9 Hz, 1H), 4.32 (s, 2H), 3.33 (s, 3H), 3.11 - 2.99 (m, 1H), 2.97 - 2.83 (m, 1H), 2.60 - 2.51 (m, 1H), 2.34 - 2.25 (m, 1H), 2.04 - 1.89 (m, 1H), 1.22 - 1.06 (m, 4H). LRMS (ES) 354.1 [M+H] 164 (R)-5-(5- isopropyl- W l1,3,4- oxadiazol-2- y!)-2,3- dihydro-lH- O"Ninden-1 -amine (R)-N-(5-(5-isopropyl-l,3,4-oxadiazol-2-yl)- hydrochloride 2- 2,3-dihydro-lH-inden-l-yl)-3- methoxyacet (methoxymethyl)-l,2,4-oxadiazol-5-amine. onitrile ‘H NMR (400 MHz, DMSO-6) 68.89 (d, J =8.3 Hz, 1H), 7.95 - 7.80 (m, 2H), 7.47 (d, J = 7.9 Hz, 1H), 5.26 (q, J = 7.9 Hz, 1H), 4.33 (s, 2H), 3.33 - 3.23 (m, 2H), 3.22 (s, 2H), 3.14 - 3.02 (m, 1H), 2.98 - 2.86 (m, 1H), 2.64 - 2.54 (m, 1H), 1.98 (dq, 7= 12.6, 8.6 Hz, 1H), 1.37 (d, J = 7.0 Hz, 6H). LRMS (ES) 356.1[M+H]170 (R)-5-(5-ethyl- 1,3,4- oxadiazol-2- y!)-2,3- 2-0COdihydro-lH- methoxyacet NH— C [I inden-1 -amine onitrile O"Nhydrochloride (R)-N-(5-(5-ethyl-l,3,4-oxadiazol-2-yl)-2,3- dihydro- IH-inden- 1 -yl)-3-(methoxymethyl)-l,2,4-oxadiazol-5-amine.174MF-365146518498922021940‘H NMR (400 MHz, DMSO-6) 88.88 (d, J= 8.3 Hz, 1H), 7.92 - 7.78 (m, 2H), 7.46 (d, J = 7.9 Hz, 1H), 5.25 (q, J = 7.9 Hz, 1H), 4.32 (s, 2H), 3.13 - 3.01 (m, 2H), 2.99 - 2.87 (m, 3H), 2.64 - 2.52 (m, 2H), 1.97 (dq, J = 12.5, 8.5 Hz, 2H), 1.32 (t, 7= 7.5 Hz, 3H). LRMS (ES) 342.1 [M+H]183 (S)-6-(5-ethyl- \ / ^N1,3,4-X'1oxadiazol-2- yl)-2,3-0iCOdihydrobenzof NH— II uran-3-amine CTNhydrochloride (S)-N-(6-(5-ethyl-l,3,4-oxadiazol-2-yl)-2,3- 2- dihydrobenzofuran-3-yl)-3- methoxyacet(methoxymethyl)-l,2,4-oxadiazol-5-amine. onitrile1H NMR (400 MHz, Chloroform-) 67.66 (d, J = 7.8 Hz, 1H), 7.60 - 7.45 (m, 2H), 5.70 - 5.59 (m, 2H), 4.83 (dd, J= 10.6, 7.3 Hz, 1H), 4.56 (dd, 7= 10.5, 3.3 Hz, 1H), 4.43 (s, 2H), 3.49 (s, 3H), 2.96 (q, 7= 7.6 Hz, 2H), 1.44 (t, 7= 7.6 Hz, 3H). LRMS (ES) 344.1[M+H]192 (S)-6-(5- methyl- 1,3,4- — N-N ILoxadiazol-2- y!)-2,3-0iCOdihydrobenzofuran-3-amineNH^0X hydrochloride 2- (S)-3-(methoxymethyl)-N-(6-(5-methyl- methoxyacet 1,3,4-oxadiazol-2-yl)-2,3- onitrile dihydrobenzofuran-3-yl)-l,2,4-oxadiazol-5- amine.1H NMR (400 MHz, Chloroform-) 6 7.65 (dd, 7 = 7.8, 1.6 Hz, 1H), 7.57 - 7.47 (m, 2H), 5.74 - 5.54 (m, 2H), 4.83 (dd, 7= 10.5, 7.4 Hz, 1H), 4.56 (dd, 7= 10.5, 3.4 Hz, 1H), 4.43 (s, 2H), 3.49 (s, 3H), 2.62 (s, 3H).LRMS (ES) 330.1 [M+H]197 (R)-5-(5- methyl- 1,3,4- oxadiazol-2- y!)-2,3-0oO2- dihydro-lH- methoxyacetinden-1 -amineonitrileNH^0X hydrochloride (R)-3-(methoxymethyl)-N-(5-(5-methyl- 1,3,4-oxadiazol-2-yl)-2,3-dihydro- 1H- inden-1-yl)-1,2,4-oxadiazol-5-amine.LRMS (ES) 328.1 [M+H], ’H NMR (400175MF-365146518498922021940MHz, DMSO-d6) δ 8.87 (d, J = 8.3 Hz, 1H), 7.88 (s, 1H), 7.82 (d, J = 7.9, 1.6 Hz, 1H), 7.46 (d, J = 7.9 Hz, 1H), 5.25 (q, J = 7.9 Hz, 1H), 4.32 (s, 2H), 3.27 (s, 3H), 3.12 - 3.00 (m, 2H), 2.97 - 2.85 (m, 1H), 2.57 (s, 3H), 1.97 (dq, J = 12.6, 8.5 Hz, 1H). LRMS (ES)328.1 [M+H]231 (S)-6-(5- \ / ^Nisopropyl- ) — '11,3,4- oxadiazol-2- yl)-2,3- NH— II dihydrobenzof CTNuran-3-amine 2- (S)-N-(6-(5-isopropyl-l,3,4-oxadiazol-2-yl)- hydrochloride methoxyacet 2,3-dihydrobenzofuran-3-yl)-3- onitrile (methoxymethyl)-l,2,4-oxadiazol-5-amine.’H NMR (400 MHz, DMSO-6?6) 89.14 (d, J= 7.5 Hz, 1H), 7.58 (q, J= 8.9, 8.3 Hz, 2H), 7.43 (s, 1H), 5.61 - 5.52 (m, 1H), 4.88 - 4.81 (m, 1H), 4.53 - 4.45 (m, 1H), 4.34 (s, 2H), 3.33 (s, 3H), 3.31 - 3.25 (m, 1H), 1.36 (d, J = 7.0 Hz, 6H). LRMS (ES) 358.1 [M+H] 232 (S)-6-(5- N'Ncyclopropyl- 11,3,4- oxadiazol-2-01^0y!)-2,3- dihydrobenzofNH^0}C° uran-3-amine (S)-N-(6-(5-cyclopropyl-l,3,4-oxadiazol-2- 2- hydrochloride yl)-2,3-dihydrobenzofuran-3-yl)-3- methoxyacet(methoxymethyl)-l,2,4-oxadiazol-5-amine. onitrile‘H NMR (400 MHz, DMSO-6) 69.13 (d, J = 7.5 Hz, 1H), 7.61 - 7.50 (m, 2H), 7.41 (s, 1H), 5.59 - 5.52 (m, 1H), 4.87 - 4.79 (m, 1H), 4.49 (d, J= 4.4 Hz, 1H), 4.33 (s, 2H), 3.43 - 3.36 (m, 3H), 2.30 (t, J= 8.2 Hz, 1H), 1.21 - 1.11 (m, 4H). LRMS (ES) 356.1[M+H]466 (R)-5-(5- — C) N'N(methoxymethxyl)- 1,3,4- oxadiazol-2- 2-0LX>y!)-2,3-zNV^o / methoxyacetdihydro-lH- onitrileinden-1 -amine (R)-3-(methoxymethyl)-N-(5-(5- hydrochloride (methoxymethyl)-l,3,4-oxadiazol-2-yl)-2,3- dihydro- IH-inden- 1 -yl)- 1,2,4-oxadiazol-5-amine. LRMS (ES) 358.30 [M+H], ’H176MF-365146518498922021940NMR (400 MHz, Chloroform-d) 68.00 (s, 1H), 7.95 (d, J = 7.4 Hz, 1H), 7.48 (d, J = 7.9 Hz, 1H), 5.57 (d, J = 9.0 Hz, 1H), 5.44 (q, J = 7.9 Hz, 1H), 4.72 (s, 2H), 4.43 (s, 2H), 3.50 (s, 3H), 3.48 (s, 3H), 3.11 (ddd, J = 16.2, 8.8, 3.5 Hz, 1H), 3.04 - 2.91 (m, 1H), 2.85 - 2.74 (m, 1H), 2.09 - 1.97 (m, 1H).395 (S)-6-(5-ethyl- \ / ^N1,3,4-X'1oxadiazol-2- yl)-4-fluoro-0iCOT V2,3- dihydrobenzofuran-3-amine (S)-N-(6-(5-ethyl-l,3,4-oxadiazol-2-yl)-4- 2- hydrochloride fluoro-2,3-dihydrobenzofuran-3-yl)-3- methoxyacet(methoxymethyl)-l,2,4-oxadiazol-5-amine. onitrile1H NMR (400 MHz, Chloroform-) 67.46 - 7.36 (m, 2H), 5.79 (td, J = 7.6, 3.3 Hz, 1H), 5.69 (d, J= 7.8 Hz, 1H), 4.89 (dd, J= 10.6, 7.6 Hz, 1H), 4.67 (dd, 7= 10.5, 3.4 Hz, 1H), 4.46 (s, 2H), 3.51 (s, 3H), 2.99 (q, J= 7.6 Hz, 2H), 1.47 (t, J = 7.6 Hz, 3H). LRMS (ES)362.1 [M+H]165 (R)-5-(5- cyclopropyl- r>—1,3,4- oxadiazol-2- ° £? —1y!)-2,3- dihydro-lH-NH^0Xinden-1 -amine (R)-N-(5-(5-cyclopropyl- 1,3,4-oxadiazol-2- hydrochloride yl)-2,3-dihydro-lH-inden-l-yl)-3-(oxetan-3- yl)-l,2,4-oxadiazol-5-amine. ’ll NMR (400 oxetane-3- MHz, DMSO-6) 88.90 (d, J= 8.3 Hz, 1H), carbonitrile7.86 (s, 1H), 7.82 (dd, J = 7.9, 1.6 Hz, 1H), 7.47 (d, J = 7.9 Hz, 1H), 5.28 (q, J = 7.9 Hz, 1H), 4.85 (ddd, 7 = 8.5, 5.7, 1.3 Hz, 2H), 4.72 (ddd, 7= 7.3, 5.8, 1.8 Hz, 2H), 4.22 (tt, 7 = 8.5, 6.7 Hz, 1H), 3.06 (ddd, 7= 16.0, 8.7, 3.4 Hz, 1H), 2.97 - 2.87 (m, 1H), 2.63 - 2.54 (m, 1H), 2.34 - 2.26 (m, 1H), 1.97 (dq, 7= 12.5, 8.4 Hz, 1H), 1.21 - 1.06 (m, 4H). LRMS (ES) 366.1 [M+H]166 (R)-5-(5- isopropyl- W l1,3,4- oxetane-3- " “ '(Y) r? oxadiazol-2- carbonitriley!)-2,3-dihydro-lH-177MF-365146518498922021940inden- 1 -amine (R)-N-(5-(5-isopropyl-l,3,4-oxadiazol-2-yl)- hydrochloride 2,3-dihydro-lH-inden-l-yl)-3-(oxetan-3-yl)- l,2,4-oxadiazol-5-amine. NMR (400 MHz, DMSO-d6) δ 8.91 (d, J = 8.3 Hz, 1H), 7.90 (s, 1H), 7.85 (dd, J = 7.9, 1.6 Hz, 1H), 7.49 (d, J = 7.9 Hz, 1H), 5.28 (q, J = 8.0 Hz, 1H), 4.85 (ddd, J = 8.6, 5.7, 1.3 Hz, 2H), 4.79 - 4.64 (m, 2H), 4.23 (tt, J = 8.5, 6.7 Hz, 1H), 3.30 - 3.22 (m, 1H), 3.08 (ddd, J = 15.9, 8.5, 3.3 Hz, 1H), 2.98 - 2.88 (m, 1H), 2.63 - 2.53 (m 1H), 1.98 (dq, J = 12.4, 8.5 Hz, 1H), 1.41 - 1.32 (m, 6H). LRMS (ES) 368.1 [M+H] 393 (S)-6-(5-ethyl- \ / ^"N1,3,4- oxadiazol-2- yl)-4-fluoro- 2,3- dihydrobenzof Juran-3-amine (S)-N-(6-(5-ethyl-l,3,4-oxadiazol-2-yl)-4- hydrochloride fluoro-2,3-dihydrobenzofuran-3-yl)-3- oxetane-3- (oxetan-3-yl)-l,2,4-oxadiazol-5-amine. ’ll carbonitrileNMR (400 MHz, DMSO-d6) δ 9.24 (d, J = 8.2 Hz, 1H), 7.36 (d, J = 9.1 Hz, 1H), 7.33 (s, 1H), 5.81 - 5.76 (m, 1H), 4.91 (dd, J = 10.1, 8.4 Hz, 1H), 4.84 (dd, J = 8.5, 5.8 Hz, 2H), 4.70 (t, J = 6.2 Hz, 2H), 4.58 (dd, J = 10.1, 3.9 Hz, 1H), 4.28 - 4.18 (m, 1H), 2.95 (q, J = 7.6 Hz, 2H), 1.33 (t, J = 7.5 Hz, 3H). LRMS (ES) 374.1 [M+H]199 (R)-5-(5-ethyl- 1,3,4-x( ifoxadiazol-2- y!)-2,3- ° O0dihydro-lH- inden-1 -amineFhydrochloride (R)-N-(5-(5-ethyl-l,3,4-oxadiazol-2-yl)-2,3- dihydro- IH-inden- 1 -yl)-3-((2,2,2- 2-(2,2,2- trifluoroethoxy)methyl)-l,2,4-oxadiazol-5- trifluoroethoamine. LRMS (ES) 410.1 [M+H], ’H NMR xy)acetonitril(400 MHz, DMSO-6) 68.97 (d, 7= 8.3 Hz, e1H), 7.90 (s, 1H), 7.84 (dd, 7 = 7.9, 1.6 Hz, 1H), 7.48 (d, 7= 7.9 Hz, 1H), 5.27 (q, 7= 8.0 Hz, 1H), 4.61 (s, 2H), 4.21 (q, 7= 9.3 Hz, 2H), 3.08 (ddd, 7= 15.6, 8.7, 3.3 Hz, 1H), 2.94 (qd, 7= 7.6, 3.8 Hz, 3H), 2.58 (dtd, 7 = 11.2, 7.7, 3.4 Hz, 1H), 1.98 (dq, 7= 12.7, 8.5 Hz, 1H), 1.33 (t, 7 = 7.5 Hz, 3H)178MF-365146518498922021940200 (S)-6-(5-ethyl- \ / ^'N1,3,4-X1oxadiazol-2- yl)-2,3- dihydrobenzofuran-3-amineNHXNFhydrochloride 2-(2,2,2- (S)-N-(6-(5-ethyl-l,3,4-oxadiazol-2-yl)-2,3- trifluoroetho dihydrobenzofuran-3-yl)-3-((2,2,2- xy)acetonitril trifluoroethoxy)methyl)-l,2,4-oxadiazol-5- e amine.1H NMR (400 MHz, DMSO-6) δ9.22 (s, 1H), 7.68 - 7.49 (m, 2H), 7.43 (d, J = 1.4 Hz, 1H), 5.58 (s, 1H), 4.85 (dd, J= 10.1, 8.5 Hz, 1H), 4.62 (s, 2H), 4.50 (dd, 7= 10.1, 4.4 Hz, 1H), 4.20 (q, J= 9.3 Hz, 2H), 2.94 (q, 7= 7.5 Hz, 2H), 1.33 (t, 7 = 7.5 Hz, 3H).LRMS (ES) 412.1 [M+H]201 (S)-6-(5- N-Nmethyl- 1,3,4- — '1oxadiazol-2-0TQQ J y!)-2,3- dihydrobenzofNHJZLuran-3-amine CTNhydrochloride (S)-N-(6-(5-methyl-l,3,4-oxadiazol-2- yD- 2-(2,2,2- 2,3-dihydrobenzofuran-3-yl)-3-((2,22- trifluoroetho trifluoroethoxy )methyl)-l, 2, 4-oxadiaz< 31-5- xy)acetonitril amine. LRMS (ES) 398.1 [M+H],1H > JMR e (400 MHz, DMSO-6) 69.22 (d, 7= 7.4 Hz,1H), 7.61 (d, 7= 7.8 Hz, 1H), 7.55 (dd, 7 = 7.8, 1.5 Hz, 1H), 7.41 (d, 7= 1.5 Hz, 1 H), 5.58 (td, 7 = 7.9, 4.4 Hz, 1H), 4.85 (dd, 7 = 10.1, 8.4 Hz, 1H), 4.62 (s, 2H), 4.50 (dd, 7 = 10.1, 4.4 Hz, 1H), 4.20 (q, 7= 9.3 Hz, 2 H),2.58 (s, 3H).202 (R)-5-(5- methyl- 1,3,4- oxadiazol-2-0(V>y!)-2,3- dihydro-lH- inden-1 -amine 2-(2,2,2-NH^0I hydrochloride trifluoroetho (R)-N-(5-(5-methyl-l,3,4-oxadiazol-2- yD- xy)acetonitril 2,3-dihydro-lH-inden-l-yl)-3-((2,2,i 1- e trifluoroethoxy)methyl)-1,2,4-oxadiazol-5- amine.1H NMR (400 MHz, Methylene Chloride-d2) δ 7.86 (s, 1H), 7.81 (d, J = 7.9 Hz, 1H), 7.40 (d, J = 7.9 Hz, 1H), 5.64 (d, J = 8.6 Hz, 1H), 5.32 (q, J = 7.8 Hz, 1H), 4.52 (s,2H), 3.93 (q, 7= 8.7 Hz, 2H), 3.04 (ddd 7 =179MF-36514651849892202194016.2, 8.8, 3.7 Hz, 1H), 2.91 (dt, J= 16.2, 8.2 Hz, 1H), 2.76 - 2.62 (m, 1H), 2.50 (s, 3H), 1.96 (dq, J= 13.0, 8.3 Hz, 1H). LRMS (ES)396.1 [M+H]220 (S)-6-(5- isopropyl- 1,3,4- oxadiazol-2- yl)-2,3- dihydrobenzofuran-3-amine (S)-N-(6-(5-isopropyNl-HlX,3,4-oxNadiazol-2F-yl)- 2-(2,2,2- hydrochloride 2,3-dihydrobenzofuran-3-yl)-3-((2,2,2- trifluoroethotrifluoroethoxy)methyl)-l,2,4-oxadiazol-5- xy)acetonitrilamine.1H NMR (400 MHz, DMSO-6) δ e9.22 (d, J = 7.5 Hz, 1H), 7.66 - 7.50 (m, 2H), 7.44 (d, J = 1.4 Hz, 1H), 5.58 (td, J = 8.0, 4.5 Hz, 1H), 4.85 (dd, J = 10.0, 8.4 Hz, 1H), 4.62 (s, 2H), 4.50 (dd, J = 10.1, 4.5 Hz, 1H), 4.20 (q, J = 9.3 Hz, 2H), 3.27 (h, J = 7.0 Hz, 1H), 1.37 (d, J = 7.0 Hz, 6H). LRMS (ES) 426.1[M+H]209 (S)-6-(5-ethyl- 1,3,4- \ / ^Noxadiazol-2- y!)-2,3- dihydrobenzofuran-3-aminehydrochlorideNH^0TN-((S)-6-(5-ethyl-l,3,4-oxadiazol-2-yl)-2,3- (ls,3s)-3- dihydrobenzofuran-3-yl)-3-((ls,3R)-3- methoxycyclmethoxy cyclobutyl)- 1,2,4-oxadiazol-5- obutane-1- amine.carbonitrile’H NMR (400 MHz, DMSO-6) 69.10 (d, J= 7.6 Hz, 1H), 7.72 - 7.64 (m, 2H), 7.51 (d, J = 1.4 Hz, 1H), 5.70 - 5.61 (m, 1H), 4.94 (dd, 7= 10.0, 8.4 Hz, 1H), 4.57 (dd, 7= 10.1, 4.5 Hz, 1H), 3.96 (p, 7= 7.4 Hz, 1H), 3.25 (s, 3H), 3.12 - 2.98 (m, 3H), 2.69 - 2.63 (m, 2H), 2.24 - 2.13 (m, 2H), 1.42 (t, 7 = 7.6 Hz, 3H). LRMS (ES) 384.1 [M+H] 218 (R)-5-(5- cyclopropyl- r>— < N-N 111,3,4- (ls,3s)-3-0rY°Hoxadiazol-2- hydroxycycly!)-2,3- obutane-1- dihydro-lH- carbonitrileNH^0Xinden-1 -amine (lS,3s)-3-(5-(((R)-5-(5-cyclopropyl-l,3,4-hydrochloride oxadiazol-2-yl)-2,3-dihydro-lH-inden-l-180MF-365146518498922021940yl)amino)-l,2,4-oxadiazol-3-yl)cyclobutan- l-ol. ’H NMR (400 MHz, DMSO-d6) 88.71 (d, J = 8.4 Hz, 1H), 7.92 - 7.78 (m, 2H), 7.45 (d, J = 7.9 Hz, 1H), 5.24 (q, J = 8.0 Hz, 2H), 4.07 (p, J = 7.7 Hz, 1H), 3.11 - 2.99 (m, 1H), 2.99 - 2.74 (m, 2H), 2.64 - 2.55 (m, 1H), 2.48 - 2.42 (m, 1H), 2.30 (tt, J= 8.3, 5.0 Hz, 1H), 2.18 - 2.02 (m, 2H), 2.02 - 1.89 (m, 2H), 1.28 - 1.05 (m, 4H). LRMS (ES) 380.1 [M+H] 225 (S)-6-(5-ethyl- 1,3,4- oxadiazol-2- yl)-2,3- dihydrobenzofuran-3-amine O-N hydrochlorideN-((S)-6-(5-ethyl-l,3,4-oxadiazol-2-yl)-2,3- dihydrobenzofuran-3-yl)-3-((2S,3S)-2- 5- methyltetrahydrofuran-3-yl)- 1,2,4- methyltetrahoxadiazol-5-amine.1H NMR (400 MHz, ydrofuran-3- DMSO-d6) δ 9.08 (d, J= 7.5 Hz, 1H), 7.62 - carbonitrile7.54 (m, 2H), 7.41 (s, 1H), 5.58 - 5.49 (m, 1H), 4.83 (dd, J = 10.0, 8.4 Hz, 1H), 4.48 (dd, J= 10.1, 4.5 Hz, 1H), 3.94 - 3.85 (m, 2H), 3.82 - 3.74 (m, 1H), 2.94 (q, J = 7.5 Hz, 2H), 2.83 (q, J = 8.4 Hz, 1H), 2.31 - 2.22 (m, 1H), 2.20 - 2.11 (m, 1H), 1.32 (t, J = 7.5 Hz, 3H), 1.24 (dd, J = 6.0, 1.2 Hz, 3H).LRMS (ES) 384.1 [M+H],219 (S)-6-(5- N-Ncyclopropyl- r>— < 111,3,4- oxadiazol-2- y!)-2,3- dihydrobenzofFuran-3-amine (S)-N-(6-(5-cyclopropyl-l,3,4-oxadiazol-2- hydrochloride 2-(2,2,2- yl)-2,3-dihydrobenzofuran-3-yl)-3-((2,2,2- trifluoroetho trifluoroethoxy)methyl)-l,2,4-oxadiazol-5- xy)acetonitril amine.e ’H NMR (400 MHz, DMSO-d6) 69.21 (d, J =7.5 Hz, 1H), 7.59 (d, J = 7.8 Hz, 1H), 7.53 (dd, J = 7.8, 1.5 Hz, 1H), 7.41 (d, J = 1.4 Hz, 1H), 5.57 (td, J = 8.0, 4.4 Hz, 1H), 4.84 (dd, J = 10.1, 8.5 Hz, 1H), 4.49 (dd, J = 10.1, 4.5 Hz, 2H), 4.20 (q, J = 9.3 Hz, 2H), 2.31 (tt, J = 8.1, 4.9 Hz, 2H), 1.23 - 1.05 (m, 4H). LRMS(ES) 424.1 [M+H]181MF-365146518498922021940224 (S)-6-(5-ethyl- (R)- 1,3,4- tetrahydro- \ - (zIIoxadiazol-2- _ / 0-,2H-pyran-3- yl)-2,3- carbonitriledihydrobenzofuran-3-amineNH^0IN hydrochloride N-((S)-6-(5-ethyl-l,3,4-oxadiazol-2-yl)-2,3- dihydrobenzofuran-3-yl)-3-((R)- tetrahydro-2H-pyran-3-yl)-l,2,4-oxadiazol- 5-amine.1H NMR (400 MHz, DMSO-6) δ 9.04 (d, J = 7.6 Hz, 1H), 7.63 - 7.49 (m, 2H), 7.41 (d, J = 1.4 Hz, 1H), 5.53 (td, J = 8.0, 4.4 Hz, 1H), 4.83 (dd, J= 10.0, 8.4 Hz, 1H), 4.47 (dd, J= 10.1, 4.5 Hz, 1H), 4.01 - 3.91 (m, 1H), 3.86 - 3.76 (m, 1H), 3.48 (dd, 7= 11.1, 9.7 Hz, 1H), 3.44 - 3.36 (m, 1H), 2.94 (q, J = 7.6 Hz, 2H), 2.88 - 2.75 (m, 1H), 2.09 - 1.98 (m, 1H), 1.80 - 1.54 (m, 3H), 1.32 (t, 7= 7.5 Hz, 3H). LRMS (ES) 384.1 [M+H] 226 (S)-6-(5- (S)- N-Ncyclopropyl- tetrahydro- — (z'I1,3,4- 2H-pyran-3- oxadiazol-2- carbonitriley!)-2,3- NH— Ji dihydrobenzof CTNuran-3-amine N-((S)-6-(5-cyclopropyl-l,3,4-oxadiazol-2- hydrochloride yl)-2,3-dihydrobenzofuran-3-yl)-3-((S)- tetrahydro-2H-pyran-3-yl)-l,2,4-oxadiazol- 5-amine.1H NMR (400 MHz, Methylene Chloride-d2) δ 7.47 (dd, J = 7.8, 1.4 Hz, 1H), 7.42 (d, J = 7.9 Hz, 1H), 7.35 (d, J = 1.5 Hz, 1H), 5.89 (d, J = 7.9 Hz, 1H), 5.47 (td, J = 7.8, 3.8 Hz, 1H), 4.73 (dd, J = 10.4, 7.9 Hz, 1H), 4.45 (dd, J = 10.4, 4.0 Hz, 1H), 3.95 (ddd, J = 11.2, 4.2, 1.8 Hz, 1H), 3.84 - 3.69 (m, 1H), 3.48 (dd, J = 11.2, 9.8 Hz, 1H), 3.42 - 3.27 (m, 1H), 2.80 (tt, J = 10.3, 4.0 Hz, 1H), 2.20 - 2.07 (m, 1H), 2.02 (tdd, J = 11.5, 5.9, 3.7 Hz, 1H), 1.73 (dddd, J = 15.2, 10.4, 7.6, 5.2 Hz, 1H), 1.67 - 1.52 (m, 2H), 1.10 (d, J = 7.9 Hz, 4H). LRMS (ES) 396.1 [M+H] 227 (S)-6-(5- (S)- isopropyl- tetrahydro- \ — (zII1,3,4- 2H-pyran-3- oxadiazol-2- carbonitriley!)-2,3-NH^ZJidihydrobenzof crN182MF-365146518498922021940uran-3-amine N-((S)-6-(5-isopropyl-l,3,4-oxadiazol-2-yl)- hydrochloride 2,3-dihydrobenzofuran-3-yl)-3-((S)- tetrahydro-2H-pyran-3-yl)-l,2,4-oxadiazol- 5-amine.2H NMR (400 MHz, Methylene Chloride-d2) δ 7.53 (dd, J = 7.8, 1.4 Hz, 1H), 7.48 - 7.30 (m, 2H), 6.02 (d, J = 7.1 Hz, 1H), 5.49 (s, 1H), 4.74 (dd, J = 10.4, 7.9 Hz, 1H), 4.47 (dd, J = 10.4, 3.9 Hz, 1H), 4.04 - 3.88 (m, 1H), 3.79 (dt, J = 11.5, 3.7 Hz, 1H), 3.50 (dd, J = 11.2, 9.6 Hz, 1H), 3.38 (ddd, J = 11.2, 8.8, 4.8 Hz, 1H), 3.16 (hept, J = 7.0 Hz, 1H), 2.82 (tt, J = 9.9, 4.0 Hz, 1H), 2.11 - 1.95 (m, 1H), 1.81 - 1.67 (m, 1H), 1.67 - 1.53 (m, 2H), 1.34 (d, J = 7.0 Hz, 6H). LRMS (ES)398.1 [M+H]228 (S)-6-(5-ethyl- (S)- \ z^N1,3,4- tetrahydro- < l[oxadiazol-2- 2H-pyran-3- Z°> yl)-2,3- carbonitriledihydrobenzofuran-3-amineNH^0X hydrochloride N-((S)-6-(5-ethyl-l,3,4-oxadiazol-2-yl)-2,3- dihydrobenzofuran-3-yl)-3-((S)-tetrahydro- 2H-pyran-3-yl)-l,2,4-oxadiazol-5-amine.1H NMR (400 MHz, Methylene Chloride-d2) δ 7.64 (dd, J = 7.9, 1.5 Hz, 1H), 7.60 - 7.43 (m, 2H), 5.99 (d, J = 7.9 Hz, 1H), 5.60 (td, J = 7.8, 3.9 Hz, 1H), 4.86 (dd, J = 10.4, 7.9 Hz, 1H), 4.58 (dd, J = 10.4, 3.9 Hz, 1H), 4.13 - 3.99 (m, 1H), 3.91 (dt, J = 11.6, 3.7 Hz, 1H), 3.60 (dd, J = 11.2, 9.8 Hz, 1H), 3.54 - 3.40 (m, 1H), 3.05 - 2.82 (m, 3H), 2.20 - 1.99 (m, 1H), 1.94- 1.78 (m, 1H), 1.78 - 1.58 (m, 2H), 1.44 (t, J = 7.6 Hz, 3H). LRMS (ES)384.1 [M+H]229 (R)-5-(5-ethyl- (S)- 1,3,4- tetrahydro- oxadiazol-2- 2H-pyran-3- y!)-2,3- carbonitrileM"¥ r> N^Z D^Z dihydro-lH- NH^ZJi inden-1 -amine CTNhydrochloride N-((R)-5-(5-ethyl-l,3,4-oxadiazol-2-yl)-2,3- dihydro- IH-inden- 1 -yl)-3-((S)-tetrahydro- 2H-pyran-3-yl)-l,2,4-oxadiazol-5-amine.1H NMR (400 MHz, Methylene Chloride-d2) δ 7.98 (s, 1H), 7.93 (d, J = 7.9 Hz, 1H), 7.52 (d, J = 7.9 Hz, 1H), 5.97 (s, 1H), 5.48 - 5.38(m, 1H), 4.09 (ddd, J = 11.3, 4.3, 1.7 Hz, 1H),183MF-3651465184989220219404.00 - 3.81 (m, 1H), 3.62 (dd, J = 11.2, 9.6 Hz, 1H), 3.16 (ddd, J = 16.3, 8.7, 3.6 Hz, 1H), 3.00 (dq, J = 22.7, 7.7, 7.3 Hz, 4H), 2.78 (dtd, J = 11.7, 7.7, 3.6 Hz, 2H), 2.23 - 1.99 (m, 2H), 1.94 - 1.79 (m, 1H), 1.75 (dt, J = 9.0, 4.4 Hz, 2H), 1.45 (t, J = 7.6 Hz, 3H). LRMS (ES)382.1 [M+H]245 (S)-6-(5- 2- cyclopropyl- isopropoxyac r>— < N~N ii1,3,4- etonitrile° rx> i oxadiazol-2- yl)-2,3- dihydrobenzofNH^0Xuran-3-amine (S)-N-(6-(5-cyclopropyl-l,3,4-oxadiazol-2- hydrochloride yl)-2,3-dihydrobenzofuran-3-yl)-3- (isopropoxymethyl)-l,2,4-oxadiazol-5- amine.1H NMR (400 MHz, Methylene Chloride-d2) δ 7.62 (dd, J = 7.8, 1.4 Hz, 1H), 7.55 (d, J = 7.8 Hz, 1H), 7.49 (d, J = 1.4 Hz, 1H), 5.89 (d, J = 8.0 Hz, 1H), 5.64 (td, J = 7.8, 3.8 Hz, 1H), 4.87 (dd, J = 10.4, 7.9 Hz, 1H), 4.59 (dd, J = 10.4, 3.9 Hz, 1H), 4.44 (s, 2H), 3.78 (hept, J = 6.2 Hz, 1H), 2.24 (p, J = 6.9 Hz, 2H), 1.28 - 1.17 (m, 9H). LRMS (ES) 384.1 [M+H]246 (R)-5-(5- 2- isopropyl- isopropoxyac1,3,4- etonitriler° l T> 1 oxadiazol-2- y!)-2,3- dihydro-lH-NH^O1inden-1 -amine (R)-3-(isopropoxymethyl)-N-(5-(5- hydrochloride isopropyl- 1,3,4-oxadiazol-2-yl)-2,3- dihydro- IH-inden- 1 -yl)- 1,2,4-oxadiazol-5- amine.1H NMR (400 MHz, Methylene Chloride-d2) δ 7.98 (s, 1H), 7.93 (d, J = 7.9 Hz, 1H), 7.52 (d, J = 7.9 Hz, 1H), 5.77 (d, J = 8.8 Hz, 1H), 5.44 (q, J = 7.9 Hz, 1H), 4.43 (s, 2H), 3.77 (hept, J = 6.1 Hz, 1H), 3.28 (hept, J = 7.0 Hz, 1H), 3.15 (ddd, J = 16.0, 8.7, 3.6 Hz, 1H), 3.02 (dt, J = 16.2, 8.1 Hz, 1H), 2.79 (dtd, J = 11.5, 7.7, 3.6 Hz, 1H), 2.07 (dq, J = 12.9, 8.3 Hz, 1H), 1.47 (d, J = 6.9 Hz, 6H), 1.23 (d, J = 6.1 Hz, 6H). LRMS (ES) 384.1[M+H]184MF-365146518498922021940247 (S)-6-(5-ethyl- 2- \ / ^'N1,3,4- isopropoxyacX1oxadiazol-2- etonitrileyl)-2,3-0TOO x dihydrobenzofuran-3-amineNH^0T^° hydrochloride (S)-N-(6-(5-ethyl-l,3,4-oxadiazol-2-yl)-2,3- dihydrobenzofuran-3-yl)-3- (isopropoxymethyl)-l,2,4-oxadiazol-5- amine.1H NMR (400 MHz, Methylene Chloride-d2) δ 7.65 (dd, J = 7.8, 1.4 Hz, 1H), 7.56 (d, J = 7.9 Hz, 1H), 7.52 (d, J = 1.4 Hz, 1H), 6.02 (d, J = 8.0 Hz, 1H), 5.65 (dt, J = 11.3, 5.6 Hz, 1H), 4.87 (dd, J = 10.4, 7.9 Hz, 1H), 4.60 (dd, J = 10.4, 3.9 Hz, 1H), 4.44 (s, 2H), 3.78 (hept, J = 6.2 Hz, 1H), 2.96 (q, J = 7.6 Hz, 2H), 1.45 (dd, J = 8.2, 7.2 Hz, 3H), 1.28 - 1.18 (m, 6H). LRMS (ES) 372.1[M+H]248 (R)-5-(5-ethyl- 2- 1,3,4- isopropoxyacoxadiazol-2- etonitrile0rr> i y!)-2,3- dihydro-lH- inden-1 -amineNC0 hydrochloride (R)-N-(5-(5-ethyl-l,3,4-oxadiazol-2-yl)-2,3- dihydro- IH-inden- 1 -yl)-3- (isopropoxymethyl)-l,2,4-oxadiazol-5- amine.1H NMR (400 MHz, Methylene Chloride-d2) δ 7.98 (s, 1H), 7.93 (d, J = 8.0 Hz, 1H), 7.52 (d, J = 7.9 Hz, 1H), 5.72 (d, J = 8.9 Hz, 1H), 5.44 (q, J = 7.9 Hz, 1H), 4.43 (s, 2H), 3.78 (p, J = 6.2 Hz, 1H), 3.15 (ddd, J = 16.0, 8.7, 3.5 Hz, 1H), 3.00 (dq, J = 22.8, 7.9 Hz, 3H), 2.79 (dtd, J = 11.6, 7.7, 3.7 Hz, 1H), 2.06 (dq, J = 12.9, 8.3 Hz, 1H), 1.45 (t, J = 7.6 Hz, 3H), 1.23 (d, J = 6.1 Hz, 6H). LRMS (ES) 370.1 [M+H]249 (R)-5-(5- 2- methyl- 1,3,4- isopropoxyac Cloxadiazol-2- etonitrile00 1 y!)-2,3- dihydro-lH- NH— [Iinden-1 -amine CTNhydrochloride (R)-N-(5-(5-methyl-l,3,4-oxadiazol-2-yl)- 2,3-dihydro-lH-inden-l-yl)-3- (isopropoxymethyl)-l,2,4-oxadiazol-5-amine.1H NMR (400 MHz, Methylene185MF-365146518498922021940Chloride-d2) δ 7.94 (s, 1H), 7.89 (d, J = 7.9 Hz, 1H), 7.50 (d, J = 7.9 Hz, 1H), 6.30 (d, J = 8.7 Hz, 1H), 5.41 (q, J = 7.9 Hz, 1H), 4.47 - 4.24 (m, 2H), 3.74 (hept, J = 6.1 Hz, 1H), 3.15 (s, 3H), 3.14 (ddd, J = 16.2, 8.7, 3.5 Hz, 1H), 3.00 (dt, J = 16.3, 8.2 Hz, 1H), 2.84 - 2.67 (m, 1H), 2.08 (dq, J = 12.9, 8.4 Hz, 1H), 1.21 (d, J = 6.1 Hz, 6H). LRMS (ES) 356.1[M+H]250 (R)-5-(5-ethyl- 2- 1,3,4- ethoxyacetonoxadiazol-2- itrileyl)-2,3- ° i T> dihydro-lH- inden-1 -aminehydrochloride (R)-N-(5-(5-ethyl-l,3,4-oxadiazol-2-yl)-2,3- dihydro- IH-inden- 1 -yl)-3-(ethoxymethyl)- l,2,4-oxadiazol-5-amine. ’ll NMR (400 MHz, DMSO-d6) δ 8.87 (d, J = 8.3 Hz, 1H), 7.89 (s, 1H), 7.87 – 7.79 (m, 1H), 7.46 (d, J = 7.9 Hz, 1H), 5.26 (q, J= 7.9 Hz, 1H), 4.35 (s, 2H), 3.54 (q, J = 7.0 Hz, 2H), 3.13 - 3.01 (m, 1H), 3.00 - 2.84 (m, 3H), 2.64 - 2.53 (m, 1H), 2.04 - 1.89 (m, 1H), 1.32 (t, J = 7.5 Hz, 3H), 1.13 (t, J = 7.0 Hz, 3H). LRMS (ES)356.1 [M+H]262 (S)-6-(5- 2- cyclopropyl- ethoxyaceton r>— < N-N a1,3,4- itrile° moxadiazol-2- y!)-2,3- dihydrobenzofNH^0Xuran-3-amine (S)-N-(6-(5-cyclopropyl-l,3,4-oxadiazol-2- hydrochloride yl)-2,3-dihydrobenzofuran-3-yl)-3- (ethoxymethyl)-l,2,4-oxadiazol-5-amine.’H NMR (400 MHz, DMSO-d6) 69.11 (d, J= 7.5 Hz, 1H), 7.63 - 7.50 (m, 2H), 7.40 (d, J = 1.4 Hz, 1H), 5.76 (s, 1H), 5.56 (td, J= 8.0, 4.5 Hz, 1H), 4.83 (t, J= 10.1, 8.4 Hz, 1H), 4.48 (dd, J = 10.0, 4.4 Hz, 1H), 3.53 (q, J = 7.0 Hz, 2H), 2.30 (tt, J= 8.0, 4.9 Hz, 2H), 1.31 - 0.87 (m, 7H). LRMS (ES) 370.1[M+H]186MF-365146518498922021940272 (R)-5-(5- 2- isopropyl- ethoxyaceton1,3,4- itrileoxadiazol-2-r ji x>yl)-2,3- dihydro-lH- X iinden-1 -amine (R)-3-(ethoxymethyl)-N-(5-(5-isopropyl- hydrochloride 1,3,4-oxadiazol-2-yl)-2,3-dihydro-1H- inden-l-yl)-l,2,4-oxadiazol-5-amine. X NMR (400 MHz, DMSO-d6) δ 8.87 (d, J = 8.3 Hz, 1H), 7.94 – 7.81 (m, 2H), 7.47 (d, J = 7.9 Hz, 1H), 5.26 (q, J = 8.0 Hz, 1H), 4.35 (s, 2H), 3.54 (q, J = 7.0 Hz, 2H), 3.30 - 3.23 (m, 1H), 3.13 - 3.02 (m, 1H), 2.98 - 2.86 (m, 1H), 2.62 - 2.55 (m, 1H), 1.97 (dq, J = 12.4, 8.5 Hz, 1H), 1.37 (d, J= 6.9 Hz, 6H), 1.13 (t, J = 7.0 Hz, 3H). LRMS (ES) 370.1 [M+H] 276 (S)-6-(5- 2- \ / Xisopropyl- ethoxyacetonN1,3,4- itrileoxadiazol-2- y!)-2,3- dihydrobenzofNHXX° uran-3-amine (S)-3-(ethoxymethyl)-N-(6-(5-isopropyl- hydrochloride 1,3,4-oxadiazol-2-yl)-2,3- dihydrobenzofuran-3-yl)-l,2,4-oxadiazol-5- amine. X NMR (400 MHz, DMSO-d6) δ 9.12 (d, J = 7.6 Hz, 1H), 7.64 - 7.53 (m, 2H), 7.43 (s, 1H), 5.57 (td, J= 8.0, 4.5 Hz, 1H), 4.84 (t, J= 10.0, 8.5 Hz, 1H), 4.52 - 4.45 (m, 1H), 4.36 (s, 2H), 3.53 (q, 7= 7.0 Hz, 2H), 3.31 - 3.22 (m, 2H), 1.36 (d, J = 6.9 Hz, 6H), 1.13 (t, J = 7.0 Hz, 2H). LRMS (ES) 372.1[M+H]309 (S)-6-(5- 2- methyl- 1,3,4- ethoxyaceton — N-N '1oxadiazol-2- itriley!)-2,3-0iQOdihydrobenzofuran-3-amineNH^<crNhydrochloride (S)-3-(ethoxymethyl)-N-(6-(5-methyl-l,3,4- oxadiazol-2-yl)-2,3-dihydrobenzofuran-3- yl)-l,2,4-oxadiazol-5-amine. ’ll NMR (400 MHz, DMSO-d6) δ 9.12 (d, J = 7.6 Hz, 1H), 7.65 – 7.48 (m, 2H), 7.41 (s, 1H), 5.62 - 5.50 (m, 1H), 4.84 (t, J= 10.0, 8.5 Hz, 1H), 4.48(dd, J= 10.1, 4.4 Hz, 1H), 4.36 (s, 2H), 3.54187MF-365146518498922021940(q, J= 7.0 Hz, 2H), 2.58 (s, 3H), 1.13 (t, J = 7.0 Hz, 3H). LRMS (ES) 344.1 [M+H] 252 (R)-5-(5- 2- cyclopropyl- ethoxyaceton r>-< l1,3,4- itrileoxadiazol-2-0TX>yl)-2,3-NH1I dihydro-lH- inden-1 -amine (R)-N-(5-(5-cyclopropyl- 1,3,4-oxadiazol-2- hydrochloride yl)-2,3-dihydro-lH-inden-l-yl)-3- (ethoxymethyl)-l,2,4-oxadiazol-5-amine.LRMS (ES) 368.2 [M+H], ’H NMR (400 MHz, DMSO-d6) δ 8.86 (d, J = 8.3 Hz, 1H), 7.94 – 7.72 (m, 2H), 7.45 (d, J = 7.9 Hz, 1H), 5.76 (s, 1H), 5.25 (q, J= 7.9 Hz, 1H), 3.54 (q, J = 7.0 Hz, 2H), 3.12 - 2.99 (m, 1H), 2.98 - 2.82 (m, 1H), 2.64 - 2.53 (m, 1H), 2.30 (tt, J= 8.2, 4.9 Hz, 1H), 1.96 (dq, J= 12.5, 8.5 Hz, 2H), 1.36 - 0.94 (m, 7H).438 (S)-6-(5- 2- — o N-N(methoxymeth ethoxyaceton ' - 1yl)- 1,3,4- itrileoxadiazol-2- ° coy!)-2,3- dihydrobenzof O-Nuran-3-amine (S)-3-(ethoxymethyl)-N-(6-(5- hydrochloride (methoxymethyl)-l,3,4-oxadiazol-2-yl)-2,3- dihydrobenzofuran-3-yl)-l,2,4-oxadiazol-5- amine. LRMS (ES) 374.1 [M+H], ’H NMR (400 MHz, DMSO-d6) δ 9.13 (d, J= 7.6 Hz, 1H), 7.63 - 7.57 (m, 2H), 7.45 (s, 1H), 5.58 (td, J = 8.1, 4.5 Hz, 1H), 4.85 (dd, J= 10.1, 8.5 Hz, 1H), 4.73 (s, 2H), 4.49 (dd, 7= 10.1, 4.5 Hz, 1H), 4.36 (s, 2H), 3.53 (q, J = 7.0 Hz, 2H), 3.39 (s, 3H), 1.13 (t, J = 7.0 Hz, 3H).253 (R)-5-(5-ethyl- (lR,5S)-3- 1,3,4- oxabicyclo[3.oxadiazol-2- 1.0]hexane- y!)-2,3- 1 -carbonitrile0co O dihydro-lH- NH— II,Yinden-1 -amine O"Nhydrochloride 3-((lR,5S)-3-oxabicyclo[3.1.0]hexan-l-yl)- N-((R)-5-(5-ethyl-l,3,4-oxadiazol-2-yl)-2,3- dihydro- IH-inden- 1 -yl)- 1,2,4-oxadiazol-5- amine.1H NMR (400 MHz, DMSO-d6) δ 8.82 (d, J = 8.4 Hz, 1H), 7.88 (s, 1H), 7.84 (d, J = 7.7 Hz, 1H), 7.45 (d, 7= 7.9 Hz, 1H),5.21 (q, 7 = 7.9 Hz, 1H), 4.00 - 3.88 (m, 2H),188MF-3651465184989220219403.80 (d, J= 8.5 Hz, 1H), 3.74 (dd, J= 8.6, 2.8 Hz, 1H), 3.10 - 3.01 (m, 1H), 2.98 - 2.96 (m, 3H), 2.61 - 2.53 (m, 1H), 2.11 - 2.04 (m, 1H), 2.02 - 1.88 (m, 1H), 1.37 - 1.28 (m, 4H), 0.98 (t, J = 4.7 Hz, 1H). LRMS (ES)380.1 [M+H]258 (S)-6-(5-ethyl- (lR,5S)-3- \ / ^'N1,3,4- oxabicyclo[3. > — 1oxadiazol-2- 1.0]hexane- yl)-2,3- 1 -carbonitriledihydrobenzofNH^O1 V uran-3-aminehydrochloride 3-((l S,5R)-3-oxabicyclo[3.1.0]hexan- 1 -yl)- N-((S)-5-(5-ethyl-l,3,4-oxadiazol-2-yl)-2,3- dihydro- IH-inden- 1 -yl)- 1,2,4-oxadiazol-5- amine.1H NMR (400 MHz, DMSO-6) δ 9.07 (d, J = 7.6 Hz, 1H), 7.63 - 7.52 (m, 2H), 7.41 (s, 1H), 5.51 (td, J = 8.0, 4.3 Hz, 1H), 4.82 (dd, 7= 10.0, 8.5 Hz, 1H), 4.46 (dd, J = 10.1, 4.4 Hz, 1H), 3.98 - 3.90 (m, 2H), 3.80 (d, J = 8.5 Hz, 1H), 3.73 (dd, J = 8.5, 2.8 Hz, 1H), 2.94 (q, J = 7.5 Hz, 2H), 2.11 - 2.04 (m, 1H), 1.36 - 1.28 (m, 4H), 0.99 (t, J = 4.7 Hz, 1H). LRMS (ES) 382.1 [M+H], 259 (R)-5-(5-ethyl- (lS,5R)-3- 1,3,4- oxabicyclo[3. \ £oxadiazol-2- 1.0]hexane- y!)-2,3- 1 -carbonitriledihydro-lH- inden-1 -aminehydrochloride 3-((l S,5R)-3-oxabicyclo[3.1.0]hexan- 1 -yl)- N-((R)-6-(5-ethyl-l,3,4-oxadiazol-2-yl)-2,3- dihydrobenzofuran-3-yl)-l,2,4-oxadiazol-5- amine.1H NMR (400 MHz, DMSO-d6) δ 8.82 (d, J = 8.4 Hz, 1H), 7.88 (s, 1H), 7.83 (d, J = 7.9 Hz, 1H), 7.45 (d, J= 8.0 Hz, 1H), 5.20 (q, J = 8.0 Hz, 1H), 3.94 (q, J = 8.4 Hz, 2H), 3.79 (d, J = 8.5 Hz, 1H), 3.73 (dd, 7 = 8.6, 2.8 Hz, 1H), 3.10 - 3.01 (dd, 7= 9.9, 6.7 Hz, 1H), 2.98 - 2.85 (m, 3H), 2.61 - 2.52 (m, 1H), 2.12 - 2.05 (m, 1H), 1.99 - 1.88 (m, 1H), 1.36 - 1.27 (m, 4H), 0.96 (t, 7 = 4.7 Hz,1H). LRMS (ES) 380.1 [M+H],189MF-365146518498922021940265 (R)-5-(5-ethyl- (R)- \ / ^'N1,3,4- tetrahydrofur > — ( Jkoxadiazol-2- an-2- yl)-2,3- carbonitriledihydro-lH- inden-1 -amineNH^0IN hydrochloride N-((R)-5-(5-ethyl-l,3,4-oxadiazol-2-yl)-2,3- dihydro- IH-inden- 1 -yl)-3-((R)- tetrahydrofuran-2-yl)-l,2,4-oxadiazol-5- amine.1H NMR (400 MHz, DMSO-6) δ 8.84 (d, J= 8.3 Hz, 1H), 7.88 (s, 1H), 7.84 (d, J = 7.9 Hz, 1H), 7.46 (d, J = 7.9 Hz, 1H), 5.24 (q, J = 8.0 Hz, 1H), 4.79 (dd, J = 7.6, 5.2 Hz, 1H), 3.90 - 3.83 (m, 1H), 3.79 (td, J = 7.7, 5.3 Hz, 1H), 3.12 - 3.02 (m, 1H), 2.98 - 2.86 (m, 3H), 2.61 - 2.53 (m, 1H), 2.24 - 2.13 (m, 1H), 2.10 - 1.85 (m, 4H), 1.32 (t, 7= 7.5 Hz, 3H). LRMS (ES) 368.1 [M+H] 266 (S)-6-(5-ethyl- (R)- 1,3,4- tetrahydrofuroxadiazol-2- an-2-0[Pr°> O y!)-2,3- carbonitriledihydrobenzofuran-3-amineNH^0IN hydrochloride N-((S)-6-(5-ethyl-l,3,4-oxadiazol-2-yl)-2,3- dihydrobenzofuran-3-yl)-3-((R)- tetrahydrofuran-2-yl)-l,2,4-oxadiazol-5- amine.1H NMR (400 MHz, DMSO-d6) δ 9.09 (d, J = 7.6 Hz, 1H), 7.63 - 7.50 (m, 2H), 7.42 (s, 1H), 5.58 - 5.51 (m, 1H), 4.88 - 4.76 (m, 2H), 4.48 (dd, 7= 10.1, 4.5 Hz, 1H), 3.90 - 3.83 (m, 1H), 3.82 - 3.74 (m, 1H), 2.94 (q, 7 = 7.6 Hz, 2H), 2.25 - 2.14 (m, 1H), 2.10 - 1.98 (m, 2H), 1.97 - 1.85 (m, 1H), 1.32 (t, 7= 7.5 Hz, 3H). RMS (ES) 370.1 [M+H] 267 (S)-6-(5- (R)- isopropyl- tetrahydrofur1,3,4- an-2- oxadiazol-2- carbonitriley!)-2,3- NH— Ji dihydrobenzof O"Nuran-3-amine N-((S)-6-(5-isopropyl-l,3,4-oxadiazol-2-yl)- hydrochloride 2,3-dihydrobenzofuran-3-yl)-3-((R)- tetrahydrofuran-2-yl)-l,2,4-oxadiazol-5- amine.1H NMR (400 MHz, DMSO-d6) δ 9.10 (d, 7 = 7.5 Hz, 1H), 7.64 - 7.54 (m, 2H), 7.43 (s, 1H), 5.55 (td, 7= 8.1, 4.4 Hz, 1H),4.88 - 4.77 (m, 2H), 4.48 (dd, 7 = 10.1, 4.5190MF-365146518498922021940Hz, 1H), 3.90 - 3.83 (m, 1H), 3.82 - 3.76 (m, 1H), 3.31 - 3.23 (m, 1H), 2.24 - 2.14 (m, 1H), 2.10 - 1.97 (m, 2H), 1.96 - 1.87 (m, 1H), 1.40 - 1.33 (m, 6H). LRMS (ES) 384.1[M+H]300 (S)-6-(5- (R)- cyclopropyl- tetrahydrofur1,3,4- an-2- oxadiazol-2- carbonitrileyl)-2,3- NH— J, dihydrobenzof CTNuran-3-amine N-((S)-6-(5-cyclopropyl-l,3,4-oxadiazol-2- hydrochloride yl)-2,3-dihydrobenzofuran-3-yl)-3-((R)- tetrahydrofuran-2-yl)-l,2,4-oxadiazol-5- amine.1H NMR (400 MHz, DMSO-d6) δ 9.09 (d, J = 7.5 Hz, 1H), 7.67 – 7.48 (m, 2H), 7.40 (s, 1H), 5.60 - 5.48 (m, 1H), 4.94 - 4.75 (m, 2H), 4.47 (dd, J = 10.1, 4.4 Hz, 1H), 3.93 - 3.74 (m, 2H), 2.34 - 2.25 (m, 1H), 2.24 - 2.14 (m, 1H), 2.12 - 1.84 (m, 3H), 1.31 - 0.94 (m, 4H). LRMS (ES) 382.1 [M+H] 274 (R)-5-(5-ethyl- (S)- \1,3,4- tetrahydrofur \oxadiazol-2- an-2-0O^\ y!)-2,3- carbonitriledihydro-lH- inden-1 -amineNHY01 hydrochloride N-((R)-5-(5-ethyl-l,3,4-oxadiazol-2-yl)-2,3- dihydro- IH-inden- 1 -yl)-3-((S)- tetrahydrofuran-2-yl)-l,2,4-oxadiazol-5- amine.1H NMR (400 MHz, DMF-d7) δ 8.84 (d, J = 8.3 Hz, 1H), 7.93 – 7.78 (m, 2H), 7.46 (d, J = 7.9 Hz, 1H), 5.24 (q, J = 8.0 Hz, 1H), 4.79 (dd, J = 7.5, 5.1 Hz, 1H), 3.91 – 3.74 (m, 2H), 3.12 – 3.00 (m, 1H), 2.99 – 2.84 (m, 3H), 2.63 – 2.53 (m, 1H), 2.24 – 2.12 (m, 1H), 2.10 – 1.85 (m, 4H), 1.32 (t, J = 7.5 Hz, 3H). LRMS (ES) 368.1 [M+H] 275 (R)-5-(5- (S)- isopropyl- tetrahydrofur1,3,4- an-2-0O^\ oxadiazol-2- carbonitriley!)-2,3- dihydro-lH-NHYOJinden-1 -amine N-((R)-5-(5-isopropyl-l,3,4-oxadiazol-2-yl)- hydrochloride 2,3-dihydro-lH-inden-l-yl)-3-((S)- tetrahydrofuran-2-yl)-l,2,4-oxadiazol-5-amine.1H NMR (400 MHz, DMSO-d6) 6191MF-3651465184989220219408.84 (d, J = 8.3 Hz, 1H), 7.92 - 7.80 (m, 2H), 7.46 (d, J = 7.9 Hz, 1H), 5.24 (q, J = 7.9 Hz, 1H), 4.79 (dd, J = 7.5, 5.1 Hz, 1H), 3.91 - 3.74 (m, 2H), 3.30 - 3.22 (m, 1H), 3.12 - 3.00 (m, 1H), 2.98 - 2.84 (m, 1H), 2.62 - 2.54 (m, 1H), 2.25 - 2.11 (m, 1H), 2.10 - 1.85 (m, 4H), 1.37 (d, J = 7.1 Hz, 6H). LRMS (ES)382.1 [M+H]283 (S)-6-(5-ethyl- (S)- 1,3,4- tetrahydrofuroxadiazol-2- an-2- ° (PT'Syl)-2,3- carbonitriledihydrobenzofuran-3-amineNHP, IN hydrochloride N-((S)-6-(5-ethyl-l,3,4-oxadiazol-2-yl)-2,3- dihydrobenzofuran-3-yl)-3-((S)- tetrahydrofuran-2-yl)-l,2,4-oxadiazol-5- amine.1H NMR (400 MHz, DMSO-d6) δ 9.09 (d, J = 7.5 Hz, 1H), 7.63 – 7.51 (m, 2H), 7.42 (s, 1H), 5.54 (td, J = 8.0, 4.4 Hz, 1H), 4.89 - 4.75 (m, 2H), 4.48 (dd, J = 10.1, 4.4 Hz, 1H), 3.93 - 3.75 (m, 2H), 2.94 (q, J = 7.5 Hz, 2H), 2.26 - 2.12 (m, 1H), 2.10 - 1.84 (m, 3H), 1.32 (t, J = 7.5 Hz, 3H). LRMS (ES)370.1 [M+H]297 (S)-6-(5- (S)- isopropyl- tetrahydrofur1,3,4- an-2- / ooxadiazol-2- [PT0} C> T> carbonitriley!)-2,3- dihydrobenzofNHP, IN uran-3-amine N-((S)-6-(5-isopropyl-l,3,4-oxadiazol-2-yl)- hydrochloride 2,3-dihydrobenzofuran-3-yl)-3-((S)- tetrahydrofuran-2-yl)-l,2,4-oxadiazol-5- amine.1H NMR (400 MHz, DMSO-d6) δ 9.09 (d, J = 7.5 Hz, 1H), 7.65 – 7.54 (m, 2H), 7.43 (s, 1H), 5.54 (td, 7= 8.0, 4.5 Hz, 1H), 4.92 - 4.74 (m, 2H), 4.53 - 4.41 (m, 1H), 3.84 (dq, J= 30.9, 7.5 Hz, 2H), 3.32 - 3.23 (m, 3H), 2.24 - 2.12 (m, 1H), 2.10 - 1.85 (m, 3H), 1.36 (d, J = 6.9 Hz, 4H). LRMS (ES)384.1 [M+H]284 (S)-6-(5- (S)- N-Ncyclopropyl- tetrahydrofur r>— < 111,3,4- an-2- oxadiazol-2- carbonitriley!)-2,3-NHP, Idihydrobenzof192MF-365146518498922021940uran-3-amine N-((S)-6-(5-cyclopropyl-l,3,4-oxadiazol-2- hydrochloride yl)-2,3-dihydrobenzofuran-3-yl)-3-((S)- tetrahydrofuran-2-yl)-l,2,4-oxadiazol-5- amine.1H NMR (400 MHz, DMSO-d6) δ 9.08 (d, J = 7.5 Hz, 1H), 7.62 – 7.49 (m, 2H), 7.40 (d, J = 1.4 Hz, 1H), 5.53 (q, J = 8.0, 4.4 Hz, 1H), 4.88 - 4.75 (m, 2H), 4.47 (dd, J = 10.2, 4.4 Hz, 1H), 3.94 - 3.74 (m, 2H), 2.36 - 2.25 (m, 1H), 2.25 - 2.12 (m, 1H), 2.09 - 1.84 (m, 3H), 1.21 - 1.10 (m, 4H). LRMS (ES)382.1 [M+H]298 (R)-5-(5- (S)- N-Ncyclopropyl- tetrahydrofur r>— (1,3,4- an-2-0°^> oxadiazol-2- carbonitrileyl)-2,3- NH— J, dihydro-lH- CTNinden-1 -amine N-((R)-5-(5-cyclopropyl-l,3,4-oxadiazol-2- hydrochloride yl)-2,3-dihydro-lH-inden-l-yl)-3-((S)- tetrahydrofuran-2-yl)-l,2,4-oxadiazol-5- amine.1H NMR (400 MHz, DMSO-d6) δ 8.84 (d, J = 8.3 Hz, 1H), 7.89 – 7.78 (m, 2H), 7.45 (d, J = 7.9 Hz, 1H), 5.23 (q, J = 7.9 Hz, 1H), 4.85 - 4.75 (m, 1H), 3.93 - 3.76 (m, 2H), 3.12 - 2.99 (m, 1H), 2.98 - 2.84 (m, 1H), 2.61 - 2.54 (m, 1H), 2.35 - 2.25 (m, 1H), 2.25 - 2.12 (m, 1H), 2.12 - 1.83 (m, 4H), 1.22 - 1.04 (m, 4H). LRMS (ES) 380.1[M+H]482 (R)-5-(5- (S)- — o N-N(methoxymeth tetrahydrofur s — C jLyl)- 1,3,4- an-2- oxadiazol-2- carbonitriley!)-2,3-NH^O1 dihydro-lH- inden-1 -amine N-((R)-5-(5-(methoxymethyl)-l,3,4- hydrochloride oxadiazol-2-yl)-2,3-dihydro- IH-inden- 1 -y I ) - 3-((S)-tetrahydrofuran-2-yl)-l,2,4- oxadiazol-5-amine.1H NMR (400 MHz, DMSO-d6) δ 8.85 (d, J = 8.4 Hz, 1H), 7.92 (s, 1H), 7.87 (d, J = 8.0 Hz, 1H), 7.48 (d, J = 8.0 Hz, 1H), 5.25 (q, J = 7.9 Hz, 1H), 4.80 (dd, J = 7.6, 5.2 Hz, 1H), 4.73 (s, 2H), 3.90 - 3.76 (m, 2H), 3.39 (s, 3H), 3.11 - 3.03 (m, 1H), 2.97 - 2.88 (m, 1H), 2.61 - 2.54 (m, 1H), 2.22 - 2.13 (m, 1H), 2.06 - 1.90 (m, 4H). LRMS(ES) 384.1 [M+H]193MF-365146518498922021940278 (S)-6-(5-ethyl- 2-(2, 2,3,3- \ / ^N1,3,4- tetrafluoroprX'1oxadiazol-2- opoxy)aceton °^P=r0\yl)-2,3- itriledihydrobenzof NH— T FFuran-3-amine O"Nhydrochloride (S)-N-(6-(5-ethyl-l,3,4-oxadiazol-2-yl)-2,3- dihydrobenzofuran-3-yl)-3-((2, 2.3.3- tetrafluoropropoxy)methyl)-l,2,4- oxadiazol-5-amine.1H NMR (400 MHz, DMSO-d6) δ 9.22 (d, J = 7.5 Hz, 1H), 7.60 (d, J = 7.8 Hz, 1H), 7.55 (d, J = 7.8 Hz, 1H), 7.42 (s, 1H), 6.53 (tt, J= 52.0, 5.1 Hz, 1H), 5.57 (td, J= 8.0, 4.4 Hz, 1H), 4.92 - 4.79 (m, 1H), 4.59 (s, 2H), 4.49 (dd, J= 10.1, 4.4 Hz, 1H), 4.07 (t, J= 14.0 Hz, 2H), 2.94 (q, J= 7.5 Hz, 2H), 1.32 (t, J = 7.5 Hz, 3H). LRMS (ES) 444.1 [M+H]286 (S)-6-(5-ethyl- (R)- 1,3,4- tetrahydro- oxadiazol-2- 2H-pyran-2- y!)-2,3- carbonitrile ° rl? O dihydrobenzofuran-3-aminehydrochloride N-((S)-6-(5-ethyl-l,3,4-oxadiazol-2-yl)-2,3- dihydrobenzofuran-3-yl)-3-((R)- tetrahydro-2H-pyran-2-yl)-l,2,4-oxadiazol- 5-amine.1H NMR (400 MHz, DMSO-d6) δ 9.08 (d, J = 7.5 Hz, 1H), 7.63 – 7.51 (m, 2H), 7.42 (s, 1H), 5.62 – 5.48 (m, 1H), 4.84 (t, J = 10.1, 8.4 Hz, 1H), 4.47 (dd, 7= 10.1, 4.4 Hz, 1H), 4.37 (dd, J = 9.9, 3.1 Hz, 1H), 3.93 (d, J = 11.5 Hz, 1H), 3.57 - 3.44 (m, 1H), 2.93 (q, J= 8.2, 6.9 Hz, 2H), 1.90 - 1.66 (m, 3H), 1.66 - 1.45 (m, 3H), 1.32 (t, J = 7.5, 1.5 Hz, 3H). LRMS (ES) 384.1 [M+H] 292 (R)-5-(5-ethyl- (S)- \ / ^N1,3,4- tetrahydro- \oxadiazol-2- 2H-pyran-2- y!)-2,3- carbonitriledihydro-lH-NHA0Iinden-1 -aminehydrochloride N-((R)-5-(5-ethyl-l,3,4-oxadiazol-2-yl)-2,3- dihydro- IH-inden- 1 -yl)-3-((S)-tetrahydro- 2H-pyran-2-yl)-l,2,4-oxadiazol-5-amine.1H NMR (400 MHz, Acetone-d6) δ 8.01 – 7.83 (m, 2H), 7.70 (d, J = 8.5 Hz, 1H), 7.56(d, J = 7.9 Hz, 1H), 5.41 (q, J = 8.0 Hz, 1H),194MF-3651465184989220219404.39 (dd, J = 8.8, 4.3 Hz, 1H), 3.99 (d, J = 10.9 Hz, 1H), 3.57 (td, J = 10.8, 3.3 Hz, 1H), 3.16 (ddd, J = 16.1, 8.7, 3.6 Hz, 1H), 3.10 - 2.90 (m, 3H), 2.79 - 2.65 (m, 1H), 2.19 - 2.12 (m, 1H), 1.99 - 1.88 (m, 1H), 1.88 - 1.77 (m, 2H), 1.76 - 1.50 (m, 3H), 1.41 (td, J = 7.6, 1.3 Hz, 3H). LRMS (ES) 382.1 [M+H] 294 (S)-6-(5-ethyl- cyclopropyl \ / ^'N1,3,4- cyanide \ 1oxadiazol-2- yl)-2,3- ° lX> A dihydrobenzofuran-3-amineNH^0IN hydrochloride (S)-3-cyclopropyl-N-(6-(5-ethyl-l,3,4- oxadiazol-2-yl)-2,3-dihydrobenzofuran-3- yl)-l,2,4-oxadiazol-5-amine. ’ll NMR (400 MHz, DMSO-d6) δ 8.95 (d, J = 7.5 Hz, 1H), 7.56 (s, 2H), 7.41 (s, 1H), 5.53 - 5.44 (m, 1H), 4.81 (t, J= 9.3 Hz, 1H), 4.45 (dd, 7 = 10.0, 4.5 Hz, 1H), 2.94 (q, J = 7.5 Hz, 2H), 1.89 (tt, J= 8.5, 4.8 Hz, 1H), 1.32 (t, J= 7.5 Hz, 3H), 1.02 - 0.92 (m, 2H), 0.90 - 0.78 (m, 2H). LRMS (ES) 340.1 [M+H] 295 (S)-6-(5- cyclopropyl N-Ncyclopropyl- cyanide r>— < u1,3,4- oxadiazol-2- ° lX> A y!)-2,3- dihydrobenzofNHAOX uran-3-amine (S)-3-cyclopropyl-N-(6-(5-cyclopropyl- hydrochloride 1,3,4-oxadiazol-2-yl)-2,3- dihydrobenzofuran-3-yl)-l,2,4-oxadiazol-5- amine.1H NMR (400 MHz, DMSO-d6) δ 8.95 (d, J = 7.6 Hz, 1H), 7.60 - 7.47 (m, 2H), 7.39 (s, 1H), 5.53 - 5.41 (m, 1H), 4.81 (t, J = 9.2 Hz, 1H), 4.44 (dd, 7= 10.0, 4.5 Hz, 1H), 2.35 - 2.23 (m, 1H), 1.95 - 1.82 (m, 1H), 1.23 - 1.05 (m, 4H), 0.96 (d, 7 = 8.4 Hz, 2H), 0.91 - 0.75 (m, 2H). LRMS (ES) 352.1 [M+H] 296 (S)-6-(5-ethyl- 2-(2,2- 1,3,4- difluoroethox N— - |loxadiazol-2- y) acetonitriley!)-2,3- dihydrobenzofuran-3-amineNHA0I F hydrochloride (S)-3-((2,2-difluoroethoxy)methyl)-N-(6-(5- ethyl-l,3,4-oxadiazol-2-yl)-2,3-dihydrobenzofuran-3-yl)-l,2,4-oxadiazol-5-195MF-365146518498922021940amine.1H NMR (400 MHz, DMSO-d6) δ 9.19 (d, J = 7.6 Hz, 1H), 7.68 -7.51 (m, 2H), 7.43 (s, 1H), 6.20 (t, J = 3.7 Hz, 1H), 5.58 (td, 7= 7.8, 4.3 Hz, 1H), 4.85 (t, J= 10.1, 8.4 Hz, 1H), 4.50 (dd, J = 10.1, 4.4 Hz, 3H), 3.82 (td, J = 15.2, 3.7 Hz, 2H), 2.95 (q, J = 7.6 Hz, 2H), 1.33 (t, J = 7.5 Hz, 3H). LRMS (ES)394.1 [M+H].324 (S)-6-(5- 2-(2,2- N-Ncyclopropyl- difluoroethox 'i1,3,4- y) acetonitrileoxadiazol-2- yl)-2,3-Fdihydrobenzofuran-3-amine (S)-3-((2,2-difluoroethoxy)methyl)-N-(6-(5- hydrochloride cyclopropyl- 1.3.4-oxadiazol-2-y 1 )-2,3- dihydrobenzofuran-3-yl)-l,2,4-oxadiazol-5- amine.1H NMR (400 MHz, Acetone-d6) δ 8.05 (dd, J = 8.0, 4.9 Hz, 1H), 7.67 (d, J = 7.8 Hz, 1H), 7.59 (dd, J = 7.8, 1.5 Hz, 1H), 7.43 (d, J = 1.5 Hz, 1H), 6.11 (t, J = 3.9 Hz, 1H), 5.70 (td, J = 7.9, 4.2 Hz, 1H), 4.92 (dd, J = 10.3, 8.3 Hz, 1H), 4.64 (dd, J = 10.2, 4.3 Hz, 1H), 4.59 (s, 2H), 3.90 (td, J = 14.5, 3.9 Hz, 2H), 2.29 (tt, J = 8.2, 5.1 Hz, 1H), 1.31 - 1.10 (m, 4H). LRMS (ES) 406.1 [M+H] 325 (S)-6-(5- 2-(2,2- \ / ^Nisopropyl- difluoroethox \— < II1,3,4- y) acetonitrileoxadiazol-2- y!)-2,3- F dihydrobenzofuran-3-amine (S)-3-((2,2-difluoroethoxy)methyl)-N-(6-(5- hydrochloride isopropyl- 1,3,4-oxadiazol-2-yl)-2,3- dihydrobenzofuran-3-yl)-l,2,4-oxadiazol-5- amine.1H NMR (400 MHz, Acetone-d6) δ 8.07 (d, J = 7.5 Hz, 1H), 7.69 (d, J = 7.8 Hz, 1H), 7.63 (dd, J = 7.8, 1.4 Hz, 1H), 7.47 (d, J = 1.3 Hz, 1H), 5.71 (td, J = 7.8, 4.1 Hz, 2H), 4.93 (dd, J = 10.2, 8.3 Hz, 1H), 4.64 (dd, J = 10.2, 4.3 Hz, 2H), 3.90 (td, J = 14.5, 3.8 Hz, 2H), 3.30 (hept, J = 6.9 Hz, 1H), 1.44 (d, J =7.0 Hz, 7H). LRMS (ES) 408.1 [M+H]196MF-365146518498922021940326 (R)-5-(5-ethyl- 2-(2,2- 1,3,4- difluoroethoxoxadiazol-2- y) acetonitrileyl)-2,3-0>00dihydro-lH- inden-1 -amineNHXNFhydrochloride (R)-N-(5-(5-ethyl-l,3,4-oxadiazol-2-yl)-2,3- dihydro- IH-inden- 1 -yl)-3-((2,2- difluoroethoxy)methyl)-l,2,4-oxadiazol-5- amine.1H NMR (400 MHz, Acetone-d6) δ 7.94 (s, 1H), 7.90 (d, J = 8.0 Hz, 1H), 7.83 (d, J = 8.5 Hz, 1H), 7.58 (d, J = 7.9 Hz, 1H), 5.43 (q, J = 7.9 Hz, 1H), 4.58 (s, 2H), 3.90 (td, J = 14.5, 3.9 Hz, 2H), 3.17 (ddd, J = 16.1, 8.7, 3.8 Hz, 2H), 3.00 (dq, J = 26.2, 7.9 Hz, 3H), 2.79 - 2.66 (m, 1H), 2.22 - 2.13 (m, 1H), 1.41 (t, J = 7.5 Hz, 3H). LRMS (ES) 392.1 [M+H] 327 (R)-5-(5- 2-(2,2- N-Ncyclopropyl- difluoroethox r>-~^ i1,3,4- y) acetonitrileoxadiazol-2-0>ooy!)-2,3- dihydro-lH-NHA0I F inden-1 -amine (R)-N-(5-(5-cyclopropyl- 1,3,4-oxadiazol-2- hydrochloride yl)-2,3-dihydro-lH-inden-l-yl)-3-((2,2- difluoroethoxy)methyl)-l,2,4-oxadiazol-5- amine.1H NMR (400 MHz, Acetone-d6) δ 7.91 (s, 1H), 7.87 (d, J = 8.0 Hz, 1H), 7.82 (d, J = 8.5 Hz, 1H), 7.57 (d, J = 7.9 Hz, 1H), 5.42 (q, J = 7.9 Hz, 1H), 4.58 (s, 2H), 3.90 (td, J = 14.5, 3.9 Hz, 2H), 3.16 (ddd, J = 16.0, 8.8, 3.7 Hz, 2H), 3.02 (dt, J = 16.1, 8.1 Hz, 1H), 2.79 - 2.67 (m, 1H), 2.29 (tt, J = 8.0, 4.9 Hz, 1H), 2.20 - 2.11 (m, 1H), 1.30 - 1.10 (m, 4H).LRMS (ES) 404.1 [M+H]328 (R)-5-(5- 2-(2,2- \ / ^Nisopropyl- difluoroethox \-Y £1,3,4- y) acetonitrileoxadiazol-2- iQOy!)-2,3- F dihydro-lH- inden-1 -amine (R)-N-(5-(5-isopropyl-l,3,4-oxadiazol-2-yl)- hydrochloride 2,3-dihydro-lH-inden-l-yl)-3-((2,2- difluoroethoxy)methyl)-l,2,4-oxadiazol-5- amine.1H NMR (400 MHz, Acetone-d6) δ 7.95 (s, 1H), 7.91 (d, J = 8.1 Hz, 1H), 7.83 (d,J = 8.4 Hz, 1H), 7.58 (d, J = 7.9 Hz, 1H), 5.43197MF-365146518498922021940(q, J = 7.9 Hz, 1H), 4.58 (s, 2H), 3.90 (td, J = 14.5, 3.9 Hz, 2H), 3.30 (p, J = 7.0 Hz, 2H), 3.17 (ddd, J = 16.0, 8.7, 3.7 Hz, 1H), 3.03 (dt, J = 16.1, 8.1 Hz, 1H), 2.74 (dtd, J = 12.8, 7.9, 3.7 Hz, 1H), 2.22 - 2.13 (m, 1H), 1.44 (d, J = 6.9 Hz, 6H). LRMS (ES) 406.1 [M+H] 321 (S)-6-(5-ethyl- 1,3,4-X'1oxadiazol-2- yl)-2,3- MYdihydrobenzofuran-3-amineNHYX hydrochloride (S)-3-(2-(2,2-difluoroethoxy)ethyl)-N-(6-(5- 3-(2,2- ethyl-l,3,4-oxadiazol-2-yl)-2,3- difluoroethox dihydrobenzofuran-3-yl)-l,2,4-oxadiazol-5- y)propanenitr amine.1H NMR (400 MHz, DMSO-6) δ ile 9.03 (d, J = 7.5 Hz, 1H), 7.60 (d, J = 7.8 Hz,1H), 7.58 - 7.53 (m, 1H), 7.42 (s, 1H), 6.13 (tt, J= 54.8, 3.7 Hz, 1H), 5.54 (td, J= 8.1, 4.7 Hz, 1H), 4.90 - 4.79 (m, 1H), 4.47 (dd, J = 10.2, 4.4 Hz, 1H), 3.83 (t, J = 6.7 Hz, 2H), 3.71 (td, 7= 15.2, 3.7 Hz, 2H), 2.94 (q, J = 7.5 Hz, 2H), 2.78 (t, J= 6.6 Hz, 2H), 1.32 (t, J = 7.5 Hz, 3H). LRMS (ES) 408.1 [M+H] 305 (R)-5-(5- 3- cyclopropyl- ethoxypropa M l1,3,4- nenitrileoxadiazol-2- rx>y!)-2,3- NH— J, dihydro-lH- CTNinden-1 -amine (R)-3-(2-ethoxyethyl)-N-(5-(5-cyclopropyl- hydrochloride 1,3,4-oxadiazol-2-yl)-2,3-dihydro-1H- inden-l-yl)-l,2,4-oxadiazol-5-amine. ’ll NMR (400 MHz, DMSO-d6) δ 8.75 (d, J = 8.3 Hz, 1H), 7.89 - 7.76 (m, 2H), 7.44 (d, J = 7.9 Hz, 1H), 5.22 (q, 7= 7.9 Hz, 1H), 3.67 (t, 7= 6.7 Hz, 2H), 3.44 (q, 7= 7.0 Hz, 2H), 3.12 - 2.98 (m, 1H), 2.97 - 2.83 (m, 1H), 2.72 (t, 7= 6.6 Hz, 2H), 2.62 - 2.53 (m, 1H), 2.37 - 2.24 (m, 1H), 2.03 - 1.87 (m, 1H), 1.27 - 1.00 (m, 7H). LRMS (ES) 382.1 [M+H] 311 (S)-6-(5-ethyl- 2- 1,3,4- propoxyaceto \X( / XN '1oxadiazol-2- nitriley!)-2,3- dihydrobenzof NH—uran-3-amine O"Nhydrochloride198MF-365146518498922021940(S)-N-(6-(5-ethyl-l,3,4-oxadiazol-2-yl)-2,3- dihydrobenzofuran-3-yl)-3- (propoxymethyl)-l,2,4-oxadiazol-5-amine.1H NMR (400 MHz, Acetone-d6) δ 7.99 (d, J = 7.7 Hz, 1H), 7.69 (d, J = 7.8 Hz, 1H), 7.62 (dd, J = 7.8, 1.5 Hz, 1H), 7.46 (s, 1H), 5.69 (td, J = 7.9, 4.2 Hz, 1H), 5.03 - 4.82 (m, 1H), 4.68 - 4.58 (m, 1H), 4.41 (d, J = 1.4 Hz, 2H), 3.53 (td, J = 6.6, 1.4 Hz, 2H), 3.05 - 2.91 (m, 2H), 1.60 (p, J = 7.1 Hz, 2H), 1.41 (td, J = 7.6, 1.4 Hz, 3H), 0.94 (td, J = 7.4, 1.4 Hz, 3H). LRMS (ES) 372.1 [M+H] 312 (S)-6-(5- 2- isopropyl- propoxyaceto ) - ( '11,3,4- nitrileoxadiazol-2- yl)-2,3- NH— dihydrobenzof O"Nuran-3-amine (S)-N-(6-(5-cyclopropyl-l,3,4-oxadiazol-2- hydrochloride yl)-2,3-dihydrobenzofuran-3-yl)-3- (propoxymethyl)-l,2,4-oxadiazol-5-amine.1H NMR (400 MHz, Acetone-d6) δ 7.99 (d, J = 7.5 Hz, 1H), 7.69 (d, J = 7.8 Hz, 1H), 7.66 - 7.58 (m, 1H), 7.47 (d, J = 1.6 Hz, 1H), 5.69 (td, J = 8.0, 4.3 Hz, 1H), 5.02 - 4.81 (m, 1H), 4.69 - 4.56 (m, 1H), 4.41 (d, J = 1.5 Hz, 2H), 3.53 (td, J = 6.6, 1.4 Hz, 2H), 3.30 (hept, J = 7.0 Hz, 1H), 1.61 (h, J = 7.1 Hz, 2H), 1.44 (dd, J = 7.0, 1.4 Hz, 6H), 0.93 (td, J = 7.4, 1.3 Hz, 3H). LRMS (ES) 386.1 [M+H] 314 (R)-5-(5-ethyl- 2- 1,3,4- propoxyaceto MNIoxadiazol-2- nitriley!)-2,3- ° TX>dihydro-lH- NH—inden-1 -amine CTNhydrochloride (R)-N-(5-(5-ethyl-l,3,4-oxadiazol-2-yl)-2,3- dihydro- IH-inden- 1 -yl)-3- (propoxymethyl)-l,2,4-oxadiazol-5-amine.1H NMR (400 MHz, Acetone-d6) δ 7.94 (s, 1H), 7.90 (d, J = 8.0 Hz, 1H), 7.75 (d, J = 8.5 Hz, 1H), 7.57 (d, J = 7.9 Hz, 1H), 5.42 (q, J = 7.9 Hz, 1H), 4.40 (d, J = 1.6 Hz, 2H), 3.52 (t, J = 6.6 Hz, 2H), 3.17 (ddd, J = 16.1, 8.7, 3.6 Hz, 1H), 3.04 (t, J = 8.2 Hz, 1H), 3.01 - 2.90 (m, 2H), 2.73 (dtd, J = 11.7, 7.8, 3.8 Hz, 1H),2.20 - 2.12 (m, 1H), 1.60 (q, J = 7.1 Hz, 2H),199MF-3651465184989220219401.41 (td, J = 7.6, 1.6 Hz, 3H), 0.93 (dd, J = 8.1, 6.6 Hz, 3H). LRMS (ES) 370.1 [M+H] 315 (R)-5-(5- 2- methyl- 1,3,4- propoxyaceto TNoxadiazol-2- nitrileyl)-2,3- ° rx> / Nw / '''0 / X / dihydro-lH- NHXZIIinden-1 -amine O'Nhydrochloride (R)-N-(5-(5-methyl-l,3,4-oxadiazol-2-yl)- 2,3-dihydro-lH-inden-l-yl)-3- (propoxymethyl)-l,2,4-oxadiazol-5-amine.1H NMR (400 MHz, Acetone-d6) δ 7.98 – 7.83 (m, 2H), 7.75 (d, J = 8.5 Hz, 1H), 7.57 (d, J = 7.9 Hz, 1H), 5.42 (q, J = 7.9 Hz, 1H), 4.40 (d, J = 1.4 Hz, 2H), 3.53 (td, J = 6.5, 1.4 Hz, 2H), 3.17 (ddd, J = 16.0, 8.6, 3.7 Hz, 1H), 3.02 (dt, J = 16.3, 8.2 Hz, 1H), 2.79 - 2.66 (m, 1H), 2.60 (d, J = 1.4 Hz, 3H), 2.20 - 2.12 (m, 1H), 1.60 (q, J = 7.1 Hz, 2H), 0.93 (td, J = 7.4, 1.4 Hz, 3H). LRMS (ES) 356.1 [M+H] 316 (R)-5-(5-ethyl- 4- 1,3,4- methoxybutaoxadiazol-2- nenitriley!)-2,3-0LD / dihydro-lH- NH— Jiinden-1 -amine O'Nhydrochloride (R)-N-(5-(5-ethyl-l,3,4-oxadiazol-2-yl)-2,3- dihydro- IH-inden- 1 -yl)-3-(3- methoxypropyl)-l,2,4-oxadiazol-5-amine.1H NMR (400 MHz, Methanol-d4) δ 8.02 – 7.76 (m, 2H), 7.51 (d, J = 7.9 Hz, 1H), 5.32 (t, J = 7.6 Hz, 1H), 3.48 (t, J = 6.2 Hz, 2H), 3.36 (s, 3H), 3.15 (ddd, J = 16.3, 8.6, 3.6 Hz, 1H), 3.00 (q, J = 7.4 Hz, 3H), 2.79 - 2.54 (m, 3H), 2.18 - 1.87 (m, 3H), 1.44 (t, J = 7.6 Hz, 3H).LRMS (ES) 370.1 [M+H]317 (R)-5-(5- 4- cyclopropyl- methoxybuta1,3,4- nenitrileoxadiazol-2- ° ILX) / y!)-2,3- NH— J, dihydro-lH- CTNinden-1 -amine (R)-N-(5-(5-cyclopropyl- 1,3,4-oxadiazol-2- hydrochloride yl)-2,3-dihydro-lH-inden-l-yl)-3-(3- methoxypropyl)-l,2,4-oxadiazol-5-amine.1H NMR (400 MHz, Methanol-d4) δ 8.01 – 7.75 (m, 2H), 7.50 (d, J = 7.9 Hz, 1H), 5.32 (t,J = 7.6 Hz, 1H), 3.48 (t, J = 6.3 Hz, 2H), 3.36200MF-365146518498922021940(s, 3H), 3.14 (ddd, J = 16.1, 8.8, 3.7 Hz, 1H), 2.99 (dt, J = 16.2, 8.2 Hz, 1H), 2.77 - 2.59 (m, 3H), 2.30 (tt, J = 8.1, 5.0 Hz, 1H), 2.01 (dp, J = 27.4, 7.6, 6.9 Hz, 3H), 1.35 - 1.06 (m, 4H). LRMS (ES) 382.1 [M+H] 362 (S)-6-(5-ethyl- 4- \ / ^N1,3,4- methoxybutaoxadiazol-2- nenitrileyl)-2,3-0 / dihydrobenzof NH— Iluran-3-amine CTNhydrochloride (S)-N-(6-(5-ethyl-l,3,4-oxadiazol-2-yl)-2,3- dihydrobenzofuran-3-yl)-3-(3- methoxypropyl)-l,2,4-oxadiazol-5-amine.1H NMR (400 MHz, Methanol-d4) δ 7.70 – 7.54 (m, 2H), 7.48 (s, 1H), 5.58 (dd, J = 8.3, 4.3 Hz, 1H), 4.85 (td, J = 8.9, 8.1, 1.5 Hz, 2H), 4.53 (ddd, J = 10.2, 4.4, 1.5 Hz, 1H), 3.36 (s, 3H), 3.33 (s, 1H), 3.09 - 2.91 (m, 2H), 2.65 (t, J = 7.5 Hz, 2H), 2.08 - 1.85 (m, 2H), 1.44 (td, J = 7.6, 1.5 Hz, 3H). LRMS (ES) 372.1 [M+H]329 (R)-5-(5-ethyl- 2- 1,3,4- (difluorometoxadiazol-2- hoxy)acetoniy!)-2,3- trile0CO 1 dihydro-lH- inden-1 -aminehydrochloride (R)-3-((difluoromethoxy)methyl)-N-(5-(5- ethyl- 1,3,4-oxadiazol-2-yl)-2,3-dihydro- 1H- inden-l-yl)-l,2,4-oxadiazol-5-amine. ’ll NMR (400 MHz, DMSO-d6) δ 9.01 (d, J = 8.3 Hz, 1H), 7.89 (s, 1H), 7.84 (dd, J = 7.9, 1.6 Hz, 1H), 7.47 (d, J = 7.9 Hz, 1H), 6.83 (t, J = 74.8 Hz, 1H), 5.27 (q, J = 7.9 Hz, 1H), 4.84 (s, 2H), 3.07 (ddd, J = 12.0, 8.6, 4.2 Hz, 1H), 2.98 – 2.97 (m, 3H), 2.63 – 2.53 (m, 1H), 2.03 – 1.92 (m, 1H), 1.33 (t, J = 7.5 Hz, 3H). LRMS (ES) 378.1 [M+H] 330 (S)-6-(5-ethyl- 2- 1,3,4- (difluoromet V-C 'Ioxadiazol-2- hoxy)acetoni O^pv°\y!)-2,3- triledihydrobenzof N^CAFFuran-3-aminehydrochloride (S)-3-((difluoromethoxy)methyl)-N-(6-(5- ethyl-l,3,4-oxadiazol-2-yl)-2,3-dihydrobenzofuran-3-yl)-l,2,4-oxadiazol-5-201MF-365146518498922021940amine.1H NMR (400 MHz, DMSO-6) δ 9.27 (d, J = 7.5 Hz, 1H), 7.65 - 7.52 (m, 2H), 7.43 (s, 1H), 6.83 (t, 7= 74.8, 1H), 5.58 (td, J= 8.0, 4.4 Hz, 1H), 4.89 - 4.80 (m, 3H), 4.49 (dd, J= 10.1, 4.4 Hz, 1H), 2.94 (q, J = 7.5 Hz, 2H), 1.32 (t, J= 7.6 Hz, 3H).LRMS (ES) 380.1 [M+H]331 (S)-6-(5- 2- cyclopropyl- (difluoromet r>— < N-N n1,3,4- hoxy)acetonioxadiazol-2- trileyl)-2,3- NH— II dihydrobenzof O'Nuran-3-amine (S)-3-((difluoromethoxy)methyl)-N-(6-(5- hydrochloride cyclopropyl- 1.3.4-oxadiazol-2-y 1 )-2,3- dihydrobenzofuran-3-yl)-l,2,4-oxadiazol-5- amine.1H NMR (400 MHz, DMSO-6) δ 9.26 (d, J = 7.4 Hz, 1H), 7.59 (d, J = 7.8 Hz, 1H), 7.53 (dd, J = 7.8, 1.5 Hz, 1H), 7.42 - 7.39 (m, 1H), 6.83 (t, J = 74.8 Hz 1H), 5.57 (td, J = 7.9, 4.3 Hz, 1H), 4.89 - 4.80 (m, 3H), 4.49 (dd, J = 10.1, 4.4 Hz, 1H), 2.34 - 2.25 (m, 1H), 1.21 - 1.08 (m, 4H). LRMS (ES)392.1 [M+H]332 2- (S)-6-(5- \ / ^'Nisopropyl- (difluoromet \— < II1,3,4- hoxy)acetoni / 0]PV°\Foxadiazol-2- triley!)-2,3- N^O^F dihydrobenzofNHC^ uran-3-amine (S)-3-((difluoromethoxy)methyl)-N-(6-(5- hydrochloride isopropyl- 1,3,4-oxadiazol-2-yl)-2,3- dihydrobenzofuran-3-yl)-l,2,4-oxadiazol-5- amine.1H NMR (400 MHz, DMSO-d6) δ 9.27 (d, J = 7.6 Hz, 1H), 7.64 – 7.55 (m, 2H), 7.45 – 7.43(m, 1H), 6.83 (t, J = 74.9 Hz, 1H), 5.58 (td, J = 8.0, 4.4 Hz, 1H), 4.89 – 4.81 (m, 3H), 4.49 (dd, J = 10.1, 4.5 Hz, 1H), 3.31 – 3.24 (m, 1H), 1.40 – 1.32 (m, 6H). LRMS (ES) 394.1 [M+H]2- 350 (R)-5-(5- methyl- 1,3,4- (difluorometoxadiazol-2- hoxy)acetoniy!)-2,3- trile0CO 1 dihydro-lH- inden-1 -amineNHCN hydrochloride (R)-3-((difluoromethoxy)methyl)-N-(5-(5-methyl-l,3,4-oxadiazol-2-yl)-2,3-dihydro-202MF-3651465184989220219401H-inden-1-yl)-1,2,4-oxadiazol-5-amine.1H NMR (400 MHz, DMSO-d6) δ 9.02 (d, J = 8.4 Hz, 1H), 7.89 (s, 1H), 7.88 – 7.79 (m, 1H), 7.47 (d, J = 8.0 Hz, 1H), 6.83 (t, J = 75.4 Hz, 1H), 5.28 (q, J = 7.9 Hz, 1H), 4.85 (s, 2H), 3.16 – 3.04 (m, 1H), 2.99 – 2.87 (m, 1H), 2.62 – 2.54 (m, 1H), 2.58 (s, 3H), 2.06 – 1.89 (m, 1H). LRMS (ES) 364.1 [M+H] 349 (S)-6-(5- 2- N-Nmethyl- 1,3,4- (difluoromet — <z'1oxadiazol-2- hoxy)acetoni F yl)-2,3- triledihydrobenzofuran-3-amineNH^0X hydrochloride (S)-3-((difluoromethoxy)methyl)-N-(6-(5- methyl-l,3,4-oxadiazol-2-yl)-2,3- dihydrobenzofuran-3-yl)-l,2,4-oxadiazol-5- amine.1H NMR (400 MHz, DMSO-d6) δ 9.27 (d, J = 7.2 Hz, 1H), 7.61 (d, J = 7.8 Hz, 1H), 7.55 (dd, J = 7.9, 1.5 Hz, 1H), 7.43 – 7.40 (m, 1H), 6.83 (t, J = 74.9 Hz, 1H), 5.58 (td, J = 7.9, 4.4 Hz, 1H), 4.90 – 4.80 (m, 3H), 4.49 (dd, J = 10.1, 4.4 Hz, 1H), 2.58 (s, 3H).LRMS (ES) 366.1 [M+H]333 (S)-6-(5-ethyl- 2- \ / ^N1,3,4- cyclobutoxyaoxadiazol-2- cetonitriley!)-2,3- lX> >0 dihydrobenzof NH—uran-3-amine O" INI hydrochloride (S)-3-(cyclobutoxymethyl)-N-(6-(5-ethyl- 1,3,4-oxadiazol-2-yl)-2,3- dihydrobenzofuran-3-yl)-l,2,4-oxadiazol-5- amine.1H NMR (400 MHz, DMSO-6) 6 9.12 (d, J = 6.6 Hz, 1H), 7.63 - 7.53 (m, 2H), 7.43 (s, 1H), 5.64 - 5.50 (m, 1H), 4.85 (dd, J = 10.0, 8.4 Hz, 1H), 4.49 (dd, J = 10.0, 4.5 Hz, 1H), 4.28 (s, 2H), 4.09 - 3.98 (m, 1H), 2.95 (q, J = 7.5 Hz, 2H), 2.20 - 2.08 (m, 2H), 1.93 - 1.78 (m, 2H), 1.70 - 1.57 (m, 1H), 1.53 - 1.38 (m, 1H), 1.33 (t, J = 7.5 Hz, 3H).LRMS (ES) 384.1 [M+H]337 (S)-6-(5-ethyl- 3- 1,3,4- methoxypropoxadiazol-2- anenitrile0vr°>y!)-2,3- '°- dihydrobenzofNH^0I203MF-365146518498922021940uran-3-amine (S)-N-(6-(5-ethyl-l,3,4-oxadiazol-2-yl)-2,3- hydrochloride dihydrobenzofuran-3-yl)-3-(2- methoxyethyl)-l,2,4-oxadiazol-5-amine.1H NMR (400 MHz, Chloroform-d) δ 7.69 (d, J = 7.9 Hz, 1H), 7.59 – 7.50 (m, 2H), 7.28 (s, 3H), 5.59 (s, 1H), 5.51 (d, J = 8.0 Hz, 1H), 4.85 (dd, J = 10.1, 7.7 Hz, 1H), 4.61 – 4.54 (m, 1H), 3.78 (t, J = 6.6 Hz, 2H), 3.42 (d, J = 1.5 Hz, 2H), 3.04 – 2.86 (m, 3H), 1.47 (dd, J = 8.4, 6.8 Hz, 2H). LRMS (ES) 358.1[M+H]375 (R)-5-(5-ethyl- 3- 1,3,4- methoxypropoxadiazol-2- anenitrile0V'Oyl)-2,3- -°- dihydro-lH- inden-1 -amineNH^0I hydrochloride (R)-N-(5-(5-ethyl-l,3,4-oxadiazol-2-yl)-2,3- dihydro- IH-inden- 1 -yl)-3-(2- methoxyethyl)-l,2,4-oxadiazol-5-amine. ’ll NMR (400 MHz, Chloroform-) 67.91 - 7.80 (m, 2H), 7.40 (d, J = 7.9 Hz, 1H), 5.48 (d, J = 8.8 Hz, 1H), 5.30 (q, 7= 7.9 Hz, 1H), 3.67 (t, 7= 6.6 Hz, 2H), 3.42 (s, 1H), 3.32 (s, 3H), 3.04 (ddd, 7= 16.2, 8.8, 3.6 Hz, 1H), 2.90 (p, 7= 8.1 Hz, 3H), 2.79 (t, 7= 6.7 Hz, 2H), 2.70 (dtd, 7= 11.4, 7.6, 3.5 Hz, 1H), 1.94 (dq, 7 = 12.9, 8.3 Hz, 1H), 1.38 (t, 7 = 7.6 Hz, 2H). LRMS (ES) 356.1 [M+H] 377 (R)-5-(5- 3- cyclopropyl- methoxyprop ^N-N1,3,4- anenitrile° TT>oxadiazol-2- y!)-2,3- dihydro-lH-NH^0Xinden-1 -amine (R)-N-(5-(5-cyclopropyl- 1,3,4-oxadiazol-2- hydrochloride yl)-2,3-dihydro-lH-inden-l-yl)-3-(2- methoxyethyl)-l,2,4-oxadiazol-5-amine. ’ll NMR (400 MHz, Chloroform-) 67.89 - 7.78 (m, 2H), 7.43 (d, 7 = 7.9 Hz, 1H), 6.48 (d, 7 = 8.5 Hz, 1H), 5.34 (q, 7= 7.9 Hz, 1H), 3.67 (t, 7= 6.7 Hz, 2H), 3.34 (s, 3H), 3.09 (ddd, 7= 16.2, 8.7, 3.5 Hz, 1H), 2.95 (dt, 7 = 16.2, 8.2 Hz, 1H), 2.74 (pd, 7= 8.2, 3.4 Hz, 3H), 2.27 - 2.16 (m, 1H), 2.02 (dq, 7 = 12.8, 8.4 Hz, 1H), 1.25-1.17 (m, 4H). LRMS (ES)368.1 [M+H]204MF-365146518498922021940340 (S)-6-(5-ethyl- 1- 1,3,4- (hydroxymetoxadiazol-2- hyl)cycloproyl)-2,3- pane-1- Y. OH dihydrobenzof carbonitrile NH— J.uran-3-amine O"Nhydrochloride (S)-(l-(5-((6-(5-ethyl-l,3,4-oxadiazol-2-yl)- 2,3-dihydrobenzofuran-3-yl)amino)- 1,2,4- oxadiazol-3-yl)cyclopropyl)methanol.1H NMR (400 MHz, DMSO-d6) δ 8.94 (d, J = 7.5 Hz, 1 H), 7.58 (d, J = 7.8 Hz, 1 H), 7.55 (dd, J = 7.7, 1.4 Hz, 1 H), 7.41 (s, 1 H), 5.50 (dq, J = 7.7, 4.6 Hz, 1 H), 4.83 (dd, J = 10.1, 8.5 Hz, 1 H), 4.68 (t, J = 5.9 Hz, 1 H), 4.46 (dd, J = 10.0, 4.6 Hz, 1 H), 3.70 (d, J = 5.8 Hz, 2 H), 2.94 (q, J = 7.5 Hz, 2 H), 1.33 (t, J = 7.5 Hz, 3 H), 1.02-0.91 (m, 4 H).LRMS (ES) 370.1 [M+H]341 (S)-6-(5- 1- cyclopropyl- (hydroxymet1,3,4- hyl)cyclopro0V7 oxadiazol-2- pane-1-NJC0Hy!)-2,3- carbonitrile NH— J, dihydrobenzof O"Nuran-3-amine (S)-(l-(5-((6-(5-cyclopropyl-l,3,4-oxadiazol- hydrochloride 2-yl)-2,3-dihydrobenzofuran-3-yl)amino)- l,2,4-oxadiazol-3-yl)cyclopropyl)methanol.‘H NMR (400 MHz, DMSO-6) 68.86 (d, 7 = 7.6 Hz, 1 H), 7.49 (d, 7= 7.9 Hz, 1 H), 7.45 (dd, 7= 7.8, 1.5 Hz, 1 H), 7.32 (s, 1 H), 5.41 (td, 7= 8.1, 4.7 Hz, 1 H), 4.74 (dd, 7= 10.1, 8.5 Hz, 1 H), 4.60 (t, 7= 5.8 Hz, 1 H), 4.38 (dd, 7= 10.1, 4.5 Hz, 1 H), 3.62 (d, 7= 5.5 Hz, 2 H), 2.28-2.19 (m, 1 H), 1.10 (dt, 7 = 8.2, 2.8 Hz, 2 H), 1.06 (td, 7= 5.0, 2.1 Hz, 2 H), 0.94-0.85 (m, 4 H). LRMS (ES) 382.1[M+H]342 (S)-6-(5- 1- isopropyl- (hydroxymet1,3,4- hyl)cyclopro IPT0) v oxadiazol-2- pane-1- Y. OH y!)-2,3- carbonitrile NH— J. dihydrobenzof O"Nuran-3-amine (S)-(l-(5-((6-(5-isopropyl-l,3,4-oxadiazol-2- hydrochloride yl)-2,3-dihydrobenzofuran-3-yl)amino)- l,2,4-oxadiazol-3-yl)cyclopropyl)methanol.’H NMR (400 MHz, DMSO-6) 68.94 (d, 7 =7.5 Hz, 1 H), 7.62-7.53 (m, 2 H), 7.43 (s, 1205MF-365146518498922021940H), 5.50 (td, J= 8.1, 4.5 Hz, 1 H), 4.83 (dd, J= 10.1, 8.5 Hz, 1 H), 4.68 (t, J= 5.8 Hz, 1 H), 4.46 (dd, J = 10.0, 4.6 Hz, 1 H), 3.70 (dd, 7= 6.0, 1.4 Hz, 2 H), 3.28 (p, J= 6.9 Hz, 1 H), 1.37 (d, J = 7.0 Hz, 6 H), 1.03-0.91 (m, 4 H). LRMS (ES) 384.1 [M+H] 343 (R)-5-(5-ethyl- 1- 1,3,4- (hydroxymetoxadiazol-2- hyl)cycloproy0TOO vl)-2,3- pane-1- V-YNJC0Hdihydro-lH- carbonitrile NH— J.inden-1 -amine O'Nhydrochloride (R)-(l-(5-((5-(5-ethyl-l,3,4-oxadiazol-2-yl)- 2,3-dihydro- 1 H-inden- 1 -yl)amino)- 1,2,4- oxadiazol-3-yl)cyclopropyl)methanol. ’ll NMR (400 MHz, DMSO-6) δ 8.62 (d, J = 8.3 Hz, 1 H), 7.81 (s, 1 H), 7.78-7.72 (m, 1 H), 7.37 (d, J = 7.9 Hz, 1 H), 5.12 (q, J = 7.9 Hz, 1 H), 4.59 (t, J= 5.9 Hz, 1 H), 3.63 (d, J= 5.9 Hz, 2 H), 2.99 (ddd, J= 15.5, 8.6, 3.4 Hz, 1 H), 2.87 (q, J = 7.5 Hz, 2 H), 2.86- 2.77 (m, 1 H), 2.54-2.46 (m, 1 H), 1.87 (dq, J = 12.6, 8.5 Hz, 1 H), 1.26 (t, J = 7.5 Hz, 3 H), 0.93-0.83 (m, 4 H). LRMS (ES) 368.1[M+H]347 (R)-5-(5-ethyl- (S)-2- 1,3,4- methoxypropoxadiazol-2- anenitriley!)-2,3-0rr>? dihydro-lH- NH— c inden-1 -amine O'Nhydrochloride N-((R)-5-(5-ethyl-l,3,4-oxadiazol-2-yl)-2,3- dihydro- IH-inden- 1 -yl)-3-((S)-l - methoxyethyl)-l,2,4-oxadiazol-5-amine. ’ll NMR (400 MHz, DMSO-6) 68.87 (d, J = 8.4 Hz, 1 H), 7.90 (s, 1 H), 7.85 (d, J = 7.9 Hz, 1 H), 7.47 (d, J = 7.9 Hz, 1 H), 5.26 (q, J = 8.0 Hz, 1 H), 4.32 (q, J = 6.5 Hz, 1 H), 3.25 (s, 3 H), 3.13-3.03 (m, 1 H), 2.96-2.88 (m, 1 H), 2.95 (q, J = 7.5 Hz, 2 H), 2.65-2.54 (m, 1 H), 2.03-1.91 (m, 1 H), 1.40 (d, J = 6.5 Hz, 3 H), 1.33 (t, J = 7.6 Hz, 3 H). LRMS (ES) 356.1[M+H]206MF-365146518498922021940351 (S)-6-(5-ethyl- 2-(l- 1,3,4- methoxycycl '1oxadiazol-2- opropyl)acet oV H yO\ \ 0 yl)-2,3- onitrile N-^^U-7 dihydrobenzofuran-3-amineNH^0X hydrochloride (S)-N-(6-(5-ethyl-l,3,4-oxadiazol-2-yl)-2,3- dihydrobenzofuran-3-yl)-3-((l- methoxycyclopropyl)methyl)-l,2,4- oxadiazol-5-amine.1H NMR (400 MHz, DMSO-d6) δ 9.01 (d, J = 7.4 Hz, 1H), 7.61 (d, J = 7.8 Hz, 1H), 7.55 (dd, J = 7.8, 1.5 Hz, 1H), 7.42 – 7.40 (m, 1H), 5.53 (td, J = 7.9, 4.4 Hz, 1H), 4.84 (dd, J = 10.0, 8.5 Hz, 1H), 4.48 (dd, J = 10.0, 4.5 Hz, 1H), 3.20 (s, 3H), 2.94 (q, J = 7.6 Hz, 2H), 2.87 – 2.78 (m, 2H), 1.32 (t, J = 7.6 Hz, 3H), 0.78 – 0.68 (m, 2H), 0.68 – 0.58 (m, 2H). LRMS (ES) 384.1 [M+H] 384 (R)-5-(5-ethyl- 2-(l- 1,3,4- methoxycycl \ ( ifoxadiazol-2- opropyl)acet0Y [1 Y\ \ O y!)-2,3- onitriledihydro-lH- NH— 1Vinden-1 -amine O"Nhydrochloride (R)-N-(5-(5-ethyl-l,3,4-oxadiazol-2-yl)-2,3- dihydro-lH-inden-l-yl)-3-(l- methoxymethylcyclopropyl)-l,2,4- oxadiazol-5-amine. LRMS (ES) 382.1 [M+H], ’H NMR (400 MHz, DMSO-6) 6 8.73 (d, J = 8.3 Hz, 1 H), 7.88 (s, 1 H), 7.84 (d, J = 7.3 Hz, 1 H), 7.45 (d, J = 7.9 Hz, 1 H), 5.19 (q, J= 8.0 Hz, 1 H), 3.59 (s, 2 H), 3.26 (s, 3H), 3.06 (ddd, J = 16.3, 8.6, 3.4 Hz, 1 H), 2.94 (q, J = 7.5 Hz, 2 H), 2.92-2.86 (m, 1 H), 2.56 (ddd, 7= 12.2, 7.9, 3.5 Hz, 1 H), 1.95 (dq, 7= 12.6, 8.5 Hz, 1 H), 1.33 (t, 7= 7.5 Hz, 3 H), 1.06 (q, 7 = 4.0, 3.4 Hz, 2 H), 0.96 (q, 7 = 4.4, 3.9 Hz, 2 H).352 (S)-6-(5- 2-(l- N-Ncyclopropyl- methoxycycl r>— < ii1,3,4- opropyl)acet|l 0 oxadiazol-2- onitriley!)-2,3- dihydrobenzofNH^0IN uran-3-amine (S)-N-(6-(5-cyclopropyl-l,3,4-oxadiazol-2- hydrochloride yl)-2,3-dihydrobenzofuran-3-yl)-3-((l- methoxycyclopropyl)methyl)-l,2,4-oxadiazol-5-amine.1H NMR (400 MHz,207MF-365146518498922021940DMSO-d6) δ 9.00 (d, J = 7.4 Hz, 1H), 7.60 (d, J = 7.8 Hz, 1H), 7.52 (dd, J = 7.8, 1.4 Hz, 1H), 7.41 – 7.38 (m, 1H), 5.52 (td, J = 7.9, 4.4 Hz, 1H), 4.83 (dd, J = 10.1, 8.5 Hz, 1H), 4.47 (dd, J = 10.1, 4.5 Hz, 1H), 3.20 (s, 3H), 2.87 – 2.77 (m, 2H), 2.36 – 2.24 (m, 1H), 1.24 – 1.04 (m, 4H), 0.79 – 0.68 (m, 2H), 0.68 – 0.57 (m, 2H). LRMS (ES) 396.1 [M+H] 371 (R)-5-(5-ethyl- 2-(l- \ A 'N1,3,4- methoxycycloxadiazol-2- opropyl)acet0\H Oyl)-2,3- onitriledihydro-lH- NH^ HVinden-1 -amine O"Nhydrochloride (R)-N-(5-(5-ethyl-l,3,4-oxadiazol-2-yl)-2,3- dihydro-lH-inden-l-yl)-3-((l- methoxycyclopropyl)methyl)-l,2,4- oxadiazol-5-amine.1H NMR (400 MHz, DMSO-d6) δ 8.76 (d, J = 8.2 Hz, 1H), 7.88 (s, 1H), 7.83 (d, J = 8.0 Hz, 1H), 7.47 (d, J = 7.9 Hz, 1H), 5.22 (q, J = 7.9 Hz, 1H), 3.20 (s, 3H), 3.11 – 3.02 (m, 1H), 2.98 – 2.87 (m, 3H), 2.82 (s, 2H), 2.61 – 2.54 (m, 1H), 2.03 – 1.91 (m, 1H), 1.33 (t, J = 7.5 Hz, 3H), 0.77 – 0.70 (m, 2H), 0.65 – 0.59 (m, 2H). LRMS (ES) 382.1 [M+H]372 (S)-6-(5- 2-(l- \ / ^'isopropyl- methoxycyclN1,3,4- opropyl)acet |l J > o oxadiazol-2- onitriley!)-2,3- NH— J,Vdihydrobenzof O"Nuran-3-amine (S)-N-(6-(5-isopropyl-l,3,4-oxadiazol-2-yl)- hydrochloride 2,3-dihydrobenzofuran-3-yl)-3-((l- methoxycyclopropyl)methyl)-l,2,4- oxadiazol-5-amine.1H NMR (400 MHz, DMSO-d6) δ 9.01 (d, J = 7.4 Hz, 1H), 7.62 (d, J = 7.8 Hz, 1H), 7.55 (dd, J = 7.8, 1.5 Hz, 1H), 7.43 (s, 1H), 5.53 (td, J = 8.1, 4.5 Hz, 1H), 4.84 (dd, J = 10.0, 8.6 Hz, 1H), 4.48 (dd, J = 10.1, 4.5 Hz, 1H), 3.30 – 3.23 (m, 1H), 3.20 (s, 3H), 2.88 – 2.78 (m, 2H), 1.40 – 1.30 (m, 6H), 0.79 – 0.69 (m, 2H), 0.67 – 0.58(m, 2H). LRMS (ES) 398.1 [M+H]208MF-365146518498922021940353 (S)-6-(5-ethyl- 2-(l- \ / ^N1,3,4- methoxycycl ' — '1oxadiazol-2- obutyl) aceto [1 J > 0 yl)-2,3- nitriledihydrobenzofuran-3-amineNHYN hydrochloride (S)-N-(6-(5-ethyl-l,3,4-oxadiazol-2-yl)-2,3- dihydrobenzofuran-3-yl)-3-((l- met...

Claims

1. 498922021940CLAIMSWHAT IS CLAIMED IS:

1. A compound of formula (I):NH (I),or a pharmaceutically acceptable salt thereof, wherein:Y is -CH2- or -O-;X1, X2, and X3are each independently -N- or -C(RX)-, wherein each Rxis independently selected from the group consisting of H, halogen, and Ci-Ce alkyl, provided that no more than one of X1, X2, and X3is -N-;R1is selected from the group consisting of:5- to 6-membered heteroaryl, wherein the 5- to 6-membered heteroaryl is optionally substituted with 1 to 4 independently selected R1Asubstituents, -C(O)H,-C(O)CH3,-C(O)NRaRb, and-Ci-Ce alkyl substituted with 1 to 5 independently selected halogens;each R1Ais independently selected from the group consisting of:-C3-C8 cycloalkyl optionally substituted with 1 to 5 substituents independently selected from the group consisting of SO2Rc, Ci-Ce alkoxy, and Ci-Ce alkyl, wherein the Ci-Ce alkyl is optionally substituted with 1 to 5 substituents independently selected from the group consisting of OH and Ci-Ce alkoxy, -4 to 10 membered heterocycloalkyl optionally substituted with 1 to 5 substituents independently selected from the group consisting of SO2RC, Ci-Ce alkoxy, and Ci-Ce alkyl, wherein the Ci-Ce alkyl is optionally substituted with 1 to 5361MF-365146518498922021940substituents independently selected from the group consisting of OH and Ci- Ce alkoxy, and-Ci-Ce alkyl optionally substituted with 1 to 3 substituents independently selected from the group consisting of Ci-Ce alkoxy, halogen, OH, and -C3-C8 cycloalkyl, wherein the -C3-C8 cycloalkyl is optionally substituted with 1 to 5 independently selected Ci-Ce alkyl substituents, wherein the Ci-Ce alkyl is optionally substituted with OH or Ci-Ce alkoxy;each Rais independently selected from the group consisting of H and Ci-Ce alkyl;each Rbis independently selected from the group consisting of Ce-Cio aryl, -C3-C8 cycloalkyl, and Ci-Ce alkyl, wherein the Ci-Ce alkyl is optionally substituted with Ce-Cio aryl; each Rcis independently Ci-Ce alkyl;R2is 5 to 10 membered heteroaryl optionally substituted with 1 to 5 independently selected R2Asubstituents;each R2Ais independently selected from the group consisting of:-Ci-C 10 alkyl optionally substituted with 1 to 5 substituents independently selected from the group consisting of:-OH,-ORn,halogen,-N(C1-C6alkyl)C(O)(C1-C6alkyl)-CO2C1-C6 alkyl,-Ci-Ce alkoxy optionally substituted with 1 to 5 substituents independently selected from the group consisting of halogen, OH, and Ci-Ce alkoxy, -C3-C8 cycloalkyl optionally substituted with 1 to 5 substituents independently selected from the group consisting of OH, halogen, -Ci-Ce alkyl, and Ci-Ce alkoxy, wherein the Ci-Ce alkyl is optionally substituted with Ci-Ce alkoxy or OH,-4 to 10 membered heterocycloalkyl optionally substituted with 1 to 5 substituents independently selected from the group consisting of OH,362MF-365146518498922021940halogen, -Ci-Ce alkyl, and Ci-Ce alkoxy, wherein the Ci-Ce alkyl is optionally substituted with Ci-Ce alkoxy or OH, and-Ce-Cio aryl optionally substituted by 1 to 5 substituents independently selected from the group consisting of halogen, OH, Ci-Ce alkoxy, and Ci-C6alkyl, wherein the Ci-Ce alkyl is optionally substituted with OH or Ci-C6alkoxy,-C3-C8 cycloalkyl optionally substituted with 1 to 5 substituents independently selected from the group consisting of halogen, OH, SO2-C1-C6 alkyl, -CO2-C1- Ce alkyl, Ci-Ce alkoxy, and Ci-Ce alkyl, wherein the Ci-Ce alkyl is optionally substituted with 1 to 5 substituents independently selected from the group consisting of OH and Ci-Ce alkoxy,-4 to 10 membered heterocycloalkyl optionally substituted with 1 to 5 substituents independently selected from the group consisting of halogen, oxo, -CO2-C1-C6 alkyl, SO2-C1-C6 alkyl, Ci-Ce alkoxy, and Ci-Cs alkyl, wherein the Ci-Cs alkyl is optionally substituted with 1 to 5 substituents independently selected from the group consisting of halogen, Ci-Ce alkoxy, and OH,-Ce-Cio aryl optionally substituted with 1 to 5 substituents independently selected from the group consisting of Ci-Ce alkyl, OH, SO2-C1-C6 alkyl, -CO2-C1-C6 alkyl, Ci-Ce alkoxy, and halogen,-5 to 10 membered heteroaryl optionally substituted with 1 to 5 substituents independently selected from the group consisting of Ci-Ce alkyl, OH, SO2-C1- Ce alkyl, -CO2-C1-C6 alkyl, Ci-Ce alkoxy, and halogen,-Ci-Ce alkoxy optionally substituted with 1 to 5 independently selected halogens, -halogen,-SO2Re,-CN,-C(O)NRfRg,-C(O)ORh,-C(O)C1-C6alkyl,-NRiRj,-OH, and-NRkCORm;363MF-365146518498922021940each Reis independently selected from the group consisting of H and Ci-Ce alkyl;each Rfis independently selected from the group consisting of H and Ci-Ce alkyl;each Rgis independently selected from the group consisting of H and Ci-Ce alkyl;each Rhis independently selected from the group consisting of H and C1-C6alkyl;each Riis independently selected from the group consisting of H and C1-C6alkyl;each Rjis independently selected from the group consisting of H and Ci-Ce alkyl;each Rkis independently selected from the group consisting of H and Ci-Ce alkyl;each Rmis independently selected from the group consisting of H and Ci-Ce alkyl; and each Rnis independently selected from the group consisting of 4 to 10 membered heterocycloalkyl and -C3-C8 cycloalkyl each of which is optionally substituted with 1 to 5 independently selected halogens;provided that the compound is not N-(5-(5-methyl-l,2,4-oxadiazole-3-yl)-2,3-dihydro-lH- inden-l-yl)pyrazin-2-amine or 3-(3-((5-(trifluoromethyl)-2,3-dihydro-lH-inden-l- yl)amino)pyrazin-2-yl)- 1,2,4-oxadiazol-5 (2H)-one.

2. The compound of claim 1, or a pharmaceutically acceptable salt thereof, wherein R2is selected from the group consisting of 5-membered heteroaryl, pyridinyl, pyridazinyl, pyrimidinyl, and 9- or 10-membered heteroaryl.

3. The compound of claim 1 or 2, or a pharmaceutically acceptable salt thereof, having the formula (la):

4. The compound of any one of claims 1 to 3, or a pharmaceutically acceptable salt thereof, wherein Rxis selected from the group consisting of H, fluoro, and methyl.364MF-3651465184989220219405. The compound of any one of claims 1 to 4, or a pharmaceutically acceptable salt thereof, wherein Rxis H.

6. The compound of any one of claims 1 to 3, or a pharmaceutically acceptable salt thereof, wherein X1, X2, and X3are each independently -C(RX)-, wherein each Rxis independently selected from the group consisting of H, halogen, and Ci-Ce alkyl.

7. The compound of any one of claims 1 to 6, or a pharmaceutically acceptable salt thereof, wherein X1, X2, and X3are each -CH-.

8. The compound of any one of claims 1 to 5, or a pharmaceutically acceptable salt thereof, wherein X1is -N-.

9. The compound of any one of claims 1 to 5, or a pharmaceutically acceptable salt thereof, wherein X2is -N-.

10. The compound of any one of claims 1 to 5, or a pharmaceutically acceptable salt thereof, wherein X3is -N-.

11. The compound of any one of claims 1 to 10, or a pharmaceutically acceptable salt thereof, wherein Y is -CH2-.

12. The compound of any one of claims 1 to 10, or a pharmaceutically acceptable salt thereof, wherein Y is -O-.

13. The compound of any one of claims 1 to 12, or a pharmaceutically acceptable salt thereof, wherein R1is selected from the group consisting of:5- to 6-membered heteroaryl, wherein the 5- to 6-membered heteroaryl is optionally substituted with 1 to 4 independently selected R1Asubstituents, -C(O)NRaRb, andCi-Ce alkyl substituted with 1 to 5 independently selected halogens.365MF-36514651849892202194014. The compound of any one of claims 1 to 13, or a pharmaceutically acceptable salt thereof, wherein R1is 5-membered heteroaryl optionally substituted with 1 to 4 independently selected R1Asubstituents.

15. The compound of any one of claims 1 to 14, or a pharmaceutically acceptable salt thereof, wherein R1is a 5-membered heteroaryl substituted with one R1Asubstituent.

16. The compound of any one of claims 1 to 15, or a pharmaceutically acceptable salt n-N M" N 9 N s thereof, wherein R1is selected from the group consisting of R1A, R17. The compound of any one of claims 1 to 16, or a pharmaceutically acceptable saltthereof, whereinR1is R1A18. The compound of any one of claims 1 to 17, or a pharmaceutically acceptable salt thereof, wherein each R1Ais independently -Ci-Ce alkyl optionally substituted with 1 to 3 substituents independently selected from the group consisting of Ci-Ce alkoxy, halogen, OH, and -C3-C8 cycloalkyl, wherein the -C3-C8 cycloalkyl is optionally substituted with 1 to 5 independently selected Ci-Ce alkyl substituents, wherein the Ci-Ce alkyl is optionally substituted with OH or Ci-Ce alkoxy.

19. The compound of any one of claims 1 to 18, or a pharmaceutically acceptable salt thereof, wherein each R1Ais independently unsubstituted -Ci-Ce alkyl.

20. The compound of any one of claims 1 to 19, or a pharmaceutically acceptable salt thereof, wherein each R1Ais independently unsubstituted -C1-C3 alkyl.366MF-36514651849892202194021. The compound of any one of claims 1 to 20, or a pharmaceutically acceptable salt thereof, wherein each R1Ais unsubstituted ethyl.

22. The compound of any one of claims 1 to 18, or a pharmaceutically acceptable salt thereof, wherein each R1Ais independently substituted -Ci-Ce alkyl.

23. The compound of any one of claims 1 to 18 or 22, or a pharmaceutically acceptable salt thereof, wherein each R1Ais independently -Ci-Ce alkyl substituted with Ci-Ce alkoxy.

24. The compound of any one of claims 1 to 18, 22, or 23, or a pharmaceutically acceptable salt thereof, wherein each R1Ais -CH2OMe.

25. The compound of any one of claims 1 to 18 or 22, or a pharmaceutically acceptable salt thereof, wherein each R1Ais independently -Ci-Ce alkyl substituted with halogen.

26. The compound of any one of claims 1 to 18, 22, or 25, or a pharmaceutically acceptable salt thereof, wherein each R1Ais -CHF2.

27. The compound of any one of claims 1 or 3 to 26, or a pharmaceutically acceptable salt thereof, wherein R2is 5- to 6-membered heteroaryl optionally substituted with 1 to 4 independently selected R2Asubstituents.

28. The compound of any one of claims 1 or 3 to 26, or a pharmaceutically acceptable saltthereof, wherein R2is selected from the group consisting ofO-N N-N367MF-365146518498922021940Hwherein: n is 0 or 1,p is 0, 1, or 2,q is 0, 1, 2, or 3, andr is 0, 1, 2, 3, or 4.

29. The compound of any one of claims 1 to 27, or a pharmaceutically acceptable salt thereof, wherein R2is 5-membered heteroaryl optionally substituted with 1 to 3 independently selected R2Asubstituents.

30. The compound of any one of claims 1 to 27 or 29, or a pharmaceutically acceptable salt thereof, wherein R2is 5-membered heteroaryl substituted with one R2Asubstituent.

31. The compound of any one of claims 1 to 30, or a pharmaceutically acceptable saltthereof, wherein R2is selected from the group consisting ofO-N N-N, wherein n, p, and q are 1.368MF-36514651849892202194032. The compound of any one of claims 1 to 31, or a pharmaceutically acceptable saltthereof, whereinR2is33. The compound of any one of claims 1 or 3 to 27, or a pharmaceutically acceptable salt thereof, wherein R2is 6-membered heteroaryl optionally substituted with 1 to 4 independently selected R2Asubstituents.

34. The compound of any one of claims 1 to 26, or a pharmaceutically acceptable salt thereof, wherein R2is 9-membered heteroaryl optionally substituted with 1 to 5 independently selected R2Asubstituents.

35. The compound of any one of claims 1 to 34, or a pharmaceutically acceptable salt thereof, wherein each R2Ais independently selected from the group consisting of:-Ci-C io alkyl optionally substituted with 1 to 5 substituents independently selected from the group consisting of:-OH,-ORn,halogen,-Ci-Ce alkoxy optionally substituted with 1 to 5 substituents independently selected from the group consisting of halogen, OH, and Ci-Ce alkoxy, -C3-C8 cycloalkyl optionally substituted with 1 to 5 substituents independently selected from the group consisting of OH, halogen, -Ci-Ce alkyl, and Ci-Ce alkoxy, wherein the Ci-Ce alkyl is optionally substituted with Ci-Ce alkoxy or OH,-4 to 10 membered heterocycloalkyl optionally substituted with 1 to 5 substituents independently selected from the group consisting of OH, halogen, -Ci-Ce alkyl, and Ci-Ce alkoxy, wherein the Ci-Ce alkyl is optionally substituted with Ci-Ce alkoxy or OH, and-Ce-Cio aryl optionally substituted by 1 to 5 substituents independently selected from the group consisting of halogen, OH, Ci-Ce alkoxy, and369MF-365146518498922021940Ci-C6alkyl, wherein the Ci-Ce alkyl is optionally substituted with OH or Ci-C6alkoxy,-C3-C8 cycloalkyl optionally substituted with 1 to 5 substituents independently selected from the group consisting of halogen, OH, SO2-C1-C6 alkyl, -CO2-C1- Ce alkyl, Ci-Ce alkoxy, and Ci-Ce alkyl, wherein the Ci-Ce alkyl is optionally substituted with 1 to 5 substituents independently selected from the group consisting of OH and Ci-Ce alkoxy,-4 to 10 membered heterocycloalkyl optionally substituted with 1 to 5 substituents independently selected from the group consisting of halogen, oxo, -CO2-C1-C6 alkyl, SO2-C1-C6 alkyl, Ci-Ce alkoxy, and Ci-Cs alkyl, wherein the Ci-Cs alkyl is optionally substituted with 1 to 5 substituents independently selected from the group consisting of halogen, Ci-Ce alkoxy, and OH, -Ce-Cio aryl optionally substituted with 1 to 5 substituents independently selected from the group consisting of Ci-Ce alkyl, OH, SO2-C1-C6 alkyl, -CO2-C1-C6 alkyl, Ci-Ce alkoxy, and halogen,-Ci-Ce alkoxy optionally substituted with 1 to 5 independently selected halogens, -halogen,-SO2Re,-CN,-C(O)ORh,-C(O)Ci-Ce alkyl, and-NRkCORm.

36. The compound of any one of claims 1 to 35, or a pharmaceutically acceptable salt thereof, wherein each R2Ais independently selected from the group consisting of:-Ci-C 10 alkyl optionally substituted with 1 to 5 substituents independently selected from the group consisting of:-OH,-ORn,halogen,-Ci-Ce alkoxy optionally substituted with 1 to 5 substituents independently selected from the group consisting of halogen, OH, and Ci-Ce alkoxy,370MF-365146518498922021940-C3-C8 cycloalkyl optionally substituted with 1 to 5 substituents independently selected from the group consisting of OH, halogen, -Ci-Ce alkyl, and Ci-C6alkoxy, wherein the Ci-Ce alkyl is optionally substituted with Ci-C6alkoxy or OH,-4 to 10 membered heterocycloalkyl optionally substituted with 1 to 5 substituents independently selected from the group consisting of OH, halogen, -Ci-Ce alkyl, and Ci-Ce alkoxy, wherein the Ci-Ce alkyl is optionally substituted with Ci-Ce alkoxy or OH, and-Ce-Cio aryl optionally substituted by 1 to 5 substituents independently selected from the group consisting of halogen, OH, Ci-Ce alkoxy, and Ci-C6alkyl, wherein the Ci-Ce alkyl is optionally substituted with OH or Ci-C6alkoxy,-C3-C8 cycloalkyl optionally substituted with 1 to 5 substituents independently selected from the group consisting of halogen, OH, SO2-C1-C6 alkyl, -CO2-C1- Ce alkyl, Ci-Ce alkoxy, and Ci-Ce alkyl, wherein the Ci-Ce alkyl is optionally substituted with 1 to 5 substituents independently selected from the group consisting of OH and Ci-Ce alkoxy, and-4 to 10 membered heterocycloalkyl optionally substituted with 1 to 5 substituents independently selected from the group consisting of halogen, oxo, -CO2-C1-C6 alkyl, SO2-C1-C6 alkyl, Ci-Ce alkoxy, and Ci-Cs alkyl, wherein the Ci-Cs alkyl is optionally substituted with 1 to 5 substituents independently selected from the group consisting of halogen, Ci-Ce alkoxy, and OH.

37. The compound of any one of claims 1 to 36, or a pharmaceutically acceptable salt thereof, wherein each R2Ais:-Ci-C 10 alkyl optionally substituted with 1 to 5 substituents independently selected from the group consisting of:-OH,-ORn,halogen,-Ci-Ce alkoxy optionally substituted with 1 to 5 substituents independently selected from the group consisting of halogen, OH, and Ci-Ce alkoxy,371MF-365146518498922021940-C3-C8 cycloalkyl optionally substituted with 1 to 5 substituents independently selected from the group consisting of OH, halogen, -Ci-Ce alkyl, and Ci-C6alkoxy, wherein the Ci-Ce alkyl is optionally substituted with Ci-C6alkoxy or OH, and-4 to 10 membered heterocycloalkyl optionally substituted with 1 to 5 substituents independently selected from the group consisting of OH, halogen, -Ci-Ce alkyl, and Ci-Ce alkoxy, wherein the Ci-Ce alkyl is optionally substituted with Ci-Ce alkoxy or OH.

38. The compound of any one of claims 1 to 37, or a pharmaceutically acceptable salt thereof, wherein each R2Ais:-Ci-Cio alkyl substituted with 1 to 5 substituents independently selected from the group consisting of:-OH,-ORn,halogen,-Ci-Ce alkoxy optionally substituted with 1 to 5 substituents independently selected from the group consisting of halogen, OH, and Ci-Ce alkoxy, -C3-C8 cycloalkyl optionally substituted with 1 to 5 substituents independently selected from the group consisting of OH, halogen, -Ci-Ce alkyl, and Ci-Ce alkoxy, wherein the Ci-Ce alkyl is optionally substituted with Ci-Ce alkoxy or OH, and-4 to 10 membered heterocycloalkyl optionally substituted with 1 to 5 substituents independently selected from the group consisting of OH, halogen, -Ci-Ce alkyl, and Ci-Ce alkoxy, wherein the Ci-Ce alkyl is optionally substituted with Ci-Ce alkoxy or OH.

39. The compound of any one of claims 1 to 38, or a pharmaceutically acceptable salt thereof, wherein each R2Ais -C1-C3 alkyl substituted with one 4 to 10 membered heterocycloalkyl, wherein the 4 to 10 membered heterocycloalkyl is optionally substituted with 1 to 3 substituents independently selected from the group consisting of OH, halogen, -372MF-365146518498922021940Ci-C6alkyl, and Ci-Ce alkoxy, wherein the Ci-Ce alkyl is optionally substituted with Ci-Ce alkoxy or OH.

40. The compound of any one of claims 1 to 39, or a pharmaceutically acceptable salt thereof, wherein each R2Ais -C1-C3 alkyl substituted with one unsubstituted 4 to 6 membered heterocycloalkyl.

41. The compound of any one of claims 1 to 40, or a pharmaceutically acceptable salt thereof, wherein each R2Ais -C1-C3 alkyl substituted with one unsubstituted 4 to 6 memberedheterocycloalkyl selected from the group consisting of42. The compound of any one of claims 1 to 40, or a pharmaceutically acceptable salt thereof, wherein each R2Ais -Ci alkyl substituted with one unsubstituted oxetane.

43. The compound of any one of claims 1 to 38, or a pharmaceutically acceptable salt thereof, wherein each R2Ais -C1-C10 alkyl substituted with 1 to 3 -Ci-Ce alkoxy substituents, wherein each -Ci-Ce alkoxy is optionally substituted with 1 to 3 substituents independently selected from the group consisting of halogen, OH, and Ci-Ce alkoxy.

44. The compound of any one of claims 1 to 38 or 43, or a pharmaceutically acceptable salt thereof, wherein each R2Ais -C1-C3 alkyl substituted with one -C1-C3 alkoxy substituent.

45. The compound of any one of claims 1 to 35, or a pharmaceutically acceptable salt thereof, wherein each R2Ais:-C3-C8 cycloalkyl optionally substituted with 1 to 5 substituents independently selected from the group consisting of halogen, OH, SO2-C1-C6 alkyl, -CO2-C1- Ce alkyl, Ci-Ce alkoxy, and Ci-Ce alkyl, wherein the Ci-Ce alkyl is optionally substituted with 1 to 5 substituents independently selected from the group consisting of OH and Ci-Ce alkoxy.373MF-36514651849892202194046. The compound of any one of claims 1 to 35 or 45, or a pharmaceutically acceptablesalt thereof, wherein each R2Ais selected from the group consisting of, each of which is optionally substituted with 1 to 5 substituents independently selected from the group consisting of halogen, OH, SO2-C1-C6 alkyl, -CO2-C1-Ce alkyl, Ci-Ce alkoxy, and Ci-Ce alkyl, wherein the Ci-Ce alkyl is optionally substituted with 1 to 5 substituents independently selected from the group consisting of OH and Ci-Ce alkoxy.

47. The compound of any one of claims 1 to 35, or a pharmaceutically acceptable salt thereof, wherein each R2Ais:-4 to 10 membered heterocycloalkyl optionally substituted with 1 to 5 substituents independently selected from the group consisting of halogen, oxo, -CO2-C1-C6 alkyl, SO2-C1-C6 alkyl, Ci-Ce alkoxy, and Ci-Cs alkyl, wherein the Ci-Cs alkyl is optionally substituted with 1 to 5 substituents independently selected from the group consisting of halogen, Ci-Ce alkoxy, and OH.

48. The compound of any one of claims 1 to 35 or 47, or a pharmaceutically acceptable salt thereof, wherein each R2Ais a 4 to 6 membered heterocycloalkyl optionally substituted with 1 to 5 substituents independently selected from the group consisting of halogen, oxo, -CO2-C1-C6 alkyl, SO2-C1-C6 alkyl, Ci-Ce alkoxy, and Ci-Cs alkyl, wherein the Ci-Cs alkyl is optionally substituted with 1 to 5 substituents independently selected from the group consisting of halogen, Ci-Ce alkoxy, and OH.

49. The compound of any one of claims 1 to 35, 47, or 48, or a pharmaceuticallyacceptable salt thereof, wherein each R2Ais selected from the group consisting of374MF-365146518498922021940, and each of which is optionally substituted with 1 to 5 substituents independently selected from the group consisting of halogen, oxo, -CO2-C1-C6 alkyl, SO2-C1-C6 alkyl, Ci-Ce alkoxy, and Ci-Cs alkyl, wherein the Ci-Cs alkyl is optionally substituted with 1 to 5 substituents independently selected from the group consisting of halogen, Ci-Ce alkoxy, and OH.

50. The compound of any one of claims 1 to 35 or 47-49, or a pharmaceutically acceptable salt thereof, wherein each R2Ais tetrahydrofuran.

51. The compound of claim 1 or 2, wherein the compound is52. The compound of claim 1 or 2, wherein the compound is375MF-36514651849892202194053. The compound of claim 1 or 2, wherein the compound isthereof.

54. The compound of claim 1 or 2, wherein the compound isthereof.

55. A compound selected from the group consisting of the compounds of Table 1, or a pharmaceutically acceptable salt thereof.

56. A pharmaceutical composition comprising a compound according to any one of claims 1-55, or a pharmaceutically acceptable salt thereof, and a pharmaceutically acceptable excipient.

57. A method of treating a neuromuscular disease in a subject in need thereof, comprising administering to the subject a compound of any one of claims 1-55, or a pharmaceutically acceptable salt thereof, or a pharmaceutical composition of claim 56.

58. The method of claim 57, wherein the neuromuscular disease is tremor, spasticity, distal arthrogryposis, muscular dystrophy, multiple sclerosis, or cerebral palsy; or wherein the neuromuscular disease is associated with movement, gait, hypertonia, hypercontractility, muscle stiffness, spasms, involuntary contractions, tendinitis, carpal tunnel376MF-365146518498922021940syndrome, stroke, physical trauma, brain injury, or spinal cord injury.

59. The method of claim 57, wherein the neuromuscular disease is resting tremor, action tremor, essential tremor, dystonic tremor, orthostatic tremor, distal arthrogryposis associated with a mutation in myosin binding protein Cl (MYBPC1), Duchenne Muscular Dystrophy, Becker muscular dystrophy, myotonic dystrophy 1, myotonic dystrophy 2, facioscapulohumeral muscular dystrophy, oculopharyngeal muscular dystrophy, or limb girdle muscular dystrophy.

60. A method of inhibiting fast skeletal muscle myosin, comprising contacting the fast skeletal muscle myosin with a compound of any one of claims 1-55, or a pharmaceutically acceptable salt thereof, or a pharmaceutical composition of claim 56.377MF-365146518

Images